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Section 4: Abstract 
Normocalcaemic hyperparathyroidism (NPHPT) is characterised by persistently normal 
calcium levels, elevated PTH values on at least two consecutive measurements, after 
excluding other causes of secondary hyperparathyroidism.  The prevalence of the disease in 
the literature varies significantly due to various definitions used; it is reported to be between 
0.1 and 8.9%. The data on the natural history of this disease are sparse and inconclusive. 
Normocalcaemic hypoparathyroidism (NHYPO) is characterised by persistently low levels of 
parathyroid hormone (PTH) with normal levels of calcium. There is little in current literature on 
this disease, with only two studies published on its prevalence whilst its natural history remains 
relatively unknown. 
The aims of this study were: to identify the prevalence of NPHPT in a UK referral population 
using the international criteria and study the natural history of this disorder and the variability 
of serum calcium; to compare the variability of calcium in NPHPT and PHPT; to identify the 
prevalence of NHYPO and to study the natural history of the disorder and the variability of 
serum calcium.  
The prevalence of NPHPT in our UK referral population was found to be low. NPHPT patients 
often have episodes of hypercalcemia, so they probably suffer from PHPT. The variability of 
NPHPT and PHPT patients is similar. 
The prevalence of NHYPO calculated from this UK referral population is lower when compared 
to results from previous studies. NHYPO patients often have episodes of hypocalcaemia with 
some cases having no apparent reason for calcium levels below the reference range. The 
next steps are to find out the cause of this biochemical abnormality and the consequences, if 
any. 
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Section 5: Abbreviations 
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ALB Albumin 
ALP Alkaline phosphatase  
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CKD-EPI Chronic kidney disease epidemiology collaboration  
CLIA Competitive chemiluminescence immunoassay  
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CLSI Clinical & Laboratory Standards Institute  
cQCT Central quantitative computed tomography 
CrCl Creatinine clearance  
CRP C reactive protein  
CT Computerised tomography 
CTX Collagen type 1 cross-linked C-telopeptide 
CV Coefficient of variation  
CVA Cerebrovascular accident 
DAG Diacylglycerol 
DBP Vitamin D binding protein  
DCH Danish Diet, Cancer, and Health Study  
DHS Dallas Heart Study 
DM Diabetes mellitus 
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ECF Extracellular fluid  
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ECLIA Electrochemiluminescence immunoassay  
EDTA Ethylenediaminetetraacetic acid 
eGFR Estimated glomerular filtration rate  
EQA External quality assurance  
EQAS External quality assessment schemes 
ESR Erythrocyte sedimentation rate  
FDA American Food and Drug Administration 
FHH Familial hypocalciuric hypercalcaemia 
FNA Fine needle aspiration 
FRAS Fracture risk assessment service  
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FSH Follicle-stimulating hormone 
FT Foundation trust 
GDPR General Data Protection Regulation  
GFR Glomerular Filtration Rate 
GGT Gamma-glutamyl transpeptidase 
GP General practitioner 
GPCR G-protein coupled receptor 
HADS Hospital Anxiety and Depression Scale 
HAMA human anti-mouse antibodies  
HCL Hydrochloric acid  
HDL High density lipoprotein 
HH Hyperparathyroid hypercalcaemia  
HOMA-IR Homeostatic model assessment for insulin resistance 
HR Hazard ratio 
HTA Human Tissue Authority  
iCa Ionised calcium 
IDMS Isotope-dilution mass spectrometry  
IGF-1 Insulin growth factor 1  
IGT Impaired glucose tolerance 
IH Idiopathic hypercalciuria 
IHD Ischaemic heart disease 
IOF International Osteoporosis Foundation  
IOM US Institutes of Medicine  
IP3 Inositol 1,4,5-trisphosphate 
IQR Interquartile range  
IRMA Immunoradiometric assay 
ISCD International Society for Clinical Densitometry  
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IT Information Technology 
JCTLM Joint Committee for Traceability in Laboratory Medicine  
KDIGO Kidney Disease Improving Global Outcomes  
LDL Low density lipoprotein  
LH Luteinizing hormone  
LPA Lipoprotein A  
LRP6 Low-density lipoprotein receptor related protein 6  
LSC Least significant change 
MBC Metabolic bone centre 
MD Mahalanobis distance  
MDRD Modification of diet in renal disease  
MEN Multiple endocrine neoplasia 
MIP Minimally invasive parathyroidectomy 
MREC Multi-Centre Research Ethics Committee  
MRI Magnetic resonance imaging 
MrOS Osteoporotic Fractures in Men Study  
MTA Material Transfer Agreement  
MVE Minimum volume ellipsoid estimator 
NGH Northern General hospital 
NHANES III National Health and Nutrition Examination Survey  
NHS National health service 
NPHPT Normocalcaemic hyperparathyroidism  
NHYPO Normocalcaemic hypoparathyroidism 
NICE National Institute for Health and Care Excellence  
NIGB National Information Governance Board for Health & Social Care  
NS Not significant 
o-CPC o-cresolphthalein complexone 
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OGTT Oral glucose tolerance test 
OGTT  Glucose tolerance test 
OPG Osteoprotegerin 
OPUS Osteoporosis and Ultrasound Study 
P1NP Procollagen type 1 N-terminal propeptide 
PCA Principal component analysis 
PHPT Primary hyperparathyroidism 
PIAG Patient Information Advisory Group  
PIP2 Phosphatidylinositol-4,5-bisphosphate 
PKA Protein kinase A 
PKC Protein kinase C 
PLA2 Phospholipase A2  
PLC Phospholipase C 
PLD Phospholipase D  
PPI Proton pump inhibitors 
PTH Parathyroid hormone 
PTHrP Parathyroid hormone related peptide 
QC Quality control  
RANK Receptor activator of nuclear factor-kappa B 
RANKL Receptor activator of nuclear factor κB ligand 
RF Rheumatoid factor  
RHH Royal Hallamshire hospital 
RIA Radioimmunoassay 
RLU Relative light units  
ROI Region of interest  
ScHARR School of Health and Related Research  
SCr Serum creatinine  
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SD Standard deviation 
SE Standard error 
SF-36 Short Form 36  
SHBG Sex hormone-binding globulin  
SNP Nucleotide polymorphism  
SOP Standard Operating Procedures  
STH Sheffield Teaching Hospitals 
Sw Within-subject standard deviation  
tCa Total calcium 
TRACP 5b Tartrate-resistant acid phosphatase 5b  
TRCa Tubular reabsorption of calcium 
TRPV6 Transient receptor potential cation channel  
TSH Thyroid-stimulating hormone  
UCCR 24hour urine calcium to creatinine ratio 
UV-B Ultraviolet B  
VDBP Vitamin D binding protein  
VFA Vertebral fracture assessment 
VLDL Very low density lipoprotein 
WHO World Health Organization  
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Section 6: Overview of the thesis chapters 
The alternative format for writing a thesis was applied in this document, as approved 
by the University of Sheffield in 2019. This implies that some information might be 
mentioned more than once, as the final results are presented in a scientific manuscript 
format eligible for publication. The outline of this thesis is as follows. 
 
Chapter 1: Introduction 
The introduction is giving some background information on calcium metabolism and 
parathyroid disorders related to hypercalcaemia (primary hyperparathyroidism) and 
hypocalcaemia (hypoparathyroidism).  Endocrine disorders are often characterised by 
a clinical and a subclinical form. Following a similar pattern, two disorders related to 
calcium and the parathyroid glands were recently described in literature. 
Normocalcaemic hyperparathyroidism (NPHPT) is a disorder of calcium metabolism 
which is characterised by persistently normal calcium levels and consistently elevated 
parathyroid hormone (PTH) values. A pathophysiological counterpart to NPHPT is 
normocalcaemic hypoparathyroidism (NHYPO), which is characterised by normal 
levels of calcium with low levels of PTH. A literature review is presented and the gap 
in literature is identified.  
The introduction is followed by the rationale of the study and the aims of the thesis.  
 
Chapter 2: Methods and method development 
The main data for this thesis were retrieved from a tertiary metabolic bone referral 
centre. The methods section gives some information on the centre and describes the 
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theory behind the different methods used in the studies. This is then followed by a 
method development section, where the results from initial analyses are presented. 
This is done in order to describe the thought process followed before reaching the final 
analysis presented in the next chapters.  
 
Chapter 3: Metabolic Bone Centre studies 
NPHPT and NHYPO. Prevalence and natural history  
This chapter contains the final results of the analyses performed using data from the 
tertiary referral centre. The format used is a scientific paper format as indicated in the 
alternative thesis format guidance by the University of Sheffield. Both the manuscripts 
included were formatted for submission in peer reviewed journals. 
Some extra analyses performed to complement the chapter are added in the end. 
 
Chapter 4: UK Biobank studies 
As the main part of the study was performed in a referral centre, a population-based 
database was used to further study the variability of calcium and compare the findings 
with the ones presented in Chapter 3.  
 
Chapter 5: Final discussion and future plans 
Although each chapter contains a summary of the findings and discussion, a final one 
is included in the end of the thesis to also introduce future research plans 
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Appendix 
A list of tables on published studies performed on normocalcaemic 
hyperparathyroidism is added to supplement the introduction.  
These are followed by the intermediate analyses performed before the final one 
presented in Chapter 3.  
The bibliography used in this thesis is also attached in this section. 
 
Supplementary material 
These include the codes done in R and are attached in a CD. 
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Section 1: The physiology of calcium 
Calcium is an important mineral in the human body; its regulation within tight normal 
limits is of great importance. Calcium is involved in several processes like cell division 
and adhesion, secretion of proteins from cells, muscle and nerve function, glycogen 
metabolism and, it also acts as a co-factor during coagulation procedures. The human 
body contains approximately 1000g of calcium, mainly located in the bones as 
hydroxyapatite (99%); the remaining 1% is located extracellularly, in the blood and soft 
tissues. Calcium can be found in three different forms in the blood. Approximately 45% 
of the total calcium (tCa) is ionised (iCa) and this is the biologically active form, 45% 
is bound to plasma proteins, mainly albumin, and 10% forms complexes with citrate 
or PO4 ions (Favus & Goltzman, 2013). Because of this affinity of calcium with 
proteins, total calcium levels can vary according to the albumin concentrations. 
Therefore, in the case of dehydration or haemoconcentration during venepuncture, 
where albumin increases, there are false elevations of the total calcium. To avoid this, 
the value of calcium is adjusted for the albumin concentration using an equation based 
on their regression. Changes in the blood pH can also affect calcium levels; ionised 
calcium increases in acidosis due to reduced binding by albumin (Barth et al, 1996; 
Vautour & Goltzman, 2018). 
Parathyroid hormone (PTH) is the main regulator of calcium homeostasis and it is 
secreted by the chief cells of the parathyroid glands (Favus & Goltzman, 2013). 
 
1.1.1 Parathyroid glands 
Developmentally, the parathyroid glands derive from the pharyngeal pouches. These 
are transient structures which differentiate from the foregut endoderm; the superior 
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glands derive from the fourth ones and the thymus and inferior glands from the third 
ones. They first appear in the fifth week of gestation. Their development is associated 
with a conservative hierarchy of genes (Rubin & Levine, 2013).  
The first reference to the parathyroid glands in the literature was made in 1852 by Sir 
Richard Owen, a Conservator of the Hunterian Collection of the Royal College of 
Surgeons. He performed a necroscopy of an Indian rhinoceros and reported “a small 
compact yellow glandular body, attached to the thyroid at the point where the veins 
emerge”. The full credit for the description and naming of the glands (glandulae 
parathyroidae) belongs to Ivar Sandström, a Swedish anatomist, who first noticed the 
glands in a dog and then identified and described them in several species (rabbits, 
cats, horses and humans). He found “on both sides at the inferior border of the thyroid 
gland an organ of the size of a small pea”. He published his work in 1880 in a local 
journal, but it was not really noticed for some years. The importance of these glands 
was recognised in 1891 by Eugene Glay, professor of physiology in Paris, who proved 
that it was their removal after a thyroidectomy that caused the fatal seizures already 
described as “tetany”. Two Italian researchers, Giulio Vassale and Francesco Generali 
showed in 1896, that tetany was caused by parathyroidectomy alone, leaving the 
thyroid gland intact. The assumption was that parathyroid glands were responsible for 
the removal of some toxins from the body and that the tetany was caused by 
intoxication. The toxin suggested was methyl guanidine. This theory was kept until 
several years later, when William MacCollum and Carl Voegtlin working at Johns 
Hopkins Medical first suggested in 1909 that it was the parathyroid glands that were 
responsible for the regulation of calcium and that tetany was caused by calcium 
deficiency and could be prevented by the administration of calcium (Eknoyan, 1995; 
Johansson, 2015). 
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1.1.2 Parathyroid hormone (PTH)  
The identification of the hormone responsible for the effects on calcium was performed 
by two independent researchers, Adolph Hanson in 1923 and James Collip in 1925. 
They both used similar methods to extract the hormone, but the credit was given to 
Collip, a person already known for his contribution to the discovery of insulin. He used 
hot hydrochloric acid to retrieve parathyroid extracts and could treat the tetany caused 
by parathyroidectomy by giving these extracts subcutaneously to dogs. This resulted 
in the normalisation of calcium. The researcher established the parathyroid glands as 
endocrine organs, producing parathyroid hormone. However, it was not until several 
years later (1959), that Aurbach, Rasmussen and Craig managed to purify PTH using 
improved procedures (Eknoyan, 1995; Gardella et al, 2010; Johansson, 2015) 
Parathyroid hormone is an 84-amino acid polypeptide whose gene is located on the 
short arm of chromosome 11p15. It is produced by the chief cells of the parathyroid 
glands and has a molecular weight of 9400 daltons. The amino acid sequence of PTH 
is extensively conserved amongst mammalians, especially in the N-terminal where 32 
out of 38 residues are conserved. This part of the hormone is necessary and sufficient 
for the binding and activation of the PTH receptor and for the mineral ion homeostasis.  
The part with the greatest variation is the middle one (amino acids 39-52), which has 
limited importance. There is also high homology in the C terminal (Gardella et al, 2010; 
Murray et al, 2005). 
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Figure 1-1: Amino acid sequencing of PTH in different species.  
Shading indicates that the residues are conserved in other species, while the bold letters indicate that 
the residues are conserved in all species. The amino acids are G: Glycine, P: Proline, A: Alanine, V: 
Valine, L: Leucine, I: Isoleucine, M: Methionine,  C: Cysteine, F:  Phenylalanine, Y:  Tyrosine,  W: 
Tryptophan, H: Histidine,  K:  Lysine, R: Arginine,  Q: Glutamine,  N: Asparagine,  E: Glutamic Acid ,  
D: Aspartic Acid,  S: Serine , T:  Threonine. From: Parathyroid Hormone Secretion and Action: Evidence 
for Discrete Receptors for the Carboxyl Terminal Region and Related Biological Actions of Carboxyl-
Terminal Ligands, Endocr Rev. 2005;26(1):78-113. doi:10.1210/er.2003-0024, Endocr Rev | Copyright 
© 2005 by The Endocrine Society 
 
There is a 141 amino acid protein, called PTH-related protein (PTHrP), which shares 
homology with PTH. This is encoded in chromosome 12. It was first thought to just be 
a mediator of hypercalcaemia in malignancy, but nowadays, it is believed that it has a 
role in the development of the skeleton and that it regulates calcium through 
pregnancy and lactation. These two proteins have eight out of the first 13 residuals of 
the amino acid sequence identical. That explains the shared actions on the PTH 
receptor (Vautour & Goltzman, 2018). 
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1.1.2.1 Synthesis 
PTH is synthetized as a pre-pro-PTH molecule with a 25-amino acid sequence in the 
N terminal, followed by the 90-amino acid sequence of pro-PTH. This is the first 
molecule formed form the translation of the mRNA in the ribosomes. This 25-amino 
acid sequence is rich in hydrophobic amino acids, which is considered to be important 
for the binding to the endoplasmic reticulum and for entering the cisternal space.  The 
pre sequence is removed and the pro-PTH is transported to the Golgi network where 
the pro-sequence (amino acids -6 to -1) is cleaved with the enzyme furin. The mature 
form (PTH 1-84) is then packed into secretory vesicles within 20-30 minutes from the 
beginning of the process. The content of these vesicles can be stored, degraded or 
secreted in the bloodstream. Calcium and vitamin D do not seem to affect the 
synthesis of the hormone, but can adapt the degradation of the hormone in the 
vesicles. Proteases cathepsin B and H are involved in the degradation of the hormone 
and generation of the carboxyl fragments (Cohn & MacGregor, 1981; Gardella et al, 
2010).  
 
1.1.2.2 PTH receptors 
PTH mainly binds on the PTHR1 receptor (also called PTH/PTHrP common receptor), 
which belongs to the G protein receptor superfamily. This receptor can be found in the 
surfaces of bone cells like osteoblasts and osteocytes and on the tubular cells in the 
kidney. The gene encoding the receptor is located at chromosome 3 (Silva & 
Bilezikian, 2015). It is formed by three parts, an extracellular part of approximately 165 
amino acids, a transmembrane part with seven membrane helices and loops 
connecting them and, an intracellular part of 130 amino acids (Figure 1-2). This 
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receptor is highly expressed in the kidney and bones and can be stimulated by both 
PTH and PTH related peptide (PTHrP) by the “two-site” model of binding (Figure 1-3). 
After the receptor is activated, it acts through different second messenger pathways; 
through the GSa subunit, it stimulates adenyl cyclase, which in turn, catalyses the 
conversion of ATP to cyclic AMP and thus activates protein kinase A (PKA). Moreover, 
it can act through the Gq subunit and activate phospholipase C (PLC), a membrane 
bound enzyme which, by hydrolysing phospholipid phosphatidylinositol-4,5-
bisphosphate (PIP2), leads to the production of inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG). The former moves into the cytoplasm and by stimulating 
receptors on the endoplasmic reticulum, it stimulates calcium mobilization. DAG on 
the other hand, is membrane-bound and is responsible for the activation of protein 
kinase C (PKC).  Another possible action of PTH is the translocation of β-arrestins to 
the cell membrane, proteins known for their effect to regulate G receptors. These 
proteins then downregulate the cAMP activation and stimulate the mitogen-activated 
protein kinase (extracellular signal-regulated kinase [ERK1/2]) signaling cascade 
(Gardella & Vilardaga, 2015; Murray et al, 2005; Silva & Bilezikian, 2015).  
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Figure 1-2: The PTH receptor type 1.  
The receptor consists of 593 amino acids, with a large extracellular part of about 160 amino acids (the 
initial N-terminal is removed), a transmembrane part of seven helices with loops connecting and an 
intracellular part. Reprinted from Gardella TJ, Vilardaga JP. International Union of Basic and Clinical 
Pharmacology. XCIII. The parathyroid hormone receptors--family B G protein-coupled receptors. 
Pharmacol Rev 2015; 67:310-337. Permission from the American Society for Pharmacology & 
Experimental Therapeutics 
 
A second receptor has been identified, called PTH2 receptor (PTH2R). This receptor 
is not located at the kidneys or bones but in other tissues like hypothalamus, heart, 
somatostatin cells at the pancreas, thyroid parafollicular cells, vascular endothelium, 
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gastrointestinal tract, etc. This receptor is only activated by PTH, not by PTHrP; 
however, its endogenous ligand is not PTH, but a 39-amino acid polypeptide called 
tuberoinfundibular peptide 39 (TIP39). This peptide was found to have functions in the 
neuroendocrine system (increase production of hormones) and spermatogenesis. 
More recently, a third type of receptor (PTH3R) has been discovered in animals but 
not in mammals and its role is uncertain (Gardella & Vilardaga, 2015; Murray et al, 
2005). 
 
Figure 1-3: The “two-site” model of PTH/PTHR1 interaction.  
The 15-34  terminal of PTH binds to the extracellular part of the receptor (ECD) and then the N-terminal 
binds to the transmembrane. This leads to changes in the receptor and hence coupling of the G 
proteins. Reprinted from Gardella TJ, Vilardaga JP. International Union of Basic and Clinical 
Pharmacology. XCIII. The parathyroid hormone receptors--family B G protein-coupled receptors. 
Pharmacol Rev 2015; 67:310-337. Permission from the American Society for Pharmacology & 
Experimental Therapeutics 
 
Chapter 1: Introduction 
Section 1:The physiology of calcium  
 
 55 
1.1.2.3 Actions 
1.1.2.3.1 Skeleton: catabolic and anabolic actions 
PTH has both catabolic and anabolic effects on the skeleton. Its effects are direct on 
osteoblasts and osteocytes and indirect on osteoclasts. The effects depend on the 
duration and periodicity of exposure. When there is continuous exposure to high levels 
of PTH, the effect is catabolic, therefore increasing bone resorption. This effect is 
mediated through the OPG–RANKL–RANK pathway. PTH acts on osteoblasts and 
stimulates the production of the receptor activator of nuclear factor κB ligand (RANKL) 
and its decoy receptor osteoprotegerin (OPG). RANKL binds to the receptor activator 
of nuclear factor-kappa B (RANK) found on osteoclasts and their hematopoietic 
precursors. The differentiation and survival of the precursors is promoted and so is the 
stimulation of the fully formed osteoclast. OPG is able to inhibit the bone resorption by 
binding to RANK and the balance between the concentration of OPG and RANKL 
regulates the degree of bone resorption. The bone resorption releases minerals 
including calcium from the bone (Favus & Goltzman, 2013; Gardella & Vilardaga, 
2015; Silva & Bilezikian, 2015).  
Continuous infusions of PTH in rats have shown that PTH increases the mRNA 
encoding for RANKL and decreases the OPG mRNA. PTH also increases the 
expression of monocyte chemoattractant protein-1 (MCP-1), a chemokine for 
macrophages and monocytes. MCP-1 increases the chemoattraction of pre-
osteoclasts and thus increases bone resorption (Silva & Bilezikian, 2015).  
If PTH is administered in low, intermittent doses, its effects on the skeleton are 
anabolic, meaning it increases bone formation. For this reason, a synthetic analogue 
of the amino-terminal fragment of PTH is used in the treatment of osteoporosis 
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[teriparatide, rhPTH(1-34)]. When given intermittently, PTH acts on osteoblasts and 
promotes osteoblastogenesis, reduces their apoptosis and differentiates quiescence 
lining cells into active osteoblasts (Silva & Bilezikian, 2015).  
The mediators that regulate the actions of PTH on bone formation are not fully 
understood. One of the possible mediators seems to be sclerostin, the product of the 
SOST gene, located on chromosome 17q12–q21 in humans. Sclerostin is a 
glycoprotein produced by osteocytes and it can inhibit the Wnt/β- catenin pathway and 
thus inhibit bone formation. This pathway is activated when a Wnt ligand binds to a 
dimeric receptor complex formed by the transmembrane Frizzled (Fz) receptor and its 
co-receptor, low-density lipoprotein receptor related protein 6 (LRP6) or its close 
relative LRP5. Sclerostin binds to the LRP receptors and inhibits the Wnt pathway and 
this leads to decreased bone formation. PTH, through the cAMP pathway, seems to 
inhibit the SOST gene, and thus reduces sclerostin. There is a negative correlation 
between circulating sclerostin and PTH levels and patients with primary 
hyperparathyroidism, a disease with an increase in PTH levels, have been found to 
have lower sclerostin levels. Results from studies evaluating whether dickkopf1 
(Dkk1), another inhibitor of the Wnt pathway, is also a mediator of PTH action are 
controversial. Another potential mediator of the PTH action is EphrinB2 which 
stimulates the interaction between two osteoblastic cells (Silva & Bilezikian, 2015).  
 
1.1.2.3.2 Effects on kidneys 
PTH has effects on the kidneys at several levels; at the proximal tubule (65% 
reabsorption of calcium) it increases the 1α-hydroxylase activity, thus increases the 
production of the active form of vitamin D [1,25(OH)2D]. At the same level, it inhibits 
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the apical type 3 Na+/H+ exchanger and the Na+/K+-ATPase located in the basolateral 
membrane, thus inhibiting the Na+ and HCO3- reabsorption. It can also inhibit the 
sodium dependent phosphate cotransport by inhibiting  NaPi-IIa and NaPi-IIc, leading 
to phosphaturia. Approximately 20% of the calcium is reabsorbed at the thick 
ascending limp of the loop of Henle. In this part of the kidney, the calcium sensing 
receptor described in more detail later, also has a role in the regulation of calcium, by 
antagonising the hypercalcaemic actions of PTH. Therefore, if there is a raised 
extracellular fluid (ECF) calcium in the nephron, this is sensed by the receptor which 
in turn antagonises the PTH action. Elevated ECF calcium decreases  the activity of 
the Na/K/2Cl cotransporter and thus decreases the calcium paracellular reabsorption. 
That is why it is considered to act in an analogous way to loop diuretics. A further 15% 
of the calcium is absorbed from the distal tubule. At this level, PTH can actually 
influence  calcium levels directly, by stimulating the calcium transfer in the renal tubule 
via the transient receptor potential cation channel (TRPV5), by assisting the transport 
of calcium through the cell with proteins like calbidin-D28K and by assisting the 
transfer of calcium into the blood through the Na+/Ca2+ exchanger (NCX1) (Favus & 
Goltzman, 2013; Gardella & Vilardaga, 2015; Vautour & Goltzman, 2018). 
 
1.1.2.3.3 Effects on intestine 
PTH acts directly on the calcium levels, as described above, but also it has an indirect 
action though the increase of 1,25(OH)2D. The active form of vitamin D acts at the 
intestine where calcium is absorbed (90% in duodenum and jejunum). Calcium is 
absorbed both with an energy-dependent pathway (10-15% of the dietary load), mainly 
regulated by vitamin D and a passive paracellular path regulated by electrochemical 
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gradients.  The energy-dependent pathway includes the transfer of calcium into the 
intestinal cell via the transient receptor potential cation channel (TRPV6), then the 
transport of calcium through the cell via the annexin2 calbidin D9K, and finally the 
extraction of calcium through the basolateral membrane into the blood via the 
PMCA1b. Vitamin D increases the expression of these proteins. Vitamin D can also 
regulate claudin 2 and claudin 12, both parts of paracellular channels, and enhance 
the passive absorption of calcium. However, this absorption is reduced in cases of 
high dietary intake (Favus & Goltzman, 2013; Vautour & Goltzman, 2018). 
 
1.1.2.4 Metabolism 
PTH is cleared by both the liver (40-75%) and the kidney (20-30%) and has a half-life 
is approximately 2-4 minutes  (Gardella et al, 2010). Moreover, as mentioned above, 
PTH is degraded into different fragments, known as N and C-terminal fragments. This 
is important because, firstly, their existence can affect the measurement of the 
hormone (as described below) and, secondly, it has been suggested that these 
fragments might have a biological action. C-terminal fragments are secreted by the 
parathyroids, along with the intact hormone. The ratio of fragments to intact hormone 
is increased in the case of hypercalcaemia and reduced in the case of hypocalcaemia. 
It has also been suggested that the pattern of proteolysis depends on the levels of 
calcium. Although circulating PTH is cleared by both the kidney and the liver, the 
kidneys are not able to produce fragments of the hormone, just clear them. On the 
contrary, the liver produces these fragments in the Kupffer cells and they can re-enter 
the circulation (Murray et al, 2005).  
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The existence of N-fragments has also been studied. It has been suggested that are 
produced in the liver and rapidly degraded and do not normally exist in measurable 
quantities in the blood but can be found in renal failure, hyperparathyroidism or both 
(Murray et al, 2005). 
 
1.1.3 Calcium-sensing receptor 
The relationship between calcium and PTH is described by a sigmoidal curve (Figure 
1-4). 
 
Figure 1-4: Sigmoidal curve characterising the inverse relationship between ionised calcium and PTH. 
There are four characteristic points. A: maximum secretion rate of PTH in hypocalcaemia. B: slope at 
midpoint. C: level of calcium at the midpoint or the level of calcium needed to suppress 50% of PTH 
secretion. D: minimum secretion rat in hypercalcaemia 
 
PTH is secreted by the parathyroid glands which act like a “calciostat” in the human 
body; its secretion is regulated by the calcium-sensing receptor (CaSR). The receptor 
Chapter 1: Introduction 
Section 1:The physiology of calcium 
 
 60 
belongs in the G-protein coupled receptor (GPCR) superfamily and it is a member of 
the subgroup known as family C, characterised by the presence of a large extracellular 
domain. It was first cloned from bovine parathyroid glands in 1993 and in 1995 in 
humans. The receptor can be found mainly in the parathyroid cells, but also in other 
organs like the kidneys, gastrointestinal tract, bones, nervous system, breast, heart 
and in cells like the epidermal. The receptor senses the levels of circulating calcium 
by binding extracellular calcium in a “venus flytrap” way (Figure 1-5) and through 
complex intracellular signalling pathways, it adjusts the levels of PTH. It has three 
parts: a large 612-amino acid large extracellular one, a 250-amino acid 
transmembrane domain and a 216-amino acid C-terminus tail (Magno et al, 2011). 
The CaSR’s gene is located on chromosome 3q21.1 (Hannan & Thakker, 2013).   
 
Figure 1-5: Schematic model of the extracellular part of the CaSR.  
The model is based on the related structure of the metabotropic glutamate receptors (mGLUR1). The 
receptor is presented as a dimer; each monomer contains a “venus flytrap” part, used as a binding site 
for calcium. Slightly modified form from the original (Huang et al, 2007). Copyright: American Society 
for Biochemistry and Molecular Biology 
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Although calcium is the main agonist of this receptor, other substances have been 
found to stimulate it (Figure 1-6), either by direct by activation (type I) or by sensitizing 
the receptor to its agonists (allosteric modulators or type II). Pharmacological agents 
like cinacalcet, which is a calcimimetic, can enhance the sensitivity of the receptor to 
calcium, and are used to treat primary hyperparathyroidism (Magno et al, 2011).  
The intracellular signaling includes several messengers. To start with, the receptor 
can act through phospholipases like the phospholipase C (PLC) pathway. It has also 
been suggested that it stimulates phospholipase D (PLD) and A2 (PLA2). The 
activation of PLA2 and thus the release of arachidonic acid, is a result of different 
pathways. It can be activated both through PKC and by the release of intracellular 
calcium, as a result of the PLC pathway. Intracellular calcium stimulates calmodulin, 
which then stimulates calmodulin-dependent protein kinase (CaMK), both needed to 
activate PLA2. Another pathway that is activated through the CaSR is the MAPK 
signaling pathway, which involves several proteins (tyrosine kinase Src, Ras, Raf, 
MEK, ERK). A further second messenger that is involved is cAMP. It has been shown 
that the receptor activation can inhibit cAMP, although there can be cell specific 
differences in the responses, thus some cells can actually increase the level of cAMP. 
Phosphorylation and activation of the protein kinase Akt which is antiapoptotic can 
also take place. Finally, the Rho pathway can be involved and that can ultimately 
activate phospholipase D. Recent studies have shown that there are several proteins 
that can interact with the receptor and either protect it from degradation (filamin A) or 
lead to its destruction (β-arrestin, dorfin) (Magno et al, 2011). 
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When CaSR is activated by increased calcium in the parathyroids, its role is to inhibit 
PTH secretion. The actual mechanism behind this is unknown. Possible mechanisms 
suggested include the rearrangement of the cytoskeleton to prevent the vesicles 
containing PTH to approach the membrane. CaSR also acts on the PTH mRNA and 
causes its destabilisation and may also have an post-translational effect on PTH by 
promoting the cleavage of the PTH molecule (Hendy, 2018).  
On the other hand, CaSR is located mainly at the basolateral surface of the cells in 
the cortical thick ascending limb in the kidneys. In this part of the kidney, it antagonises 
the hypercalcaemic actions of PTH. Elevated ECF calcium decreases the activity of 
the Na/K/2Cl cotransporter and thus decreases the calcium paracellular reabsorption 
leading to hypercalciuria. In this way, hypercalcaemia causes excretion of sodium, 
chloride and water in the urine, thus causing dehydration. In the distal convoluted 
tubule, the receptor stimulates TRPV5, therefore it stimulates the reabsorption of 
calcium. In the cortical collecting duct, it enhances the secretion of H+ to the urine, 
thus preventing nephrolithiasis. Finally, in the case of hypercalciuria, and in order to 
protect from nephrolithiasis, the CaSR located in the inner medullary collecting duct, 
inhibits the reabsorption of water mediated by vasopressin and thus dilutes the calcium 
in the urine. This is the reason why diabetes insipidus can be a result of 
hypercalcaemia (Hendy, 2018).   
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Figure 1-6: The intracellular signalling of the calcium sensing receptor.  
DAG, Diacylglycerol; CaMK, calmodulin-dependent protein kinase; MMP, matrix metalloprotease; Rho-
GEF, Rho- guanine nucleotide exchange factor. From: The Calcium-Sensing Receptor: A Molecular 
Perspective. Endocr Rev. 2011;32(1):3-30. doi:10.1210/er.2009-0043, Endocr Rev | Copyright © 2011 
by The Endocrine Society 
 
1.1.4 Vitamin D 
Vitamin D is another important regulator of plasma calcium and the term refers to both 
ergocalciferol (vitamin D2) and colecalciferol (vitamin D3). The main source of vitamin 
D in the human body is the production of colecalciferol by the skin. The pro-vitamin 7-
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dehydroxycholesterol (7-DHC), under the effect of ultraviolet B (UV-B) light, forms 
previtamin D3 and then isomerizes to vitamin D3. Another source of vitamin D is diet. 
D3 can be mainly found in fatty fish, whereas ergosterol (the pro-vitamin D 
ergocalciferol), can be found in mushrooms and can be irradiated into ergocalciferol 
by UV-B. Fortified foods also contain vitamin D. The dietary vitamin D is absorbed by 
chylomicrons in the small intestine. These forms of vitamin D however, are not 
biologically active (Holick et al, 2011). 
Through a series of cytochrome P540 enzymes, vitamin D matures gradually into its 
active form. First, it is hydroxylased in the liver by 25-hydroxylase (CYP2R1 the most 
important) and forms 25(OH)D. This molecule is considered the best indicator for 
vitamin D status and has a half-life of 2-3 weeks. After formation, 25(OH)D is released 
into the circulation. A further 1α hydroxylation takes place in the kidneys by 1α-OHase 
(CYP21B1), to form the biologically active form, 1,25(OH)2D or calcitriol (half-life 4 
hours). As mentioned above, PTH stimulates this conversion (Holick et al, 2011). Both 
25(OH)D and 1,25(OH)2D are mainly bound to vitamin D binding protein (DBP). When 
released from this protein, 1,25(OH)2D can act on its intracellular receptor (vitamin D 
receptor, VDR) (Pludowski et al, 2018).  
Vitamin D regulates the calcium levels by its actions in the bones, intestine and 
kidneys. Osteoblasts have receptors for vitamin D and calcitriol can stimulate their 
differentiation to mature cells. It can also upregulate RANKL and downregulate OPG 
therefore, it can benefit bone resorption in an indirect way (Bikle et al, 2018).  
The actions of vitamin D in increasing calcium through the intestine have been 
described above. Finally, vitamin D can enhance the PTH receptor expression in the 
kidneys. The effects of PTH and vitamin D in the kidney are synergistic. The levels of 
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active vitamin D are controlled by the kidneys, through a different hydroxylation than 
the one described above. The enzyme 24-hydroxylase (CYP24A1) is responsible for 
this process. Active calcitriol has a negative feedback loop of CYP21B1, while it 
stimulates CYP24A1. PTH on the other hand stimulates CYP21B1 (Bikle et al, 2018).  
Finally, calcitriol has the ability to supress the activity of PTH and inhibits the 
proliferation of parathyroid cells. It can also upregulate the transcription of the CaSR 
at the parathyroids, thus sensitising the gland (Bikle et al, 2018). 
Recently, there has been some controversy to what is defined as vitamin D sufficiency 
and deficiency and there have been various recommendations to what would be the 
ideal intake in the general population. The recommended intake of vitamin D was 200 
IU/day up to 2010. This was because this dose would be enough to prevent rickets. In 
2010, the US Institutes of Medicine (IOM) recommended 600 IU for adults <70 years 
of age and 800 IU for any adult above this age. They defined vitamin D deficiency as 
any level below 50 nmol/L (20 ng/ml) as this would be sufficient to prevent 
osteomalacia in at least 97.5% of the population (Ross et al, 2011). The Endocrine 
Society, defined deficiency as a level of 25(OH)D below 50nmol/L, while insufficiency 
was defined as a level of 50-75 nmol/L. They stated that adults might require at least 
1500-2000 IU to raise vitamin D to the recommended limits (Holick et al, 2011).  
There have been a variety of guidelines and recommendations since then, published 
in different countries and using different ways to what is considered normal. The IOM 
guidelines (issued in North America) were based on evidence regarding calcium and 
phosphate metabolism and bone health requirements. In contrary, the Endocrine 
Society, American Academy of Developmental Disability and the Central European 
recommendations were developed using the available the evidence on both skeletal  
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and the non-skeletal effects of vitamin D (Pludowski et al, 2018). Higher levels of 
vitamin D have been correlated with higher bone mineral density results, improvement 
in strength and reduction of falls and levels of at least 75 nmol/L have been reported 
to be related to antifracture efficacy (Holick et al, 2011).  
Vitamin D deficiency is a cause of secondary hyperparathyroidism, i.e. elevated PTH.  
The levels of vitamin D needed to normalise the values of PTH, are considered an 
indicator of what can be classified as deficiency. There have been studies that showed 
that PTH levels have an inverse relationship with vitamin D and a plateau in PTH is 
starting to be observed in levels of 25(OH)D above 75 nmol/L but not all studies agree 
with this finding (Figure 1-7) (Holick et al, 2011).  
Another approach to define the ideal vitamin D threshold is by evaluating  the effect of 
supplementation with vitamin D on the levels of PTH. A threshold of 50 nmol/L has 
been suggested to be sufficient to lower PTH levels (Malabanan et al, 1998).  
In the UK, both the National Osteoporosis Society and the National Institute for Health 
and Care Excellence (NICE) recommend a cut-off of 50nmol/L to define sufficiency 
(Aspray et al, 2014; NICE, 2018).  
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Figure 1-7: PTH concentration against 25(OH)D.  
Serum PTH values began to increase with 25(OH)D concentrations less than 29.8 ng/ml. Figure from 
Holick et al, Prevalence of Vitamin D Inadequacy among Postmenopausal North American Women 
Receiving Osteoporosis Therapy, The Journal of Clinical Endocrinology & Metabolism, 2005, 90(6): 
3215-3224 by permission of Oxford University Press (Holick et al, 2005) 
  
1.1.5 Biochemical assessment of calcium homeostasis 
1.1.5.1 Measurements 
1.1.5.1.1 PTH Measurement 
PTH measurement has evolved over the past years. The first-generation PTH 
radioimmunoassays (RIAs) were introduced in the 1960s and 1970s and they included 
multivalent antibodies against PTH of different species. These assays mainly reacted 
with the carboxyl-domain of PTH (amino acids 53-84) or the mid carboxyl-domain 
(amino acids 44-68) and thus identified inactive C-PTH fragments in a large extent 
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(approximately 80%). Since these fragments can be produced in chronic 
hypercalcaemia, and they are also accumulated in chronic kidney disease (CKD), it 
was difficult to distinguish non-PTH induced hypercalcaemia from mild PHPT and it 
was also difficult to interpret the results in chronic kidney disease. Comparing results 
from different assays was also a challenge. Second generation immunoradiometric 
assays (IRMA), also known as “intact PTH assays”, were introduced a few years later. 
The principal behind these assays was to use an antibody to capture the carboxyl-
domain of human PTH (39-84) and detect the amino-domain (1-34) with a second 
labelled antibody. These methods allowed comparisons between studies, distinction 
between patients with chronic hypercalcaemia and mild PHPT and were easier to use 
in chronic kidney disease. However, it was subsequently proven, that these assays 
cross-react with large amino-truncated PTH fragments that are present in the 
circulation. The most abundant ones are the (7-84) and the (15-84). In normal 
subjects, these fragments represent 20% of the immunoreactivity, but in patients with 
chronic kidney disease, they represent up to 50%. Hence, in 1999, the third generation 
PTH assays were introduced, also known as the “whole PTH assays”. The capture 
antibody aimed against the carboxyl domain (39-84), but the labelled antibody in this 
case, aimed against a smaller region in the amino-terminal (1-4). However, it was 
shown that these assays also detect a modified PTH (1-84) molecule, formed post 
translationally, and characterised by phosphorylation of serine 17. This form 
represents <10% of the PTH values in normal subjects and approximately 15% in CKD 
patients. It can also be produced in higher concentrations in some patients with severe 
hyperparathyroidism and parathyroid carcinoma (Eastell et al, 2009). The diagnostic 
sensitivity for PHPT is similar between the second and third generation assays (Eastell 
et al, 2014). 
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The measurement of PTH can be performed using a random sample (NICE, 2019). 
The preferred way is by using an EDTA tube, as it is more stable in room temperatures 
(Roche, 2019). More details about PTH measurement can be found in Chapter 2. 
 
1.1.5.1.1.1 Factors that affect the PTH level 
The levels of PTH determine whether there is a parathyroid disorder or not, therefore, 
the use of the correct reference intervals of great importance. It has been recently 
suggested that reference intervals have to be established for second- and third-
generation PTH assays using population studies with vitamin D-replete individuals. 
Moreover, the importance of stratifying these intervals according to age, sex, race, 
glomerular filtration rate, and body mass index (BMI) has also been discussed (Eastell 
et al, 2014). 
In order to establish reference ranges for PTH a lot of things have to be taken into 
account. Any conditions that could have an effect on the level of PTH have to be 
excluded. As mentioned before, vitamin D deficiency is a cause of secondary 
hyperparathyroidism, i.e. elevated PTH. The levels of vitamin D needed to normalise 
the values of PTH, are considered an indicator of what can be classified as deficiency 
(Holick et al, 2011). When excluding patients with low vitamin D, the upper normal limit 
is found to be decreased (Souberbielle et al, 2017). However, as mentioned in the 
relevant vitamin D section, the cut-off for vitamin D deficiency is debated.  
Decreased kidney function should also be an exclusion criterion, with eGFR<60 
ml/min/1.73m2 being the appropriate cut-off, as PTH tends to increase higher than this 
level. PTH also seems to increase in cases of chronic low calcium intake (Souberbielle 
et al, 2017). 
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Moreover, other factors seem to affect the PTH level. PTH is higher in obese people, 
and in black individuals when compared to white. However, in both cases, this effect 
could be due to lower 25(OH)D in all these individuals (Souberbielle et al, 2017). 
Several studies have shown that PTH is increasing with age. Several factors have 
been speculated to explain this phenomenon. Some are decreasing renal function, 
reduced oestrogen, decrease in the number of vitamin D receptors in the intestine and 
thus reduced absorption of calcium, along with reduced responsiveness of 1α 
hydroxylase to PTH with age (Carrivick et al, 2015; Need et al, 2004).  
Overall,  age seems to be an independent predictor of PTH level. Need et al found 
that age, weight, ionised calcium and 25(OH)D, were all independent predictors, with 
25(OH)D being the most significant (Need et al, 2004). A few years later, a group of 
researchers in Denmark found that vitamin D had the highest correlation coefficient, 
followed by BMI and age. Renal function did not reach statistical significance. In total, 
16% of the PTH variability was explained by these factors. They also found that PTH 
levels started to increase at  25(OH)D <82 nmol/L (Rejnmark et al, 2011). A study 
performed using laboratory databases showed, that PTH increased with age and this 
increase was independent of 25(OH)D, ionised calcium, phosphate, and renal 
function. They found that each 10-year increase in age was associated with a 5% 
increase in PTH. In a subgroup analysis including only individuals with eGFR of ≥60 
mL/ min/1.73m2 and  25(OH)D of ≥50 nmol/L, they found that each 10-year increase 
in age was associated with a 6.1% increase in PTH  (Carrivick et al, 2015). A recent 
study from France confirmed that PTH increases with age and this is independent from 
vitamin D status and kidney function. When studying only subjects with vitamin D ≥7 
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5nmol/L, they found that only age remained significantly associated with PTH 
(Souberbielle et al, 2016). Further details on these studies can be found in Table 1-1. 
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Publication Recruitment Factors included in 
linear regression 
Independent predictors of PTH 
(Need et al, 
2004) 
Evaluating 918 postmenopausal women attending an osteoporosis center. 
Excluded individuals on treatment for osteoporosis, or  other medication or 
disease affecting calcium metabolism. 
Age, weight, calcium 
absorption, ionised 
calcium, 25(OH)D, 
and creatinine 
25(OH)D was the most 
significant followed by calcium, 
weight and age 
(Rejnmark et 
al, 2011). 
2316 women aged 17–84 years and measured intact PTH between 8:00 and 
13:00. They excluded women on treatment with drugs known to affect calcium 
homoeostasis (thiazides, loop diuretics, lithium, glucocorticoids, 
anticonvulsants and anti-osteoporotic drugs). They also excluded participants 
with creatinine levels >150 μmol/L. 
25(OH)D, age, BMI, 
calcium intake, total 
calcium, smoking 
Positive correlation with age, 
BMI 
Inverse correlation with total 
daily calcium intake, plasma 
calcium and 25(OH)D levels. 
PTH levels were also lower in 
smokers 
Vitamin D had the highest 
correlation coefficient, followed 
by BMI and age 
(Carrivick et al, 
2015). 
Laboratory databases in Western Australia (n= 17275 participants, mean age 
60 years, 80% female).  
The exclusion criteria were history of osteoporosis, hypoparathyroidism or 
hyperparathyroidism, ionised calcium or phosphate outside the reference 
range, eGFR< 30 mL/min/1.73m2 and age <20 years. 
As this was a study based on laboratory data, information on medical history 
was limited. Information on factors like ethnicity, BMI, menopause status, 
calcium intake, and use of medications was lacking 
Sex, ionized calcium, 
25(OH)D, phosphate, 
and eGFR 
The increase in PTH with age is 
independent of 25(OH)D, 
ionised calcium, phosphate, 
and renal function 
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(Souberbielle 
et al, 2016). 
This study evaluated 898 healthy subjects aged 18–89 years with a normal 
BMI (18-28.5 kg/m2) and eGFR. They excluded participants with a history of 
thyroid, renal, hepatic, cardiovascular, pulmonary, intestinal or psychiatric 
disorders, cancer, epilepsy, intercurrent illness occurring during the week 
preceding inclusion, current consumption of tobacco or other toxics, and 
treatment potentially modifying calcium/phosphorus metabolism. 
25(OH)D, phosphate, 
calcium and eGFR, 
age and BMI 
Vitamin D level and age  
When studying only subjects 
with vitamin D ≥75nmol/L, only 
age remained significantly 
associated  
Table 1-1: Recent studies evaluating the effect of different factors on PTH levels 
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1.1.5.1.2 Total calcium measurement  
Serum calcium is measured with colourimetric assays using different reagents to 
induce the change in colour. The colour intensity resulting from the chemical 
interaction is directly proportional to the calcium concentration and can be measured 
photometrically. The measurement of calcium is described further in the methods 
section.  
Several causes of contamination can cause falsely elevated serum calcium levels and 
falsely low levels are seen more rarely. In the case of dehydration or 
haemoconcentration during venepuncture, where albumin increases, there are falsely 
elevations of the total calcium (Goldstein, 1990). This is a theoretical concern and it 
unlikely that this difference is clinically significant. Moreover, it is not practical to follow 
in everyday practice.  
 
1.1.5.1.3 Albumin-adjusted calcium calculation 
Total calcium can vary significantly depending on protein concentration as 
approximately forty percent is protein bound, mainly to albumin. Adjusting total calcium 
for albumin concentration is therefore a more practical means of determining serum 
calcium (Barth et al, 1996). 
 
1.1.5.1.4 Ionised calcium measurement 
Ionised calcium can be measured in plasma, serum or whole blood. Unfortunately, 
there are not any commercially available auto analysers, and the measurement is 
usually performed in blood gas analysers. Measuring ionised calcium can be a 
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challenge. This is due mainly to influences from the pH. Even the slightest exposure 
to air and loss of CO2 by non-anaerobic handling, can increase the pH (alkalosis) and 
thus decrease the ionised calcium. Moreover, if the analysis is not rapid, the 
production of lactic acid by the red blood cell glycolysis would decrease the pH and 
thus increase the ionised calcium. There are also limitations due to binding of calcium 
to the common anticoagulants. As mentioned above, the measurement is usually 
performed in gas analysers and this is problematic because of frequent electrode 
dysfunction. The performance depends on staff training and quality control standards. 
The instrument must be perfectly calibrated, and the measurement has to be 
performed immediately after the collection. Finally, the lack of well-established 
reference ranges, does limit its use  (Baird, 2011; Boink et al, 1991; Brandi et al, 2016; 
Crowley & Gittoes, 2016).  
 
1.1.5.2 Variability of measurements 
When a test is repeated more than once, the results will rarely be similar. There are 
three sources of variation: pre-analytical, analytical and within subject biological 
variation. Pre-analytical variation relates to patient preparation and can be affected by 
factors like fasting, exercise and posture. It also relates to the different processes of 
collection and handling like, amongst others, whether an anticoagulant was used, 
whether the sample was stored or not and whether a tourniquet was applied (Fraser, 
2013).  
The analytical source of variation is related to the technique used and can be 
subdivided into random variation or precision (repeated analysis of the same sample) 
and systematic variation or bias. Random variation can be a result of the variability in 
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the sample volume as a result of pipetting, changing of temperature and environmental 
conditions. The random measurement variation follows a Gaussian distribution by 
definition. Thus, the coefficient of variation (CV) can be calculated. This is the ratio of 
the SD by the mean and multiplied by 100. If a method has a good precision, this 
means that the random variation is low. On the other hand, bias is the difference 
between the results obtained and an estimate of the true value. These values are 
usually given in proficiency testing programs (PT) or external quality assessment 
schemes (EQAS) (Fraser, 2013). 
The third source of variation is the within patient biological variation.  There are 
changes to many analytes throughout life for example gonadal hormones. Another 
source of variation is the circadian rhythm, where the analyte differs according to the 
time of the day. Some analytes also have monthly and seasonal cycles (Fraser, 2013).  
The biological variation can also just be described as the random fluctuation around a 
homeostatic setting point. This is called the within-subject or intra-individual biological 
variation. When the same analyte is measured in different people, each one would 
have a different setting point. This is represented by the between-subject or inter-
individual biological variation (Fraser, 2013).  
 
1.1.5.2.1 Variability of PTH 
There seems to be a circadian rhythm of PTH that has two peaks and two troughs 
(Figure 1-8). There is a trough mid-morning (10-11am), a peak late afternoon (5-6pm), 
a trough evening (8-9pm) and a peak early morning (2-3 am) (Calvo et al, 1991; el-
Hajj Fuleihan et al, 1997). The underlying rhythm is mainly endogenous and the 
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amplitude of change is reported to be between 4- 10 pg/ml (el-Hajj Fuleihan et al, 
1997). 
 
 
Figure 1-8: The daily variation of PTH.  
Figure el-Hajj Fuleihan G, Klerman EB, Brown EN, Choe Y, Brown EM, Czeisler CA. The parathyroid 
hormone circadian rhythm is truly endogenous--a general clinical research center study. J Clin 
Endocrinol Metab 1997; 82:281-286, by permission of Oxford University Press 
The circadian rhythm has been found to have alterations in women with osteoporosis 
(no nocturnal increase of PTH), female gender (late evening increase in PTH is 
blunted), prolonged fasting (no nocturnal rise after a 96-hour fast) and it has also been 
found to be lost in patients with PHPT (Calvo et al, 1991; Fraser et al, 1998) 
As far as the seasonal variability of PTH is concerned, this is affected by the levels of 
vitamin D and this association is inverse. 25(OH)D is lower during winter and early 
spring months and higher in summer and early autumn. PTH on the other hand, is 
lower in the summer and higher in the winter (Rapuri et al, 2002). 
 
Chapter 1: Introduction 
Section 1:The physiology of calcium 
 
 78 
1.1.5.2.2 Variability of calcium 
There is a circadian rhythm for ionised calcium, with a peak in the morning. This 
rhythm differs by gender. A study in young men (17-30 years) several years ago, 
showed that there is a peak in ionised calcium late morning (~10am) and a nadir in 
the afternoon (~16:30) (Markowitz et al, 1981; Markowitz et al, 1988) (Figure 1-9).  
 
Figure 1-9: Variations of ionised (left) and total calcium (right) in health men.  
Figure from Markowitz ME, Arnaud S, Rosen JF, Thorpy M, Laximinarayan S. Temporal 
interrelationships between the circadian rhythms of serum parathyroid hormone and calcium 
concentrations. J Clin Endocrinol Metab 1988; 67:1068-1073, by permission of Oxford University Press 
Another study a few years later, in 25 women and 24 men (20-69 years), showed that 
there is a circadian rhythm in both sexes, but the pattern was different especially early 
morning (6-8am), with iCa decreasing in women and reaching a plateau in men. The 
mean maximal change was 0.066 mmol/L for women and 0.058 mmol/L for men 
(Figure 1-10). In women, the mean serum ionised calcium correlated significantly with 
total daily calcium intake (women more dependent on calcium intake than men) (Calvo 
et al, 1991). 
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Figure 1-10: Circadian variation in serum iCa. 
 Men are shown in black, while women in grey. Meals were taken at times indicated by arrows, and a 
snack was consumed at 2000 h in some, but not all. The stippled horizontal bar indicates that the 
subjects were recumbent. Figure by Calvo MS, Eastell R, Offord KP, Bergstralh EJ, Burritt MF. 
Circadian variation in ionized calcium and intact parathyroid hormone: evidence for sex differences in 
calcium homeostasis. J Clin Endocrinol Metab 1991; 72:69-76, by permission of Oxford University 
Press 
Ionised calcium is also affected by food ingestion but remains stable overnight (Eastell 
et al, 1992).  
On the contrary, total calcium seems to be affected by postural changes, with a peak 
once again late morning and a nadir starting in the evening and persisting until early 
morning (1-6am). (Markowitz et al, 1981; Markowitz et al, 1988) (Figure 1-9). This 
early morning decrease corresponds closely to a reduction in protein. The average 
increase in plasma volume during an hour’s rest in the horizontal position was found 
to be 9% in healthy ambulatory subjects (Pedersen, 1972). A change from supine to 
a standing position can result in an increase of 0.05 to 0.20 mmol/L. Food intake can 
also affect the result slightly, with an increase as much as 0.15 mmol/L. Men in general 
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have slightly higher calcium levels than women (0.02 to 0.05 mmol/L) (Goldstein, 
1990). 
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Section 2: Parathyroid gland disorders 
Primary hyperparathyroidism (PHPT), is a classic endocrine calcium abnormality, and 
the most common cause of hypercalcaemia; along with malignancy-related 
hypercalcaemia, they constitute 90% of all the presentations of hypercalcaemia 
(Walsh et al, 2016). PHPT is characterised by parathyroid gland hyperfunction 
expressed with hypercalcaemia and increased levels of PTH.  
This disease was first characterised in the beginning of the 20th century and since then 
its presentation has evolved significantly, from a symptomatic disease, to an 
asymptomatic form and finally, to what is now called normocalcaemic 
hyperparathyroidism (NPHPT). 
 
1.2.1 Classical primary hyperparathyroidism: the first era. A historical overview 
Diseases of the bones were described before their connection to the parathyroid 
glands. The German pathologist Friedrich Daniel von Recklinghausen described the 
bone disease called “osteitis fibrosa cystica” in 1891. Max Askanazy described a 
patient with this disease and the existence of a parathyroid tumour in 1903 but the first 
who suggested their connection, was Jacob Erdheim in 1907. He claimed that the 
enlargement of the parathyroid glands is a compensatory process to the skeletal 
disease. It was not until 1915 when Friedrich Schlagenhaufer observed that one gland 
was enlarged in this disease, thus proposed that this was the primary event causing 
the bone disease. Having that in mind, the suggested treatment would be 
parathyroidectomy. The first parathyroidectomy to treat a bone disease, was 
performed ten years later (1925) in Vienna, by Felix Mandl. His patient was a 38-year 
old man, called Albert Jahne who at the age of 34 developed leg pain and fatigue. At 
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36 he had osteopenia and cysts in his X-rays. He developed a femur fracture about a 
year later. Mandl found high serum and urine calcium and tried to treat him with 
parathyroid extract and parathyroid tissue transplant. This worsened the patient’s 
symptoms, so Mandl decided to operate. A parathyroid tumour was removed and the 
operation resulted in the reversal of the bone changes. The patient had a recurrence 
seven years later and died of renal failure.  Within the next few years, several surgeons 
treated their hyperparathyroid patients with surgery. The most famous case of PHPT 
was that of captain Martell (Figure 1-11). His disease was presented by Fuller Albright, 
a person that devoted his life in the study of parathyroid diseases. The patient was 
operated twice in 1926 without success. A few years later (1932), Edward Churchill 
and Oliver Cope opened the chest of the captain after his request and managed to 
find a gland there. The captain died of renal failure a few weeks after the operation 
(Dorairajan & Pradeep, 2014; Eknoyan, 1995; Kafetzis et al, 2011). 
 
Figure 1-11: Captain Martell, the most famous patient with PHPT 
 
Classical hyperparathyroidism, described as a disorder affecting “stones and bones” 
and having “abdominal groans and psychic moans”, included symptomatic 
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hypercalcaemia (nausea, vomiting, polyuria, constipation, anorexia, 
electrocardiogram findings like short QT, coma) and involvement of the skeleton 
(osteitis fibrosa cystica) and the kidney (recurrent kidney stones and 
nephrocalcinosis). Symptoms and signs from other organs and systems could also be 
present: cardiovascular (arrhythmias, left ventricular hypertrophy, hypertension, 
atherosclerosis and valve calcification), gastrointestinal (peptic ulcer, pancreatitis), 
muscular (muscle weakness) and psychiatric (anxiety, psychosis, apathy, irritability) 
(Bandeira & Bilezikian, 2016).  The classic radiological findings included salt and 
pepper degranulation of the skull, subperiosteal bone resorption, distal clavicle 
tapering, bone cysts and brown tumours (Silva et al, 2018). 
 
1.2.2 Asymptomatic primary hyperparathyroidism: the second era 
During the last decades, asymptomatic PHPT has been the main clinical phenotype, 
mainly because of the more frequent laboratory investigations and hence, earlier 
diagnosis. The reported prevalence of PHPT varies in the literature and is reported to 
be 0.89% in the United States and 1.07% in Europe. It affects women more than men 
(approximately 4:1 ratio) and the disease usually presents after menopause (Khan et 
al, 2017; Silva et al, 2018).  
 
1.2.2.1 Aetiology 
Single parathyroid adenoma is identified in about 80-85% of patients. Four gland 
hyperplasia is diagnosed in about 15-20% of PHPT patients and can occur 
sporadically or in the clinical set of genetic syndromes. Parathyroid carcinoma is rare 
(<1%) (Silverberg, 2013).  Factors associated with developing PHPT include low 
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calcium intake, low physical activity, higher body weight, hypertension, furosemide 
use, external radiation to the neck and use of lithium (Silva et al, 2018).  
In most patients, PHPT presents as a sporadic disease (in 90-95% of cases). Although  
hereditary forms are not so common, they are important to consider when PHPT is 
diagnosed in young ages, when there is a family history of hypercalcaemia, when there 
are other tumours associated with syndromes or when there is multiglandular disease 
(Bandeira & Bilezikian, 2016; Khan et al, 2017). These forms can be seen in Table 
1-2. 
Disorder Gene/ protein Clinical presentation 
Multiple Endocrine neoplasia 
(MEN) type 1 
 
MEN1 (menin) 
Autosomal dominant 
PHPT 95% 
Endocrine pancreatic tumours  
Pituitary adenomas  
Other: adrenocorticoid or 
carcinoid tumours, lipomas, 
collagenomas, cutaneous 
angiofibromas 
MEN2 
 
RET 
Autosomal dominant 
PHPT 20% 
Medullary thyroid carcinomas 
Pheochromocytomas 
MEN4 
 
CDKN1B  
Autosomal dominant 
PHPT 80% 
Pituitary tumours 
Endocrine pancreatic tumours  
Other: adrenal, gonadal, 
thyroid and renal tumours 
 
HPT-JT (hyperparathyroid jaw-
tumour syndrome) 
 
CDC73 (parafibromin) 
Autosomal dominant 
PHPT but high prevalence of 
carcinoma (15%) 
Fibromas of mandible and 
maxilla 
Renal and uterine tumours 
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FIHP (familial isolated 
hyperparathyroidism) 
MEN1 (menin), CDC73 
(parafibromin), CASR, GCM2, 
CDKN1B (p21), CDKN2B 
(p15), CDKN2C (p18) 
Autosomal dominant 
Isolated PHPT 
NSHPT (neonatal severe 
primary hyperparathyroidism) 
CASR 
Autosomal dominant or 
recessive 
Neonatal PHPT 
Non-syndromic PHPT 
(nsPHPT) 
PTH  
Table 1-2: Hereditary forms of primary hyperparathyroidism.  
Adapted from original (Eastell et al, 2014; Silva et al, 2018). CDC73: cell division cycle 73; CDKN: 
cyclin-dependent kinase inhibitor; RET: rearranged during transfection proto-oncogene 
 
1.2.2.2 Clinical presentation 
Primary hyperparathyroidism mainly affects the kidneys and the skeleton. The most 
common renal feature observed now in patients with the asymptomatic form is 
nephrolithiasis, present in about 7-20% approximately. Other consequences of renal 
involvement are nephrocalcinosis and reduced kidney function (Khan et al, 2017).  
An accelerated bone loss can also be observed, especially at the distal 1/3 radius 
which is mainly formed by cortical bone. This can be seen in everyday practice by 
measuring the bone mineral density (BMD). The spine, which is mainly a trabecular 
site, is more preserved (Silverberg et al, 2014). PHPT patients appear to have an 
increased risk of fractures, especially vertebral (Khan et al, 2017) 
These patients could also present with neurocognitive features, like anxiety, poor 
concentration and reduced quality of life. Moreover, even with the asymptomatic form, 
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endothelial dysfunction, left ventricular hypertrophy and vascular calcification can be 
present resulting in increased risk of cardiovascular mortality (Silva et al, 2018).  
 
1.2.2.3 Diagnosis 
As mentioned above, PHPT is presented with elevated levels of calcium and PTH. 
Another laboratory abnormality that can be observed is low-normal serum 
phosphorus; low levels can be observed in approximately one third of patients. 
Alkaline phosphatase (ALP), a bone formation marker, can be elevated or at the upper 
range of normal. Hypercalciuria can also be present in one third of patients. Elevated 
1,25(OH)2D levels can also be seen in 25% of patients, and they are usually 
accompanied by low normal 25(OH)D levels (Silverberg, 2013). The assessment of 
PHPT should include laboratory measurements [calcium, PTH, phosphate, ALP, renal 
function, 25(OH)D, 24-hour urine collection for calcium and creatinine], BMD 
measurement including the forearm and vertebral spine assessment. In case of high 
urine calcium, a stone profile should also be assessed and abdominal imaging to 
assess for renal stones should be performed (NICE, 2019; Silva et al, 2018). 
 
1.2.2.4 Management  
The management of asymptomatic PHPT has been revised over the last years and 
the patients need to meet any of the following criteria described in Table 1-3 to be 
advised for surgery. Surgery is also indicated in patients for whom medical 
surveillance is neither desired nor possible. The patient’s choice for surgery is also an 
indication, as long as there are no medical contraindications (Bilezikian et al, 2014).  
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Surgery can have really high cure rates (95%) when performed by an experienced 
surgeon (Khan et al, 2017). 
 
  1990  2002  2008  2013  
Serum calcium 
(>upper limit of 
normal)  
1–1.6 mg/dL 
(0.25–0.4 
mmol/L)  
1.0 mg/dL  
(0.25 mmol/L)  
1.0 mg/dL  
(0.25 mmol/L)  
1.0 mg/dL  
(0.25 mmol/L)  
Skeletal  BMD by DXA:  
Z-score <−2.0 
(site 
unspecified)  
BMD by DXA:  
T-score <−2.5 
at any site 
BMD by DXA:  
T-score <−2.5 
at any site 
A. BMD by DXA:  
T-score < −2.5 at 
lumbar spine, total hip, 
femoral neck, or distal 
1/3 radius  
      Previous 
fragility fracture  
B. Vertebral fracture by x-
ray, CT, MRI, or VFA  
Renal  A. eGFR 
reduced by 
>30% from 
expected  
A. eGFR 
reduced by 
>30% from 
expected  
A. eGFR < 60 
ml/min  
 
A. Creatinine clearance 
<60 ml/min  
 
 B. 24-h urine 
for calcium 
>400 mg/d (>10 
mmol/d)  
B. 24-h urine 
for calcium 
>400 mg/d 
(>10 mmol/d)  
B. 24-h urine for 
calcium not 
recommended  
B. 24-h urine for calcium 
>400 mg/d (>10 mmol/d) 
and increased stone risk 
by biochemical stone risk 
analysis 
    C. Presence of 
nephrolithiasis or 
nephrocalcinosis by x-ray, 
ultrasound, or CT  
Age, years <50  <50  <50  <50  
 
Table 1-3: Guidelines for surgery in asymptomatic PHPT: a comparison of current recommendations 
with previous ones.  
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(Adapted from Bilezikian et al, Guidelines for the Management of Asymptomatic Primary 
Hyperparathyroidism: Summary Statement from the Fourth International Workshop, The Journal of 
Clinical Endocrinology & Metabolism. By permission of Oxford University Press) 
 
Preoperative localisation is used to identify patients for minimally invasive 
parathyroidectomy (MIP) and when recurrence or persistence is suspected after 
surgery. The main imaging techniques used are either technetium-99m-sestamibi or 
parathyroid gland ultrasound. Computerised tomography (CT) and magnetic 
resonance imaging (MRI) are mainly used to detect ectopic parathyroid tissue 
(Silverberg, 2013).  
The medical management of PHPT includes bisphosphonates, mainly alendronate, 
and the calcimimetic drug cinacalcet. Bisphosphonates aim at improving the BMD 
without affecting calcium levels. Cinacalcet on the other hand, does not affect the 
BMD, but can lower the calcium back to normal in many patients, and can result in a 
modest reduction of PTH (Bilezikian et al, 2014). The National Institute for Health and 
Care Excellence (NICE) suggests cinacalcet for patients where surgery is not an 
option and when their calcium is above 2.85 mmol/L with symptoms of hypercalcaemia 
or above 3.0 mmol/L regardless of symptoms (NICE, 2019). Nutritional advice should 
also be given in these patients, including adequacy of calcium intake and vitamin D 
supplementation in patients who are deficient (Silva et al, 2018). 
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1.2.2.5 Monitoring  
Monitoring of this disease in patients who do not have surgery, also changed over the 
years. The different recommendations are summarised in Table 1-4. If the individual 
develops any indications for surgery during monitoring, then parathyroidectomy should 
be the next step (Bilezikian et al, 2014). 
 
Measurement  1990  2002  2008  2013  
Serum 
calcium  
Biannually  Biannually  Annually  Annually  
Skeletal  DXA, annually 
(forearm)  
DXA, annually (3 
sites)  
DXA, every 1–2y 
(3 sites) 
Every 1–2 y (3 sites) 
X-ray or VFA of 
spine if clinically 
indicated  
Renal  eGFR, 
annually; 
serum 
creatinine, 
annually  
eGFR, not 
recommended; 
serum creatinine, 
annually  
eGFR, not 
recommended; 
serum creatinine, 
annually  
eGFR, annually; 
serum creatinine, 
annually 
If renal stones 
suspected, 24-h 
biochemical stone 
profile, renal imaging 
by x-ray, ultrasound, 
or CT  
Table 1-4: Guidelines for monitoring patients with asymptomatic PHPT who do not undergo parathyroid 
surgery: a comparison of current recommendations with previous ones.  
(Adapted from Bilezikian et al, Guidelines for the Management of Asymptomatic Primary 
Hyperparathyroidism: Summary Statement from the Fourth International Workshop, The Journal of 
Clinical Endocrinology & Metabolism. By permission of Oxford University Press) 
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1.2.2.6 Natural history 
In patients who do not have surgery, biochemical abnormalities can remain stable over 
the first 15 years, with calcium gradually starting to increase after the thirteenth year. 
BMD also remains stable for a few years and begins to decrease after the first eight 
years (Rubin et al, 2008). 
Surgery results in the correction of biochemical measurements, improvements in BMD 
and lower rates of vertebral fractures. The risk of renal stones also decreases, but 
remains higher than that of the general population. Moreover, surgery prevents further 
decreases in the kidney function. Some studies have shown that cognitive symptoms 
could have an improvement (Khan et al, 2017).  
 
1.2.2.7 Differential diagnosis  
There is another disorder of calcium metabolism also causing high levels of PTH, 
called familial hypocalciuric hypercalcaemia (FHH) and it is crucial to distinguish PHPT 
from it, because the latter can be treated with surgery, while patients with FHH do not 
require parathyroidectomy. FHH is an autosomal dominant disorder, characterised by 
lifelong, non-worsening hypercalcaemia, accompanied by hypocalciuria and, in 10-
15% patients, high PTH values. There are three forms of this disorder, FHH type 1, 2 
and 3. FHH 1 (approximately 65% of the patients with FHH), is caused by loss-of-
function mutations of CaSR; as a result, higher concentrations of calcium are needed 
in order to suppress the PTH release (Hannan & Thakker, 2013). FHH2 is caused by 
loss-of-function of the G-protein subunit a11 (encoded by the GNA11 gene, located 
on chromosome 19p13.3), which takes part in the CaSR signalling (Nesbit et al, 
2013a). Finally, FHH3 is caused by adaptor protein-2 sigma subunit (AP2σ2) 
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mutations (gene AP2S1, chromosome 19q13.3), a component involved in the 
endocytosis of G-protein coupled receptors, and thus affecting CaSR levels on the cell 
surface (Nesbit et al, 2013b). 
In everyday practice, PHPT and FHH are distinguished using the 24-h urine calcium 
to creatinine clearance ratio (CCCR):  
CCCR= [24h urine Ca x serum creatinine] ÷ [serum Ca x 24h urine creatinine] 
A cut off of <0.01 is used to identify FHH patients, while a value >0.02 is suggestive 
of PHPT. This technique has some limitations, since according to a study a few years 
ago, the cut point of <0.01 only identifies 65% of patients with FHH, and misclassifies 
4% of patients with PHPT. Not all patients with PHPT have hypercalciuria with a CCCR 
of >0.02; that is because they either have a mild disease or vitamin D deficiency. This 
paper suggests a two-step procedure, with a cut off value of 0.02; this would identify 
98% of the FHH patients and misclassify 35% of PHPT. The second step should 
include genetic studies (Christensen et al, 2008). 
More recently, a new tool was developed, called Pro-FHH. The authors suggested the 
use of this tool to predict whether a patient has PHPT. In order to develop this tool, 
they used participants from two prospective cohorts, one in Paris, France and one in 
Aarhus, Denmark. Using these patients, they developed the following equation: 
 
MBR: Marker of bone remodelling (osteocalcin or ALP). For PTH and MBR, they used 
the ratio of measured value to upper limit of normal due to various analytical methods 
used throughout the study.  
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The area under the curve (AUC) for Pro-FHH was significantly higher (0.961) than that 
of 24h-CCCR (0.862) and using pro-FHH would had prevented unnecessary surgery 
in 2 patients out of 100 with FHH and unnecessary genetic testing in 21 out of 140 
patients with PHPT. Although this method looks really promising to be used in 
everyday practice, its disadvantage is that it has only been tested in a population with 
normal PTH, because only 20% of FHH patients have high PTH (Bertocchio et al, 
2018).
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1.2.3 Normocalcaemic hyperparathyroidism: the third era? 
As mentioned above, a specific phenotype of asymptomatic PHPT, called 
normocalcaemic hyperparathyroidism (NPHPT) was recognised in one of the last 
workshops on asymptomatic PHPT (Silverberg et al, 2009). It had been described by 
several researchers since the 1960s and was characterised by normocalcaemia with 
elevated PTH levels as described below.  
In everyday practice, NPHPT is usually diagnosed during the evaluation of secondary 
osteoporosis and thus, mainly found in referral centres. Until now, there are limited 
data on the prevalence, causes, clinical presentation, natural history and 
consequences of this disease. 
 
1.2.3.1 Definition 
NPHPT is characterised by persistent normal calcium levels, accompanied by 
elevated levels of PTH on at least two consecutive measurements over a three to six-
month-period (Eastell et al, 2014). It is important to have both the total and ionised 
calcium within the normal range, since cases of PHPT with normal total, but increased 
ionised calcium levels, have been reported (Wade et al, 2012). Other factors that 
cause high levels of PTH have to be excluded. These are:  
• medications known to affect PTH levels (diuretics, lithium, denosumab, 
bisphosphonates, anticonvulsants) 
• vitamin D insufficiency with 25(OH)D<50nmol/L (although levels >75nmol/L 
would be more desirable for the diagnosis) 
• chronic kidney disease (eGFR <60 ml/min/1.73m2) 
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• diseases of the gastrointestinal tract known to affect calcium absorption 
(coeliac disease, inflammatory bowel disease, bariatric surgery)  
• renal calcium loss (hypercalciuria), defined by calcium excretion greater than 
300mg/day in men, >250mg/day in women, or >4mg/kg body weight in either 
gender 
(Eastell et al, 2009; Eastell et al, 2014; Yacobi-Bach et al, 2015) 
As mentioned above, medications known to affect PTH levels have to be excluded 
when investigating NPHPT. During the Third International Workshop on Asymptomatic 
Primary Hyperparathyroidism, loop acting diuretics (furosemide) were included as a 
cause of secondary elevation of PTH (Eastell et al, 2009). On the contrary, the 
definition at the Fourth Workshop, included thiazides and not furosemide (Eastell et 
al, 2014). Sometime later,  there was another publication in the same journal, 
commenting the definition used at this workshop and reviewing the literature on the 
effects of both thiazides and loop acting diuretics on PTH in humans; the authors 
suggested the removal of thiazides from the list of medications causing secondary 
hyperparathyroidism, since their effect on PTH has not been proven in humans 
(Yacobi-Bach et al, 2015).  
Loop diuretics have been proven to increase PTH. In a study with postmenopausal 
women treated for at least two years with loop diuretics, treatment increased urinary 
calcium by 17% and PTH by 28% when compared to controls (Rejnmark et al, 2005). 
This result was consistent in a previous trial with a shorter duration of treatment (seven 
days). In the same trial, women treated with thiazides showed a non-significant 
increase of PTH and a significant increase of calcium reabsorption (Rejnmark et al, 
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2001). In another randomised, double-blinded trial of thiazides in subjects aged 60–
79 years, no changes were found in the PTH levels (Ott et al, 2008).  
Another topic of controversy, is the cut-off for vitamin D. In the UK, both the National 
Osteoporosis Society and the National Institute for Health and Care Excellence (NICE) 
recommend a cut-off of 50nmol/L to define sufficiency (Aspray et al, 2014; NICE, 
2018).  
 
1.2.3.2 Initial assessment for NPHPT 
When a patient with normal calcium and high PTH is identified, the albumin-adjusted 
calcium should be calculated, ideally with an equation based on the local patient 
population. Ionised calcium would be appropriate to measure in the setting of really 
low albumin, where adjusted calcium could be unreliable. Vitamin D status should be 
assessed by using 25(OH)D and supplemented if low. Kidney function should also be 
assessed to exclude patients with CKD. A detailed history and medical examination 
should also be performed to assess poor calcium intake, causes of malabsorption and 
medication use (as defined above). Only if the above named causes of secondary 
hyperparathyroidism are excluded, can the diagnosis of NPHPT be made (Crowley & 
Gittoes, 2016) 
 
1.2.3.3 Pathophysiology 
1.2.3.3.1 Theory: NPHPT is the first phase of a biphasic disease course 
There have been limited theories on the pathophysiology of this disease. It has been 
proposed that it is the first phase of a biphasic disease course, which can be followed 
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by hypercalcaemic hyperparathyroidism (Figure 1-12). The study suggesting this 
theory, recruited 22 patients from a referral centre with normal adjusted calcium and 
high PTH, confirmed on at least two occasions. Ionised calcium was measured in eight 
patients and it was normal. All the patients had 25(OH)D>20 ng/ml and the exclusion 
criteria were FHH, liver disease, renal disease, urinary calcium> 8.75 mmol/24h, 
gastrointestinal disease with malabsorption, metabolic bone disease, medications 
(lithium, thiazide, oestrogens, loop diuretics, bisphosphonates, anticonvulsants). The 
patients were referred due to osteoporosis (n=10), vertebral fracture (n=1) and kidney 
stone (n=3). The rest were self-referred. Four patients had mild hypercalciuria, seven 
had elevated levels of 1,25 dihydroxyvitamin D and phosphate was low in one patient. 
The researchers reported a positive relation between serum calcium and PTH (i.e. as 
calcium goes up, PTH goes up). This is a difference from the general population, 
where this relationship is inverse. The researchers conclude that NPHPT patients 
have abnormal PTH secretory dynamics (Silverberg & Bilezikian, 2003).  
These patients were then followed for up to twelve months and three of them 
developed hypercalcaemia. These patients had higher PTH levels. One of them was 
operated and had two adenomas removed. After this finding of subsequent 
hypercalcaemia, they formed their assumption about the biphasic course (Silverberg 
& Bilezikian, 2003).  
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Figure 1-12: Proposed model for a biphasic disease course of primary hyperparathyroidism 
Adapted form of the original (Silverberg & Bilezikian, 2003) 
 
1.2.3.3.2 Theory: NPHPT is caused by a lower hypersecretion of PTH than in PHPT 
This theory has been inconsistent between the different studies, with some supporting 
this finding (Castrillon et al, 2015; Diaz-Soto et al, 2015; Marques et al, 2011; Maruani 
et al, 2003; Siprova et al, 2016) and some contradicting it (Amaral et al, 2012; 
Koumakis et al, 2013; Tuna et al, 2015). More details for these studies can be seen in 
the table on the skeletal findings of NPHPT in the Appendix. 
 
1.2.3.3.3 Theory: NPHPT is caused by PTH resistance 
In a publication by Maruani and colleagues, it is proposed that NPHPT is caused by 
both kidney and bone resistance to PTH (target organs), as approximately 20% of the 
patients with elevated PTH, maintained a normal calcium level despite the similar level 
of PTH (Maruani et al, 2003).  
The researchers retrospectively identified patients being diagnosed as primary 
hyperparathyroidism in their department (Department of Physiology in Paris) from 
1990 to 1998. They identified 649 patients and then excluded 471 of them because 
of: 25(OH)D <15 nmol/L, magnesium deficiency (<0.71 mmol/L),  impaired renal 
function (defined as a plasma creatinine value higher than 110 μmol/L or a creatinine 
clearance lower than 50 ml/min per 1.73m2), medications interacting with bone and 
mineral metabolism (bisphosphonates, lithium, loop diuretics or thiazides, 
corticosteroids), an associated disease (such as a progressive endocrine disorder, 
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neoplasia, or granulomatosis), or because they did not follow a low-calcium diet on 
the day before the investigation (Maruani et al, 2003). It is worth mentioning at this 
point, that the definition they used is not absolutely consistent with the one mentioned 
in the previous section.  
The rest of the patients (178) were divided into two groups. Thirty-four (34) patients 
with normocalcaemia (based on fasting iCa≤1.35 mmol/L) were compared to a group 
of hypercalcaemic patients (mean age 55 and 53 respectively). In 27 out of the 144 
patients with high ionised calcium (1.36-1.86 mmol/L), the total serum calcium was 
normal. The NPHPT patients were referred because of nephrolithiasis (35%), 
hypercalciuria (18%), radiographic bone demineralization (18%), discovery of a 
parathyroid tumour during ultrasonography and high serum PTH level value (21%), 
chondrocalcinosis (6%), and hypophosphatemia (9%) (Maruani et al, 2003).  
The researchers identified that patients with normal calcium levels had lower PTH 
levels than hypercalcaemic patients, but their values overlapped (75±19 vs 93±49 
pg/ml respectively, P<0.001). Their urinary calcium excretion was also significantly 
lower than the hypercalcaemic and so was their 1,25 dihydroxyvitamin D. Out of the 
178 patients, 94 were operated because they fulfilled the 1990 guidelines mentioned 
above. Out of them, 21 were NPHPT and 73 were PHPT. The NPHPT patients had a 
smaller size of the removed gland than the hypercalcaemic (Maruani et al, 2003).  
An oral calcium load test was performed in almost all patients to study several 
determinants of iCa levels. The test was not performed in patients with iCa >1.60 
mmol/L. The patients were consuming food free from dairy products and were also 
given calcium-free water on the day before the test and were then fasted overnight. 
On the day of the test, they were given sufficient water to produce adequate urine 
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samples. An oral load of 1gr of elemental calcium was given, together with milk, after 
doing a 2-hour baseline urine test. Urine collected 90 minutes after this was discarded 
and a repeat 2-hour urine test was performed later. Halfway through the test, a blood 
measurement was performed without a tourniquet. Both the PHPT and NPHPT 
patients who had the test, showed an increase in ionised calcium with a slight (24% 
and 25% respectively) decrease of their PTH (Maruani et al, 2003). 
As mentioned before, there was an overlap in the subjects’ PTH values at baseline, 
which suggested that a given level of rise in PTH could induce hypercalcaemia in some 
patients but not all. In order to try and give an answer to this question, the researchers 
matched the 34 normocalcaemic with an equal number of hypercalcaemic patients. 
The matching was based on their age (within 5 years), sex and PTH levels (within 10 
pg/ml). During this study, the researchers found a lower urine calcium excretion 
(fasting urinary calcium/creatinine) and a lower index of tubular calcium reabsorption 
(TRCa/GFR) in NPHPT than PHPT patients, which, nevertheless, was still higher than 
the one calculated in normal subjects. They also found lower markers of bone turnover 
(osteocalcin and fasting deoxypyridinoline), lower 1,25(OH)D synthesis and higher 
values of renal phosphate threshold in the patients with NPHPT, findings consistent 
with both kidney and bone PTH resistance (Maruani et al, 2003). 
Conclusively, this study showed that the maintenance of normal calcium in these 
patients can be partly explained by the lower PTH values. This was supported by the 
fact that the parathyroid tumour mass was lower in these patients. Another explanation 
could be the fact that NPHPT is the first form of this disease, as mentioned above. 
However, this was not supported by this study, as the diagnosis was made in a similar 
age, and although these patients were followed up to 76 months, no-one became 
hypercalcaemic. The problem was that not all the patients had higher levels of PTH, 
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as these levels overlapped between the two groups. Therefore, there has to be a 
different explanation for the presentation. The researchers found milder PTH-induced 
bone effects in these patients (net bone release assessed by UCa/UCr and lower bone 
turnover markers) and milder PTH-renal effects (normocalcaemic patients had lower 
ability to reabsorb calcium, lower ability to decrease phosphate reabsorption and lower 
ability to synthesize calcitriol). One explanation for this resistance was thought to be 
the presence of the N-terminally truncated PTH fragment, which could antagonise the 
effect of PTH if it would be higher in the normocalcaemic patients. However, the 
nephrogenous cAMP secretion was similar in the two matched groups, indicating that 
the amount of serum bioactive 1– 84 PTH was the same. Another argument, was that 
other molecules rather than just PTH could be affecting the calcium handling, like 
sodium levels, acid-base balance and magnesium concentrations. However, the levels 
of urinary sodium excretion, pH, bicarbonate and serum magnesium were similar. 
Another possible explanation for this presentation, was thought to be a difference in 
vitamin D levels (vitamin D deficiency in the normocalcaemic patients). However, the 
levels of 25(OH)D were similar between the groups (Maruani et al, 2003).  
In this study, body mass index (BMI) was higher in the NPHPT group and that could 
explain a higher oestrogen production and therefore a degree of resistance to the 
effects of PTH. Unfortunately, oestrogen levels were not measured in this study. 
Previous studies showed that oestrogen can protect the bones from PTH-induced 
calcium absorption and that, by giving oestrogen to PHPT patients, the serum and 
urinary calcium and the bone turnover markers can be reduced. Therefore, the 
researchers of the above-mentioned study, argued that normocalcaemic patients may 
unmask their hypercalcaemia after menopause, due to the oestrogen deficiency 
observed then. Some women with a sufficient endogenous production of oestrogen 
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after menopause may remain normocalcaemic (Maruani et al, 2003). The problem with 
this hypothesis is the fact that NPHPT is mainly seen in postmenopausal oestrogen-
deficient women (Cusano et al, 2013b).  
Based on the hypothesis that NPHPT can be caused by PTH resistance, and the fact 
that the single nucleotide polymorphism (SNP) rs17251221 (A986S) in the CaSR has 
been linked to PTH resistance, researchers in Spain recently investigated the effect of 
this SNP to NPHPT patients. They recruited and prospectively studied 61 consecutive 
patients with NPHPT and asymptomatic PHPT from their Endocrinology and Nutrition 
Service (for NPHPT, n=41, 83% female, mean age 63 years; for PHPT, n=20, 80% 
female, mean age 66 years). These patients had a follow up of one year to check for 
the persistence of their laboratory investigations on at least two occasions. They 
checked ionised calcium levels in their patients and they also used the following 
exclusion criteria for all their patients: eGFR<60 ml/min, 25(OH)D<30 ng/ml, FHH, 
hypercalciuria (>250mg/24h in females and >300mg/24h in men), other metabolic 
diseases and medications (thiazides, bisphosphonates, lithium). All the women were 
postmenopausal. There were significantly higher levels of PTH,  and bone turnover 
markers in the PHPT group and lower levels of 25(OH)D, serum phosphate, 
magnesium and phosphate tubular reabsorption. Their BMD results were similar. 
There were 38 patients (62.3%, n=24 NPHPT and n=14 PHPT) with the wild type 
genotype A986A, and 23 (36.7%, n=17 NPHPT and n=6 PHPT) S allele carriers (n=20 
A986S or n=3 S986S) (Diaz-Soto et al, 2015).  
Seventeen NPHPT patients were S allele carriers. In these patients, the S allele was 
associated with significant higher levels of serum intact PTH (P=0.024) when 
compared with the wild type ones. No other comparison reached significant difference. 
On the contrary, the S allele PHPT patients, were older, had lower PTH, ALP and 
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PINP values (p<0.05).  After adjusting for factors like vitamin D, calcium, albumin, 
phosphate and GFR, the association of PTH with the genotype remained significant 
for the NPHPT group. All the other predictors were not significant. This was not found 
in PHPT patients, in which only serum calcium was independently predicting the PTH 
level and not the genotype. Therefore, PTH levels might be regulated by the S 
genotype in NPHPT, which could be acting as a resistance factor (Diaz-Soto et al, 
2015).  
The underlying pathology of this disease seems to be similar to PHPT. A few studies 
report that multiglandular disease is more common in NPHPT (Koumakis et al, 2013) 
but not all reach statistical significance (Gómez-Ramírez et al, 2019; Kiriakopoulos et 
al, 2018). Most studies report that the average adenoma weight was lower in the 
NPHPT group compared to the PHPT group of patients (Kiriakopoulos et al, 2018; 
Koumakis et al, 2013; Maruani et al, 2003). 
 
1.2.3.4 Prevalence 
Due to the different definitions and methodologies used in publications on NPHPT, it 
is difficult to draw conclusions on the prevalence of this disease. The problem is that 
not all causes of secondary hyperparathyroidism were always excluded, thus the 
reported prevalence may be overestimated. Moreover, some of these studies did not 
test the persistence of the high PTH and normal calcium levels before evaluating the 
epidemiology. Finally, these reports include different age/gender specific populations. 
The prevalence of the disease in the literature varies between 0.1 and 8.9% 
(Pawlowska & Cusano, 2015) (Figure 1-13).  
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Figure 1-13: Prevalence of normocalcaemic hyperparathyroidism according to different publications 
The issue of how the different definitions affect the prevalence reported, is specifically 
stressed in a recent publication. In this study, the researchers prospectively recruited 
adults ≥18 years who would be submitted to thyroidectomy due to nodular disease. 
They excluded patients who had an ultrasound due to PHPT, patients with a history of 
nephrolithiasis, nephrocalcinosis and pathological fracture, personal or family history 
of multiple endocrine neoplasia or diagnosis of medullary thyroid cancer. Their total 
cohort was 676 patients. Then, they estimated the prevalence of NPHPT based on the 
following criteria: normal adjusted and ionised calcium and high PTH, confirmed at two 
measurements, 25(OH)D ≥ 20 ng/dl, eGFR ≥ 40 ml/min/1.73m2. They excluded people 
on diuretics, lithium, bisphosphonates, denosumab, recombinant PTH, 
corticosteroids, patients with primary aldosteronism, suspicion or known diagnosis of 
malabsorption, hyperphosphatemia, calcium/urinary creatine ratio ≥ 0.25, or thyroid 
dysfunction. They also screened for coeliac disease and excluded patients with 
positive antibodies. They found 46 (6.8%) patients with NPHPT. However, out of them 
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only 8.7% had altered parathyroid glands  (adenoma) during bilateral gland exploration 
(0.6% of the cohort). They then calculated the prevalence based on different criteria 
on vitamin D deficiency  and kidney function. They first used cut-offs of 20 ng/dl and 
60 ml/min/1.73m2 respectively. In this occasion, the prevalence was 4.4%, with 
confirmed pathology in 13.3%. When the cut-offs were 30 ng/dl and 40 ml/min/1.73m2, 
the prevalence was 1.8%, with confirmed pathology of 33.3%. Finally, when using 30 
ng/dl and 60 ml/min/1.73m2, the prevalence was 0.74%,  with confirmed pathology of 
80% (Rosário & Calsolari, 2019).  
In summary, NPHPT seems to be affecting the female gender more, and it is mostly 
observed after menopause, mainly between 60 and 70 years of age (Figure 1-14) 
(Cusano et al, 2013b; Siprova et al, 2016).  
In surgical series, the prevalence on NPHPT amongst the patients that undergo 
parathyroidectomy, varies, and is reported to be approximately 10 to 20% (Gómez-
Ramírez et al, 2019; Lim et al, 2017; Pandian et al, 2019; Pierreux et al, 2018; Sho et 
al, 2019; Yu et al, 2019). 
More details on the prevalence are given in the subsequent chapter on NPHPT. 
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Figure 1-14: Age and gender distribution in a study of patients with normocalcaemic 
hyperparathyroidism 
Reprinted from Endocrine Practice 2016 Vol 22, Šiprová H, Fryšák Z, Souček M., Primary 
hyperparathyroidism, with a focus on management of the normocalcemic form. To treat or not to treat, 
Pages 294-301, Copyright 2016, with permission from the American Association of Clinical 
Endocrinologists 
 
1.2.3.5 Clinical presentation 
NPHPT is usually encountered during the evaluation of secondary osteoporosis and 
has been linked to consequences known to affect patients with primary 
hyperparathyroidism (accelerated bone loss, kidney stones, higher levels of blood 
pressure, higher levels of fasting glucose and higher pre-existing glucose intolerance), 
but there is no clear evidence of a relationship. Data is mainly available from referral 
centres. There are limited studies comparing NPHPT patients to controls and the 
definition of NPHPT is not always the same in these studies. These results are 
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summarised below, but they should be treated with caution. More details can be seen 
in the tables in the Appendix. 
 
1.2.3.5.1 Effects on skeleton and kidneys 
Lowe et al identified 37 (95% female) NPHPT patients (although iCa was not identified 
for all), that were referred to the Metabolic Bone Disease Unit at Columbia University 
Medical Centre between 1998 and 2005. The presenting symptom in 57% of them was 
osteoporosis (mainly observed at the spine and hip rather than distal radius), while 
11% had recent fragility fractures and 14% nephrolithiasis. They excluded cases with 
25(OH)D<20 ng/ml, eGFR<40 ml/min/1.73m2, liver disease, hypercalciuria 
>350mg/24h, thiazide or lithium use, metabolic bone diseases (Lowe et al, 2007). The 
problem with this study is that it is not clear whether they excluded patients on 
bisphosphonates or loop acting diuretics and it is not clear whether they checked the 
persistence of their laboratory measurements. The eGFR level was lower than the one 
described in the definition.  
 
Comparing NPHPT to PHPT: A few years after the study described above, a group of 
researchers from an endocrine centre reported an 18.2% prevalence of nephrolithiasis 
and a 15.2% history of fractures in 33 normocalcaemic patients. The frequency of 
these complications was also studied in a group of hypercalcaemic subjects (18.9% 
and 10.8% respectively) and there was no statistically significant difference. The distal 
radius BMD was preserved compared to other sites in the NPHPT group, as reported 
by Lowe et al (Amaral et al, 2012). It is not clear whether persistence was checked.  
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The absence of statistically significant differences in the frequencies of nephrolithiasis, 
osteopenia and osteoporosis between NPHPT and PHPT patients was also confirmed 
in more recent publications (Pierreux et al, 2018; Tuna et al, 2015). Another centre in 
Spain, recruited 26 normocalcaemic and 16 hypercalcaemic patients and there was 
no significant difference in lumbar spine, femoral neck and total hip BMD between the 
two groups. However, they found that vitamin D receptor (VDR) polymorphisms were 
associated with differences in BMD measurement only in NPHPT patients. 
Homozygous NPHPT patients for the rs1544410 GG polymorphism and the rs731236 
TT polymorphism, had lower hip BMD (Castrillon et al, 2015). 
 
When comparing NPHPT patients to controls, as performed by some researchers in 
2011, the prevalence of kidney stones reported in the subjects’ medical files, was 
significantly higher in the normocalcaemic group (28.6% vs 0.7%, P<0.001), while 
there was not a significant difference observed in skeletal abnormalities (Marques et 
al, 2011). Another study showed similar percentages of nephrolithiasis (Temizkan et 
al, 2015). Analysis of the data from the Osteoporotic Fractures in Men Study (MrOS), 
also failed to prove significant differences in lumbar spine and femoral neck BMDs 
between NPHPT patients and controls (Cusano et al, 2013a).   
 
As mentioned before, the majority of the studies were performed in referral centres, 
thus the prevalence of skeletal and renal abnormalities is expected to be higher. Only 
one study has been performed in the normal population. This was a prospective study 
in a cohort of 100 healthy postmenopausal women (age 56±3 years). NPHPT was 
defined as normal adjusted calcium and high PTH, with 25(OH)D>30 ng/ml, normal 
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renal function (creatinine clearance>70 ml/min/1.73m2). In total 6 participants (6%) 
were identified. The bone turnover markers and bone mass assessed by quantitative 
ultrasound were normal (Garcia-Martin et al, 2012). 
 
1.2.3.5.2 Cardiovascular risk factors 
1.2.3.5.2.1 Glucose and lipid metabolism 
The first study identifying possible cardiovascular risks in NPHPT was published in 
2006; the researchers compared 30 postmenopausal women having both normal 
calcium and high PTH (study group) with 30 age-matched controls with similar levels 
of exercise and smoking. Higher levels of fasting glucose and a worse lipid profile 
(lower HDL, higher VLDL and triglycerides, higher LDL/HDL ratio) was observed in the 
study group. However, one of the main limitations of this study was the absence of 
vitamin D measurement (Hagstrom et al, 2006). 
A few years later, the glucose metabolism of NPHPT patients and controls was 
evaluated in three case-control studies using an OGTT test and the homeostatic model 
assessment for insulin resistance (HOMA-IR). There was no statistically significant 
difference between the two groups (Cakir et al, 2012; Tassone et al, 2013; Temizkan 
et al, 2015). Moreover, the prevalence of DM and IGT was not significantly different 
between them (Tassone et al, 2013). Two of these studies also evaluated lipid levels 
and found no statistically significant difference (Cakir et al, 2012; Temizkan et al, 
2015).  
More recent publications though performed in Turkey, started to question these 
findings again. One study found higher levels of fasting glucose and higher pre-
existing glucose intolerance (IGT/DM) in NPHPT patients compared to controls. These 
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levels were similar when comparing normocalcaemic and hypercalcaemic 
hyperparathyroid patients. Moreover, a positive correlation of both calcium and PTH 
to fasting insulin and HOMA-IR was identified. There was no statistically significant 
difference in lipid levels, although there was a higher usage of antilipidemics in the 
hyperparathyroid groups compared to controls. PTH was positively correlated to 
triglyceride levels (Yener Ozturk et al, 2015).  
A more recent one found the prevalence of diabetes, dyslipidaemia, hypertension and 
insulin resistance to be similarly increased in the PHPT and NPHPT groups (p > 0.05) 
compared with the controls (p < 0.05). Moreover, glucose metabolism (glucose, 
insulin, HOMA-IR) and lipid profiles (total cholesterol, LDL, triglycerides) were similarly 
increased in the PHPT and NPHPT groups (p > 0.05) compared with the controls (p < 
0.05). The levels of smoking and obesity were similar (Beysel et al, 2019). 
Finally, one publication identified higher low-density lipoprotein (LDL) levels to a group 
of 23 patients (87% females, aged 54±11.4 years) compared to hypercalcaemic 
patients. These patients also had higher TSH values and that could explain the 
difference in LDL (Tuna et al, 2015). 
 
1.2.3.5.2.2 Blood pressure and other cardiovascular risks 
Increased systolic and diastolic blood pressure values were found in Chinese NPHPT 
patients when compared to controls matched for age, gender, calcium, BMI, glucose 
and lipid levels. This study’s main limitations were the absence of ionised calcium 
measurement and the fact that the researchers did not evaluate smoking, alcohol 
consumption, physical activity or special diets in their subjects, factors that could affect 
blood pressure levels (Chen et al, 2015). These findings were not confirmed by Yener 
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Ozturk et al, although higher prevalence of pre-existing hypertension and use of anti-
hypertensive drugs was observed in the NPHPT and PHPT groups compared to 
controls (Yener Ozturk et al, 2015). Absence of any statistically significant differences 
in blood pressure levels between NPHPT and age and BMI-matched controls, was 
reported recently in a separate centre in Turkey (Temizkan et al, 2015).  
Similar prevalence of hypertension between NPHPT and PHPT groups, was observed 
in three further studies (Beysel et al, 2019; Tordjman et al, 2010; Tuna et al, 2015). In 
one of these studies, the levels of both systolic and diastolic blood pressure in PHPT 
and NPHPT were statistically higher than in controls (Beysel et al, 2019).  In another 
study, NPHPT patients were found to have lower incidence of ischemic heart disease 
(IHD) and/or cerebrovascular accidents (CVA) compared to hypercalcaemic ones. 
Moreover, this study evaluated some non-invasive arterial stiffness parameters and 
found no differences between the 3 groups (NPHPT, PHPT, controls) (Tordjman et al, 
2010).  
 
1.2.3.5.3 Other features 
The authors of a recent study on NPHPT, reported that patients with this disorder have 
less frequent symptoms (fatigue, indigestion, mood disorders, musculoskeletal pain) 
than PHPT ones (23.5% vs 71%, P<0.001). Furthermore, 76% of the 187 patients 
studied, had another endocrine disorder, mainly originating in the thyroid (Siprova et 
al, 2016). 
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1.2.3.6 Natural history 
The problem with the study of the natural history of this disease, is that the persistence 
of the laboratory abnormalities is not always tested at baseline, and so the result of 
subsequent hypercalcaemia on follow-up should be treated with caution. The results 
from different studies performed on the natural history of calcium, can be seen in the 
subsequent chapter on NPHPT. 
After a follow-up of 3.1±0.3 years, Lowe et al identified a patient with a new presenting 
kidney stone, one with a fracture and 11% with new developed osteoporosis. Two 
patients developed marked hypercalciuria (≥400mg/24h). Moreover, BMD decreased 
more than 5% at one or more skeletal sites in 43% of the patients and more than 10% 
in 20% , with the hip and forearm being the more severely affected. The magnitude of 
BMD change did not correlate with the PTH levels (Lowe et al, 2007).  
When studying the natural history of calcium, seven patients (19%) developed 
hypercalcaemia.  None of the patients that became hypercalcaemic met the criterion 
of surgery for elevation of calcium more than 1 mg/dl above the normal range. The 
patients who became hypercalcaemic were older and had higher serum and urine 
calcium at baseline (Lowe et al, 2007). Progression to hypercalcaemia was also 
confirmed in some patients in other studies. Higher calcium levels at baseline were 
considered to predict progression to hypercalcaemia in one of these studies (19% 
progression). Lower phosphate level was also a predictive factor (Siprova et al, 2016). 
Silverberg et al found hypercalcaemia in three patients (14%) after one year of follow 
up; these patients had higher PTH levels compared to the ones that remained 
normocalcaemic. The patients of this study had confirmed persistence of laboratory 
results at baseline (Silverberg & Bilezikian, 2003).  
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On the other hand, there are several publications failing to prove a progression to 
hypercalcaemia (Ayturk et al, 2006; Garcia-Martin et al, 2012; Hagstrom et al, 2006; 
Tordjman et al, 2004; Tordjman et al, 2010).  
 
1.2.3.7 Management 
1.2.3.7.1 Monitoring 
It has been proposed that calcium and PTH should be tested every year, while a BMD 
check should be performed every 1-2 years.  If there is a progression to 
hypercalcaemia, patients should be treated according to the guidelines on 
asymptomatic primary hyperparathyroidism. If calcium remains normal, but an 
accelerated bone loss or a fracture is observed, or if the patient develops a kidney 
stone or nephrocalcinosis, then surgery should be an option (Figure 1-15) (Bilezikian 
et al, 2014).  
 
Figure 1-15: Monitoring of patients with normocalcaemic hyperparathyroidism as advised at the Fourth 
International Workshop on Asymptomatic Primary Hyperparathyroidism 
Figure adapted from the original (Bilezikian et al, 2014) 
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There have been some publications questioning possible treatment effects, using 
either surgical or medical treatments. These are described in the next sections. 
 
1.2.3.7.2 Surgical management 
The number of publications reporting surgical outcomes on NPHPT have increased 
dramatically over the last few years. The results are summarised here and more 
details can be found in the tables for NPHPT in the Appendix. 
 
1.2.3.7.2.1 Results 
1.2.3.7.2.1.1 Effect on the skeletal and kidney abnormalities 
One study evaluated 413 consecutive patients referred to a Metabolic Bone Centre in 
Paris between 2008-2010. Amongst them, 193 had PHPT and 220 had secondary 
hyperparathyroidism. They looked at the data of 168 patients that had 
parathyroidectomy by the same surgeon and then excluded any patients that had no 
BMD follow up (n=98), patients that had hypercalcaemia after surgery (n=11) and had 
normal parathyroid at the histological analysis (n=2). In total, they studied 60 patients 
and divided them into two groups:  39 were in the normocalcaemic group and 21 were 
in the hypercalcaemic one. The diagnosis of PHPT was based on elevated or 
inappropriately normal PTH with increased adjusted calcium or ionised calcium. 
NPHPT was defined as normal adjusted calcium and high PTH, after excluding causes 
of secondary hyperparathyroidism like: 25(OH)D<20 ng/ml, renal impairment 
(GFR<40 ml/min/1.73m2), bisphosphonate, thiazides, anticonvulsants, lithium, 
gastrointestinal diseases related to malabsorption and liver disease. In those with 
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hypercalciuria, a thiazide diuretic test was performed. An oral calcium load test was 
performed in all the patients and NPHPT was defined as total calcium and/or ionised 
calcium increasing to supranormal values with only a minimal reduction in PTH. 
Patients that did not have an increase of more than 1.42 mmol/L of ionised calcium, 
were also given a 20-minute infusion of 2mg/kg elemental calcium (Koumakis et al, 
2013). 
 In the normocalcaemic group (only 41% had normal iCa), there was a significant 
increase of the BMD both at the spine and hip (+2.3±5.0%, P=0.016 and +1.9±5.7%, 
P=0.048 respectively) compared to baseline. Similar increases were seen in the PHPT 
group. The only difference was a drop in the distal 1/3 of radius BMD in the NPHPT 
group (-1.5±3.5%, P=0.02). On the contrary, BMD remained stable in the radius in the 
PHPT group. This study reported that there were more cases of multiple adenomas 
and hyperplasia in the normocalcaemic group compared to the hypercalcaemic one 
(P=0.04). The weight of the adenomas was also lower (Koumakis et al, 2013). 
Due to the fact that this study identified a significant decrease in the BMD measured 
at the distal 1/3 of radius in NPHPT patients, the researchers conducted a further study 
on the same group of patients, in order to evaluate the benefit of surgery in an 
individual patient. They only included 36 of the patients that had BMDs at all sites of 
interest and considered BMD gain significant for an individual patient if it was ≥0.030 
g/cm2 at any site, without any loss of BMD of ≥0.030 g/cm2 at another site during the 
same period of time. A year after the recruitment, 44.4% normocalcaemic patients had 
an individual BMD gain in at least one site (spine, hip, forearm), without any loss at 
any other site, compared to 73.7% in the hypercalcaemic ones (p=0.049). There was 
no difference statistically when comparing the gain between the patients with normal 
or elevated ionised calcium within the normocalcaemic group. Pre-surgery level of 
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ALP above the median was identified as a predictive factor of BMD gain after the 
surgery. The researchers conclude by saying that the short-term decrease in BMD at 
the radius does not reflect the global change in BMD and that surgery should be an 
option to these patients (Koumakis et al, 2014). 
Promising results after surgery also come from another study performed a few years 
later. In this study, all patients that had a parathyroidectomy in a single centre between 
2006 and 2016 were evaluated. They only included patients with post-surgery 
biochemical data available more than six months after surgery. They also had data on 
some patients on BMD results performed more than two years after surgery. In total, 
they included 71 patients with NPHPT, defined as normal calcium and high PTH (only 
patients with peak calcium within the reference range within one year prior to surgery). 
They excluded patients with 25(OH)D<20 nmol/L and eGFR<60 ml/min/1.73m2. They 
found that persistently elevated PTH was common, occurring in 46.5% of patients after 
surgery. BMD results (spine, hip, femur neck) were available to 38 of them, showing 
a BMD improvement of 5.6% (p < 0.01) in patients with normal PTH after surgery. No 
significant change was observed in patients with persistently elevated PTH after 
surgery (- 2.2%, p = 0.47) (Sho et al, 2019). At this point, it has to be pointed out that 
some of the patients had 25(OH)D<20 nmol/L, so probably not all causes of secondary 
hyperparathyroidism were excluded.  
In terms of kidney effects, one recent study followed up patients for 72.9 ± 46.8 months 
after surgery. Ten patients with prior kidney stones had a follow up. Four patients 
(40%) had no evidence of kidney stones. One patient had persistence of microlithiasis 
without symptoms. The rest had stable results (Traini et al, 2018).  
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1.2.3.7.2.1.2 Effect on the cardiovascular abnormalities 
As far as the effect of surgery on metabolic abnormalities is concerned, no conclusions 
can be made from the current literature. A publication in 2006, showed that patients 
had an improvement of their lipid profile (total and LDL cholesterol, LDL/HDL ratio) 
after surgery, but also reported an increase of glucose and urate. The specific study 
though, did not evaluate vitamin D levels (Hagstrom et al, 2006). More recently, a 
publication from Turkey showed a  reduction in both systolic and diastolic blood 
pressure, total cholesterol and HOMA-IR in NPHPT and PHPT patients six months 
after parathyroidectomy. The cardiovascular risk score also decreased (Beysel et al, 
2019). 
 
1.2.3.7.2.1.3 Other effects  
Recently, there was a study published investigating the effect of parathyroidectomy 
on cognitive function in patients with NPHPT followed up at Columbia University in 
New York; there was no improvement observed six months after surgery (Liu et al, 
2019). 
The cure rate is reported to be similar in the PHPT and NPHPT group (97.53% vs 
91.43% respectively, p=0.108). The incidence of temporary hypocalcaemia also 
seems to be similar (Yu et al, 2019). One group reported a percentage of 2% of 
permanent hypocalcaemia (Traini et al, 2018). 
In terms of normalisation of postoperative PTH, a recent study showed that 
persistently elevated PTH was common, occurring in 46.5% of patients after surgery. 
This increase was found at a median time of 7.7 months. Preoperative PTH levels 
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>100 pg/ml were related to persistently elevated levels after surgery, However, this 
study only excluded patients based on 25(OH)D<20 nmol/L (Sho et al, 2019). In the 
study by Koumakis et al, three months after surgery, 21% of the operated NPHPT 
patients had elevated PTH levels but these were found to be related to vitamin D 
deficiency and were normalised after supplementation (Koumakis et al, 2013). Another 
group divided the patients to the ones having normal ionised calcium prior to surgery 
and the ones having high. Amongst the group with normal ionised calcium, 25% still 
had elevated PTH after surgery compared to 8% with elevated ionised calcium; the 
difference was not statistically significant (Wade et al, 2012).  
 
1.2.3.7.2.2 Histology 
The underlying pathology of this disease seems to be similar to PHPT. A few studies 
report that multiglandular disease is more common in NPHPT (Koumakis et al, 2013; 
Lim et al, 2017; Pandian et al, 2019; Traini et al, 2018) but not all reach statistical 
significance (Gómez-Ramírez et al, 2019; Kiriakopoulos et al, 2018; Yu et al, 2019). 
This means, that NPHPT patients are be more likely to have bilateral exploration (53.9 
vs 44.2%, in the PHPT group,  p < 0.05) (Traini et al, 2018).  
According to one of these studies, patients with NPHPT were over eight times as likely 
to have multiglandular disease (odds ratio 8.17, 95% confidence interval 4.49 to 14.83) 
(Lim et al, 2017). However, the criteria used for NPHPT were unclear in this study, but 
it seems that they included patients with eGFR<60 ml/min/1.73m2, lithium use and/or 
25(OH)D<30 ng/ml in the NPHPT group, which could theoretically explain the findings. 
The study by Pandian et al also included patients with low vitamin D, and did not have 
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data on kidney function, so probably several of these patients had secondary 
hyperparathyroidism (Pandian et al, 2019).  
Most studies report that the average adenoma weight was lower in the NPHPT group 
compared to the PHPT group of patients (Kiriakopoulos et al, 2018; Koumakis et al, 
2013; Maruani et al, 2003). To my knowledge, no study has reported parathyroid 
cancer in NPHPT.  
 
1.2.3.7.2.3 Presurgical assessment: issues to be considered 
1.2.3.7.2.3.1 Ionised calcium 
A recent publication from a surgical department in Wisconsin, mentions the 
importance of measuring ionised calcium before surgery. The authors of this 
manuscript retrospectively evaluated records from 771 patients who had 
parathyroidectomy between 1999 and 2008 and defined NPHPT as patients having 
normal calcium levels during the three months prior to surgery. Patients with recurrent, 
familial, secondary or tertiary hyperparathyroidism were excluded, although the criteria 
for exclusions are not clear. Out of these patients, 93 (12%) had normal total calcium 
and 58 of them also had available ionised calcium. Amongst these, 50 (86%) had 
elevated ionised calcium and only eight (14%) had both total and ionised calcium 
within the normal range. When comparing the two last groups (elevated and normal 
ionised calcium), there was no difference in age and gender. The prevalence of 
nephrolithiasis (24% vs 24% respectively), osteoporosis (18% vs 25%), bone fracture 
(12% vs 13%) were similar (p>0.05). The levels of PTH, 24-urine calcium and vitamin 
D were also similar (Wade et al, 2012). At this point, it has to be pointed out that some 
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of the patients had 25(OH)D<20 nmol/L, so probably not all causes of secondary 
hyperparathyroidism were excluded.  
The results of the surgery did not differ between the groups (similar number of single 
gland and multiple gland disease, similar gland weight) and the intraoperative PTH 
measurement was successful in the same number of patients. After a median follow 
up of 13 months, patients from both groups had similar levels of total and ionised 
calcium, however, there was a significantly higher level of PTH in the normal ionised 
calcium group (Wade et al, 2012).  
The importance of ionised calcium was also mentioned in a more recent publication, 
where 104 patients (77.0% female, mean age 60.5) were enrolled after being referred 
for parathyroidectomy between 2015 and 2017 in an Endocrine Surgery department 
in Madrid. When considering adjusted calcium levels, 45 (43.3%) were classified as 
NPHPT. When assessing ionised calcium, 64% of the patients who were initially 
classified as NPHPT had high ionised calcium levels, leaving only 16 to study further 
in the NPHPT group (Gómez-Ramírez et al, 2019). 
 
1.2.3.7.2.3.2 Free 25(OH)D 
Another issue that came up recently was the fact that NPHPT patients seem to have 
lower free 25(OH)D than healthy controls and thus may actually have secondary 
hyperparathyroidism. This study recruited 10 NPHPT patients based on the following 
criteria: normal calcium level, elevated PTH and 25(OH)D 30-40 ng/ml, having normal 
liver and renal function. They excluded alcoholics or chronic smokers, people on 
medications like contraceptive pills, proton pump inhibitors, diuretics, or any 
medications that affect calcium or bone metabolism, and patients with evidence of 
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bone disease in the past year. At the same time, they included 20 age, sex, and BMI-
matched subjects with normal PTH in their control group. All subjects were on vitamin 
D supplements (400 IU). Although the levels of 25(OH)D were similar between the 
groups, the free 25(OH)D levels were 20% lower in the NPHPT group (p < 0.05). PTH 
was inversely correlated with free 25(OH)D but not with total 25(OH)D (Wang et al, 
2019).  
 
1.2.3.7.2.4 Preoperative localisation 
The localisation of the parathyroid pathology was reported to be different in NPHPT 
and PHPT patients by a study in Czech Republic. NPHPT patients who ultimately 
evolved to hypercalcaemia had an adenoma identified in 4% of the cases when they 
were at their normocalcaemic state, while an adenoma was identified in 73% of the 
cases when they were in their hypercalcaemic state (p=0.001) (Siprova et al, 2016).  
Both sestamibi and neck ultrasound were found to underperform in NPHPT compared 
to PHPT in a study in Madrid, but the difference was not statistically significant (Tc-
sestamibi: sensitivity in PHPT 81% vs 56.2% in NPHPT; ultrasound sensitivity in PHPT 
50.6% vs 31.2% in NPHPT) (Gómez-Ramírez et al, 2019). A recent analysis showed 
that there is a higher probability of accordance between the two imaging techniques 
the higher adenoma size and lower accordance in multigland disease, although the 
difference was not statistically significant for the second comparison (Kiriakopoulos et 
al, 2018).  
The fact that NPHPT has been reported to be correlated to multigland disease, could 
complicate the localisation imaging studies. In one study, both the sestamibi and 
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ultrasound together, failed in detecting all the diseased glands in 85.0% NPHPT 
patients and in 79.5% PHPT (Traini et al, 2018). 
A recent study in Brazil evaluated 18 patients with surgically proven PHPT and a 
histological diagnosis of adenoma. Eight had NPHPT (mean age 55.1 ±14.4 years, 
83% female). They all underwent three preoperative imaging techniques [ultrasound, 
Tc-99-sestamibi scintigraphy and 4-dimensional computed tomography (4D CT)]. The 
sensitivity of all the techniques was lower for the NPHPT group compared to the PHPT 
group. Four-dimensional computed tomography performed better for NPHPT. The 
results were as follows: ultrasound 22% vs 58.3%, scintigraphy 11.1% vs 75%, and 4-
dimensional computed tomography 55.6% vs 75% (Cunha-Bezerra et al, 2018). 
PET/CT with 18F-Fluorocholine (18F-FCH) also seems to be having positive results 
in NPHPT patients. Researchers in Italy enrolled 34 consecutive patients with PHPT 
and amongst them, 7 had NPHPT. The detection rates in NPHPT and PHPT were 57 
and 70% for ultrasound respectively, 70 and 71% for 18F-FCH-PET/CT, and 0% and 
18% for sestamibi (Bossert et al, 2019).  
 
1.2.3.7.3 Pharmacological management 
There are limited data on the medical approach of NPHPT. A prospective open label 
randomized study was published recently, evaluating possible pharmacological 
treatment for NPHPT, using a combination of weekly oral alendronate (70mg) and 
colecalciferol (2800IU) in 15 NPHPT postmenopausal women (treatment group) and 
comparing them to the same number of patients treated only with colecalciferol 
(control group).  The inclusion criteria were: postmenopausal status of more than five 
years, osteoporosis, high PTH or in the upper third of the reference range and normal 
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adjusted calcium, normal vitD (≥30 ng/ml). The researchers excluded patients with 
secondary hyperparathyroidism, concurrent systematic illness, thyroid disease, 
hepatic or renal dysfunction, disorders known to influence BMD, medication use 
(bisphosphonate, oestrogen, vitamin D or calcium supplements, drugs to interfere with 
bone metabolism during the last 12 months), reported family or personal history of 
recurrent kidney stone disease (Cesareo et al, 2015). Ionised calcium was not 
included in the definition criteria and it is not clear if the researchers looked for 
persistence. 
The two groups had no differences at baseline in terms of PTH, calcium, phosphate, 
vitD, osteocalcin, CTX and 24h urine calcium. After one year of treatment, there was 
a significant BMD increase in the treatment group, mainly observed at the lumbar 
spine (mean increase 4.7%) than the hip (mean increase 4%). On the other hand, 
there was a significant decrease of the BMD at all sites in the control group. The radius 
BMD was not evaluated. Moreover, there was a significant decrease in bone turnover 
markers (osteocalcin and urinary CTX) in the treatment group observed after 3 months 
of treatment; the values remained reduced when retested at 6 months (not tested at 
12 months). The two groups did not show any statistically significant differences in 
serum and urinary calcium levels when tested at 3-month intervals, thus indicating that 
it was safe to treat with vitamin D (Cesareo et al, 2015). The results of this study are 
not really surprising. Giving alendronate would increase BMD in all older women with 
osteoporosis, not just with NPHPT. Including a control group with osteoporosis but 
without NPHPT would had been more helpful. 
There was another prospective randomized pilot study published in 2014, testing the 
effect of cinacalcet in normocalcaemic (n=6) and hypercalcaemic (n=4) 
hyperparathyroid patients with active kidney stone disease (≥2 stones in the past 2 
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years). The normocalcaemic patients were defined based on their consistently high 
PTH, after excluding causes of secondary hyperparathyroidism like 25(OH)D < 20 
ng/ml, eGFR<50 ml/min, medication (thiazide, lithium), gastrointestinal disorders 
related with malabsorption, idiopathic hypercalciuria (>300 mg/24h in men, >250 
mg/24h in women or greater than 4mg/kg of body weight for both genders, in the 
absence of other causes of hypercalciuria). For patients  with a urinary calcium of 
>4mg/kg of body weight, they performed a thiazide test; they treated the patients for 
three months with a thiazide diuretic like hydrochlorothiazide 12.5 mg twice a day and 
observed that in these patients, PTH remained high and even elevated further despite 
the decrease in urinary calcium and the elevation of the serum calcium. This confirmed 
that hypercalciuria was not the cause of the elevated PTH (Brardi et al, 2015).  
The included patients were treated with either potassium citrate and allopurinol, or 
cinacalcet for 10 months (dose titrated to lower PTH to normal limits and maintain 
normal calcium). At the same time, they followed the same dietary (normal calcium 
intake (800-1000mg daily) and hydration instructions (> 2 litres). By the end of the 
treatment period, there was a reduction in the number and diameter of the stones in 
patients treated with cinacalcet, both in the normocalcaemic and hypercalcaemic 
group (Brardi et al, 2015). The small number of patients included in this study is a 
major limitation; it is difficult to draw conclusions. 
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1.2.4 Hypoparathyroidism 
On the other side of the spectrum of calcium related disorders, hypoparathyroidism is 
a rare disorder, characterised by low levels of calcium due to a low PTH secretion. 
Hypoparathyroidism was characterised as an orphan disease by the European 
Commission in January 2014 (Bollerslev et al, 2015). 
 
1.2.4.1 Aetiology and prevalence  
The most common cause is acquired hypoparathyroidism, mainly seen after anterior 
neck surgery resulting in the damage of the parathyroid glands (approximately 75% of 
cases). Chronic hypoparathyroidism after surgery, is defined as the one persistent six 
months postoperatively. In general, surgery can cause permanent hypoparathyroidism 
in 0.12 to 4.6% of cases (Bollerslev et al, 2015; Brandi et al, 2016).  
Another cause is autoimmune hypoparathyroidism, which can be isolated or part of a 
polyglandular syndrome. Destruction of the parathyroids can also occur after radiation 
or infiltration by neoplastic or granulomatous tissue. Primary causes are rarer, and 
include several inherited syndromes summarised in Table 1-5 (Bollerslev et al, 2015; 
Brandi et al, 2016).  
There are not many reports available regarding the prevalence of this disease and 
most of them use hospitalisation codes to identify patients, and so the prevalence is 
probably underestimated. The prevalence of this disorder was studied by a group in 
Denmark. They used data from the National Hospital Patient Registry in order to 
identify patients with non-surgical hypoparathyroidism. Using discharge codes, they 
identified 180 patients diagnosed with non-surgical hypoparathyroidism between 1997 
and 2012 (prevalence 2.3/100000 inhabitants) (Underbjerg et al, 2015). Post-surgical 
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hypoparathyroidism had a prevalence of 22/100000 inhabitants (Underbjerg et al, 
2013). Similar estimates come from the United States (Clarke et al, 2016). 
 
1.2.4.2 Diagnosis 
Hypoparathyroidism is characterised by undetectable or inappropriately low PTH 
along with hypocalcaemia (measured by albumin-adjusted calcium and ideally ionised 
calcium), confirmed on at least two occasions at least two weeks apart. Phosphate 
can be in the upper normal or elevated. Usually, 1,25-dihydroxyvitamin D and bone 
markers are low. Generally, urinary calcium is expected to be high, but due to the 
filtered calcium load being lower than normal, urinary excretion might be normal, 
especially before treatment. During the evaluation for hypoparathyroidism, 
magnesium also has to be assessed to exclude deficiency (Brandi et al, 2016). The 
renal function also has to be evaluated.  
 
1.2.4.3 Clinical manifestations 
The symptoms depend on whether hypocalcaemia developed acutely or not and on 
the absolute levels of calcium in the blood. In cases of surgery, where acute 
hypocalcaemia is often seen, dramatic symptoms can be present like seizures, 
laryngospasm, acute cardiomyopathy and heart failure due to decreased contractility 
(Abate & Clarke, 2016). Chronic hypocalcaemia on the other hand can be mild with 
non-specific symptoms and can result in multiple organ dysfunction with neurological, 
muscular and cardiac manifestations. Low calcium in combination with high 
phosphate, can result in high calcium-phosphate product, and can cause to soft tissue 
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calcifications (basal ganglia, stones and nephrocalcinosis, joints, eyes, skin, 
vasculature) (Brandi et al, 2016). 
Classical clinical signs of hypoparathyroidism are Chvostek’s sign (induction of  facial 
muscle spasm by tapping the parotid gland over the facial nerve) and Trousseau’s 
sign (inflation of a blood pressure cuff around the arm to greater than the systolic 
pressure, can cause carpopedal spasm) (Cooper & Gittoes, 2008). 
Hypoparathyroidism is characterised by reduced bone turnover and increased bone 
mass, although whether this has an effect on fracture risk is really unknown (Abate & 
Clarke, 2016; Brandi et al, 2016). These patients when treated often become 
hypercalciuric and are at risk of renal calcium deposition (Brandi et al, 2016). A 
common complication in this disorder is renal insufficiency (41%). Mitchell et al 
reported stage 3-5 chronic kidney disease to be 2-to-17-fold greater compared to 
normal controls with 31% of the patients that had imaging, having renal calcifications 
(Mitchell et al, 2012). 
Hypoparathyroidism was found to affect quality of life, with patients reporting 
symptoms of “brain fog”, fatigue and higher incidence of psychiatric disorders like 
anxiety and depression (Abate & Clarke, 2016). In a study performed in Norway, they 
invited the patients to participate in the study by completing a questionnaire, and they 
found worse scores on the Short Form 36 (SF-36) and the Hospital Anxiety and 
Depression Scale (HADS) when compared to the normative population (Astor et al, 
2016).  
Other manifestations include increased risk of subcapsular cataract, cardiac 
arrhythmias and basal ganglia calcifications (reported in 52% of those imaged). The 
hospitalisation rates are also high (33%) (Mitchell et al, 2012).  
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The complications were recently described by a group in Denmark and surgical and 
non-surgical forms were distinguished. They compared the hypoparathyroidism 
patients identified, with a group of gender and year of birth controls to assess mortality 
and morbidity.  In the non-surgical ones, the mortality was not found to be increased 
but, the patients were found to have increased risk for renal insufficiency (HR 6.01), 
cardiovascular disease (HR 1.91), seizures (HR 10.05), cataract (HR 4.21), 
neuropsychiatric diseases (HR 2.45), fractures in the upper extremities (HR 1.93) and 
infections (HR 194). They also showed that the patients had reduced risk of 
malignancy compared to controls (HR 0.44) (Underbjerg et al, 2015). In the patients 
with postsurgical hypoparathyroidism, they found increased risk of renal complications 
(HR 3.67), hospitalisation due to infections (HR 1.42) or seizures (HR 3.82) and an 
increased risk of depression and/or bipolar affective disorders (HR 1.99). There was 
not an increased risk of cardiovascular diseases or death and the risk of 
gastrointestinal cancers was lower (HR 1.99). The risk of cataract or any fracture was 
not increased, whereas the risk of fractures of the upper extremities was reduced (HR 
0.69) (Underbjerg et al, 2013; 2014). 
 
1.2.4.4 Treatment 
1.2.4.4.1 Acute hypocalcaemia 
This is a medical emergency and has to be treated. In general, calcium gluconate is 
preferred, because calcium chloride can cause local irritation when given 
intravenously. One or two 10 ml ampoules of 10% calcium gluconate, diluted in 50-
100 ml of 5% dextrose, should be slowly infused over 10 minutes. If persistent, ten 10 
ml ampoules of 10% calcium gluconate diluted in one litre of 5% dextrose or 0.9% 
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saline can be given at a rate of 50 ml/hour and adjusted accordingly. This should 
increase the calcium by 0.3-0.5 mmol/L over four to six hours (Cooper & Gittoes, 
2008). In general, postsurgical hypocalcaemia can be managed with oral 
supplements. 
 
1.2.4.4.2 Chronic hypocalcaemia 
1.2.4.4.2.1 Conventional therapy  
Treatment should be given to patients with adjusted calcium <2.0 mmol/L and to 
symptomatic patients with calcium between 2.0 mmol/L and the lower limit of the 
range. The goal of treatment is to prevent signs and symptoms of low calcium, to 
maintain calcium slightly above normal or slightly below the lower limit of normal and 
to avoid hypercalciuria. The serum calcium–phosphate product should be below 4.4 
mmol2/L2. Dietary phosphate should be decreased (Bollerslev et al, 2015; Brandi et al, 
2016). 
Calcium carbonate is the most common form of calcium given (contains 40% 
elemental calcium). However, it needs an acidic environment in the stomach in order 
to be absorbed. Therefore, calcium citrate  (20% elemental calcium) can be used in 
patients with achlorhydria, proton pump inhibitor use or constipation caused by 
calcium carbonate. Calcium should be used in 2 to 4 divided doses (Abate & Clarke, 
2016).  
Because of the impaired conversion of 25(OH)D to its active form, the active analogue 
of vitamin D (calcitriol) is used for treatment. Usually the dose varies between 0.25 
and 2μg daily. Alphacalcidol can also be used alternatively (0.5-4.0 μg/day). Any 
changes in the dose should be adjusted every four to seven days. Patients should also 
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be given supplementation with ergocalciferol or colecalciferol (400-800 IU) because 
that can enhance the action of vitamin D. Vitamin D deficiency was associated with 
myopathy and neuromuscular complains (Abate & Clarke, 2016; Bollerslev et al, 2015; 
Cooper & Gittoes, 2008).  
Thiazide diuretics along with low salt diet can also be used in cases with 
hypercalciuria, since they reduce the urine calcium. Patients on this treatment should 
be monitored for hypokalaemia and hypomagnesemia. Magnesium supplementation 
should also be given in patients with low magnesium. Phosphate diets and phosphate 
binders are considered in cases where phosphate is extremely high (>6.5mg/dL) 
(Bollerslev et al, 2015; Brandi et al, 2016). 
 
1.2.4.4.2.2 PTH treatment 
Recently (in 2015), the use of PTH (1-84) has been approved by the American Food 
and Drug Administration (FDA) for the treatment of patients with hypoparathyroidism, 
excluding the ones with autosomal dominant hypocalcaemia (ADH). Treatment should 
be considered in patients with not well controlled serum calcium, taking large doses of 
calcium or vitamin D supplementation (>2.5g calcium or >1.5μg calcitriol or >3.0μg of 
alphacalcidol), having renal complications (hypercalciuria, stone risk, nephrolithiasis, 
nephrocalcinosis, eGFR<60 ml/min/1.73m2), having high phosphate or high calcium 
phosphate product (>55mg2/dL2 or 4.4 mmol2/L2). Moreover, malabsorption and 
reduced quality of life are also indications. The treatment should start by giving 50μg 
daily sc and a 50% reduction to the active form of vitamin D should be performed. The 
goal is to reduce the use of calcitriol, decrease the dose of calcium to 500mg daily and 
maintain serum calcium at the low-normal levels (Brandi et al, 2016). 
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1.2.4.5 Monitoring  
Calcium, phosphate, magnesium and eGFR should monitored every three to six 
months. Twenty four hour urine collections for calcium and creatinine should be 
repeated yearly along with a GFR estimation. If there is a history of nephrolithiasis or 
nephrocalcinosis, renal imaging should be performed every five years in asymptomatic 
patients. Follow up should be done more frequently if symptoms develop. There are 
no guidelines regarding the testing on basal ganglia calcifications. Follow up of 
cataract will depend on baseline findings. BMD is not routinely measured (Bollerslev 
et al, 2015; Brandi et al, 2016). 
Chapter 1: Introduction 
Section 2:Parathyroid gland disorders  
 
 131 
Disorder Gene; chromosomal abnormality 
Inheritance 
Phenotype 
Syndromic forms 
Autoimmune polyglandular 
syndrome type I (APS I) 
AIRE (autoimmune regulator 1), 
chromosome 21q22.3 
Sporadic, AR 
Hypoparathyroidism, adrenal insufficiency, 
mucutaneous candidiasis. Other endocrinopathies: 
hypogonadism, diabetes mellitus type 1, 
hypothyroidism. Non-endocrine disorders: 
pernicious anaemia, vitiligo, alopecia 
DiGeorge/CATCH-22 TBX1 (T-box 1); Microdeletions in 
22q11 
AD 
Cardiac abnormality, abnormal facies, thymic 
hypoplasia (impaired T cell immunity and 
infections), cleft palate, hypocalcaemia 
(hypoparathyroidism 60%), with deletion in 
chromosome 22 
CHARGE CHD7 (chromodomain helicase DNA-
binding protein 7); 8q12.1–q12.2, 
7q21.11 
AD 
Coloboma of the eye, heart malformation, choanal 
atresia, retardation of growth and development, 
and genital and ear abnormalities, gonadotropin 
deficiency, anosmia 
Hereditary deafness and renal 
dysplasia syndrome (HDR)  
GATA3 (GATA-binding protein 3); 
10p14 
AD 
Deafness, renal dysplasia 
Kenny-Caffey syndrome 1, 
Sanjad-Sakati syndrome 
TBCE (tubulin specific chaperone E); 
1q42.3 
AD, AR 
Short stature, osteosclerosis, cortical thickening of 
long bones, delayed anterior fontanel closure, 
basal ganglia calcification, hyperopia  
Kenny-Caffey syndrome 2 FAM111A (family with sequence 
similarity 111 member A), 
chromosome 11q12.1 
AR 
  
Dubowich syndrome Unknown 
AR 
Microcephaly, abnormal facies, short stature, 
mental retardation 
Bartter syndrome type 5 CaSR (3q21.1) Hypokalaemia, metabolic alkalosis 
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AD 
Nephropathy, nerve deafness Unknown 
AD 
  
Nerve deafness without renal 
dysplasia 
Unknown 
AD 
  
Kearns-Sayre syndrome Mitochondrial defects 
Maternal 
Muscle defect: ophthalmoplegia, proximal muscle 
weakness, bilateral pigmented retinopathy, cardiac 
conduction abnormality, cerebral ataxia, 
deafness, diabetes mellitus, growth hormone 
deficiency, short stature 
Mitochondrial trifunctional 
protein deficiency syndrome 
(MTPDS) 
Mitochondrial encephalopathy, 
stroke like episodes and lactic 
acidosis (MELAS) 
 
Non-syndromic forms  
Isolated hypoparathyroidism GCM2 (gliad cell missing gene), 
chromosome 6p24.2 
AR 
  
SOX3 (sry related HMG box), Xq26-
q27 
X-linked 
Males with infantile seizures 
PTH, chromosome 11p15 
AD, AR 
  
Autosomal dominant 
hypocalcaemia 1 (ADH) 
CaSR activating mutations; 3q21.1 
AD 
Hypocalcaemia, low PTH, hypercalciuria, low Mg 
ADH2 GNA11 (G protein subunit alpha 11); 
10p13 
AD 
Table 1-5: Inherited causes of hypoparathyroidism.  
Adapted from original (Abate & Clarke, 2016). AD: autosomal dominant, AR: autosomal recessive; PTH: parathyroid hormone; CaSR: calcium-sensing receptor
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1.2.5 Normocalcaemic hypoparathyroidism 
Normocalcaemic hypoparathyroidism (NHYPO), is characterised by normal levels of 
calcium with persistent low levels of parathyroid hormone (PTH). There is little in 
current literature on this disease, with only two studies (reporting three different 
populations) published on its prevalence, whilst its natural history remains relatively 
unknown (Cusano et al, 2013a; Palermo et al, 2015). The prevalence in these studies 
is reported to be 1.1-2.4% at baseline.  Two of these populations were then checked 
six and eight years later and only 0.6% and 0.09% respectively were still characterised 
as having NHYPO. None developed hypocalcaemic hypoparathyroidism. Serum 
calcium and PTH was only checked on two occasions in these studies, so the natural 
history of serum calcium is unclear. To our knowledge, no one has evaluated this 
before. Further information can be found in the relevant chapter on NHYPO. 
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Section 3: Rationale of the study and aims 
As mentioned before, the prevalence of NPHPT in the literature varies considerably. 
The reasons for this variation are that different definitions and methodologies were 
used in the reporting studies; not all causes of secondary hyperparathyroidism were 
excluded, and some studies did not test the persistence of high PTH and normal 
calcium before evaluating the prevalence; thus the results were probably 
overestimated. Moreover, the prevalence has not been studied in a United Kingdom-
only population in the past and the numbers may differ because of vitamin D deficiency 
and different genetic background.  
The data on the natural history of this disease are also sparse and inconclusive.  Some 
studies show progression to hypercalcemia, but others fail to show that. The way that 
many studies identify NPHPT patients, is by testing calcium and PTH at baseline, and 
then they retest the patients after some time to check whether they progressed to 
hypercalcemia. Since the persistence is not always checked at baseline, the result of 
subsequent hypercalcemia should be treated with caution. The variability of calcium 
in NPHPT during the follow-up period has been poorly described.  
According to the proceedings of the Fourth International Workshop on Asymptomatic 
Primary Hyperparathyroidism, NPHPT remains incompletely described, especially 
regarding its epidemiology, natural history and management. The criteria are not clear 
concerning how many measurements are needed to establish a diagnosis, which 
makes the matter complicated for the clinician and confusing for the patient. This study 
aimed to identify the prevalence of NPHPT and study the natural history of this 
disorder in more detail. It also aimed to compare the variability of calcium between 
PHPT and NPHPT patients. 
Chapter 1: Introduction 
Section 3:Rationale of the study and aims 
 
 136 
Normocalcaemic hypoparathyroidism could be the subclinical form of 
hypoparathyroidism. Patients having this disorder might be more prone to developing 
hypocalcaemia after they receive medications that can affect calcium levels (eg 
bisphosphonates, loop diuretics, denosumab). Further information on this disorder are 
needed before any official recommendations are made but NHYPO may have to 
mentioned in any future guidelines on hypoparathyroidism; its pathophysiological 
counterpart, normocalcaemic hyperparathyroidism, is already part of international 
guidelines.  
The primary aims of this study were to identify the prevalence of NHYPO and to study 
the natural history of the disorder. We considered that NHYPO could be a 
consequence of greater changes in serum calcium and PTH over time, so a second 
aim was to compare the variability of adjusted calcium between NHYPO patients and 
a group of normal individuals from the same cohort.  
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1.3.1 Aims 
1.3.1.1 Normocalcaemic hyperparathyroidism 
• To study the prevalence of normocalcaemic hyperparathyroidism by using 
information from a referral centre in the United Kingdom 
• To study the natural history of this disorder over time and identify whether there 
is progression to primary hyperparathyroidism 
• To calculate the within-subject standard deviation of adjusted calcium in this 
group and compare it with the one from patients having primary 
hyperparathyroidism and a group of normal individuals from the same cohort 
 
1.3.1.2 Normocalcaemic hypoparathyroidism 
• To study the prevalence of normocalcaemic hypoparathyroidism by using 
information from a referral centre in the United Kingdom 
• To study the natural history of this disorder over time and identify whether there 
is progression to hypocalcaemic hypoparathyroidism 
• To calculate the within-subject standard deviation of adjusted calcium in this 
group and compare it with the one from patients having hypoparathyroidism 
and a group of normal individuals from the same cohort 
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Section 1: Methods 
2.1.1 Study setting 
In brief, the aims of the following studies were to study the prevalence and natural history of 
two newly described calcium disorders, called normocalcaemic hyperparathyroidism 
(NPHPT) and normocalcaemic hypoparathyroidism (NHYPO) in a metabolic bone centre 
referral population. In order to do that, information on patient data and several laboratory 
measurements, had to be identified.  
Data from patients referred for a bone mineral density (BMD) measurement were 
retrospectively evaluated. All the patients included in the database had to have a laboratory 
evaluation, including calcium and parathyroid hormone, performed within a twenty-eight day 
period from their scan. The day of the laboratory investigations was defined to be the index 
day. More results of calcium and PTH before and after the index day were retrieved from 
hospital records and were used to study the natural history of the disease.   
 
2.1.2 The referral centre: general information 
The study was performed in the Metabolic Bone Centre in Sheffield Teaching Hospitals 
National Health Service Foundation Trust (STH NHS FT). STH NHS Trust was created from 
merging the Central Sheffield University Hospitals and the Northern General Hospital NHS 
Trusts on the 1st April 2001. At the time of the study, part of the Trust were the main two 
adults’ hospitals of Sheffield, the Northern General Hospital (NGH) and the Royal 
Hallamshire Hospital (RHH), as well as the more specialised ones like Jessop Wing 
(obstetric services), Weston Park Hospital (cancer services) and Charles Clifford Dental 
Hospital. 
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At the time of the study, the Metabolic Bone Centre (MBC) was based at the Sorby wing of 
the Northern General Hospital. It was one of the largest of its kind in the UK and provided 
care to South Yorkshire and beyond. The centre offered direct-access fracture risk 
assessment to both general practitioners and hospital consultants and received 
approximately 700 referrals per month for the fracture risk assessment service (FRAS).  
Further management in the metabolic bone clinic was offered for patients with severe 
osteoporosis in whom initial investigations suggested an underlying metabolic bone 
problem. Patients with other metabolic bone diseases including Paget’s disease, 
osteomalacia, and parathyroid bone disease were also assessed in the centre. The 
department was also a tertiary referral centre for less common metabolic bone disorders 
such as fibrous dysplasia, osteogenesis imperfecta and hypophosphataemia and there were 
transition clinics in collaboration with medical practitioners from the Sheffield Children’s 
Hospital to allow smooth transition to the adult services.  
The centre had an active programme of research into the pathogenesis, diagnosis, and 
treatment of osteoporosis and other metabolic bone diseases and it worked closely with the 
Academic Unit of Bone Metabolism (AUBM) of the University of Sheffield. 
 
2.1.3 Data collection  
The extraction of the data was performed by the Medical Imaging and Medical Physics 
department. The hospital had data from 1/12/2011 onwards. All the databases were 
received in Microsoft Excel Software.  
Any extra information was collected using data from the patients’ medical records and 
different systems available on NHS computers:  
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• Fracture risk assessment reports 
• PACS and CRIS (imaging systems) 
• ICE (laboratory and imaging reports). Results were available from 2009 onwards 
• Lorenzo (electronic record for secondary care) 
• Clinical portal (access to primary care clinical information including prescribing details 
in a proportion of patients) 
 
2.1.4 Ethics 
All the patients were assigned a unique study number after the extraction and any data used 
outside NHS computers were pseudo-anonymised.  
The analysis described into the thesis did not require ethics approval; according to the 
Sheffield Teaching Hospitals Clinical Research Office, it fell under the “case note review” 
category.  
 
2.1.5 Fracture Risk Assessment at MBC 
As mentioned above, the Metabolic Bone Centre at STH, provided fracture risk assessment 
to patients referred from both general practitioners and hospital consultants. Reasons for 
referral included the following at the time of the study: 
• Patient with a history of low trauma fracture 
• Patient on, or commencing, systemic glucocorticoid treatment. This included patients 
taking steroids for more than three months or if high dose steroids was initiated 
(prednisolone >15mg) 
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• Osteopenia reported on an X-ray by a radiologist 
• Patients with a disease or medication known to cause osteoporosis (malabsorption, 
inflammatory conditions, cystic fibrosis, endocrine disorders, use of Depo-Provera, 
aromatase inhibitors, androgen deprivation therapy, eating disorders with 
amenorrhea etc) 
• Fracture probability by FRAX indicating need for BMD measurement or treatment 
All patients undergoing fracture risk assessment at the MBC, had BMD measurement of the 
lumbar spine and proximal femur and completed a risk factor questionnaire. From August 
2008 an extended one-stop assessment incorporated Vertebral Fracture Assessment (VFA) 
scans in patients at high risk of vertebral fracture. The indications included: 
• All women over 65 years and men over 70 
• Patients over 50 years but below the above age ranges with 
o Kyphosis 
o Height loss >2cm between scans or >5cm since age 25 
o Corticosteroids 
• Patients in whom the lumbar spine DXA suggested a vertebral fracture 
• Patients with hip fracture 
• Patients with low BMD for age (Z-score < -2.0) 
Spine radiographs were performed if the VFA suggested a vertebral fracture. Finally, 
laboratory investigations were performed to look for underlying causes of osteoporosis when 
clinically indicated. The indications were any of the following: 
• low BMD for age (Z-score < -2.0) 
• confirmed vertebral fracture 
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• unexplained, accelerated bone loss since the previous scan (>4.5% decrease, 
inappropriate for the duration of scans, any weight change and menopausal or 
treatment status). The expected age loss according in postmenopausal women and 
older men is 1%. In the first four to five years after menopause, this can increase to 
2% 
• if a clinical reason had been identified at the point of referral or during the BMD 
assessment (after discussion with clinician) 
The investigations included the following:  
• full blood count, erythrocyte sedimentation rate (ESR) 
• bone profile [calcium, albumin, adjusted calcium, phosphate, total protein, albumin, 
globulin, alkaline phosphatase, creatinine, estimated glomerular filtration rate 
(eGFR)] 
• Gamma-glutamyl transpeptidase (GGT), thyroid stimulating hormone (TSH), 
parathyroid hormone (PTH) 
• Serum and urine electrophoresis 
• Testosterone in men 
• Follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin in women 
with premature menopause before age 40 
• Anti-endomysial antibody 
• 25(OH)D 
All the FRAS studies were assessed and reported by specialised medical practitioners and 
provided recommendations regarding management, follow up and future referrals.  
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2.1.5.1 Bone mineral density measurement  
2.1.5.1.1 Principles 
Dual-energy X-ray absorptiometry (DXA) scanning has been in use since the late 1980s and 
it is the gold standard method for measuring bone mineral density (BMD). The scanners use 
X-rays, which are a type of high energy electromagnetic radiation, with a wavelength of 0.01 
to 10 nm. In DXA the goal is to measure the amount of bone mineral (hydroxyapatite).  
Serial DXA measurements allow the assessment of progression in BMD. However, there 
are several causes of inconsistency or “noise” between scans. These can be due to a 
number of reasons which can be patient, instrument and operator-related. Each centre 
performing DXA measurements should calculate the precision error which is a measurement 
of reproducibility. This is important when comparing BMD results over time; the change in 
BMD observed might be significant or simply a result of the “noise” of the test. The way to 
calculate this is by repeating the test in fifteen patients three times or in thirty patients twice. 
The patients should be similar in age, gender and bone density as the ones usually 
evaluated in the service, so volunteers should be avoided. The scans are usually performed 
on the same day after repositioning the patient. The standard deviation (SD) for each patient 
and the mean SD of the group are then calculated. The precision error is the root mean 
square standard deviation in absolute terms (g/cm2). The least significant change (LSC) is 
the least amount of change in BMD that can be considered as statistically significant. The 
International Society for Clinical Densitometry (ISCD) recommends calculating the LSC for 
a 95% confidence level, which is done by multiplying the precision error by 2.77 
(https://www.iscd.org). 
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2.1.5.1.2 DXA in the assessment of osteoporosis 
DXA is mainly used to scan the spine at a anteroposterior projection (L1-L4) and the hip 
(axial DXA). Two sites are used to increase the diagnostic sensitivity. Peripheral DXA 
measurements like the non-dominant forearm can be performed in certain occasions (for 
example hyperparathyroidism and when hip and/or spine cannot be measured) (ISCD, 
2019). The result is usually expressed in a T-score, which is the difference between the 
patient’s BMD and the mean BMD of healthy young adults matched for gender and ethnicity, 
divided by the young adult population standard deviation (Blake et al, 2013).  
The World Health Organization (WHO) and the International Osteoporosis Foundation (IOF) 
recommend that osteoporosis should be defined on the basis of BMD compared to the Third 
National Health and Nutrition Examination Survey (NHANES III) female reference data for 
all ethnicities and genders. This database has measurements for femoral neck in white 
females aged 20-29 years old. Osteoporosis is defined as a T-score of 2.5 SD or more below 
the female adult mean, osteopenia as T-score <−1.0 and >−2.5 SD and normal as a T-score 
greater or equal to -1.0 SD (Kanis et al, 2008).  
A different way to report DXA scans is by using the Z-score, which is following a similar 
principle to the T-score, but in this case comparing the patient’s BMD with a healthy subject 
matched for gender and ethnicity but also for age and dividing the difference by the age 
matched population SD. Z-scores are the preferred way of reporting in younger people 
(Blake et al, 2013).  
Vertebral Fracture Assessment (VFA) is a technique performed in DXA scanners for 
detecting vertebral fractures. This requires only two images to capture both the thoracic and 
lumbar spine (posteroanterior and lateral views) compared with four images that would be 
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required with conventional radiography. VFA is indicated in patients of high risk of a vertebral 
facture (ISCD, 2019).  
 
2.1.5.1.3 DXA scanning at the Metabolic Bone Centre 
At the time of the study, there were three Hologic DXA scanners within the centre. The LSC 
used in the MBC was 4.5% for the spine and hip.  
There were three scanning rooms in the department and each room had a different scanner. 
At the time of the study, these were the scanners in use:  
• Room A: Hologic Discovery A in use since 2010 
• Room B: Hologic QDR4500A was in use from 2011 until the 11th September 2013.    
The scanner was then decommissioned and replaced by a Hologic Discovery SL 
• Room C: Hologic Delphi C was in use until the 3rd November 2014.  The scanner was 
then decommissioned and replaced by a Hologic Horizon A  
 
2.1.5.1.4 Anthropometric data 
All patients coming for a DXA scan had their height (in centimetres) and weight (in kilograms) 
taken by the technicians (wherever possible) and this was recorded in the scan result. This 
information was retrieved and the body mass index (BMI) was calculated using the following 
equation (recorded in one decimal place) 
BMI (kg/m2) = 10000 * weight (kg)/ [height (cm)] 2  
In some cases, there were extreme BMI values calculated (>100kg/m2). For some of them, 
it was obvious that the height and weight had been reversely recorded in the database, and 
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so they were corrected automatically. For the rest, the next step was to check the form 
completed by the technician on the day of the BMD measurement and correct the data 
accordingly.  
 
2.1.6 Laboratory measurements at Sheffield Teaching Hospitals  
As mentioned above, a laboratory work-up was performed at MBC to check for underlying 
causes of osteoporosis when clinically indicated.  
All the samples were analysed in the chemical laboratory, STH NHS FT. Blood at the MBC 
can be drawn at any time of the day, so patients were not necessarily fasting. Only the 
methods used for the measurements of the different tests described in the thesis are 
summarised here.  
The final analysis only contains measurements performed after January 2013, as the 
laboratory changed the manufacturer to Roche Diagnostics (Roche Diagnostics GmbH, 
Mannheim, Germany) at that point and it was decided that the changes could affect the 
results of the thesis.  However, some of the results of the intermediate analyses included 
measurements performed between 2011 to 2013 and so the methods are briefly described 
below. The information on the laboratory methods performed with Roche analysers was 
obtained from https://dialog1.roche.com/gb/en_gb/eLabDoc. 
 
2.1.6.1 PTH measurement 
Intact PTH (second generation) was measured throughout the whole period using an 
electrochemiluminescence immunoassay (“ECLIA”) by the Roche Cobas 8000 e602 
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analyser (Roche Diagnostics GmbH, Mannheim, Germany). The protocol number where this 
information was obtained from Roche’s website is ms_11972103122V24.0.  
Blood can be collected in a serum or EDTA plasma tube. If collected in serum, the blood 
should be centrifuged due to the short half-life of PTH, so EDTA is preferred as it is stable 
for longer (serum: stable for 8 hours at 15-25 °C, two days at 2-8 °C, six months at -20 °C; 
plasma: stable for two days at 15-25 °C, three days at 2-8 °C, six months at -20 °C) (Roche, 
2019). 
The assay we used was second-generation. The assay employs a sandwich test principle 
which uses two antibodies specific for different epitopes of the antigen (in this case PTH). 
The first antibody is coated on the surface of the well plate and is used to facilitate the 
immobilization of PTH.  The other antibody is used to produce a measurable signal to assist 
with the detection of the antigen. In the case of intact PTH measurement, the N-terminal 
fragment (1-37) reacts with a biotinylated monoclonal antibody (mouse), while the C-terminal 
domain (38-84) reacts with a ruthenium complex labelled monoclonal antibody (mouse). The 
process starts with a first incubation using some of the sample, the biotinylated monoclonal 
PTH-specific antibody and the labelled PTH-specific antibody. These form a sandwich 
complex. During the second incubation, streptavidin-coated microparticles are added and 
the complex becomes bound to the solid phase via interaction of biotin and streptavidin. The 
mixture is aspirated to the measuring cell where the microparticles are magnetically 
captured on the electrode. Any unbound substances are removed. In order to receive a 
measurable result, a voltage is then applied to the electrode and chemiluminescent emission 
is produced which can be measured by a photomultiplier (Roche, 2019). 
In May 2015, the units for PTH were changed from ng/L to pmol/L, without a change in the 
assay. The reason for that was to be in line with the national recommendations for reporting 
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units and the General Practitioner medical records software stopped accepting results in 
ng/L. In order to convert pmol/L to ng/L, the value has to be multiplied by 9.43, while the 
conversion factor from ng/L to pmol/L is 0.106. 
The PTH assay uses two monoclonal mouse antibodies. For people who have pet mice or 
work with mice, there is a risk that they will have human anti-mouse antibodies (HAMA) 
which can potentially interfere in the assay. The effect could be to make the result falsely 
high or low. This would depend on the target of the HAMA (therefore is patient-specific) and 
how this alters the normal binding of the reaction complex. 
 As the assay uses biotin-streptavidin binding, high dose biotin therapy (vitamin B7) has the 
potential to affect the assay. Roche quotes that samples should not be taken from patients 
receiving large doses (>5mg/day) for at least eight hours after they had the supplement.  
Most over the counter supplements have concentrations in the μg range so it is very unlikely 
these will have any influence on the results. Biotin causes a negative interference. This 
means that the patients’ results will be lower than expected. If there is another source of 
biotin in the serum, this can bind to streptavidin in place of the biotin-labelled anti-PTH 
antibody. 
At the time of the study, the interassay coefficient of variation (CV) measured in the 
laboratory was 2.2 – 3.2% at 3.6 pmol/L, 1.6 – 1.7% at 10 pmol/L and 1.4 – 1.8 at 89 pmol/L, 
while the reported reference range was 15-65 pg/mL (ng/L) or 1.6 - 6.9 pmol/L. 
 
2.1.6.2 Calcium measurement 
From February 2011 until January 2013, serum calcium was measured with a colourimetric 
assay on a Roche/Hitachi Cobas automated clinical chemistry analyser using o-
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cresolphthalein complexone (o-CPC). This chemical reacts with calcium ions under alkaline 
conditions to form a violet coloured complex. The addition of 8-hydroxyquinoline prevents 
interference with magnesium and iron. The colour intensity is directly proportional to the 
calcium concentration and can be measured photometrically (Roche, 2019). 
The laboratory introduced a new method on the 7th January 2013. The protocol number 
where the information was obtained is 05928222001V5.0. This method is performed on a 
Roche/Hitachi Cobas 8000 e702 automated clinical chemistry analyser and uses 5-nitro-5’-
methyl-BAPTA (NM-BAPTA) reagent, which forms a complex with calcium ions under 
alkaline conditions. During a second step, the calcium ions are released by EDTA which 
causes a change in the absorbance of NM-BAPTA. This change in absorbance is directly 
proportional to calcium and can be measured photometrically (Roche, 2019).  
The sample should be processed so that serum or plasma are separated from blood cells 
as soon as possible, as prolonged contact with clots can cause a decrease in the calcium 
levels. Urine samples should be collected in containers having hydrochloric acid (HCL) to 
prevent calcium salt precipitation. The reported stability in serum/plasma is seven days at 
15-25 °C, three weeks at 2-8 °C and eight months at -15 to -25 °C. In urine, the stability is 
two days at 15-25 °C, four days at 2-8 °C and three weeks at -15 to	-25 °C. No significant 
interference is reported with icterus, haemolysis, lipemia, magnesium and common 
therapeutic concentrations of drugs. In rare cases, Waldenström’s macroglobulinemia, may 
cause unreliable results in serum measurements (Roche, 2019). 
The interassay coefficient of variation as measured in the laboratory is 1.1 – 1.5% at 1.52 
mmol/L and 0.6 – 1.1% at 3.07 mmol/L.  
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2.1.6.3 Albumin measurement 
Albumin displays a sufficient cationic character at a pH of 4.1 and binds with bromcresol 
green (BCG), an anionic dye, to form a blue-green complex. The colour intensity is directly 
proportional to the albumin concentration in the sample and can be measured 
photometrically. The measurement was performed using a Roche/Hitachi Cobas 8000 e702 
analyser. This colourimetric method was introduced in 2011 and has not changed since 
then. The protocol number where the information was obtained is 0005166861190c701V6.0. 
No significant interference is reported with icterus, haemolysis, lipemia, magnesium and 
common therapeutic concentrations of drugs. In rare cases, Waldenström’s 
macroglobulinemia, may cause unreliable results in the measurements (Roche, 2019). 
The interassay coefficient of variation as measured by the laboratory is 1.5 – 2.4% at 33.9 
g/L and 1.0 – 1.7% at 59.7 g/L. 
 
2.1.6.4 Albumin-adjusted calcium calculation 
Total calcium can vary significantly depending on protein concentration as approximately 
forty percent is protein bound, mainly to albumin. Adjusting total calcium for albumin 
concentration is therefore a more practical means of determining serum calcium (Barth et 
al, 1996). The equations used to calculate that in the laboratory since 2011 are shown in 
Table 2-1. The Pathology Harmony reference range (Berg, 2012) has been in use for 
adjusted calcium since 2011; the range reported is 2.20 - 2.60 mmol/L. The multiplication 
factor to convert to mg/dl is 4.008. This is the reference range that is used for this study.  
 
Chapter 2: Methods and method development 
Section 1:Methods 
 
 154 
 Time introduced Equation for albumin 
adjusted calcium 
Comments 
1 February 2011 = Total calcium + [0.02 (41.5-
albumin)] 
Introduced after the change in methods of 
calcium and albumin as a temporary 
measure until the laboratory would establish 
its own equation 
2 15 November 2011 = Total calcium + [0.0184 (45.7-
albumin)] 
The laboratory used accumulated local data 
to calculate a new equation. The average 
increase in adjusted calcium was 0.08 
mmol/L 
3 20 February 2012 = Total calcium + [0.02 (41.5-
albumin)] 
Due to the increase in mean adjusted 
calcium with the previous equation, 
concerns were raised about inappropriate 
numbers of patients with an elevated 
adjusted calcium and the effect this was 
having on patient care. Therefore, the 
laboratory decided to revert back to the 
original equation 
4 11 September 2014  = Total calcium + [0.0172 (43-
albumin)] 
The new method for calcium measurement 
was introduced on the 14th January 2013 
and the new equation was introduced a few 
months later. This equation gave an 
average increase in adjusted calcium of 
0.03 mmol/L 
 
Table 2-1: Equations used by the chemical laboratory in Sheffield Teaching Hospitals after 2011 to calculate 
albumin adjusted calcium 
 
2.1.6.4.1 Method of establishing the final adjusted calcium equation in the laboratory 
The method that the laboratory used to calculate this equation is described below. 
Information was retrieved from the laboratory’s Standard Operating Procedures (SOP), 
obtained from the Clinical Chemistry Department, STH NHS FT. The method is based on 
the paper by Barth et al (Barth et al, 1996). 
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2.1.6.4.1.1 SOP (Procedure No. CCCLIN002, revision 2, date 14/1/16) 
1. Request I.T. department to perform a search for all NGH and RHH total calcium 
results between the required period, (e.g. three months), which fit the following 
criteria: patient ≥ 18 years old, albumin (ALB) ≤ 55 g/L, urea (UR) ≤ 15 mmol/L, 
creatinine (CR) ≤ 200 µmol/L, potassium (K) ≥ 3.5 mmol/L, AST (AST) ≤ 40 U/L and/or 
ALT ≤ 41 U/L, alkaline phosphatase (ALP) ≤ 130 U/L. The search should be 
performed after excluding the locations: Endocrinology, Haematology, Oncology, 
Nephrology/Renal, General surgery. Only one total calcium and paired albumin result 
per patient should be included 
2. Manually exclude data points with an albumin concentration less than 20 g/L and for 
females only those with an AST of ≥ 33 U/L and/or an ALT of ≥ 34 U/L 
3. Using Microsoft Excel plot a graph of total calcium (y axis) against albumin (x axis) 
4. Create a trendline using least squares regression. The regression equation of y = mx 
+ c should then be determined 
5. Substitute total calcium and albumin terms into the regression equation and 
manipulate as outlined in the example below: 
a. Regression equation y = 0.0172x + 1.58 becomes Total calcium (TCa) = 
0.0172[Albumin] + 1.58 
b. Adjusted calcium (ACa) = Total calcium (TCa) – 0.0172[Alb] + (mean total 
calcium – 1.58) 
c. If the total calcium reference range is 2.20 – 2.60 mmol/L the mean calcium of 
reference range is 2.40, then 2.40 – 1.58 = 0.82 
d. ACa = TCa – 0.0172 ([Alb] – 0.82/0.0172) 
e. ACa = TCa – 0.0172 ([Alb] – 47.7) 
f. Re-arranging into the usual format gives: ACa = TCa + 0.0172 (47.7 – [Alb]). 
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6. Check the validity of the new equation by entering the old and new versions into a 
spreadsheet containing the total calcium and albumin results from the search and 
calculating the adjusted calcium concentration achieved with both equations 
7. Limitations: The relationship between calcium and albumin is not the same across 
the range of possible albumin concentrations often resulting in a different slope and 
therefore adjustment equation at the lower and higher ends of the range. However it 
has been shown that the difference in adjusted calcium results obtained if two 
separate equations are used (as opposed to one over the entire range) is small and 
not clinically significant (Barth et al, 1996). The equation is not reliable in patients with 
significant dysproteinaemias, acid-base disturbances or albumin concentrations <20 
g/L. In critically ill patients abnormal calcium binding may lead to a falsely normal or 
high adjusted calcium result. The equation may not be appropriate in paediatric 
patients less than eighteen years old. 
2.1.6.4.1.1.1 Results (obtained from laboratory, as per document May 2013) 
In order to calculate the equation, the laboratory had to collect enough data. The search 
retrieved a total number of data points of 10431 patients (3316 GPs + 7115 Hospital). Initially 
all the data points were used to create the new equation. The mean total calcium value used 
was 2.40 mmol/L, being the mean of the Pathology Harmony reference. When compared to 
the already existing equation until 2014, ACa = TCa + 0.02 (41.5 – [Alb]), this gave a mean 
increase in adjusted calcium of 0.11 mmol/L. As this seemed to be a particularly high 
increase other possibilities ( 
Table 2-2) were tried to see if any made a difference. 
Combinations tried: 
1. GP patient samples only 
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2. Hospital patient samples only 
3. Data points included only if the albumin concentration had >100 calcium results in 
total. This was done because in the Barth et al paper (Barth et al, 1996) they ensured 
they had >100 total calcium results for all their albumin concentrations. For this data 
it was only possible for albumin concentrations of 32 to 51 g/L, but this does cover 
the reference range 
4. Mean total calcium of the data set was used instead of mean of the reference range 
i.e. the mean total calcium for all 10 431 was 2.32 mmol/L. The same was done for 
the data set where the albumin concentrations had >100 total calcium results 
Data set n Mean 
total 
calciu
m used  
Albumi
n range 
ACa equation Mean 
increas
e in 
ACa  
Range of 
difference 
in ACa 
All 10431 2.40 20 to 55 TCa + 0.0172 (47.7 - 
[Alb]) 
0.11 0.05 to 0.14 
GP 3316 2.40 26 to 55 TCa + 0.0142 (47.9 - 
[Alb]) 
0.11 0.00 to 0.17 
Hospital 7115 2.40 20 to 55 TCa + 0.0177 (46.9 - 
[Alb]) 
0.10 0.05 to 0.13 
TCa n >100 for 
each alb. 
9734 2.40 32 to 51 TCa + 0.0165 (47.3 - 
[Alb]) 
0.10 0.06 to 0.13 
All 10431 2.32 20 to 55 TCa + 0.0172 (43 - [Alb]) 0.03 -0.03 to 
0.06 
TCa n >100 for 
each alb. 
9734 2.33 32 to 51 TCa + 0.0165 (43 - [Alb]) 0.03 -0.01 to 
0.06 
 
Table 2-2: Summary of all the data set combinations tried for the adjusted calcium equation and their results  
 
The data in Table 2-2 shows that of all the various combinations tried, the only factor which 
made a notable difference to the average increase in adjusted calcium was using the mean 
total calcium of the data set rather than the mean of the Pathology Harmony reference range. 
Although this is not in line with Pathology Harmony, a rise of this level would fit with 
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improving the slightly negative bias that the laboratory was running on quality assessments. 
Using the data set mean of 2.32 mmol/L to derive the equation could be somewhat justified 
by the fact that it is also the mean of the recommended Roche reference range. 
Using a mean adjusted calcium of 2.32 mmol/L and the Pathology Harmony reference 
range, this would result in 8.8% of the population being outside the reference range. 
According to the Clinical & Laboratory Standards Institute (CLSI), this percentage should be 
kept under 10%.  
  
Figure 2-1: Monthly GP adjusted calcium data over 2011 to 2013 in Sheffield Teaching Hospitals.  
The arrows on show the likely increase in GP average adjusted calcium concentration with an increase of 0.11 
and 0.03 mmol/L respectively. Cca: corrected calcium; RHH: Royal Hallamshire Hospital; NGH: Northern 
General Hospital 
 
2.1.6.5 25(OH)D measurement 
25(OH)D was measured using the IDS-iSYS automated immunoassays (Immunodiagnostic 
Systems, Boldon, UK) until 2013. This method uses a specific 25(OH)D antibody which is 
labelled with acridinium following a pre-treatment stage to release vitamin D binding protein. 
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Magnetic particles that link to 25(OH)D are added and these are attracted by a magnet. 
Following that, trigger reagents are added and light is emitted by the acridinium, which is 
inversely proportional to the concentration of 25(OH)D. The protocol number where this 
information was obtained is IS-2700PLV05 (UK-Immunodiagnostic-Systems, 2011).  
The method changed from an immunoassay to an electrochemiluminescence binding assay 
in 2013, performed by Roche modular analytics Cobas E170 (Roche Diagnostics GmbH, 
Mannheim, Germany). The protocol number where the information was obtained is 
ms_05894913190V7.0. This method uses recombinant vitamin D binding protein (VDBP) 
rather than antibodies. This is able to bind vitamin D2 and D3. The process involves 
incubating the sample with dithiothreitol and sodium hydroxide, so that vitamin D can be 
released from the VDBP. Then, the sample is incubated with ruthenium labelled vitamin D 
binding protein and a complex between the vitamin D and the ruthenylated vitamin D binding 
protein is formed. Streptavidin-coated microparticles and vitamin D labelled with biotin, are 
then added to the sample. A complex consisting of the unbound ruthenylated vitamin D 
binding protein and the biotinylated vitamin D is formed and becomes bound to the solid 
phase via interaction of biotin and streptavidin. The reaction mixture is aspirated into the 
measuring cell where the microparticles are magnetically captured onto the surface of the 
electrode. Unbound substances are then removed. Application of a voltage to the electrode 
then induces chemiluminescent emission which can be measured by a photomultiplier 
(Roche, 2019). 
The laboratory interassay coefficient of variation for this assay is 6.5 – 9.9% at 48.2 nmol/L 
and 4.5 – 6.3% at 92.3 nmol/L.  The 25(OH)D units used in this report are nmol/L. A 
multiplication by 0.4 is needed to convert the units to ng/ml (or multiply by 2.5 to convert 
ng/ml to nmol/L).  
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2.1.6.6 Creatinine measurement  
Creatinine was measured using a Roche/Hitachi Cobas c8000 e702 analyser (Roche 
Diagnostics GmbH, Mannheim, Germany). The protocol number where the information was 
obtained is 0006407137190c701V11.0. This automated assay is based on the Jaffé method; 
creatinine forms a yellow-orange complex with picric acid in an alkaline solution and the dye 
formation is proportional to the creatinine concentration in the specimen (Roche, 2019).  
The interassay coefficient of variation for this assay in the laboratory was 2.7 – 6.1% at 55.7 
μmol/L and 2.3 – 4.0% at 458 μmol/L.  
According the Kidney Disease Improving Global Outcomes (KDIGO) guidelines, serum 
creatinine should be measured using assays traceable to pure creatinine standards via a 
valid calibration hierarchy. These should be specific and minimally-biased compared with 
isotope-dilution mass spectrometry (IDMS) reference method results. Results should be 
traceable to reference materials and methods listed on the Joint Committee for Traceability 
in Laboratory Medicine (JCTLM) database (KDIGO, 2012). The Jaffe assay used by STH 
laboratory was standardized against IDMS (Roche, 2019).  
 
2.1.6.7 Glomerular Filtration Rate (GFR) and Chronic Kidney Disease (CKD) stages 
Chronic Kidney Disease stages are classified using the level of Glomerular Filtration Rate 
(GFR) as there is a link established between its level and adverse outcomes including 
mortality (Table 2-3). In the absence of evidence of kidney damage, categories G1 and G2 
do not fulfil the criteria for CKD (KDIGO, 2012).  
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Category of GFR GFR (ml/min/1.73 m2) Term used 
G1 ≥90 Normal or high 
G2 60-89 Mildly decreased  
G3a 45-59 Mildly to moderately decreased 
G3b 30-44 Moderately to severely decreased 
G4 15-29 Severely decreased 
G5 <15  Kidney failure 
 
Table 2-3: Chronic kidney disease stages according to glomerular filtration rate (GFR). Adapted from the 
original (KDIGO, 2012)  
Several equations have been developed throughout the years for the calculation of GFR 
and creatinine clearance (CrCl) in adults. In summary, the equations using creatinine need 
to include age, sex, race and body size to account for creatinine production by the muscles. 
The equations described below use serum creatinine (SCr) in mg/dL. To convert creatine 
into different units, 1 mg/dL =   0.01131222 µmol/L or 1 µmol/L = 88.4 mg/dL.  
The first equation was the Cockcroft-Gault published in 1976. This was  
#$#% &'(')*+ = (140 − 234)	6 74)3ℎ972 × =#$ 	6	0.85	()A	A4'2%4) 
The problem with equations like the Cockcroft-Gault is that they were developed before the 
standardisation of creatinine assays. Further equations after the standardisation of the 
assay were then established (KDIGO, 2012). The six-variable (age, sex, ethnicity, serum 
creatinine, urea, and albumin) was followed by the four-variable Modification of Diet in Renal 
Disease (MDRD). Study equations were developed and used (Levey et al, 1999; Levey et 
al, 2006). The four-variable equation can be seen below:  
4BCD & '(')* × 1.73	'F+ = 175 × (Serum	creatine)QRRST × 234QU.FUV × [0.742	)A	A4'2%4] 	× 	 [1.212	)A	Y%2Z[] 
Chapter 2: Methods and method development 
Section 1:Methods 
 
 162 
Finally, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was 
developed in 2009. In order to develop this equation, data from 8254 participants from six 
research studies were evaluated. 
4BCD & '(')* × 1.73	'F+ = 141 × min &=Z$[ , 1+] × max &=Z$[ , 1+QR.FU_ × 0.993abc × 1.018	[)A	A4'2%4] 	× 	1.159	[)A	Y%2Z[] 
Scr is serum creatinine in mg/dL, κ is 0.7 for females and 0.9 for males, α is -0.329 for 
females and -0.411 for males, min indicates the minimum of Scr/κ or 1, max indicates the 
maximum of Scr/κ or 1 (KDIGO, 2012).  
When the later equation was validated, it performed better than the MDRD Study equation 
especially at higher GFR levels (GFR ≥60 ml/min/1.73 m2). There was lesser bias (median 
difference between measured and estimated GFR), improved precision and greater 
accuracy (Levey et al, 2009). Due to the fact that GFR matches physiologically to kidney 
size, which is related to the body surface area, the interpretation of GFR is based on 
comparison to normative values adjusted for body surface area. The value 1.73m2 used in 
the units, is the average value of the body surface area (BSA) in 25-year old adults in the 
USA in 1927. This value was maintained throughout the years for normalisation purposes 
(KDIGO, 2012).  
The STH Clinical Chemistry Department changed the used equation for estimating eGFR 
from the MRDR to the CKD-EPI in August 2015. 
 
2.1.6.8 Alkaline phosphatase (ALP) measurement 
Alkaline phosphatase was measured using a Roche/Hitachi Cobas c8000 e702 analyser. 
The protocol number where the information was obtained is 0005166888190c701V8.0. The 
sample is added to p-nitrophenyl phosphate, which, in the presence of magnesium and zinc 
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ions, is cleaved by phosphatases into phosphate and p-nitrophenol. The p-nitrophenol 
released is directly proportional to the catalytic ALP activity and is determined by measuring 
the increase in absorbance. The interassay coefficient of variation for this assay was 2.4% 
at 92.8 IU/L and 1.7% at 224 IU/L  (Roche, 2019). 
 
2.1.6.9 Phosphate measurement 
Phosphate was measured using a Roche/Hitachi Cobas c8000 e702 analyser. The protocol 
number where the information was obtained is 0005171377190c701V11.0. Inorganic 
phosphate forms an ammonium phosphomolybdate complex with ammonium molybdate in 
the presence of sulfuric acid. The concentration of phosphomolybdate formed is directly 
proportional to the inorganic phosphate concentration and is measured photometrically. The 
interassay coefficient was 1.4% at 1.23 mmol/L and 1.2% at 2.04 mmol/L (Roche, 2019). 
 
2.1.7 Statistical analyses  
2.1.7.1 Mahalanobis distance analysis  
Since calcium and PTH are not independent variables, it was considered best to use a 
bivariate statistical approach to define the different categories of patients. This approach 
has been used in the past to study the prevalence of NHYPO (Palermo et al, 2015). The 
approach is called Mahalanobis distance and it is a classical way to define outliers in a 
multivariate space (in this case, a space with two variables, adjusted calcium and PTH). 
In univariate space, calculating the distance from one point to another is straightforward and 
is called Euclidean distance. For example, in statistics, any point can be expressed as a 
distance of a number of standard deviations (SD) from the mean (standard Normal deviate). 
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This is calculated, using the formula (x – μ) / SD, where x is the point studied, μ is the mean 
and SD the standard deviation of the distribution. From that, the probability of a point 
belonging to the set can be calculated. For example, if a point is more than two standard 
deviations from the mean, is it defined as an outlier (outside the 95% of the distribution)  
(Altman, 1991). 
Euclidean distance can also be used in multivariate space if the variables are not correlated. 
In this case, the points are distributed in a spherical way around the centre and the axes 
from the mean to two different points are in an angle of 900 from each other. However, when 
the variables are correlated, calculating the distance becomes more complicated (Figure 
2-2). In this case, the probability of a point belonging to the dataset depends not only from 
the distance, but also from the direction (Wikipedia, 2017). Hence, the shape of the cluster 
of points has to be considered. 
 
Figure 2-2: Example showing that when two variables are correlated, the distance of two points from the mean 
cannot really be calculated using Euclidean distance.  
The two squares have similar Euclidean distance from the mean of the cluster (triangle) but the square on the 
left seems more of an outlier. Figure adjusted from original (Clapham, 2016) 
 
Covariance is a measure of how two variables change together. In the case of the variables 
x1 and y1 in Figure 2-2, the covariance is positive; as x1 increases, y1 tends to increase. In 
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the case of multivariate data, covariance is expressed as the variance-covariance matrix. 
The variance covariance matrix is square, which means the number of rows and columns is 
the same and it contains the covariances of all pairs of variables. In the analyses described 
below, the number of variables analysed for each patient were two (adjusted calcium and 
PTH) and so the sample covariance matrix was a two-by-two matrix. In this matrix, the 
diagonal terms give the variances of the variables (or the covariance of a variable with itself) 
and the off-diagonal terms give the covariances between the variables (Figure 2-3). 
Covariance of (x1 x2) equals the covariance of (x2 x1), so the matrix is also symmetrical 
(Clapham, 2016). 
 
Figure 2-3: A two-by-two matrix covariance matrix.  
In this matrix, the diagonal terms give the variances of the variables (or the covariance of a variable with itself) 
and the off-diagonal terms give the covariances between the variances. Figure adjusted from original 
(Clapham, 2016) 
 
Mahalanobis distance (MD), was introduced in 1936 by P.C. Mahalanobis. It is a multi-
dimensional generalization of the idea of measuring how many SD away an observation is 
from the mean of a distribution. Mahalanobis distance creates two new axes at the cluster 
of points which are perpendicular to each other (Figure 2-4). MD then re-scales the two new 
axes in order for them to have a variance equal to one. This removes the covariance 
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between the variables. After doing so, the Mahalanobis distance equals the Euclidean 
distance (Wikipedia, 2017).  
 
Figure 2-4: Mahalanobis distance creates two new axes in the cluster of points and one is perpendicular to the 
other.  
The red axes, is considered to be the principal one, as most points are located along its direction. Figure 
adjusted from original (Clapham, 2016) 
A vector in mathematics is a quantity determining the position of a point in space and it gives 
both direction and magnitude (Figure 2-5).  
 
Figure 2-5: A vector is a quantity determining the position of a point in space.  
The length of this vector is the squared root of [(x1)2 + (y1)2]. For example, if x1= 4 and y1= 3, then the length 
would be the square root of 25, which is 5 
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An eigenvector is a column vector that when multiplied with a matrix, it results in the same 
eigenvector multiplied by an integer called eigenvalue. The equation for this relationship is 
M*V= λ*V. In this case, M is a matrix, V is the column vector and λ is the eigenvalue. 
The eigenvector is the principal axis of the graph at Figure 2-4. This is the direction of the 
greatest variability. The second eigenvector is perpendicular to the first one and they both 
have different eigenvalues. To remove the covariance, the axes have to be decreased by 
the square root of their eigenvalue (Öλ) (Clapham, 2016)  
If a matrix is a two-by-two matrix, it would have two eigenvectors. Eigenvectors are scaled 
to have a length of one. To do so, in the example of Figure 2-5, the scaled eigenvector would 
be  
 
MD is defined for each point xi, by the following equation 
MD2 = (xi – μ) T S-1 (xi – μ) 
MD: Mahalanobis distance, μ: arithmetic mean of the dataset and S: sample covariance 
matrix (as defined above). As xi and μ are both vectors, (xi – μ) is a matrix. T indicates that 
the matrix has to be transposed into a new matrix (where the rows of it are the columns of 
the first one).  
MD is a classical method of defining outliers in a multivariate point cloud. It is known that if 
the data follow a two dimensional Gaussian distribution, then the squared Mahalanobis 
distances would approximately follow a chi-squared distribution with two degrees of freedom 
(Van Aelst & Rousseeuw, 2009). In the analysis described below, the observations were 
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considered outliers if MD2>Χ22; 0.975 =7.378 (97,5th percentile of a chi-squared distribution 
with two degrees of freedom). Using this method, subjects were identified as “normal” if they 
were inside the ellipse and “abnormal” if they were outside the ellipse.  
 
2.1.7.2 Calculation of the within-subject standard deviation 
As mentioned above, the day of the laboratory investigations was defined to be the index 
day. More results of calcium and PTH before and after the index day were retrieved from 
hospital records and were used to study the natural history of the diseases described.   
When having multiple measurements from an individual, these measurements are generally 
not equal to each other and tend to vary around a “true average”. Each individual then has 
a standard deviation of these measurements which can easily be calculated. If we assume 
that each individual has similar standard deviation to the rest, we can then calculate the 
mean within-subject standard deviation (Sw). The most common way to do this, would be to 
average the variances of all the patients and then take the square root (Bland & Altman, 
1996a). However, this method can be applied in cases where the number of measurements 
is the same for each subject, which is not usually the case when dealing with real-life data.  
For this reason, the analysis of variance method was used to calculate the within-subject 
variance, as this method deals with the case of subjects having different numbers of 
observations. The value of the residual mean square is the within-subject variance. To follow 
this method, one first needs to check the assumption that the standard deviation is unrelated 
to the magnitude of the measurement. This can be done graphically, by plotting the 
individual subjects’ standard deviations against their means and analytically by calculating 
a rank correlation coefficient (Bland & Altman, 1996a).  
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In order to perform this analysis, the assumption that standard deviations across the 
subjects are similar should be made, as described above. However, this is not true in all 
clinical situations, for example the standard deviation could be increased in patients that 
were in intensive care. Using a single “mean” within-standard deviation might underestimate 
the variability for some patients (Masse, 1997). We understand that this is a limitation of this 
approach and that the true within-subject SD might be bigger.  
After calculating the within-subject SD (Sw), there are two ways of finding the confidence 
intervals for this value. One is done through calculating the standard error of the within-
subject-SD. The standard error of de is given by: =f(de) = gh√Fj, where d is the degrees of 
freedom, k = ∑ (*m − 1)nmoR , n is the number of measurements for each subject and k is the 
number of subjects. If d is greater than 30 then, the 95% confidence interval (CI) limits for de are then given by: de ± 1.96 × =f(de). To use this approach, one needs to assume that 
within the subject, the distribution of observations is normal. This approach can be used in 
the case where each subject has the same number of measurements  (Bland, 2011). As this 
is not the case in real-life data, a different approach was followed. 
For a Normal population, a sample variance follows a Chi-squared distribution multiplied by 
the population variance and divided by the degrees of freedom. In order to follow this 
approach, one needs to find the 2.5% and 97.5% points of the Chi-squared distribution with 
the degrees of freedom for the estimate. Then, these numbers need to be multiplied by the 
sample variance and divide by the degrees of freedom. This gives the 95% CI for the 
variance. When these are squared, the calculation results to the CI for the standard deviation 
(Bland, 2011). This is the approach followed in this project.  
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2.1.7.3 Mixed linear model 
For the comparison of the overall measurements of PTH and adjusted calcium resulting from 
follow up, I used a mixed linear model. This is a statistical model containing both fixed effects 
and random effects. These models are used in settings where there are repeated 
measurements and there is non-independence in the data. An example given in the literature 
is the one of observations on different patients performed by different doctors. There are 
different levels when studying this setting. First, is the variability of the outcome within 
patients seen by the same doctor. The measurements in this case are similar and are not 
independent. The second, is the variability of the outcome between doctors. In this case, 
the samples in the doctors level are independent. In order to deal with this data, one way is 
to aggregate the measurements from each doctor and take their average. The aggregated 
data would then be independent. By comparing the mean of means, one does not really 
take into account all the data. Another way is to analyse data from each doctor at a time. 
Again, this approach does not really take into account all the data. The linear mixed model, 
allows the utilisation of all the data and allows for correlations between the data (UCLA).  
In the case of repeated measurements, each patient might have a different mean from the 
group and the measurements are correlated. In this project, the aim was to calculate the 
overall mean for adjusted calcium for each category. The linear mixed model uses fixed and 
random effects to do this. The fixed effects is used when comparing means of groups 
representing different diagnoses, treatments, groups etc. The random effects is used when 
the values are a sample of a larger population and they vary (Bland, 2015). Therefore, in 
this project, individual variability was modelled using a random effect (repeated 
measurements within subject) and the difference between groups (i.e. different category) 
was estimated using a fixed effect.  
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2.1.7.4 Other analyses 
When one measurement was available per patient (for example to compare baseline data), 
appropriate tests were performed to test the hypothesis that the means between the groups 
are similar. Histograms were used in order to check whether the data were normally 
distributed. If the distribution was not Normal, the data were log transformed and checked 
again through histograms. In the case of normally distributed data, parametric tests were 
used for comparisons (Independent Student’s t test for two groups and ANOVA for more 
than two). In the case of more than two groups, Bonferroni’s correction was used for pairwise 
comparisons. If neither of these distributions was Normal, appropriate non-parametric tests 
were used (Mann-Whitney for two groups and Kruskal-Wallis for more than two groups). The 
chi-square test was used for the analysis of categorical data. The results are presented as 
mean and standard deviation when the data were normally distributed, as geometric mean 
and 95% confidence intervals when log transformation was performed in order to achieve a 
normal distribution of the data, and median and interquartile range (IQR) in the case where 
non parametric tests were used for the analysis. A p value smaller than 0.05 was considered 
as significant (Altman, 1991).  
 
2.1.7.5 Software used for analyses  
The statistical analyses have been performed using the R studio statistical software 
(RStudio, Inc. Boston), SPSS Statistics (International Business Machines Corporation, New 
York) and Microsoft Excel (Microsoft Office). 
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2.1.8 Definitions 
Using the laboratory reference intervals for serum albumin-adjusted calcium and PTH, these 
patients were divided into ten different categories as described in Table 2-4. “High” or “low” 
are referred to values of either adjusted calcium or PTH being above or below the reference 
range respectively.  
1. Normal Anyone inside the ellipse 
2. Hyperparathyroid hypercalcaemia (HH) 
Included primary hyperparathyroidism 
(PHPT) and familiar hypocalciuric 
hypercalcaemia (FHH) 
Anyone outside the ellipse having high adjusted calcium and 
high PTH 
3. Hypoparathyroidism Anyone outside the ellipse with low adjusted calcium and 
low PTH 
4. Secondary hyperparathyroidism Anyone outside the ellipse with  
• low adjusted calcium and high PTH 
OR 
• normal adjusted calcium and high PTH with 
25(OH)D<50nmol/L and/or eGFR<60 ml/min/1.73m2 
5. Non-PTH hypercalcaemia Anyone outside the ellipse with high adjusted calcium and 
low PTH  
6. Likely normocalcaemic 
hyperparathyroidism (NPHPT) 
Anyone outside the ellipse having normal adjusted calcium 
and high PTH, given that 25(OH)D≥50nmol/L and eGFR≥60 
ml/min/1.73m2 
7. Normocalcaemic hypoparathyroidism 
(NHYPO) 
Anyone outside the ellipse with normal adjusted calcium and 
low PTH 
8. Normoparathyroid hypercalcemia Anyone outside the ellipse with high adjusted calcium and 
normal PTH 
9. Normoparathyroid hypocalcaemia Anyone outside the ellipse with low adjusted calcium and 
normal PTH 
10. Unclassified abnormal Anyone with normal adjusted calcium and normal PTH, but 
outside the ellipse 
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 Table 2-4: Patients’ categories definitions 
The classification into groups was done differently in the paper by Palermo et al. After 
applying Mahalanobis distance, they used the geometric mean of the healthy reference 
range for PTH and the reference range for adjusted calcium to define their groups (Palermo 
et al, 2015). We have adjusted this method and brought it closer to the everyday clinical 
practice, by using the clinical reference ranges for both adjusted calcium and PTH. 
After dividing the patients into different groups, a careful review of the medical notes of the 
“likely NHPER patients” was performed, to further check for other exclusion criteria as 
mentioned in the introduction: 
• lack of persistently elevated levels of PTH on at least two consecutive measurements 
• use of medications on the index day known to affect PTH levels (diuretics, lithium, 
denosumab, bisphosphonates) 
• renal calcium loss (hypercalciuria) 
• diseases of the gastrointestinal tract known to affect calcium absorption (coeliac 
disease, inflammatory bowel disease, bariatric surgery)  
• other diseases of calcium metabolism 
For the NHYPO group, the patients’ medical notes were reviewed to look for other causes 
of the abnormalities found. Any unconfirmed data were excluded.  
In terms of vitamin D levels, “low” was defined as any level lower that 50 nmol/L and 
“normal”, a level ≥50 nmol/L. “Normal” eGFR was a level ≥60 ml/min/1.73m2 and “low” when 
the level was <60 ml/min/1.73m2. Hypercalciuria was defined as a 24-hour calcium urine 
level >10 mmol/24h. This was true for the first few analyses. However, this was then adapted 
to the international definition of 24-hour urine calcium ≥6.25 mmol/24h for women or 7.5 
mmol/24h for men and/or ≥ 0.1 mmol/kg/24h (Worcester & Coe, 2008).  
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Section 2: Method development 
2.2.1 Results from the initial analyses 
There were several analyses performed before the final one due to the fact that certain 
problems were identified after completing each analysis. The initial results are described 
below. Any other intermediate analyses can be found in the Appendix along with the 
problems identified and the way they were resolved. Moreover, the final codes used in R 
studio and their explanations can also be found in the Supplementary material. 
 
2.2.1.1 Analysis 1 (completed in 2016) 
2.2.1.1.1 The database 
The original database received, “SearchServiceResultsSTH15691” contained information 
on 9224 patients (74% female, mean age 66 years) that had a BMD measurement and a 
laboratory evaluation between December 2011 and May 2015. The laboratory work-up had 
to be performed within 28 days from the scan. The given data on adjusted calcium were 
used for this analysis, as calculated by the laboratory. 
Information available in this database was: Age, Gender, Hospital number, T-score spine 
total, Z-score spine total, T-score right hip total, Z-score right hip total, adjusted calcium 
calculated by the laboratory, vitamin D, eGFR, PTH, PINP, 24-hour urine calcium.  
 
2.2.1.1.2 Statistical analysis 
The processing of the database was performed using the filters and several other functions 
in Microsoft Excel. The graphs of the natural history were also done using the same 
software. The Mahalanobis distance analysis was performed using the R software and was 
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completed by the School of Health and Related Research (ScHARR) in the University of 
Sheffield.  
 
2.2.1.1.3 Baseline characteristics of the population  
In order to define the patient categories according to their calcium metabolism disorders, 
data from only 5977 patients having both serum-albumin adjusted calcium and PTH 
available, were used. Out of them, 4380 (73.3%) were women. Their mean age was 66 
years (range 17-100). Out of the 5479 patients that had a 25(OH)D measurement available, 
45% had vitamin D deficiency (<50 nmol/L). 
On the original database, there were some patients with extreme BMIs (>100kg/m2, n=71). 
For some of them, it was obvious that the height and weight had been reversely recorded in 
the database, and so they were corrected automatically. There were four patients left with 
BMI>100kg/m2. The next step was to check the form completed by the technician on the day 
of the BMD measurement. In order to make sure that there were no other false recordings, 
the ones having BMIs <14 or >50 kg/m2 were also checked using the form completed on the 
day of the BMD measurement. All these recordings were confirmed.  
After applying the statistical method described above, the ellipse seen in Figure 2-6 was 
formed.  
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Figure 2-6: Data results from adjusted calcium and PTH from analysis 1.  
The ellipse was formed using a statistical method (Mahalanobis distance) to identify “normal” subjects (black 
dots) and “abnormal” ones (red dots). The reference range of both adjusted calcium and PTH (horizontal and 
vertical dashed lines respectively), were used to identify patient categories as seen above. The white area 
includes patients with normal adjusted calcium and high PTH (n=235); these were either potentially NPHPT 
patients [given that 25(OH)D≥50nmol/L and eGFR≥60 ml/min/1.73m2] or secondary hyperparathyroidism 
patients [given that 25(OH)D<50nmol/L and/or eGFR<60 ml/min/1.73m2]. The Pearson correlation coefficient 
was -0.146 (95% CI: -0.172 to -0.119, P<0.001).  The regression line is indicated in blue. NHYPO: 
Normocalcaemic hypoparathyroidism 
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2.2.1.1.4 Normocalcaemic hyperparathyroidism patients 
Based on laboratory results on the index day, 235 patients were identified to be outside the 
ellipse and have normal adjusted calcium and high PTH. Using the international criteria on 
NPHPT, 134 patients were excluded because of either low eGFR (<60 ml/min/1.73m2) or 
no eGFR measurement. Moreover, 82 patients with normal eGFR, were excluded because 
of 25(OH)D<50nmol/L (n=71) or no vitamin D measurement (n=11). This resulted in 
identifying 19 patients, all women, with likely NPHPT (Table 2-5).  
Categories Frequency Percent 
Normal 5334 89.2 
Hyperparathyroid hypercalcaemia (HH) 183 3.1 
Hypoparathyroidism 0 0 
Secondary hyperparathyroidism 262 4.4 
Non-PTH hypercalcaemia 5 0.1 
Likely normocalcaemic hyperparathyroidism 19 0.3 
Normocalcaemic hypoparathyroidism 18 0.3 
Normoparathyroid hypercalcemia 88 1.5 
Normoparathyroid hypocalcaemia 31 0.5 
Unclassified abnormal 37 0.6 
Total 5977 100 
 
Table 2-5: The different patient categories based on their calcium metabolism disorders, after applying the 
criteria for 25(OH)D<50nmol/L and/or eGFR<60 ml/min/1.73m2 
 
Chapter 2: Methods and method development 
Section 2:Method development  
 
 179 
A further evaluation of their medical notes, excluded fourteen patients due to other exclusion 
criteria. These were as follows: 
Patient number 
1. 1236: Excluded – bisphosphonates (zoledronic acid) on index day 
2. 1784: Excluded - coeliac disease (positive antibodies, no biopsy performed) 
3. 1832: Excluded – PHPT (all other measurements of calcium high) 
4. 1849: Included 
5. 1977: Excluded – no persistence of high PTH (only one high result) 
6. 2136: Excluded - FHH 
7. 3584: Excluded – just one measurement of PTH and calcium available 
8. 3831: Excluded – just one measurement of PTH available, on bisphosphonates 
9. 4103: Included 
10. 4213: Excluded – just one measurement of PTH and calcium available 
11. 4322: Included 
12. 4403: Excluded – bisphosphonates (alendronic acid) on index day 
13. 4777: Included 
14. 5361: Excluded – loop diuretics (furosemide) on index day 
15. 5489: Included 
16. 6177: Excluded – treated pseudohypoparathyroidism 
17. 6181: Excluded – just one measurement of PTH  
18. 6715: Excluded – just one measurement of PTH and calcium available 
19. 8483. Excluded – bisphosphonates (aledronic acid) on index day 
The number of NPHPT patients identified after applying the exclusion criteria in our referral 
population was five. All the patients were female and their mean age was 68 years. NPHPT 
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had a 0.08% prevalence in this population. The consort diagram (Figure 2-7) illustrates the 
criteria used.  
 
Figure 2-7: Consort diagram illustrating the procedure for identifying the normocalcaemic hyperparathyroidism 
patients.  
Five patients (n=5, prevalence 0.08%) were identified out from a referral population of 5977 patients having 
both adjusted calcium and PTH 
 
The characteristics of these five patients can be seen in (Table 2-6). 
As far as biochemical characteristics of PHPT are concerned, one out of the five NPHPT 
patients (patient 4322), had a low phosphate level on the index day (0.69 mmol/L) and only 
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the patient with the highest PTH on the index day (patient 1849, PTH 157 ng/L), had high 
ALP (148 IU/L). 
  Minimum Maximum Mean SD 
Age (years) 58 73 68.0 6.00 
BMI (kg/m2) 22.5 44.3 32.22 7.85 
PTH (ng/L) 87.0 157.0 109.60 27.75 
Adjusted calcium (mmol/L) 2.56 2.58 2.57 0.01 
25(OH)D (nmol/L) 56.4 104.6 70.48 19.99 
ALP (IU/L) 64.0 148.0 95.40 31.89 
Phosphate (mmol/L) 0.69 1.09 0.93 0.17 
Table 2-6: Characteristics of the normocalcaemic hyperparathyroidism patients (n=5) on the index day 
 
The reasons that the patients were referred and had laboratory evaluations varied. Three 
out of five of these patients had osteoporosis, the others had osteopenia. Patient 1849 (age 
67 years) was referred for a BMD because of “mild primary hyperparathyroidism”; that was 
also the reason she had the laboratory investigations, as a follow up to her clinic visit. This 
patient had a fine needle aspiration (FNA) and the findings were compatible with parathyroid 
gland adenoma. Patient 4103 (age 71 years) was referred because of a previous low trauma 
fracture and she had laboratory investigations because of a vertebral fracture. She had 
osteoporosis at the spine. Patient 4322 (age 73 years) had the BMD scan and the laboratory 
investigations as a follow up for her clinic visit, which she attended because of “mild primary 
hyperparathyroidism”. She had osteopenia at both the spine and the hip. Patient 4777 (age 
58 years) was referred for a BMD because of borderline FRAX score. The laboratory 
evaluations were performed because BMD was low for age (spine Z score -2.3). This patient 
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had osteoporosis at both the spine and the hip. Patient 5489 (age 71 years) was referred 
for a BMD measurement because of “mild primary hyperparathyroidism” and that was the 
reason she had the laboratory investigations, as a follow up to her clinic visit. She had 
osteopenia. Due to the limited number of patients identified, there was not sufficient power 
to perform a statistical analysis in order to evaluate differences in patients’ characteristics 
amongst the different groups.  
The natural history of the five NHPER patients was studied using data from days where both 
adjusted calcium and PTH were available. The extraction of all the data was done manually, 
by looking at available results on ICE (the hospital’s laboratory software, having results from 
2009). Only the results from 2011 onwards were retrieved, so the follow up period was up 
to six years (2011-2016). That was because the laboratory changed manufacturer at 2011 
and the updated equation could not be applied in measurements performed with a different 
manufacturer.  
Two patterns were identified; intermittent hypercalcaemia and persistent normocalcaemia. 
Three out of five patients had intermittent hypercalcaemia, two had persistent 
normocalcaemia; one of them only had two measurements available. The measurement 
variations were independent of 25(OH)D levels (Figure 2-8).  
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Figure 2-8: Graphs of the adjusted calcium and PTH values for the five normocalcaemic hyperparathyroidism 
patients throughout time.  
Only the calcium measurements that are accompanied by a PTH measurement on the same day are shown. 
The blue lines indicate PTH levels [dashed= upper limit of normal range (65ng/L), continuous= patient’s PTH 
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variations]. Green lines indicate adjusted calcium levels [dashed= upper limit of normal range (2.60mmol/L), 
continuous= patient’s adjusted calcium variations]. The red line indicates the index day. The sun image 
indicates 25(OH)D levels≥50nmol/L, whereas the cloud image indicates levels <50nmol/L. Two patients 
(Subject ID 4103 and subject ID 4777) had persistent normocalcaemia. The calcium variations where 
independent of the 25(OH)D levels 
 
2.2.1.1.5 Conclusions 
The prevalence of NPHPT in the Metabolic Bone Centre referral population, was 0.08% (five 
patients out of 5977). According to the definition, NPHPT is characterised by persistent 
elevated PTH measurements and normal calcium. Only two patients out of the whole cohort 
would really have NPHPT according to the definition; one of them with just two 
measurements of both calcium and PTH.  
 
2.2.1.2 Problems identified in Analysis 1  
After completing analysis 1, several issues were identified. Their description can be found 
in detail in the Appendix.  
 
2.2.2 Further intermediate analyses 
Any other intermediate analyses can be found in the Appendix along with the problems 
identified and the way they were resolved. Moreover, the final codes used in R studio and 
their explanations can also be found in the Supplementary material. A summary of the 
different analyses and their problems can be seen in Table 2-7. 
Chapter 2: Methods and method development 
Section 2:Method development  
 
 185 
Name Number of 
patients 
Steps Results for 
NPHPT 
Problems 
Analysis 1 
 
Completed 2016 
9224 
 
Data 2011-2015 for 
both prevalence 
and natural history 
1. Mahalanobis distance 
2. Categories of patients 
3. Exclusion criteria for NPHPT 
4. Natural history 2011-2016 
19 likely 
NPHPT  
 
Final: 5 
patients 
1. Assay change in calcium in 2013, could affect 
results of prevalence 
2. Non-reproducible results of MD 
3. Problems with database (wrong age, given 
calculated adjusted calcium) 
Analysis 2 
 
Completed 2017 
7809 
Final 5713 
 
Data 2013-2017 
1. Mahalanobis distance 
2. Categories of patients 
3. Exclusion criteria for NPHPT 
based on all data 
21 likely 
NPHPT 
 
Final: 2 
patients 
1. Patients identified because of spine T score, 
underestimation of prevalence 
Analysis 3 
 
Completed 2017 
8411 
Final 6280 
1. Mahalanobis distance (final) 
2. Categories of patients (final) 
3. Exclusion criteria for NPHPT 
based on all data 
4. Natural history 2011-2017 
Final: 8 
patients  
1. Up to now, exclusion due to all available PTH, vitD 
and eGFR measurements, troublesome. Better to 
base decision on index date 
Analysis 4 
 
Completed 2018 
Same as analysis 
3 
28 likely NPHPT 
1. Exclusion criteria on NPHPT 
based on index date 
Final: 15 
patients  
1. Decided to compare with HH and control 
2. ICE not retrieving all the information, to get 
repeated measurements 
3. Wrong to study natural history from 2011, due to 
change in calcium method 
Analysis 5 
Completed 2019 
Same as analysis 
3 
28 likely NPHPT  
1. Exclusion criteria based on 
persistence of at least two 
consecutive measurements 
2. Comparison with PHPT and 
control 
Final: 13 
patients 
1. Decided to adjust the definition of hypercalciuria to 
24-hour urine calcium ≥6.25 mmol/24h for women 
or 7.5 mmol/24h for men and/or ≥ 0.1 mmol/kg/24h 
Final analysis 
Completed 2019 
Same as analysis 
3 
1. Exclusion criteria based on 
persistence of at least two 
consecutive measurements 
Final: 11 
patients 
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28 likely NPHPT 2. Comparison with PHPT and 
control 
Table 2-7: Summary of the different intermediate analyses on NPHPT and their issues 
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3.1.1 Abstract  
Context 
Normocalcemic hyperparathyroidism (NPHPT) is characterised by persistently normal 
calcium levels and elevated PTH values, after excluding other causes of secondary 
hyperparathyroidism. The prevalence of the disease varies a lot and the data on the 
natural history of this disease are sparse and inconclusive.  
Objectives 
To describe the prevalence of NPHPT and its natural history in a referral population 
and to compare the variability of serum calcium with a group of patients with primary 
hyperparathyroidism (PHPT) 
Design 
Retrospective study over five years 
Setting 
Metabolic Bone referral centre 
Patients 
6280 patients referred for a BMD measurement  
Main Outcome Measures 
Prevalence and natural history of NPHPT and variability of calcium  
Results 
We identified NPHPT patients using data from the day of the BMD measurement. We 
excluded patients with low eGFR or vitamin D, or with no measurements available. 
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Based on the evaluation of their medical files, we identified eleven patients with 
NPHPT (prevalence 0.18%). Only four patients had consistent normocalcemia 
throughout their follow up with only two also having consistently high PTH. None had 
consistently normal eGFR or vitamin D.  
Intermittent hypercalcaemia was present in seven of the eleven NPHPT patients. The 
mean adjusted calcium was found to be significantly lower in the NPHPT group 
compared with the PHPT group but higher than the control group. PTH was similar for 
NPHPT and PHPT. These two groups had similar variability in serum calcium. 
Conclusions  
NPHPT patients often have episodes of hypercalcemia. We believe that NPHPT is a 
mild form of primary hyperparathyroidism.  
 
Précis  
The prevalence and natural history of patients with normocalcemic 
hyperparathyroidism were studied. We concluded that the prevalence is low and that 
these patients probably suffer from PHPT 
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3.1.2 Introduction 
Normocalcemic hyperparathyroidism (NPHPT) is a disorder of calcium metabolism 
which, despite being mentioned in literature for several years, was only officially 
defined in 2009, during the Third International Workshop on Asymptomatic Primary 
Hyperparathyroidism (PHPT) (Eastell et al, 2009). According to the latest guidelines, 
persistently normal calcium levels (total and ionised) and consistently elevated 
parathyroid hormone (PTH) values characterise NPHPT. The panel suggested that 
normal calcium has to be confirmed on several occasions and that an elevated PTH 
measurement should be confirmed on at least two consecutive measurements. Other 
causes of secondary hyperparathyroidism have to be excluded; these include 
medications known to affect PTH levels (diuretics, lithium, denosumab, 
bisphosphonates, anticonvulsants, phosphorus), low vitamin D, chronic kidney 
disease (eGFR <60 ml/min/1.73m2), renal calcium loss (hypercalciuria) and diseases 
of the gastrointestinal tract known to affect calcium absorption (coeliac disease, 
inflammatory bowel disease, bariatric surgery)  (Eastell et al, 2009; Eastell et al, 2014; 
Yacobi-Bach et al, 2015).  
NPHPT is usually encountered during the laboratory evaluation of osteoporosis and 
has been associated with consequences known to affect patients with PHPT 
(accelerated bone loss, kidney stones, higher levels of blood pressure and higher pre-
existing glucose intolerance). However, there is no clear evidence for any such 
associations (Pawlowska & Cusano, 2015; Silverberg et al, 2014).  
The prevalence of NPHPT in the literature varies considerably, and it is reported to be 
between 0.1 and 8.9% (Pawlowska & Cusano, 2015). The reasons for this variation 
are that different definitions and methodologies were used in the reporting studies; not 
all causes of secondary hyperparathyroidism were excluded, and some studies did 
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not test the persistence of high PTH and normal calcium before evaluating the 
prevalence; thus the results were probably overestimated. 
The data on the natural history of this disease are also sparse and inconclusive.  Some 
studies show progression to hypercalcemia, but others fail to show that. The way that 
many studies identify NPHPT patients is by testing calcium and PTH at baseline, and 
then they retest the patients after some time to check whether they progressed to 
hypercalcemia. The variability of calcium in NPHPT during the follow-up period has 
been poorly described. One study has described the variability as similar to the normal 
population,  whereas patients with PHPT have been described to have more 
considerable variability in calcium levels (Norman et al, 2011). However, there are not 
enough data to draw any conclusions.  
According to the proceedings of the Fourth International Workshop on Asymptomatic 
Primary Hyperparathyroidism, NPHPT remains incompletely described, especially 
regarding its epidemiology, natural history and management (Silverberg et al, 2014). 
The criteria are not clear concerning how many measurements are needed to establish 
a diagnosis, which makes the matter complicated for the clinician and confusing for 
the patient. This study aims to identify the prevalence of NPHPT and study the natural 
history of this disorder in more detail. It also aims to compare the variability of calcium 
between PHPT and NPHPT patients.  
 
3.1.3 Materials and methods 
3.1.3.1 Study population 
The work was performed at the Metabolic Bone Centre (MBC) at Sheffield Teaching 
Hospitals National Health Service Foundation Trust (STH NHS FT) in the United 
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Kingdom. Data from patients referred for a bone mineral density (BMD) measurement 
between the 14th January 2013 to the 27th July 2017 were retrospectively evaluated. 
All the patients included in the database had to have a laboratory evaluation, including 
calcium and PTH, performed within twenty-eight days of their scan. In general, this 
department evaluated approximately 650 patients per month at the time of the study 
and a laboratory workup for secondary osteoporosis was performed in patients having 
any of the following findings: low BMD for age (Z-score≤ -2.0), vertebral fracture, 
unexplained bone loss since the previous scan. The day of the laboratory 
investigations was defined to be the index day. More results of calcium and PTH 
before and after the index day were retrieved from hospital records and were used to 
study the natural history of the disease. Only data collected after 14th January 2013 
were evaluated because at that point, the laboratory changed the assay for serum 
calcium, and this would probably affect the accuracy of the results. The end of the 
follow-up period was the 31st of July 2018.   
The analysis was considered a case note review project by Sheffield Teaching 
Hospitals and did not require a special ethical approval (Project number STH20617).   
 
3.1.3.2 Biochemical measurements 
Blood was drawn at any point of the day, so patients were not fasting. All the samples 
were analysed in the Chemical Pathology Laboratory, STH NHS FT.  Intact PTH 
(second generation) was measured using an immunoassay method by the Roche 
Cobas 8000 e602 (Roche Diagnostics GmbH, Mannheim, Germany). The interassay 
coefficient of variation (CV) measured in the laboratory is 2.2 – 3.2% at 34 ng/L, 1.6 – 
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1.7% at 94 ng/L and 1.4 – 1.8% at 839 ng/L, while the reported reference interval is 
15-65 ng/L (1.6 - 6.9 pmol/L).  
Serum calcium was measured using a Roche/Hitachi Cobas 8000 e702 automated 
clinical chemistry analyser (Roche Diagnostics GmbH, Mannheim, Germany).  This 
method uses 5-nitro-5’-methyl-BAPTA (NM-BAPTA) reagent. The interassay 
coefficient of variation as measured in the laboratory is 1.1 – 1.5% at 1.52 mmol/L and 
0.6 – 1.1% at 3.07 mmol/L. Albumin measurement was performed using a 
Roche/Hitachi Cobas 8000 e702 analyser (Roche Diagnostics GmbH, Mannheim, 
Germany). The interassay coefficient of variation as measured by the laboratory is 1.5 
– 2.4% at 33.9 g/L and 1.0 – 1.7% at 59.7 g/L. The albumin-adjusted calcium was 
used for this study and was calculated using the following equation based on data 
from the local laboratory. 
!"#$%&'"	)* = ,-&*.	)* + [0.0172(43− !.:$;<=)] 
The reference interval for adjusted calcium was 2.20-2.60 nmol/L (8.8-10.4 mg/dL). 
25(OH)D was measured using the IDS-iSYS automated immunoassays 
(Immunodiagnostic Systems, Boldon, UK) until May 2013. The interassay coefficient 
of variation reported by the manufacturer was 10.4% at 64.5 nmol/L. The assay then 
changed to a competitive binding protein one and was performed by Roche modular 
analytics Cobas E170 (Roche Diagnostics GmbH, Mannheim, Germany). The 
laboratory interassay coefficient of variation for this assay was 6.5 – 9.9% at 48.2 
nmol/L and 4.5 – 6.3% at 92.3 nmol/L.  The Sheffield Teaching Hospitals laboratory 
was participating in the UK Vitamin D External Quality Assessment Scheme (DEQAS) 
at the time of this study. 
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Creatinine was measured using a Roche/Hitachi Cobas c8000 e702 analyser (Roche 
Diagnostics GmbH, Mannheim, Germany). The interassay coefficient of variation for 
this assay was 2.7 – 6.1% at 55.7 μmol/L and 2.3 – 4.0% at 458 μmol/L. The equation 
used to calculate eGFR was the Modification of Diet in Renal Disease (MDRD) Study 
equation:  
'@AB C ;D;<= × 1.73	;FG = 175 × (Serum	creatine)STTUV × *W'SX.FXY × [0.742	<Z	Z';*.'] 	×	 [1.212	<Z	:.*[\] 
This equation changed in August 2015; the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation has been in use since then. 
'@AB C ;D;<= × 1.73	;FG = 141 × min C][^\ , 1G` × max C][^\ , 1GST.FXb × 0.993def × 1.018	[<Z	Z';*.'] 	× 	1.159	[<Z	:.*[\] 
Scr is serum creatinine in mg/dL, κ is 0.7 for females and 0.9 for males, α is -0.329 for 
females and -0.411 for males, min indicates the minimum of Scr/κ or 1, max indicates 
the maximum of Scr/κ or 1 (KDIGO, 2012). 
Alkaline phosphatase was measured using a Roche/Hitachi Cobas c8000 e702 
analyser. The interassay coefficient of variation for this assay was 2.4% at 92.8 IU/L 
and 1.7% at 224 IU/L. The same analyser was used for the measurement of serum 
phosphate and the interassay coefficient was 1.4% at 1.23 mmol/L and 1.2 at 2.04 
mmol/L. 
Bone mineral density was performed using dual-energy X-ray absorptiometry (DXA) 
of the lumbar spine and the proximal femur in posteroanterior projection. At the time 
of the study, there were three Hologic (Waltham, MA) DXA scanners within the centre. 
The least significant change (LSC) used in the MBC was 4.5% for both the spine and 
the hip. There were three scanning rooms in the department and each room has a 
different scanner. Room A: Hologic Discovery A in use since 2010. Room B: Hologic 
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QDR4500A was in use from 2011 until the 11th September 2013.    The scanner was 
then decommissioned and replaced by a Hologic Discovery SL. Room C: Hologic 
Delphi C was in use until the 3rd November 2014.  The scanner was then 
decommissioned and replaced by a Hologic Horizon A. The different DXA scanners 
were cross-calibrated upon installation. 
 
3.1.3.3 Statistical analysis  
As calcium and PTH are not independent variables, a bivariate statistical approach 
was used to define the different categories of patients. Mahalanobis distance is a multi-
dimensional generalization of the concept of measuring the number of standard 
deviations (SD) away an observation is from the mean of a distribution. It is a classical 
method of defining outliers in a multivariate point cloud and is defined for each point 
xi, by the following equation, where MDi: Mahalanobis distance, μ: arithmetic mean of 
the dataset and S: sample covariance matrix. 
hijF = (kj − l)m]ST(kj − l) 
The distance MDi gives the distance of point xi from the centre of the cluster of points, 
taking into account the shape of the cluster. Observations are considered outliers if 
MD2>Χ22;0.975 =7.378 (97,5th percentile of chi-squared distribution with two degrees of 
freedom) (Rousseeuw & van Zomeren, 1990; Van Aelst & Rousseeuw, 2009). The 
correlation analysis of adjusted calcium and PTH was performed based on a log10 
transformation of the two variables.  A similar approach has been used in the past to 
evaluate the prevalence of NPHPT in a different group of patients. Using this method, 
subjects were identified as "normal" if they were inside the ellipse and "abnormal" if 
they were outside. In order to get the different categories described below, they used 
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the reference interval for adjusted calcium. However, they used the geometric mean 
of the reference interval for PTH (Palermo et al, 2015).  We have adjusted this method 
and brought it closer to the everyday clinical practice, by using the clinical reference 
intervals for both adjusted calcium and PTH. Doing so, patients were divided into ten 
categories as described below. "High" or "low" refer to values of either adjusted 
calcium or PTH being above or below the reference interval, respectively. 
To compare the variability of different analytes in the three groups, the overall mean 
and the pooled within-subject standard deviation of each analyte was calculated. The 
analysis of variance method was used to calculate the within subject variance, as this 
method deals with the case of subjects having different numbers of observations. To 
follow this method, we first checked the assumption that the standard deviation was 
unrelated to the magnitude of the measurement. This was done graphically, by plotting 
the individual subjects’ standard deviations against their means and analytically by 
calculating a rank correlation coefficient (Bland & Altman, 1996a).  
To compare characteristics between the groups at baseline, one-way ANOVA and 
Kruskal-Wallis were used to compare the quantitative data. The results are presented 
as mean and standard deviation when ANOVA was used for the analysis, as geometric 
mean and 95% confidence intervals when log transformation was performed before 
analysis with ANOVA or as median and interquartile range (IQR) in the case where 
non parametric tests were used for the analysis. The Mann-Whitney test was used to 
compare the 24-hour urine calcium between the NPHPT and PHPT groups. For the 
comparison of the overall measurements of PTH and adjusted calcium resulting from 
follow up, we used a mixed linear model. Individual variability was modelled using a 
random effect and the difference between groups was estimated using a fixed effect.  
Chapter 3: Metabolic Bone Centre analyses 
Section 1:Normocalcaemic hyperparathyroidism  
 
201 
 
The statistical analyses have been performed using the R studio statistical software 
version 1.1.442 (RStudio, Inc. Boston). 
 
3.1.3.4 Definitions of the different groups  
As mentioned in the statistics section, patients were divided into ten categories based 
on their laboratory intervals for adjusted calcium and PTH. The cut-off for vitamin D 
deficiency was 50 nmol/L according to the Royal Osteoporosis Society guidelines 
(Aspray et al, 2014). The categories were defined as follows. Normal: anyone inside 
the ellipse; the rest of the groups described were outside the ellipse. Hyperparathyroid 
hypercalcemia (HH) included patients with PHPT and familial hypocalciuric 
hypercalcemia (FHH) and was defined as anyone outside the ellipse having high 
adjusted calcium and high PTH. Hypoparathyroidism: low adjusted calcium and low 
PTH. Secondary hyperparathyroidism: a) low adjusted calcium and high PTH or, b) 
normal adjusted calcium and high PTH with 25(OH)D<50nmol/L or eGFR<60 
ml/min/1.73m2. Non-PTH hypercalcemia: high adjusted calcium and low PTH. 
Normocalcemic hyperparathyroidism (NPHPT): normal adjusted calcium and high 
PTH, given that 25(OH)D≥50 nmol/L and eGFR≥60  ml/min/1.73m2. Normocalcemic 
hypoparathyroidism (NHYPO): normal adjusted calcium and low PTH. 
Normoparathyroid hypercalcemia: high adjusted calcium and normal PTH. 
Normoparathyroid hypocalcemia: low adjusted calcium and normal PTH. Unidentified: 
normal adjusted calcium and normal PTH, but being outside the ellipse. The groups 
of interest for this study were the normal population and the patients with HH and 
NPHPT. In order to characterise these groups further, the following procedures were 
followed.  
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For the NPHPT patients identified from the index date, a careful evaluation of their 
medical records and other laboratory investigations were performed in order to check 
for exclusion criteria according to the guidelines (see introduction). Renal calcium loss 
was defined as having 24-hour urine calcium ≥6.25 mmol/24h for women or 7.5 
mmol/24h for men and/or ≥ 0.1 mmol/kg/24h (Worcester & Coe, 2008). Moreover, and 
in order to be in line with the international guidelines on persistence, only patients with 
persistently normal adjusted calcium and elevated PTH on two consecutive occasions 
were included.  
For the hyperparathyroid hypercalcemia patients (HH), only the patients with vitamin 
D ≥50 nmol/L and eGFR≥60 ml/min/1.73m2 on the index date were chosen to be used 
for the variability analysis. An evaluation of their medical files excluded patients with 
other diseases like renal transplant. Results after parathyroid surgery were excluded. 
Once again, only patients with consistently high calcium and PTH on at least two 
consecutive occasions were included. In order to only include patients with PHPT (and 
to exclude FHH) in this group, the patients had to have one or more of the following 
criteria: 24-hour urine calcium> 2.5 mmol/24h or fractional excretion >0.02; surgically 
proven PHPT (correction of high calcium after parathyroid surgery). At this point, all 
remaining patients in this group were defined as primary hyperparathyroidism (PHPT). 
For the control population, a random sample of 300 subjects from inside the ellipse 
having normal eGFR and being vitamin D replete (as defined above) on the index date 
was chosen.  
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3.1.4 Results 
In total, 6293 patients attended the Metabolic Bone Centre and were assessed for 
secondary osteoporosis from January 2013 to July 2017. All these patients had a BMD 
measurement and a laboratory evaluation. Thirteen patients did not have PTH 
available on the index day and were excluded. The total number of patients analysed 
was 6280; their mean age was 66 years (range 16-100), and 4527 (72%) were female.  
After applying the Mahalanobis distance, the ellipse seen in Figure 3-1 was drawn. In 
total, 5574 patients were inside the ellipse and were considered as “normal” while the 
rest were outliers and were divided into disease categories using the laboratory 
reference interval for calcium and PTH (Table 3-1).   
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Figure 3-1: Data results from adjusted calcium and PTH.  
The ellipse was formed using a statistical method (Mahalanobis distance) to identify "normal" subjects 
(black dots) and "abnormal" ones (red dots). The reference interval of both adjusted calcium and PTH 
(horizontal and vertical dashed lines, respectively), were used to identify patient categories. The 
definitions used are described in the methods section. The white area includes patients with normal 
adjusted calcium and high PTH (n=265); these were either potentially NPHPT patients [given that 
25(OH)D≥50nmol/L and eGFR≥60 ml/min/1.73m2] or secondary hyperparathyroidism patients [given 
that 25(OH)D<50nmol/L and/or eGFR<60 ml/min/1.73m2]. NPHPT: Normocalcemic 
hyperparathyroidism. NHYPO: Normocalcemic hypoparathyroidism 
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Categories Number (%) 
Normal 5574 (88.76) 
Hyperparathyroid hypercalcemia (HH) 172 (2.74) 
Hypoparathyroidism 1 (0.02) 
Secondary hyperparathyroidism 291 (4.63) 
Non-PTH hypercalcemia 6 (0.10) 
Normocalcemic hyperparathyroidism (NPHPT) 28 (0.45) 
Normocalcemic hypoparathyroidism (NHYPO) 22 (0.35) 
Normoparathyroid hypercalcemia  67 (1.07) 
Normoparathyroid hypocalcemia 43 (0.68) 
Unclassified abnormal 76 (1.21) 
 
Table 3-1: The different patient categories based on their calcium metabolism disorders.  
The following definitions were used. Normal: anyone inside the ellipse; the rest of the groups described 
were outside the ellipse. Hyperparathyroid hypercalcemia (HH): high adjusted calcium and high PTH. 
Hypoparathyroidism: low adjusted calcium and low PTH. Secondary hyperparathyroidism: low adjusted 
calcium and high PTH or, b) normal adjusted calcium and high PTH with 25(OH)D<50nmol/L or 
eGFR<60 ml/min/1.73m2. Non-PTH hypercalcemia: high adjusted calcium and low PTH. 
Normocalcemic hyperparathyroidism (NPHPT): normal adjusted calcium and high PTH, given that 
25(OH)D≥50nmol/L and eGFR≥60  ml/min/1.73m2. Normocalcemic hypoparathyroidism (NHYPO): 
normal adjusted calcium and low PTH. Normoparathyroid hypercalcemia: high adjusted calcium and 
normal PTH. Normoparathyroid hypocalcemia: low adjusted calcium and normal PTH. Unclassified 
abnormal: normal adjusted calcium and normal PTH, but being outside the ellipse. 
 
In total, 28 patients initially fulfilled the inclusion criteria for NPHPT (normal calcium, 
high PTH, both on at least two occasions, normal eGFR and vitamin D replete on index 
day). A careful evaluation of their medical records and their medical history excluded 
17 patients (Table 3-2). The natural history was then studied, using calcium 
measurements available from January 2013 to the end of July 2018. Two patients 
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were excluded because of PTH inconsistency (S2406 and S3820). In total, 11 patients 
were identified as having NPHPT with confirmed persistent results of normal calcium 
and elevated PTH on at least two occasions. The prevalence was 0.18% (95% CI 0.10 
- 0.31). The mean age of these patients was 69 years, and 91% were female.   None 
had parathyroid surgery. 
 
Study 
number  
Age 
(years) 
Gender Medical files check Persistence 
of calcium 
and PTH  
Natural history of 
adjusted calcium 
S0189 65 F Excluded - anticonvulsants   
S0227 59 F Included Yes Persistent 
normocalcemia 
S0449 65 F Excluded - treated 
pseudohypoparathyroidism 
  
S0567 72 F Excluded - tertiary 
hyperparathyroidism-renal 
transplant 
  
S0696 75 F Excluded - 
bisphosphonates 
  
S0757 68 F Included Yes Intermittent 
hypercalcemia 
S0871 83 M Excluded -
bisphosphonates 
  
S0911 70 F Included Yes Persistent 
normocalcemia 
S1194 74 F Excluded - 
bisphosphonates 
  
S1620 75 F Included Yes Persistent 
normocalcemia 
S1692 79 F Excluded - 
bisphosphonates 
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S1753 86 M Included Yes Intermittent 
hypercalcemia 
S2406 67 F Included No  
S2453 57 F Included Yes Intermittent 
hypercalcemia 
S2654 88 F Excluded - Crohn's- 
bisphosphonates- 
furosemide 
  
S2720 83 F Included Yes Intermittent 
hypercalcemia 
S3021 64 F Included Yes Persistent 
normocalcemia 
S3703 72 F Excluded- anticonvulsants   
S3812 70 F Included  Intermittent 
hypercalcemia 
S3820 49 F Included No  
S3841 84 F Excluded - 
bisphosphonates 
  
S3882 69 F Excluded - hypercalciuria   
S4392 66 F Included Yes Intermittent 
hypercalcemia 
S4618 59 F Included Yes Intermittent 
hypercalcemia 
S4903 59 M Excluded - renal transplant   
S5321 78 F Excluded - 
bisphosphonates 
  
S5369 64 F Excluded - hypercalciuria   
S5408 82 F Excluded - furosemide   
 
Table 3-2: Patients checked for inclusion in the normocalcemic hyperparathyroidism group (NPHPT). 
F: female; M: male 
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Two patterns were identified while studying the natural history; persistent 
normocalcemia and intermittent hypercalcemia (Figure 3-2), (Figure 3-3). Intermittent 
hypercalcemia occurred in seven patients. Persistent normocalcemia was rare and 
only occurred in four patients (0.06% of the whole population). However, only two of 
these patients (S0227 and S1620) had consistently high PTH, but they were not 
consistently vitamin D replete and/or did not have consistently normal eGFR.  If the 
international guidelines were strictly applied, the prevalence of NPHPT in this 
population would be zero.  
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Figure 3-2: The two patterns identified in patients with normocalcemic hyperparathyroidism (NPHPT) 
when studying the natural history of adjusted calcium. 
 Persistent normocalcemia (top figure, patient S1620) and, intermittent hypercalcemia (bottom figure, 
patient S2720). The arrows represent the index day (day of bone mineral density scan). The x-axes 
represent the year of follow up. Adj.Ca: adjusted calcium.  
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Figure 3-3: Means and range of values of different analytes in the 11 NPHPT patients.  
The dashed lines represent the reference interval for adjusted calcium, the upper reference interval for 
PTH and the desired level for 25(OH)D and eGFR. Persistent normocalcemia was rare, only occurred 
in 4 patients (shown in the graph with arrows). However, only two patients (S0227 and S1620) had 
consistently high PTH. These patients were not consistently vitamin D replete and/or did not have 
consistently normal eGFR. PTH: parathyroid hormone, NPHPT: Normocalcemic hyperparathyroidism. 
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Out of the 172 patients identified with HH, 29 were vitamin D replete and had normal 
eGFR on the index date. The evaluation of their medical records excluded one patient 
due to previous renal transplant (S2706). One patient had their index date after their 
parathyroid surgery and was also excluded (S5826). Eight patients were excluded 
because they only had one result for PTH, and the persistence could not be confirmed, 
while one patient was excluded because of not having at least two measurements of 
calcium consistently high. One patient was excluded because FHH could not be ruled 
out due to lack of urine calcium (S2031). The final PHPT group had 17 patients (mean 
age 69, 89% female).  Twelve patients had persistent hypercalcemia (70%), while the 
remaining six had intermittent hypercalcemia, a pattern also seen in patients with 
NPHPT. 
The control population group consisted of 300 subjects (mean age 67 years, 71% 
female). There was no statistically significant difference in age or gender distribution 
between the groups (all p values>0.05).  
The baseline characteristics on the index date are summarised in Table 3-3. The three 
groups had significant differences in adjusted calcium on the index date. PTH did not 
differ between the NPHPT and PHPT groups. The groups had similar age and gender-
adjusted BMD results. Phosphate was significantly lower in the PHPT group compared 
to the control group. All the other variables studied did not have any differences 
between the three groups at baseline.  
 
 
 Control 
(n=300) 
NPHPT (n=11) PHPT  p value 
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(n=17) 
Female (%) 214 (71) 10 (92) 15 (88) 0.122 
Age (years)a 70 (20) 68 (11) 67 (6) 0.975 
BMI (g/cm2)c 25.6  
(25.0, 26.3) 
30.1 
(24.4, 34.0) 
26.2 
(23.4, 28.9) 
0.303 
PTH (ng/L)c 42.5  
(40.8, 44.2) 
106.8  
(86.9, 123.9) 
102.4  
(89.0, 112.4) 
<0.001 
Adjusted calcium (mmol/L)b 2.37 (0.08) 2.55 (0.05) 2.75 (0.11) <0.001 
Phosphate (mmol/L)b 1.12 (0.18) 1.04 (0.14) 0.89 (0.16) <0.001 
Alkaline phosphatase (IU/L)a 78 (37) 98 (33) 88 (27) o.070 
25(OH)D (nmol/L)a 78.9 (32.9) 62.8 (23.5) 71.4 (30.5) 0.083 
Z score spine b -0.1 (1.7) 0.2 (2.2) -0.2 (1.3) 0.932 
Z score neck b -0.4 (1.0) -0.1 (1.3) -0.4 (0.8) 0.770 
Table 3-3: Characteristics of the three groups on the index date. 
 a shown as median (interquartile range); b shown as mean (standard deviation); c shown as geometric 
mean (95% confidence interval). The results of the pairwise comparisons were as follows: PTH in the 
control group differed significantly from both the NPHPT and PHPT group, but there was no statistically 
significant difference between the NPHPT and PHPT groups. Adjusted calcium differed significantly 
between all the groups. Phosphate differed significantly only between the PHPT and control group. BMI: 
body mass index; PTH: parathyroid hormone; NPHPT: normocalcemic hyperparathyroidism; PHPT: 
primary hyperparathyroidism; n= number of patients 
 
After taking all the follow-up measurements into account, the mean adjusted calcium 
was still found to be significantly lower in the NPHPT group compared with the PHPT 
group (2.52 and 2.74 mmol/L respectively). The control group had significantly lower 
adjusted calcium levels from all the other groups (2.35 mmol/L, all pairwise 
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comparisons p<0.001). PTH did not differ significantly between NPHPT and PHPT 
(115.4 and 116.0 ng/L respectively) but was significantly higher than in the control 
group (48.1 ng/L, p<0.001) (Figure 3-4). The PHPT and NPHPT groups had similar 
calcium variability [within-subject SD (95% CI): 0.088 (0.079, 0.097) and 0.089 (0.080, 
1.000) mmol/L respectively].  The variability of calcium in the control group was slightly 
smaller than PHPT and NPHPT  [within-subject SD 0.083 (0.080, 0.085) mmol/L]. The 
24-hour urine calcium was higher in the PHPT group compared to the NPHPT groups 
(mean 7.51 and 4.25 mmol/24hour respectively) but the difference was not significant 
(p 0.063).  
 
 
Figure 3-4. Boxplots showing the variability of calcium and PTH in the normal population and patients 
with PHPT and NPHPT.  
The mean adjusted calcium was found to be significantly lower in the NPHPT group compared with the 
PHPT group (p<0.001). The normal group had significantly lower adjusted calcium levels from all the 
other groups (p<0.001). PTH did not differ significantly between these groups but was significantly 
Chapter 3: Metabolic Bone Centre analyses 
Section 1:Normocalcaemic hyperparathyroidism 
 
 214 
higher from the normal population (p<0.001). PTH: parathyroid hormone, NPHPT: Normocalcemic 
hyperparathyroidism. PHPT: Primary hyperparathyroidism 
 
3.1.5 Discussion 
The international guidelines suggest that patients with NPHPT should have 
consistently normal values of calcium. Moreover, PTH should be high on at least two 
to three consecutive measurements. However, we observed in this population that 
persistent normocalcemia is rarely the case and using an index day to identify NPHPT 
patients can lead to overestimation of the prevalence.  Patients with NPHPT usually 
have intermittent hypercalcemia as do PHPT patients, and we believe that NPHPT is 
a variant of PHPT. The intermittent nature of serum calcium in both NPHPT and PHPT 
results from the relatively high variability of serum calcium in all patient groups. 
The studies available for the prevalence of NPHPT use different definitions and patient 
populations. Often the baseline data are the only ones analysed, without evaluation of 
persistence. In order to study the natural history, only one further measurement during 
follow up is used and the variability of calcium in the follow-up period is not described. 
To our knowledge, two studies have reported the prevalence of NPHPT from referral 
centres (Table 3-4), one of them having the highest prevalence in the literature (8.9%) 
(Marques et al, 2011). The mean adjusted calcium was similar between the NPHPT 
group and the rest of the patients, a pattern not seen in our study. They also reported 
higher levels of PTH in the NPHPT group [109.5 (45.2) vs 39.1 (14.3) pg/mL, p <0.001] 
(Marques et al, 2011). Another estimate of the prevalence from a referral centre is 
from a group in the Czech Republic. They report 187 patients (1.2%) with NPHPT 
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(Siprova et al, 2016). The prevalence of NPHPT was also studied in the general 
population and was reported to be between 0.1 and 6% (Table 3-4).  
The results for the natural history remain controversial with some studies reporting no 
conversion to hypercalcemia  (Ayturk et al, 2006; Garcia-Martin et al, 2012; Tordjman 
et al, 2004), while others report a small percentage of patients becoming 
hypercalcemic (Cusano et al, 2013a; Diri et al, 2014; Kontogeorgos et al, 2015; 
Silverberg & Bilezikian, 2003; Siprova et al, 2016). The problem with the studies on 
natural history is that, although they might check persistence at baseline on two to 
three occasions, they then check the laboratory measurements on only one occasion 
after a certain period; if at that point the patient has high calcium, they conclude that 
the patient has progressed to hypercalcemia. All the studies are summarised in Table 
3-5. Silverberg et al. found hypercalcemia in three patients after one year of follow up. 
The researchers from this paper first proposed that NPHPT is the first phase of a 
biphasic disease course, which can be followed by hypercalcemic 
hyperparathyroidism (Silverberg & Bilezikian, 2003). The group from the Czech 
Republic followed the 187 patients with NPHPT for one to seven years. Out of them, 
151 patients (81%) remained normocalcemic, while 36 (19%) became hypercalcemic; 
24 (67%) increased their calcium to high levels within two years, 10 (28%) within 2 to 
4 years and 2 (5%) after more than four years. They also reported that 23 patients out 
of the 36 patients (64%) had persistent hypercalcemia, while 13 (36%) had intermittent 
hypercalcemia, a pattern also observed in our study. The baseline calcium of patients 
that remained normocalcemic was significantly lower than the ones that became 
hypercalcemic (Siprova et al, 2016). A more recent study evaluating NPHPT patients 
going through parathyroidectomy, reported that 40.8% of these patients had episodes 
of hypercalcaemia >1 year prior to surgery (Sho et al, 2019).  
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We believe that NPHPT is a variant of PHPT. This issue has been recently addressed 
by the first European Society of Endocrinology Workshop (PARAT). In their consensus 
statement, they mentioned that the individual variation in total calcium is four times 
narrower than the population reference interval and the inter individual variability. In 
order to make sure that a person has normal calcium or not, we need to know their 
individual range of variability. There is a chance that an individual might have an 
elevated calcium in comparison with their individual range, but still within the normal 
population reference interval for calcium. These patients should probably be 
characterised as having primary hyperparathyroidism and not normocalcaemic 
hyperparathyroidism and be followed up and treated accordingly. This is of course 
after excluding causes of secondary hyperparathyroidism (Bollerslev et al, 2019). 
None of our patients progressed to persistent hypercalcemia; the patterns observed 
were either persistent normocalcemia or intermittent hypercalcemia. The four patients 
with persistent normocalcemia did not fulfil all the other criteria according to the 
international guidelines. Our hypothesis is supported by the fact that the underlying 
pathology of NPHPT seems to be similar to PHPT. A few studies report that 
multiglandular disease is more common in NPHPT (Koumakis et al, 2013; Lim et al, 
2017; Pandian et al, 2019; Traini et al, 2018) but not all reach statistical significance 
(Gómez-Ramírez et al, 2019; Kiriakopoulos et al, 2018; Yu et al, 2019). However, 
patients included in these studies probably had secondary hyperparathyroidism 
resulting from vitamin D deficiency and chronic kidney disease (Lim et al, 2017; 
Pandian et al, 2019).  Most studies report that the average adenoma weight was lower 
in the NPHPT group compared to the PHPT group of patients (Kiriakopoulos et al, 
2018; Koumakis et al, 2013; Maruani et al, 2003).  
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This hypothesis, however, is not fully supported by recently published genetic data on 
NPHPT. Based on the hypothesis that NPHPT can be caused by PTH resistance 
(Maruani et al, 2003), and the fact that the single nucleotide polymorphism (SNP) 
rs17251221 (A986S) in the CaSR has been linked to PTH resistance, researchers in 
Spain recently investigated the effect of this SNP to NPHPT patients. They recruited 
and prospectively studied 61 consecutive patients with NPHPT and asymptomatic 
PHPT. These patients had a follow up of one year to check for the persistence of their 
laboratory investigations on at least two occasions. There were 38 patients (n=24 
NPHPT and n=14 PHPT) with the wild type genotype A986A and 23 S allele carriers 
(n=20 A986S or n=3 S986S). Seventeen NPHPT patients were S allele carriers. In 
these patients, the S allele was associated with significantly higher levels of serum 
intact PTH (P=0.024) after adjusting for factors like vitamin D and calcium 
concentrations. There was no association with the S allele in PHPT patients (Diaz-
Soto et al, 2015).  
In our series, we found similar variability of adjusted calcium in patients with NPHPT 
and PHPT. The variability of calcium and PTH has been studied previously in a 
prospective series of surgically proven PHPT. In this study (Norman et al, 2011), the 
definition of NPHPT was every measurement of calcium being below 10.2 mg/dL (2.55 
mmol/L), and only 1.1% of the patients fulfilled this criterion. Almost all the patients 
with PHPT had variable calcium levels, with 74% having intermittent hypercalcemia 
within the previous year. This study did not include a control group but mentioned that 
serum calcium was more variable in PHPT patients compared to the same patients 
before developing this disorder. The variability before was described to be 0.19 (0.09) 
mg/dL [0.0475 (0.0225) mmol/L].  After conversion to PHPT, the variability more than 
doubled [0.1 (0.0825) mmol/L] with calcium varying by more than 1mg/dL (0.25 
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mmol/L) from month to month in some cases. The authors suggested that this could 
be a loss of calcium homeostasis by a parathyroid tumour. Patients with 
normocalcemic hyperparathyroidism were reported as an exception, presenting with 
minimal variability, like the one in the patients before PHPT (Norman et al, 2011). 
Minimal variability is not the finding from our study, as both NPHPT and PHPT patients 
had similar calcium variability. 
The variability described in calcium in these patients complicates their monitoring. 
According to the international guidelines, calcium and PTH should be tested every 
year, while a BMD check should be performed every one to two years.  If there is a 
progression to hypercalcemia, patients should be treated according to the guidelines 
on asymptomatic primary hyperparathyroidism (Bilezikian et al, 2014). However, a 
majority of these patients have intermittent hypercalcemia; the subsequent results 
might be confusing for both the care provider and the patient on whether surgery would 
be recommended.  
We used a statistical approach to define the different categories in this population. Our 
results showed that a large percentage of subjects were considered “normal” (inside 
the ellipse) using this approach, even though they had elevated PTH according to the 
reference interval. The subjects that were normal but had higher PTH than the 
reference interval, were found to be significantly older than the ones that were normal 
and also had normal PTH according to the current reference interval (data not shown). 
These results align well with the fact that PTH is known to increase with age. This 
increase was recently found to be independent of 25(OH)D, ionised calcium, 
phosphate and renal function (Carrivick et al, 2015). It has been previously suggested 
that age-related PTH reference intervals should be established (Eastell et al, 2014). 
Our study supports this statement.  This adjustment for the range becomes more 
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relevant now that normocalcaemic hyperparathyroidism is further described in 
literature. By using the current reference interval in everyday practice we are probably 
over-diagnosing NPHPT and may be subjecting older individuals to unnecessary 
testing.  An increase of the upper limit of the reference interval in PTH could alter the 
number of patients diagnosed with this disorder.  
This study describes the largest population ever studied to identify NPHPT and 
provides data during a long follow up period (five years). There are several limitations 
to this study. The samples were not fasting and ionised calcium was not available. The 
methods for vitamin D and eGFR changed during the follow up period and that might 
have affected some results. We have used a 25(OH)D threshold of 50 nmol/L for 
identifying high PTH due to D deficiency, but the cross-sectional data indicate that 
values between 50 and 75 nmol/L might be associated with slight elevations of PTH 
thus result in overdiagnosis of NPHPT. Many researchers recommend using a higher 
cut-off of 75 nmol/L. We have used the cut-off advised by the Royal Osteoporosis 
Society guidelines and the Fourth International Workshop on Asymptomatic Primary 
Hyperparathyroidism (Aspray et al, 2014; Eastell et al, 2014). The impact of 
implementing the CKD-EPI equation is that it may have improved the accuracy in 
patients with an eGFR of 50-60 ml/min/1.73 m2 and might have resulted in fewer 
people being clustered as CKD. However, it might have increased the number of older 
people having CKD.  The equation used to calculate the pooled SD cannot really 
distinguish between variations due to the progression of the disease or those due to 
natural variation. We assume that when taking measurements close to each other, 
then the pooled SD would estimate the method variation and the variability of the 
assay. As the measurements in this population are further away, we believe that the 
variability is due to the within subject variability. Moreover, none of our patients had 
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progressive disease as seen in the natural history graphs, so we believe that this is all 
due to natural variation. This was a retrospective observational study and the number 
of measurements varied from patient to patient. The interval between the 
measurements was not the same, as expected in a real-life setting. This limited the 
possibility of further analyses. The analysis for the within-subject SD did not take into 
account the effect of time. Ideally, to give a more accurate estimate of the variance, a 
prospective observational study should be designed, having the same number of 
measurements for each patient at regular intervals. The analysis should be preferably 
done using a model that takes time into account. Despite the limitations, this study 
provided a guide to how adjusted calcium varies between the different groups 
described.  
The patients studied were identified from a referral centre, and they were evaluated 
for causes of secondary osteoporosis so that they might be different from the general 
population. On the other hand, NPHPT is usually diagnosed during the evaluation of 
secondary osteoporosis and thus, mainly found in referral centres. Studying a referral 
population has the advantage of evaluating how common NPHPT is in a referral 
population with osteoporosis and whether screening for NPHPT is useful. 
Another group that is mentioned in this cohort, is the normoparathyroid 
hypercalcaemia one. These patients were previously been described to progress to 
primary hyperparathyroidism (Rejnmark et al, 2013). It was not within the scope of this 
study to evaluate these patients further, but it is amongst our future plans. 
The question resulting from this study is whether NPHPT exists and, if it does, whether 
the current definition used is the most appropriate. We believe that there are three 
ways forward. If we adjust the reference interval for PTH for age, and use the current 
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definition, NPHPT may not exist, as shown in this study. Another approach would be 
to revisit the current definition and normocalcemic hyperparathyroidism should be 
defined as having the average calcium within normal limits (and not requiring it to be 
persistently normal). Using the same approach, PHPT should be considered as having 
a high average calcium.  In this case, 10 out of our 11 included patients would be 
classified as NPHPT, and sixteen out of seventeen PHPT patients would be classified 
as having PHPT (Figure 3-5).   
 
 
Figure 3-5: Means and range of values for adjusted calcium in the 11 NPHPT patients and the 17 PHPT 
patients.  
The dashed lines represent the reference interval. This figure shows that if the mean calcium was used 
to define the different groups, all but one patients in the left graph would be classified as NPHPT and 
all but one patient from the right graph would be classified as PHPT. NPHPT: Normocalcaemic 
hyperparathyroidism; PHPT: primary hyperparathyroidism 
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Another way forward would be  consider NPHPT as a variant of PHPT and follow up 
and treat according to the current guidelines as suggested in the consensus statement 
of the first European Society of Endocrinology Workshop (PARAT). This is supported 
by many studies in the literature showing similar characteristics from these two groups 
of patients. It is also supported by the fact that the underlying pathology of NPHPT 
seems to be similar to PHPT.  We believe, based on the results from this study, that 
this is the best approach to follow in clinical practice. 
In conclusion, persistent normocalcemia in patients with NPHPT is rare. If the 
international guidelines were strictly applied, the prevalence of NPHPT in this 
population would be zero. Our study is the first that studies the natural history of 
patients with NPHPT in so much detail and provides data from a long follow up period. 
We suggest that the definition should be revisited and normocalcemic 
hyperparathyroidism should be defined as having the average calcium within normal 
limits and not persistently normal. Subsequent hypercalcemia in these patients should 
be treated with caution, and any decisions for surgery should be made after 
persistently high levels of calcium have been confirmed. 
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Study Population Number of 
NPHPT patients 
(%); 
Mean age; 
Gender 
Definition of NPHPT Comments/limitations 
Marques et al. 
Brazil (referral 
centre) 
(Marques et al, 
2011) 
Analysed records of 156 
postmenopausal women who 
were referred to hospital to be 
screened for osteoporosis 
14 (8.9); 
60.6 years; 
100% female 
 
At least two samples of calcium and PTH 
Excluded: 25(OH)D<30ng/ml, 
GFR<40ml/min, medications 
(bisphosphonates, diuretics, anticonvulsants, 
lithium), metabolic bone diseases, 
gastrointestinal diseases with malabsorption, 
liver disease, incomplete records 
Lower cut-off for eGFR 
Šiprova et al.  
Czech Republic 
(referral centre) 
(Siprova et al, 
2016) 
Fifteen thousand three hundred 
forty-three referrals to Endocrine 
Centre. PTH measured in 1180 
(patients with pathological or 
marginal levels of total calcium, 
ionised Ca, serum phosphate, 
patients with reduced BMD and 
with a possible PHPT diagnosis 
from medical history) 
187 (1.2); 
61.1 years; 
81% female 
 
At follow-up 151 
(81%) 
Normal total and ionised calcium and high 
PTH at first visit 
25(OH)D≥20ng/ml (patients with low vitamin 
D were treated, and PTH had to be elevated 
after retested at three months).  
Excluded cases with: renal insufficiency, 
calcium malabsorption, hypercalciuria, 
medications (PPI, thiazides, lithium) 
Not clear if they excluded 
people on bisphosphonates, 
GFR cut off not given  
Berger et al. 
Canada 
(community) 
Population-based Canadian 
Multicentre Osteoporosis Study 
(CaMos):  a prospective cohort of 
9423 community-dwelling women 
62 (3.31); 
NA 
NA 
Normal adjusted calcium and high PTH, 
25(OH)D≥50 nmol/L, eGFR≥60 
ml/min/17.73m2 
 
85% were users of 
antiresorptives and diuretics. 
Not clear if they checked 
persistence or other causes 
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(Berger et al, 
2015) 
 
and men living within 50 km of 
nine Canadian cities.  
Included 566 men and 1306 
women  (n=1875) aged 35 years 
or older with available PTH 
of secondary 
hyperparathyroidism 
Cusano et al.  
USA  
(community) 
(Cusano et al, 
2013a) 
 
Dallas Heart Study (DHS): a 
population-based cohort study. 
Evaluated 3450 subjects aged 18-
65 years with calcium and PTH 
values 
2122 patients had follow-up data 
8 years later 
At baseline: 108 
(3.1); 
41.3 years; 
38% female 
 
At follow up: 13 
(0.6%)  
Normal albumin-adjusted calcium and high 
PTH 
Excluded renal insufficiency 
(GFR<60ml/min), 25(OH)D≤20ng/ml, thiazide 
or lithium use 
Only single laboratory values 
and did not check the 
persistence 
Lack of data regarding 
medical history and 
parathyroid surgery 
Not clear if they excluded 
patients on bisphosphonates 
or with hypercalciuria   
Cusano et al.  
USA  
(community) 
(Cusano et al, 
2013a) 
Osteoporotic Fractures in Men 
(MrOS) study, an unselected 
community-based study in older 
men ≥65years. Evaluated 2364 
men with calcium and PTH values 
9 (0.4); 
70.0 years; 
0% female 
Normal albumin-adjusted calcium and high 
PTH 
Excluded renal insufficiency 
(GFR<60ml/min), 25(OH)D≤20ng/ml, thiazide 
use 
Same as DHS study   
Garcia-Martin et 
al. 
Spain  
(community) 
A prospective study in a cohort of 
100 healthy postmenopausal 
women  
All the participants had follow-up 
six years later 
6 (6); 
56.3 years; 
100% female 
 
Normal adjusted calcium and high PTH 
25(OH)D>30ng/ml, normal renal function 
(creatinine clearance>70ml/min/1.73m2) 
Not clear if they excluded 
patients on medications. Not 
clear what they defined as 
"healthy." 
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(Garcia-Martin et 
al, 2012) 
 
At follow up: 6 
(6%) 
Kontogeorgos et 
al. 
Sweden 
(community) 
(Kontogeorgos 
et al, 2015) 
 
Random population sample of 
2400 men and women aged 25-
64 years from the  World Health 
Organization MONItoring of 
trends and determinants for 
CArdiovascular disease (WHO 
MONICA) project. Investigation in 
1995, data on 608  including all 
the women aged 45–64 years, 
every fourth woman aged 25–44 
and every fourth man in all age 
groups (25– 64 years), n=410. 
12 (2.0%); 
53.3 years; 
NA 
 
At follow up: 1 
(0.2%) 
Normal total calcium and high PTH, 25(OH) ≥ 
50 nmol/L, normal renal function 
Patients on 
bisphosphonates, diuretics. 
Only one blood 
measurement at baseline 
Lundgren et al.  
Sweden  
(community) 
(Lundgren et al, 
1997) 
 
Population-based mammography 
screening in 5202 women aged 
55-75 years 
28 (0.5) 
No data on age 
100% female 
Normal ionised calcium. Creatinine 
<160μmol/L and either  
a)calcium<2.50mmol/L+ PTH >55ng/l or 
b)calcium 2.50-2.60 mmol/L + PTH ≥35ng/l 
Checked for persistence (three or more 
occasions). Excluded malabsorption and 
family history of hypercalcemia 
Did not exclude patients on 
medications known to cause 
secondary 
hyperparathyroidism. 
No vitamin D check 
Palermo et al. 
Five European 
cities in the UK, 
France, Germany 
(community) 
(Palermo et al, 
2015) 
Recruited 2419 older women (55-
79y) and 258 younger women 
(30-40y) for the Osteoporosis and 
Ultrasound Study (OPUS) 
Follow up available after six years 
in 1416 patients 
1 (0.1); 
No information 
on age; 
100% female 
 
Mahalanobis distance used: NPHPT anyone 
outside the ellipse with normal adjusted 
calcium, high PTH, 25(OH)D≥50nmol.l, 
GFR≥60ml/min 
Unclear if they excluded 
patients with other causes of 
secondary 
hyperparathyroidism 
(diseases, medication) 
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At follow up: 
none 
Rosario et al.  
Brazil 
(community) 
(Rosário & 
Calsolari, 2019) 
Prospectively recruited adults ≥18 
years who would be submitted to 
thyroidectomy due to nodular 
disease. Excluded patients who 
had an ultrasound due to PHPT, 
patients with a history of 
nephrolithiasis, nephrocalcinosis 
and pathological fracture, 
personal or family history of 
multiple endocrine neoplasia or 
diagnosis of medullary thyroid 
cancer. N=676 
Criterion 1: 
46 (6.8%). Out 
of them only 
8.7% had 
altered 
parathyroid 
glands  
(adenoma) 
during gland 
exploration 
(0.6% of the 
cohort) 
 
Criterion 2: 30 
(4.4%). 
Confirmed 
pathology: 
13.3% 
Criterion 3: 12 
(1.8%). 
Confirmed 
pathology: 
33.3% 
Criterion 4: 5 
(0.74%). 
Criterion 1: Normal adjusted and ionised 
calcium and high PTH, confirmed at two 
measurements, 25(OH)D ≥ 20 ng/dl, eGFR ≥ 
40 ml/min/1.73 m2. Excluded: people on 
diuretics, lithium, bisphosphonates, 
denosumab, recombinant PTH, 
corticosteroids; patients with primary 
aldosteronism, suspicion or known diagnosis 
of malabsorption, hyperphosphatemia, 
calcium/urinary creatine ratio ≥ 0.25, or 
thyroid dysfunction. Screened for coeliac 
disease and excluded patients with positive 
antibodies 
 
Criterion 2: same as criterion 1 but 25(OH)D 
≥ 20 ng/dl, eGFR ≥ 60 ml/min/1.73 m2 
Criterion 3: same as criterion 1 but 25(OH)D 
≥ 30 ng/dl, eGFR ≥ 40 ml/min/1.73 m2 
Criterion 4: same as criterion 1 but 25(OH)D 
≥ 30 ng/dl, eGFR ≥ 60 ml/min/1.73 m2 
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Table 3-4: Studies evaluating the prevalence of normocalcemic hyperparathyroidism (NPHPT).  
PTH: Parathyroid hormone; NA: not available 
Confirmed 
pathology: 80% 
 
Vignali et al.  
Italy 
(community) 
(Vignali et al, 
2015) 
Residents of a village in Southern 
Italy in 2010 (685 with full data) 
3 (0.4) 
47 years 
0% female 
Normal adjusted calcium and high PTH, 
25(OD) ≥30 ng/mL, eGFR ≥60ml/min/1.73m2 
Excluded people on bisphosphonates and 
thiazides, overt gastrointestinal and 
metabolic bone diseases 
Did not check persistence 
and could not check urine 
calcium 
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Study Study population; 
duration of follow 
up 
Definition of NPHPT Progression to hypercalcemia 
Ayturk et al. 
(Ayturk et al, 
2006) 
20; 18 months (6-
month intervals) 
Normal calcium and high PTH confirmed in at least three measurements. 
Excluded: chronic renal or liver failure, vitamin D deficiency, secondary 
hyperparathyroidism, treatment with lithium. 
No treatments with thiazide and loop diuretics, phenytoin, lithium, 
glucocorticoids, oral contraceptives during the study 
None progressed to 
hypercalcemia 
Tordjman et al. 
(Tordjman et al, 
2004) 
 
20; 4.1±3.2 years Normal total calcium and high PTH Secondary hyperparathyroidism 
excluded (impaired renal function). Three patients had low vitamin D 
levels; however, correction did not alter PTH levels and did not unmask 
hypercalcemia. Six patients had >300mg/24h urine calcium, were given 
thiazides without affecting PTH levels 
Persistence not checked at baseline 
None of the patients developed 
hypercalcemia. Their mean 
serum calcium levels did not 
change significantly (baseline 
versus last) 
Garcia-Martin et 
al.  
(Garcia-Martin et 
al, 2012) 
6; 1 year Normal adjusted calcium and high PTH 
25(OH)D>30ng/ml, normal renal function (creatinine 
clearance>70ml/min/1.73m2) 
Persistence not checked at baseline 
All the patients remained 
normocalcemic 
Cusano et al.  
(Cusano et al, 
2013a) 
64; 8 years  Normal albumin-adjusted calcium and high PTH 
Excluded renal insufficiency (GFR<60ml/min), 25(OH)D≤20ng/ml, 
thiazide or lithium use 
Persistence not checked at baseline 
 
Hypercalcemia: 1 (1.6%). 
Persistent normal calcium, high 
PTH: 13 (20%) 
Diri et al.  
(Diri et al, 2014) 
16; 4 years Normal total calcium and high PTH, 25(OH)D >20ng/ml, repeated Ca and 
PTH measurements three times with 2-week intervals, no history of renal 
or liver diseases, no prescriptions known to affect calcium level 
 
1 (6.25%) developed 
hypercalcemia 
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Kontogeorgos et 
al. 
(Kontogeorgos et 
al, 2015) 
12; 13 years 
First assessment 
1995, second in 
2008-2009, 
participation rate 
67% 
Normal total calcium and high PTH, 25(OH) ≥ 50 nmol/L, normal renal 
function 
1 (8.33%) developed 
hypercalcaemia 
Persistent normal calcium, high 
PTH: 1 (8.33%) 
Two had vitamin D deficiency, 
normal calcium and high PTH 
Silverberg et al. 
(Silverberg & 
Bilezikian, 2003) 
22; up to 1 year Normal adjusted calcium and high PTH 
Confirmed on at least two occasions, eight patients had normal iCa, 
25(OH)D>20ng/ml. 
Excluded FHH, liver disease, renal disease, urinary 
calcium>87.5mmol/24h, GI disease with malabsorption, metabolic bone 
disease, medications (lithium, thiazide, oestrogens, loop diuretics, 
bisphosphonates, anticonvulsants) 
 
3 (14%) developed 
hypercalcemia 
Siprova et al. 
(Siprova et al, 
2016) 
187; 
1-7 years 
Normal total and ionised calcium and high PTH 
25(OH)D≥20ng/ml (patients with low vitamin D were treated, and PTH 
had to be elevated after retested at three months).  
Excluded cases with: renal insufficiency, calcium malabsorption, 
hypercalciuria, medications (PPI, thiazides, lithium) 
151 (81%) remained 
normocalcemic for the whole 
follow-up period 
 
36 (19%) became hypercalcemic 
with 13 (36%) being intermittently 
hypercalcemic 
Lowe et al. (Lowe 
et al, 2007) 
37; 3.1±0.3 years Normal adjusted calcium and high PTH, 25(OH)D ≥50 nmol/L 
Excluded cases with renal insufficiency (GFR< 40 ml/min per 1.73 m2), 
liver disease; significant hypercalciuria >350mg/24h, thiazide diuretic or 
lithium use, other metabolic bone diseases (e.g. Paget’s disease) 
Seven (19%) became 
hypercalcemic.  
Patients who became 
hypercalcaemic had higher 
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calcium levels, had higher urinary 
calcium excretion and were older 
 
Table 3-5: Studies evaluating the natural history of normocalcemic hyperparathyroidism (NPHPT).  
PPI: proton pump inhibitors; PTH parathyroid hormone 
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THE PREVALENCE AND NATURAL HISTORY OF NORMOCALCAEMIC 
HYPOPARATHYROIDISM IN A UNITED KINGDOM REFERRAL POPULATION 
Short title: NHYPO: Prevalence and natural history 
Authors: Marian Schini1, Rebecca Stirling1, Richard Jacques2, Eleanor Oakes3, Nicola 
Peel3, Jennifer Walsh1, Richard Eastell1 
1Department of Oncology and Metabolism, University of Sheffield, UK 
2School of Health and Related Research (ScHARR), University of Sheffield, UK 
3Sheffield Teaching Hospitals National Health Service Foundation Trust (STH NHS FT), UK 
 
3.2.1 Summary 
Context: Normocalcaemic hypoparathyroidism (NHYPO) is characterised by persistently low 
levels of parathyroid hormone (PTH) with normal levels of calcium. There is little in current 
literature on this disease, with only two studies published on its prevalence whilst its natural 
history remains relatively unknown.  
Objectives: to identify the prevalence of NHYPO in a UK referral population and to study the 
natural history of the disorder.  
Design: Retrospective study. Follow up five years 
Patients: 6280 patients referred for a BMD measurement in a Metabolic Bone referral centre 
Measurements: Prevalence of NHYPO and variability of calcium  
Results: Based on laboratory results on the index day, 22 patients with NHYPO were 
identified. Four patients were excluded due to non-PTH induced hypocalcaemia and 
unconfirmed data. The final prevalence was 0.29%. Only 67% had persistent 
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normocalcaemia. Two of these patients also had persistently low PTH on two occasions. 
Most of the patients had one PTH measurement available. No patient developed permanent 
hypoparathyroidism.  
Conclusions: The prevalence calculated from this UK referral population is lower when 
compared to results from previous studies. NHYPO patients often have episodes of 
hypocalcaemia with some cases having no apparent reason for calcium levels below the 
reference range. 
Keywords: parathyroid diseases; hypoparathyroidism; hypocalcemia; epidemiology; 
prevalence; calcium metabolism disorders; parathyroid gland; calcium 
 
3.2.2 Introduction 
Calcium is an important mineral in the human body; its regulation within tight normal limits 
is of great importance. Parathyroid hormone (PTH) is the main regulator of calcium 
homeostasis and it regulates calcium levels by altering bone resorption, renal calcium 
excretion and the production of 1,25(OH)2D (Favus & Goltzman, 2013).   
Endocrine disorders are often characterised by a clinical and a subclinical form, such as 
subclinical hyperthyroidism, characterised by suppressed TSH with normal thyroid hormone 
levels (Biondi et al, 2015). Following a similar pattern, a new phenotype of PHPT has been 
presented recently in literature. Normocalcaemic hyperparathyroidism (NPHPT) is a 
disorder of calcium metabolism which is characterised by persistently normal calcium levels 
and consistently elevated PTH values after other causes of secondary hyperparathyroidism 
are excluded (Eastell et al, 2014).  
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On the other side of the spectrum of calcium related disorders, hypoparathyroidism is a rare 
disorder, characterised by low levels of calcium due to a low PTH secretion. The most 
common cause is acquired hypoparathyroidism, mainly seen after anterior neck surgery 
resulting in the damage of the parathyroid glands. A pathophysiological counterpart to 
NPHPT is normocalcaemic hypoparathyroidism (NHYPO), which is characterised by normal 
levels of calcium with persistent low levels of parathyroid hormone (PTH). To our knowledge, 
there is currently no official definition for this disorder. There is little in current literature on 
this disorder, with only two studies (reporting three different populations) published on its 
prevalence, whilst its natural history remains relatively unknown (Cusano et al, 2013a; 
Palermo et al, 2015). The prevalence in these studies is reported to be 1.1-2.4% at baseline.  
Two of these three populations which were quite different, [women from five European cities 
for the Osteoporosis and Ultrasound Study (OPUS) and participants of the Dallas Heart 
Study (DHS), a population-based cohort for the evaluation of cardiovascular disease] were 
then checked six and eight years later (1416 and 2122 patients respectively from each study 
went into follow up) and only 1.1% (out of the original 57 patients, 35 had blood 
measurements and only 15 had persistent findings) and 0.09% (out of the 68 patients 
identified, 26 had a follow up and 2 had persistent findings)  respectively were still 
characterised as having NHYPO.  None developed hypocalcaemic hypoparathyroidism. 
Serum calcium and PTH was only checked on two occasions in these studies, so the natural 
history of serum calcium is unclear. To our knowledge, no one has evaluated this before.  
The primary aims of this study were to identify the prevalence of NHYPO and to study the 
natural history of the disorder, hypothesising that individuals presenting as NHYPO may 
have more labile calcium than the general population. A second aim was to compare the 
variability of adjusted calcium between NHYPO patients and a control group from the same 
cohort.  
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3.2.3 Materials and methods 
3.2.3.1 Study population 
The work was performed at the Metabolic Bone Centre (MBC) at Sheffield Teaching 
Hospitals National Health Service Foundation Trust (STH NHS FT) in the United Kingdom. 
Data from patients referred for a bone mineral density (BMD) measurement between the 
14th January 2013 to the 27th July 2017 were retrospectively evaluated. All the patients 
included in the study had a laboratory evaluation including calcium and PTH, performed 
within 28 days from their scan. In this department, a laboratory work-up for secondary 
osteoporosis is performed in patients having any of the following findings: low BMD for age 
(Z-score<-2), vertebral fracture and/or unexplained, accelerated bone loss since a previous 
scan. The day of the laboratory investigations was defined to be the index day. Any other 
results of calcium and PTH before and after the index day were retrieved from the hospital’s 
records and were used to study the natural history of the disease. Although biochemical 
data were available from 2009 onwards, only the ones performed after the 14th January 2013 
were used, because at that point the laboratory changed the assay for serum calcium and 
this would probably affect the accuracy of the results. The end of the follow up period was 
the 31st July 2018.   
The analysis did not require any ethical approval according to the Sheffield Teaching 
Hospitals Clinical Research Office; it falls under the “case note review” category.  
 
3.2.3.2 Biochemical measurements 
Blood was drawn at any point of the day, so patients were not fasting. All the samples were 
analysed in the Chemical Pathology Laboratory, Sheffield Teaching Hospitals NHS 
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Foundation Trust.  Serum calcium was measured using a Roche/Hitachi Cobas 8000 e702 
automated clinical chemistry analyser (Roche Diagnostics GmbH, Mannheim, Germany).  
The interassay coefficient of variation as measured in the laboratory is 1.1 – 1.5% at 1.52 
mmol/L and 0.6 – 1.1% at 3.07 mmol/L. Albumin measurement was performed using a 
Roche/Hitachi Cobas 8000 e702 analyser (Roche Diagnostics GmbH, Mannheim, 
Germany). The interassay coefficient of variation as measured by the laboratory is 1.5 – 
2.4% at 33.9 g/L and 1.0 – 1.7% at 59.7 g/L. The albumin-adjusted calcium was used for 
this study and was calculated using the following equation (as used by the laboratory). 
!"#$%&'"	)* = ,-&*.	)* + [0.0172(43 − !.:$;<=)] 
The Pathology Harmony reference range has been in use for adjusted calcium since 2011; 
the range reported was 2.20-2.60 nmol/L (8.8-10.4 mg/dL) (Berg, 2014). 
Intact PTH (second generation) was measured using an immunoassay method by the Roche 
Cobas 8000 e602 (Roche Diagnostics GmbH, Mannheim, Germany). The interassay 
coefficient of variation (CV) measured in the laboratory is 2.2 – 3.2% at 34 ng/L, 1.6 – 1.7% 
at 94 ng/L and 1.4 – 1.8% at 839 ng/L, while the reported reference range by the 
manufacturer was 15-65 ng/L (1.6 - 6.9 pmol/L).  
25(OH)D was measured using a competitive binding protein assay and was performed by 
Roche modular analytics Cobas E170 (Roche Diagnostics GmbH, Mannheim, Germany). 
The laboratory interassay coefficient of variation for this assay is 6.5 – 9.9% at 48.2 nmol/L 
and 4.5 – 6.3% at 92.3 nmol/L.  Patients with a level greater or equal to 50 nmol/L were 
considered replete (Aspray et al, 2014). 
Creatinine was measured using a Roche/Hitachi Cobas c8000 e702 analyser (Roche 
Diagnostics GmbH, Mannheim, Germany). The interassay coefficient of variation for this 
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assay was 2.7 – 6.1% at 55.7 μmol/L and 2.3 – 4.0% at 458 μmol/L. The equation used to 
calculate eGFR was the Modification of Diet in Renal Disease (MDRD) Study equation:  
'@AB C ;D;<= × 1.73	;FG = 175 × (Serum	creatine)STTUV × *W'SX.FXY × [0.742	<Z	Z';*.'] 	× 	 [1.212	<Z	:.*[\] 
This equation changed in August 2015; the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation has been in use since then. 
'@AB C ;D;<= × 1.73	;FG = 141 × min C][^\ , 1G` × max C][^\ , 1GST.FXb × 0.993def × 1.018	[<Z	Z';*.'] 	× 	1.159	[<Z	:.*[\] 
Scr is serum creatinine in mg/dL, κ is 0.7 for females and 0.9 for males, α is -0.329 for 
females and -0.411 for males, min indicates the minimum of Scr/κ or 1, max indicates the 
maximum of Scr/κ or 1 (KDIGO, 2012). A level ≥60 ml/min/1.73m2 was considered as normal. 
Alkaline phosphatase was measured using a Roche/Hitachi Cobas c8000 e702 analyser. 
The interassay coefficient of variation for this assay was 2.4% at 92.8 IU/L and 1.7% at 224 
IU/L. The reported reference range was 30-130 IU.  The same analyser was used for the 
measurement of serum phosphate and the interassay coefficient was 1.4% at 1.23 mmol/L 
and 1.2% at 2.04 mmol/L. The reported reference range was 0.8-1.5 mmol/L. 
Bone mineral density was performed using dual-energy X-ray absorptiometry (DXA) of the 
lumbar spine and the proximal femur in posteroanterior projection. At the time of the study, 
there were three Hologic DXA scanners within the centre. The least significant change (LSC) 
used in the MBC was 4.5% for both the spine and the hip. There were three scanning rooms 
in the department and each room has a different scanner. Room A: Hologic Discovery A in 
use since 2010. Room B: Hologic QDR4500A was in use from 2011 until the 11th September 
2013.    The scanner was then decommissioned and replaced by a Hologic Discovery SL. 
Room C: Hologic Delphi C was in use until the 3rd November 2014.  The scanner was then 
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decommissioned and replaced by a Hologic Horizon A. The different DXA scanners were 
cross-calibrated upon installation. 
 
3.2.3.3 Statistical analysis  
Due to the fact that calcium and PTH are not independent variables, it was considered best 
to use a bivariate statistical approach to define the different categories of patients. 
Mahalanobis distance is a multi-dimensional generalization of the idea of measuring how 
many standard deviations (SD) away an observation is from the mean of a distribution. It is 
a classical method of defining outliers in a multivariate point cloud and is defined for each 
point xi, by the following equation, where MDi: Mahalanobis distance, μ: arithmetic mean of 
the dataset and S: sample covariance matrix (this is a robust covariance matrix using the 
minimum volume ellipsoid method). 
hijF = (kj − l)m]ST(kj − l) 
The distance MDi gives the distance of point xi from the centre of the cluster of points, taking 
into account the shape of the cluster. Observations are considered outliers if MD2>Χ22;0.975 
=7.378 [97,5th percentile of a chi-squared (X) distribution with two degrees of freedom] 
(Rousseeuw & van Zomeren, 1990; Van Aelst & Rousseeuw, 2009). The correlation analysis 
of adjusted calcium and PTH was performed based on a log10 transformation of the two 
variables.  A similar approach has been used in the past to evaluate the prevalence of 
NHYPO in a different group of patients (Palermo et al, 2015).  Using this method, subjects 
were identified as “normal” if they were inside the ellipse and “abnormal” if they were outside. 
Using the laboratory reference intervals for calcium and PTH, patients were divided into 10 
categories as described below. “High” or “low” are referred to values of either adjusted 
calcium or PTH being above or below the reference range respectively.  
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To compare the variability of calcium in the two groups, the within-subject standard deviation 
was calculated. The analysis of variance method was used to calculate the within subject 
variance, as this method deals with the case of subjects having different numbers of 
observations. To follow this method, we first checked the assumption that the standard 
deviation was unrelated to the magnitude of the measurement. This was done graphically, 
by plotting the individual subjects’ standard deviations against their means and analytically 
by calculating a rank correlation coefficient (Bland & Altman, 1996a).  
The independent samples t-test and the Mann-Whitney test were used to compare 
quantitative data, while chi-square was used for the analysis of categorical data. The results 
are presented as mean and standard deviation when the data were normally distributed, as 
geometric mean and 95% confidence intervals when log transformation was performed in 
order to achieve a normal distribution of the data, and median and interquartile range (IQR) 
in the case where non-parametric tests were used for the analysis. For the comparison of 
the overall measurements of PTH and adjusted calcium resulting from follow up, we used a 
mixed linear model. Individual variability was modelled using a random effect and the 
difference between groups was estimated using a fixed effect. The statistical analyses have 
been performed using the R studio statistical software version 1.1.442 (RStudio, Inc. 
Boston). 
 
3.2.3.4 Definitions of the different groups  
As mentioned in the statistics section, patients were divided into ten categories based on 
their laboratory intervals for adjusted calcium and PTH. The groups of interest for this study 
were defined as follows. Normal: anyone inside the ellipse; Provisional normocalcaemic 
hypoparathyroidism (NHYPO): normal adjusted calcium and low PTH on the index date. 
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Hypoparathyroidism: low adjusted calcium and low PTH. In order to characterise these 
groups further, the following procedures were followed.  
For the NHYPO group, the patients’ medical notes were reviewed to look for other causes 
of the abnormalities found. Any unconfirmed data were excluded. For the control population, 
a random sample of 300 subjects from inside the ellipse having normal eGFR and being 
vitamin D replete (as defined above) on the index date was chosen.  
 
3.2.4 Results 
In total, 6293 patients attended the Metabolic Bone Centre and were assessed for 
secondary osteoporosis from January 2013 to July 2017. All these patients had a BMD 
measurement and a laboratory evaluation. Thirteen patients did not have PTH available on 
the index day and were excluded. The total number of patients analysed was 6280; their 
mean age was 66 years (range 16-100) and 72% were female. All these patients were given 
a study ID number starting from S0001 to S6280.  After applying the Mahalanobis distance, 
the ellipse seen on Figure 3-6 was formed by using the measurements of PTH and adjusted 
calcium from the index date (single measurement of each variable per patient).. In total, 
5574 patients were inside the ellipse and were considered as “normal” while the rest were 
outliers.  Twenty-two patients fulfilled the criteria for NHYPO. The evaluation of their medical 
files excluded four patients. Three patients were excluded because of non-PTH induced 
hypercalcaemia; S0051 due to myeloma, while S1743 and S5588 due to metastatic cancer. 
S0756 was excluded because of the results extracted by the IT department could not be 
confirmed.  
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Figure 3-6: Data results from adjusted calcium and PTH.  
The ellipse was formed using a statistical method (Mahalanobis distance) to identify “normal” subjects (black 
dots) and “abnormal” ones (red dots). The laboratory’s reference range of both adjusted calcium and PTH 
(horizontal and vertical dashed lines respectively), were used to identify patient categories. The shaded area 
includes patients with normocalcaemic hypoparathyroidism (NHYPO).  
 
The group of provisional NHYPO patients consisted of eighteen patients (mean age 45, SD 
16.4 years, 61% female). The prevalence for this population was 0.29% (95% confidence 
interval 0.18-0.45%). None of these patients had previous anterior neck surgery or radiation. 
None of them was on active vitamin D. We noted that some patients had other conditions 
that could affect PTH results [thiazides n=1, antiepileptic medications n=4 (both conditions 
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can increase PTH levels); one patient had coeliac disease which can cause secondary 
hyperparathyroidism and thalassaemia which can cause functional hypoparathyroidism; four 
patients were consuming increased levels of alcohol)..  
When studying the natural history, two patterns were identified (Figure 3-7): persistent 
normocalcaemia (in twelve patients, 67%) and intermittent hypocalcaemia (in five patients 
28%). One patient only had one measurement of calcium during the follow up period 
(S5738). The minimum, maximum and average values of the adjusted calcium were 
calculated for each patient, and the graphs of the means and the range of values were drawn 
(Figure 3-8). There were no statistical differences in these two groups in terms of age, 
gender distribution, average adjusted calcium and PTH levels (all p values >0.05). In three 
of the patients with intermittent hypocalcaemia, the observed decreases in calcium could be 
explained (the most common cause was vomiting). One patient had one low measurement 
of calcium with no apparent reason explaining the results. Finally, one patient had one 
measurement of low calcium measurements during an epileptic seizure, one linked to low 
vitamin D levels and a third one where no obvious reason for hypocalcaemia was identified.  
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Figure 3-7: The two patterns identified in patients with normocalcaemic hypoparathyroidism when studying the 
natural history of adjusted calcium.  
Persistent normocalcaemia (left top figure, patient S2157) and, intermittent hypocalcaemia (right top figure, 
patient S0161). The dotted lines represent the normal range for adjusted calcium. Both patients were on 
calcium and vitamin D supplements. The bottom graphs represent the variability of parathyroid hormone (PTH). 
None of the two patients maintained low parathyroid hormone throughout their follow up. The increase of PTH 
observed in the patient on the left, could be due to the initiation of zoledronic acid. The dotted line represents 
the lower normal of the reference range for PTH. Adj.Ca: adjusted calcium.  
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Figure 3-8: Means and range of values of different analytes in the 18 NHYPO patients.  
Out of them, only 67% had persistent normocalcaemia (shown in the red arrows). One patient had only one 
measurement available. The dashed lines represent the reference range for adjusted calcium, NHYPO: 
Normocalcemic hypoparathyroidism 
 
When looking at the number of available PTH measurements, eight patients had only one 
measurement of PTH during their follow up. Six patients had two measurements amongst 
which one was low, while one had both measurements below the reference range. Three 
patients had more than two measurements, with two of them having persistently low PTH 
on two occasions.  
Only one patient from the whole population was found to have hypoparathyroidism. This 
patient had thyroidectomy for papillary cancer and developed hypocalcaemia as a result of 
this. The patient recovered spontaneously after a few months.  The control population group 
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consisted of 300 subjects (mean age 67, SD 15.6 years, 71% female). The characteristics 
of the two groups on the index date are summarised in Table 3-6. There were statistically 
significant differences in the age and BMI of the two groups; NHYPO patients were younger 
and had lower BMI. The gender distribution did not differ between the groups. Patients with 
NHYPO had significantly lower PTH and higher phosphate. Alkaline phosphatase and 
vitamin D levels did not differ between the groups. The NHYPO group had lower age and 
gender adjusted BMD estimates.  
 
 Control (n=300) NHYPO (n=18) p value 
Female (%) 214 (71) 11 (61) 0.354 
Age (years)b 70 (20) 47 (24) <0.001 
BMI (g/cm2)c 25.6 (25.0 - 26.3) 22.6 (20.5 – 24.6) 0.020 
PTH (ng/L)c 42.5 (40.8 – 44.1) 11.1 (10.3 - 11.9) <0.001 
Adjusted calcium (mmol/L)a 2.37 (0.08) 2.43 (0.09) 0.006 
Phosphate (mmol/L)a 1.12 (0.18) 1.26 (0.18) 0.003 
Alkaline phosphatase (IU/L)b 78 (37) 93 (36) 0.059 
25(OH)D (nmol/L)b 78.9 (32.9) 78.3 (61.1) 0.561 
Z score spine a -0.2 (1.7) -1.5 (1.2) <0.001 
Z score neck a -0.4 (1.0) -1.1 (1.0) 0.011 
Table 3-6: Characteristics of the two groups on the index date. 
 a shown as mean (standard deviation); b shown as median (interquartile range); c results from multiple linear 
regression analysis after adjusting for age, weight and gender. The bold letters show the significant differences; 
BMI: body mass index; PTH: parathyroid hormone; NHYPO: normocalcemic hypoparathyroidism 
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Interestingly, the adjusted calcium on the index date was higher in the control population. 
However, after taking all the follow-up measurements into account, the mean adjusted 
calcium was found to be similar in the NHYPO group compared with the control group (mean 
adjusted 2.34 and 2.35 mmol/L for NHYPO and control group respectively, p=0.496). The 
variability of calcium in the NHYPO group was significantly higher than the control group 
[within-subject SD 0.096 (95% CI 0.085, 0.108) and 0.083 (95% CI 0.080, 0.085) mmol/L 
respectively).  After taking all the follow-up measurements of PTH into account, the mean 
PTH was found to be lower in the NHYPO compared with the control group (mean PTH 15.8 
and 48.0 ng/L respectively, p<0.001). 
 
3.2.5 Discussion 
Normocalcaemic hypoparathyroidism is a disorder characterised by low PTH and normal 
calcium on which limited information is available. To our knowledge, this is the first study of 
the prevalence in a tertiary centre and the also the first study of the natural history of this 
disease; previous studies only showed results from two time-points.  We retrospectively 
evaluated 6280 patients attending a referral centre and identified eighteen patients with 
NHYPO on the index date (prevalence 0.29%). Out of them, only 67% had persistent 
normocalcaemia. The number of PTH measurements on these patients were limited, with 
only one patient having persistently low PTH. 
The prevalence of NHYPO has been studied previously in the community. Palermo et al 
studied the prevalence in 2419 older (55-79 years old) and 258 younger (30-40 years old) 
women from five European cities for the Osteoporosis and Ultrasound Study (OPUS) and 
identified 57 subjects with NHYPO (prevalence 2.4%), using a similar approach as in our 
study. In order to get the different categories described above, they used the reference 
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range for adjusted calcium, but for PTH, they used the geometric mean of the reference 
range, which probably explains the higher baseline prevalence presented in their study 
(Palermo et al, 2015). We have adjusted this method and brought it closer to the everyday 
clinical practice, by using both the Mahalanobis distance and the reference range for both 
adjusted calcium and PTH.  In the Palermo et al study, the adjusted calcium at baseline was 
similar to the control population, while PTH was significantly lower in the NHYPO group.  
Age, BMI and 25(OH)D were similar between the two groups. Six years later, the 
measurements were repeated once in 1416 subjects; only 0.6% of the initial population 
(1.1% of the ones that went into follow up) expressed persistent characteristics of NHYPO 
(Palermo et al, 2015). Our study showed some differences in baseline characteristics, with 
NHYPO patients being younger, having a lower BMI and higher adjusted calcium than the 
control. The age inclusion criteria in the OPUS study were more strict and thus the difference 
in the results. We only found a higher adjusted calcium at the index date. When taking all 
the repeated measurements into consideration, the levels between NHYPO and control 
were similar. The cohorts differed as OPUS participants were randomly selected compared 
to our cohort in whom there was clinical concern about bone health. 
Cusano et al studied two non-referral populations, the Osteoporotic Fractures in Men 
(MrOS) and the Dallas Heart Study (DHS) (Cusano et al, 2013a).  MrOS is an unselected 
community-based study in older men aged 65 years or older that had no bilateral hip 
fractures. They randomly selected 2503 subjects, and after excluding 139 without calcium 
measurements, they evaluated 2364 men from this study. Using the baseline values, they 
identified 26 participants (prevalence 1.1%) with NHYPO. They also found lower levels of 
PTH in the NHYPO group when compared to the group having normal PTH. The level of 
adjusted calcium was similar between the groups. They did not find a significant difference 
in age between the groups, unlike our study; however, they only included patients over 65 
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years. BMI was also similar between the groups, while in our study, NHYPO patients were 
slimmer. BMD results were similar (Cusano et al, 2013a). Our study found lower Z-scores 
in the NHYPO population on the index date. One explanation for this could be the slightly 
lower BMI in this group. Another possible explanation could be the fact that younger patients 
are more likely to have causes of secondary osteoporosis and thus relatively more affected 
than the older population investigated. Interestingly, this study found significantly higher 
consumption of calcium supplements ≥1000mg in the NHYPO group (54% versus 23% in 
the group with normal PTH). The dose of vitamin D supplements was similar between the 
groups (Cusano et al, 2013a). This could be the explanation to the fact that the adjusted 
calcium at baseline was slightly higher in the NHYPO group, an observation also seen in 
our study. 
DHS is a population-based cohort for the evaluation of cardiovascular disease. In brief, this 
group evaluated 3557 subjects out of 6101 (aged 18 to 65 years) and excluded 107 because 
of lack of PTH or 25(OH)D levels, leaving 3450 subjects for the analysis (Cusano et al, 
2013a). They reported a prevalence of 1.9% (68 patients were identified) from the baseline 
measurements. Age, BMI, baseline adjusted calcium and phosphorus did not differ between 
the groups. There was a statistical difference in vitamin D, with the patients with normal PTH 
having lower levels (Cusano et al, 2013a). This was not observed in our study, however we 
only included subjects with normal vitamin D at baseline in our control group. We also found 
higher levels of phosphate in the NHYPO group on the index date. The DHS study included 
a follow up (for 2122 subjects), where a single measurement was performed eight years 
later; out of the 26 subjects with NHYPO that went into follow up, none developed 
hypocalcaemia. Only two had persistent NHYPO (prevalence 0.09% of the population that 
went into follow up). Most of them (20 out of 26) had normal PTH (Cusano et al, 2013a). 
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Normocalcemic hypoparathyroidism was previously characterised as a state of “low bone 
turnover”, as patients with this disorder were found to have lower bone ALP, collagen type 
1 cross-linked C-telopeptide (CTX) and osteocalcin compared to the normal population but 
without a significant BMD change over time (Palermo et al, 2015). The authors suggested a 
critical evaluation of potential treatment for osteoporosis in these patients, as medications 
like bisphosphonates can suppress bone turnover further and exacerbate adynamic bone 
disease (Palermo et al, 2015). Moreover, studies with teriparatide did not improve BMD in 
patients with hypoparathyroidism (Cusano et al, 2012). The question of which treatment to 
use in this group of patients becomes more relevant in our study, as all the patients were 
identified during a laboratory investigation for secondary osteoporosis.  
There was a limited number of PTH measurements throughout the patients’ follow up in our 
study; eight patients out of the eighteen identified as having NHYPO had only one 
measurement available. This suggests that physicians are not so concerned about finding 
a low level of PTH and they do not tend to follow this up further. However, this disorder could 
be the subclinical form of hypoparathyroidism. Moreover, these patients might be more 
prone to developing hypocalcaemia after they receive medications that can affect calcium 
levels (eg bisphosphonates, loop diuretics, denosumab) or after they develop common 
symptoms; in our population, three of the NHYPO patients had incidence of hypocalcaemia 
due to vomiting. Interestingly, some episodes of hypocalcaemia in our patients could not be 
explained. Therefore, the low levels could be theoretically attributed to the variability of 
calcium. A concern is that hypocalcaemia can be a cause of cardiac arrhythmias and 
epileptic seizures (Cooper & Gittoes, 2008). One of the patients from this population had 
low levels of calcium during an epileptic fit.  
Interestingly, four of our patients were known to have epilepsy and were on treatment with 
antiepileptics which are known to cause an increase in PTH, however, a low level was found 
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(Pack, 2003). One patient was on thiazides and one patient had coeliac disease, both known 
causes of high PTH.  The patient with coeliac disease also had thalassaemia, so PTH could 
had been low due to the iron load in the parathyroids, a known cause of hypoparathyroidism. 
Another four patients were consuming increased levels of alcohol, which has been reported 
to decrease the levels of PTH (Venkat et al, 2009). Unfortunately, magnesium was not 
available to check for hypomagnesaemia.  
Further information on this disorder is needed before any official recommendations are 
made but we think that NHYPO should be mentioned in any future guidelines on 
hypoparathyroidism as it is not mentioned in the current ones (Bollerslev et al, 2015; Brandi 
et al, 2016); its pathophysiological counterpart, normocalcaemic hyperparathyroidism, is 
already part of international guidelines (Bilezikian et al, 2014). As mentioned before, there 
is no official definition for NHYPO, but we propose the following definition: normal calcium 
with low PTH should be confirmed on at least two occasions, but normocalcaemia does not 
have to be persistent as long as the average level of calcium is normal; episodes of 
hypocalcaemia can be part of the presentation. As for hypoparathyroidism, we propose that 
NHYPO includes both idiopathic and functional forms of hypoparathyroidism.  
More research should be performed to further characterise this population, ideally a 
prospective, long-term study with repeated measurements of calcium and PTH. The patients 
identified should then be further characterised with more dedicated studies of calcium 
metabolism. Genetic studies would also be of interest. An explanation for this disorder could 
be that it is a mild form of activating CaSR mutation which results in the alteration of the set 
point for PTH. A mutation on the CaSR was reported in patients with normocalcaemic 
hyperparathyroidism(Díaz-Soto et al, 2016). 
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This study describes the largest population ever studied to identify provisional NHYPO and 
provides data during a long follow up period (five years). It is the first study that provides 
data on the natural history with adjusted calcium measurements available on more than two 
timepoints. There are several limitations in this study.  The patients studied were identified 
from a referral centre and they were evaluated for causes of secondary osteoporosis, so 
they might be different than the general population. The samples were not fasting, a 
tourniquet was used to take blood, ionised calcium and magnesium were not available and 
there were not many repeated measurements of PTH. The PTH molecule is rapidly 
degraded and it was difficult to exclude pre-analytical variations for an inappropriate low 
PTH level. This was a retrospective observational study and the number of measurements 
varied from patient to patient. The persistence of the results could not be always confirmed. 
The interval between the measurements was not the same, as expected in a real-life setting. 
This limited the possibility of further analyses. The analysis for the within-subject SD did not 
consider the effect of time. Ideally, to give a more accurate estimate of the variance, a 
prospective observational study should be designed, having the same number of 
measurements for each patient at regular intervals. The analysis should be preferably done 
using a model that takes time into account. Despite the limitations, this study provided a 
guide to how adjusted calcium varies between the different groups described.  
In summary, we retrospectively evaluated a referral population and found a low prevalence 
of patients with normocalcaemic hypoparathyroidism. The most common pattern was 
persistent normocalcaemia (67%), but there were patients that had intermittent 
hypocalcaemia. None developed persistent hypoparathyroidism.  The clinical implication of 
this study is that if a patient has low PTH but normal serum calcium they should have regular 
follow-up as they could become hypocalcaemic at some point and can have clinical 
consequences like epilepsy. The findings of normal calcium and low PTH have to be 
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confirmed before a certain diagnosis is made. Further studies are needed to characterise 
this group further. 
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Section 3: Further analyses  
3.3.1 Introduction 
In the previous two sections the prevalence and natural history of normocalcaemic 
hyperparathyroidism and hypoparathyroidism were studied, using a statistical approach 
called Mahalanobis distance and forming an ellipse with the different groups of patients. 
In order to check whether different characteristics of the population like age, vitamin D status 
and eGFR level would affect the ellipse, some further analyses were planned and presented 
here. 
Moreover, in order to calculate the within-subject SD in these groups, I made some 
assumptions like non-progression of the disease and used an approach described in 
literature (Bland & Altman, 1996a) which might underestimate the variability for some 
patients (Masse, 1997). In order to try and overcome these limitations and supplement the 
previous results, I performed some further analyses. One approach suggested is to use the 
90th centile of the within subject variance (Masse, 1997). I also looked whether these 
patients progressed through time and recalculated the within-subject SD after excluding 
these patients. 
 
3.3.2 Results 
3.3.2.1 The effect of various factors on the shape and position of the ellipse 
3.3.2.1.1 Original ellipse: the patients selected 
This ellipse (Figure 3-9) shows the different patients included in the analyses for 
normocalcaemic hyperparathyroidism (NPHPT). It was interesting to see that all the selected 
NPHPT were at the upper normal range of adjusted calcium. 
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Figure 3-9. Ellipse showing the selected patients from the normocalcaemic hyperparathyroidism (yellow 
squares), primary hyperparathyroidism (blue triangles) and the control group (green circles) 
 
3.3.2.1.2 Effect of age, kidney function and vitamin D status 
In order to see how the format of the ellipse described in previous chapters changes with 
increasing age, CKD and vitamin D status, different ellipses were formed as seen in the 
following figures. The code for doing this can be found in the Supplementary material (code 
4.2).  
As expected, as age increases, the number of people with higher PTH increases and the 
ellipse moves to the right. Similar results were observed with vitamin D deficiency and CKD; 
increasing numbers of subjects had higher PTH levels.  
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Figure 3-10: Comparison of the ellipse formed using all patient information (n=6280) and the one formed by 
subjects being vitamin D replete and having normal eGFR.  
Fewer people have PTH levels which are outside the reference interval 
 
 
Figure 3-11: The effect of increasing age on the shape and position of the ellipse.  
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The patients were grouped in tertiles as follows. 1: age ≤61.3 years; 2: age 61.3 - 75.4 years; 3: age ≥ 75.4 
years. As age increased, the ellipse moved towards the right and more people were found to have increased 
PTH, either presented as hypercalcaemic hypercalcaemia or isolated increased PTH with normal calcium 
 
 
Figure 3-12: The effect of vitamin D status in nmol/L on the ellipse.  
As expected, when evaluating vitamin D deficient subjects (on the right), more people were found to have high 
PTH with normal calcium (consistent with secondary hyperparathyroidism)  
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E  
Figure 3-13: The effect of kidney function on the ellipse. 
The different stages are defined as follows. G1: ≥90, G2: 60-89, G3a: eGFR 45-59, G3b: 30-44, G4: 15-29, 
G5: <15 ml/min/1.73 m2 (KDIGO, 2012). As expected, patients with lower eGFR were more likely to have 
higher PTH values (consistent with secondary hyperparathyroidism) 
 
Chapter 3: Metabolic Bone Centre analyses 
Section 3:Further analyses 
 
 262 
3.3.2.1.3 Comparison of the subjects within the normal population 
I used a statistical approach to define the different categories in this population. The results 
showed that a large percentage of subjects were considered “normal” (inside the ellipse) 
using this approach, even though they had elevated PTH according to the laboratory 
reference interval. The subjects that were inside the ellipse but had higher PTH than the 
upper limit of the reference interval (group 2), were found to be significantly older than the 
ones that were inside the ellipse and also had normal PTH according to the current reference 
interval (group 1) (Figure 3-14). Their mean age of group 1 and 2 was 64 and 71 years 
respectively (p<0.001). The mean vitamin D was lower in group 2 (45 vs 62 nmol/L in group 
1, p<0.001). The mean eGFR was also lower in group 2 (68 vs 78 ml/min/1.73m2 in group 
1, p<0.001). These results align well with the fact that PTH is known to increase with age. 
 
Figure 3-14: There were two groups of subjects inside the ellipse. 
The subjects that were inside the ellipse but had higher PTH than the upper limit of the reference interval 
(group 2); the ones that were inside the ellipse and also had normal PTH according to the current reference 
interval (group 1) 
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3.3.2.1.4 Parathyroid hormone and age 
When dividing the population in age tertiles (Q1: age ≤61.3 years; Q2: age 61.3 - 75.4 years; 
Q3: age ≥ 75.4 years), there was a significant difference in PTH in the three groups 
(p<0.001), with PTH being higher as age increased (Figure 3-15). The same results were 
found when repeating the analysis with only patients with normal eGFR and vitamin D. 
 
Figure 3-15: Boxplot of the different PTH levels according to age group  
Q1: age ≤61.3 years; Q2: age 61.3 - 75.4 years; Q3: age ≥ 75.4 years; p<0.001 
PTH was positively correlated with age. A multiple linear regression was then performed, 
adjusting for different factors (age, sex, vitamin D, eGFR, adjusted calcium, phosphate, 
BMI). Overall, age, eGFR, vitamin D, adjusted calcium and phosphate were independent 
predictors of the PTH level. 
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The multiple linear regression analysis was repeated after excluding patients with low 
vitamin D and eGFR, adjusting for the same factors as before. In this case, age, vitamin D, 
adjusted calcium, phosphate and BMI were independent predictors of the PTH level. 
 
3.3.2.2 Within subject standard deviation analyses  
3.3.2.2.1 Using the 90th centile 
I used an approach described by Bland & Altman (Bland & Altman, 1996a) to calculate the 
within-subject standard deviation for adjusted calcium in the referral population. 
In order to perform this analysis, the assumption that standard deviations across the 
subjects are similar should be made. However, this is not true in all clinical situations. Using 
a single “mean” within-standard deviation might underestimate the variability for some 
patients (Masse, 1997). I understand that this is a limitation of this approach and that the 
true within-subject SD might be bigger. 
A suggested approach to overcome this problem is to use the 90th centile of the within 
subject variance. This method is considered to be a conservative approach (Masse, 1997). 
The code to calculate these variables can be found in the Supplementary material (code 
4.1). The results are seen in Table 3-7. 
 
Previously calculated SD (mmol/L) 
using analysis of variance 
90th SD (mmol/L) 
Control 0.083  0.105 
NPHPT 0.089  0.115 
NHYPO 0.096 0.163 
PHPT 0.088  0.112 
Table 3-7: Results for within-subject standard deviation (SD) for adjusted calcium when taking into account 
the 90th centile of the variances.  
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NPHPT: normocalcaemic hyperparathyroidism, NHYPO: normocalcaemic hypoparathyroidism, PHPT: primary 
hyperparathyroidism 
 
3.3.2.2.2 Looking for disease progression and recalculating within subject SD 
Another limitation of using the above mentioned approach when calculating the within-
subject SD for the different categories of patients (NPHPT, NHYPO, PHPT, controls) is that 
I am making the assumption that all patients remain stable and there is no disease 
progression, therefore that variations are due to random variation. To check this assumption, 
I used the history graphs of adjusted calcium over time for every subject fitted with a 
regression line (n=11 NPHPT, n=17 PHPT, n=18 NHYPO, n=300 controls). I looked for 
subjects that had a significant trend, upwards or downwards (p<0.05).  
Overall, one subject with NHYPO showed a downward trend (6%), two subjects with PHPT 
showed an upward trend (12%), two subjects with NPHPT had a downward trend and one 
had an upward trend (23%) and 37 controls had a trend (12%), with 19 being downward. As 
these percentages were greater that what would be expected from a type I error (probability 
of rejecting the null hypothesis given that it is true, 5% with p value of 0.05), I decided to 
recalculate the SD after excluding these subjects.  
 
Previously calculated SD (mmol/L) 
using analysis of variance 
SD (mmol/L) after excluding  
subjects with trends 
Control 0.083  0.083 
NPHPT 0.089  0.083 
NHYPO 0.096 0.099 
PHPT 0.088  0.080 
Table 3-8: Results for within-subject standard deviation (SD) for adjusted calcium after excluding subjects that 
had a upwards or downwards trend through time when plotting adjusted calcium against time.  
NPHPT: normocalcaemic hyperparathyroidism, NHYPO: normocalcaemic hypoparathyroidism, PHPT: primary 
hyperparathyroidism 
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The recalculated SDs were slightly lower than the previous ones, as expected. The only 
exception was NHYPO. This could be due to the fact that the subjects had the greater 
variability. 
When the Bonferroni correction was applied to these analyses, no patient had a significant 
trend. 
 
3.3.2.2.3 Least significant change 
The least significant change is a term used in everyday practice in order to evaluate whether 
one measurement has significant change from the previous one. This can be calculated for 
a 95% confidence level and is done by multiplying the within-subject SD by 2.77 as 
mentioned in the methods  (Table 3-9).  
The least significant change given, could be used in two ways in these patients. First, it gives 
a range to which values are expected. For example, for a patient with NPHPT having an 
adjusted Ca of 2.55 mmol/L, the LSC is 0.25, so the next measurement would lie between 
2.30 and 2.80 mmol/L, hence it could be high. This can provide some reassurance for the 
patient and the physician. Moreover, it can be a marker of whether an individual has an 
actual significant change of his calcium. Some patients with NPHPT are being operated and 
using the given LSC estimates, the physician can make sure that there was a statistically 
significant drop in calcium as a result of the parathyroidectomy. In NHYPO patients, it can 
be a marker of whether an individual has an actual significant change of their calcium in 
case of observed hypocalcaemia after receiving a medication or after a disease that can 
cause low calcium.  
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According to the international guidelines, one of the recommendations for surgery on PHPT 
is when the serum calcium is more than 0.25 mmol/L from the upper limit of normal. The 
panel recommended this threshold based on two considerations, namely symptoms and 
variability (Bilezikian et al, 2014). It was interesting to see that the LSC in a patient with 
PHPT who does not have CKD or vitamin D deficiency at baseline in the MBC population 
was 0.24 mmol/L. Of course, if a patient fluctuates between deficiency and normal vitamin 
D status, this would have a larger LSC. 
 
LSC (mmol/L) Using the analysis of 
variance approach  
Using the conservative 
approach 
After excluding  
subjects with trends 
Control 0.23  0.29 0.23 
NPHPT 0.25  0.32 0.23 
NHYPO 0.27 0.45 0.27 
PHPT 0.24  0.31 0.22 
Table 3-9: Least significant change for the different groups.  
This was calculated using: the original data (analysis of variance approach); the results from the conservative 
approach of taking the 90th centile of the variances; the results after excluding subjects that had a upwards or 
downwards trend through time when plotting adjusted calcium against time. NPHPT: normocalcaemic 
hyperparathyroidism, NHYPO: normocalcaemic hypoparathyroidism, PHPT: primary hyperparathyroidism 
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Section 1: UK Biobank studies 
4.1.1 Introduction 
In the previous chapters, the natural history of normocalcaemic hyperparathyroidism and 
hypoparathyroidism has been reported and it was found that persistent normocalcaemia in 
these disorders is rare and these patients often experience intermittent hypercalcaemia 
(NPHPT) and hypocalcaemia (NHYPO). Measures of the variability of adjusted calcium in 
the different groups were calculated and presented (NPHPT, NHYPO, controls, primary 
hyperparathyroidism).  
This phenomenon complicates the management of these patients. However, the problem 
with these studies, was that they were performed in a tertiary referral population and the 
results may not be generalisable in the wider United Kingdom (UK) population. 
In order to study the variability of adjusted calcium further, data from the general population 
were studied. UK Biobank is the largest health resource in the United Kingdom, with data 
on half a million participants aged 40-69 years, equally represented from both sexes.  
 
4.1.2 Methods 
4.1.2.1 Setting 
In brief, I wanted to compare the results found from the MBC population projects, to data 
coming from the general population. I wanted to know how representative the MBC 
population was and whether the results could theoretically be generalised to the wider 
population. 
I looked for already collected data from a UK population and the best-established database 
for these studies at the time of the study was the UK Biobank. This project was in 
collaboration with Dr Fadil Hannan in the University of Liverpool who kindly completed the 
applications for retrieving the data and supported the project.   
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All the information included in this section is available at the official UK Biobank website 
(https://www.ukbiobank.ac.uk) (UKBiobank).  
 
4.1.2.2 The UK Biobank  
UK Biobank is a large health resource which has the aim of improving prevention, diagnosis 
and treatment of a wide range of serious illnesses. It is a registered charity with an initial 
funding of approximately £62 million. It was established by the Wellcome Trust medical 
charity, Medical Research Council, Department of Health, Scottish Government and the 
Northwest Regional Development Agency. It also had funding from the Welsh Government, 
British Heart Foundation, Cancer Research UK and Diabetes UK. It is also supported by the 
National Health Service (NHS). 
UK Biobank has data on half a million participants aged 40-69 years, equally represented 
from both sexes. These were recruited throughout the UK between 2006 and 2010. Apart 
from the baseline visit, a repeat assessment visit was also carried out between August 2012 
and June 2013 at the UK Biobank co-ordinating centre in Stockport. This included a subset 
of 20000 participants who lived within a 35 km radius of the assessment centre. 
There were twenty-two assessment centres throughout the UK (Figure 4-1). In Sheffield (ID 
11014), patients were recruited between August 2009 and July 2010 (n=30399, 5.81% of 
the total population). 
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Figure 4-1: Map of assessment centres for the UK Biobank study.  
Figure used with permission from the UK Biobank 
4.1.2.2.1 Data included in the UK Biobank 
The data available by the UK Biobank are divided in the categories described below. All the 
data are labelled in the format “F_I_A”, where F is the field ID, I is the instance index (see 
below) and A is the array index (if more than one measurement was performed on the same 
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date). An example is given for calcium: 30680-0.0 is the baseline assessment and 30680-
1.0 is the first follow up. Only one measurement was performed on each day. 
 
1. Data collected in the assessment phase (instance 0) 
UK Biobank designed twenty-two special assessment centres throughout the UK to recruit 
patients. Data collected at the assessment visit included 
• Information on a participant’s health and lifestyle, hearing and cognitive function, 
collected through a touchscreen questionnaire and brief verbal interview 
• Physical measurements, which included: blood pressure, arterial stiffness, eye 
measures, body composition measures, hand-grip strength, ultrasound bone 
densitometry, spirometry, and an exercise/fitness test  
• Samples of blood, urine and saliva  
There was a pilot phase of the recruitment performed in 2006 including over 3000 
participants. There have been some differences in the data collected between the pilot 
phase and the main recruitment and differences could be seen in the data; pilot data fields 
have the identifier “pilot” in the name.  
2. Data collected at the repeat assessment centre (instance 1) 
As mentioned above, participants living within a 35 km radius of the assessment centre were 
invited to a further appointment. This included 20000 participants. 
 
4.1.2.2.2 Timelines of data collection and release of data 
Pilot phase 
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March - June 2006: UK Biobank Pilot Assessment 
Main Phase (baseline assessment) 
April 2007 
• Opening of the first follow up centre (touchscreen questionnaire, physical 
measurements, biological samples) 
Additional data collected 
April 2009  
• Touchscreen Questionnaire: Hearing test, cognitive function tests 
• Heel ultrasound (both heels, previously just one), arterial stiffness 
• 24-hour recall diet questionnaire 
August 2009 
• Eye measures (visual acuity, autorefraction, intraocular pressure) 
• Blood collection: RNA blood sample, saliva sample 
December 2009 
• Eye measures (optical coherence tomography) 
• Exercise test/ECG 
July 2010: Recruitment ends 
March 2012: UK Biobank Resource was launched 
The data release from the UK Biobank was gradual. 
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4.1.2.2.3 Characteristics of responders versus non-responders in the repeat assessment 
The information in this section was retrieved from the UK Biobank Document Repeat 
Assessment: Participant Characteristics of responders vs. non-responders, Version 1.1 July 
2014 (UKBiobank). 
As mentioned above, participants who lived within a 35 km radius from the repeat 
assessment centre were invited to participate in the repeat assessment in Stockport, 
between August 2012 and June 2013. In total, 103514 participants were invited to 
participate. Data was available on only 20345 (response rate 20%). There were no 
differences in gender (52.8% vs 51.1% female at baseline and repeat respectively), ethnic 
background (96.3% vs 97.6% white), alcohol drinker status or self-reporting of cancer or 
diabetes status at baseline. However, there were differences in the following characteristics. 
The participants who agreed to attend for an assessment visit were more likely to be older 
(28% were between 60 and 65 years, Table 4-1). They were more likely to have a lower BMI 
(<25 kg/m2), with 37.5% attending versus 31.6% invited to attend, to have no long-standing 
illness, disability or infirmity (68% of the ones that re-attended), to be of excellent health 
(20%), be “never smokers” and have higher education. Moreover, they were more likely to 
be less socioeconomically deprived and to live closer to the centre. 
 
Age group at baseline Baseline assessment (instance 0), % Repeat assessment (instance 1), % 
<45 years 10.5 7.7 
45 to <50 years 13.6 10.7 
50 to <55 years 15.6 14.6 
55 to <60 years 18.8 22.3 
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60 to <65 years 24.4 28.2 
≥65 years 17.1 16.6 
Total N= 103514 N=20345 
 
Table 4-1: Age characteristics of the participants that were invited to participate in the repeat assessment and 
the ones that actually attended 
 
4.1.2.2.4 Ethical issues in the UK Biobank 
The UK Biobank funders developed a public Ethics and Governance Framework (EGF) to 
set the standards and the EGF went through a public consultation process. An independent 
Ethics and Governance Council (EGC) was formed in November 2004 to oversee UK 
Biobank’s adherence to the Framework. UK Biobank had approval from the North West 
Multi-Centre Research Ethics Committee (MREC), covering the UK. Moreover, and to be 
able to gain access to information that would allow it to invite participants, the project had to 
be approved in England and Wales from the Patient Information Advisory Group (PIAG). 
PIAG had been replaced by the National Information Governance Board for Health & Social 
Care (NIGB). In Scotland, UK Biobank had approval from the Community Health Index 
Advisory Group (CHIAG).  
 
4.1.2.3 Laboratory measurements available by the UK Biobank 
The information in this section was retrieved by Document Ref: BCM023, Version 1.0, 12 
Aug 2015, the Companion Document to Accompany Serum Biomarker Data, Version 1.0, 
11 March 2019 and the Biomarker assay quality procedures: approaches used to minimise 
systematic and random errors (and the wider epidemiological implications), Version 1.2, 02 
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April 2019 (UKBiobank). Some further information was obtained after communication with 
the UK Biobank. 
The biomarkers were measured in Stockport using the most up-to-date analytical methods 
that were available. At the time of this study there were 34 biomarkers available. These were 
(measured in serum unless stated otherwise): 
• Cardiovascular: Cholesterol, direct low-density lipoprotein, HDL cholesterol, 
triglyceride, apolipoprotein A (APOA), apolipoprotein B (APOB), C reactive protein 
(CRP), lipoprotein A (LPA) 
• Bone and joint: vitamin D, rheumatoid factor (RF), alkaline phosphatase, calcium  
• Cancer: Sex hormone-binding globulin (SHBG), testosterone, oestradiol, insulin 
growth factor 1 (IGF-1)  
• Diabetes: HbA1c (red blood cells), glucose 
• Renal: cystatin, creatinine, total protein, urea, phosphate, urate, creatinine 
(enzymatic, measured in urine), sodium (urine), microalbumin (urine), potassium 
(urine)  
• Liver: albumin, direct bilirubin, total bilirubin, gamma glutamyltransferase, alanine 
aminotransferase (ALT), aspartate aminotransferase (AST)  
 
4.1.2.3.1.1 Sample collection and storage 
The samples collected included blood (about 45 ml), urine (about 9 ml) and, for the last 
100,000 participants, saliva. The participants were not fasting and venepuncture was 
performed using a tourniquet. The participants could have their blood measurements at any 
point in the day. 
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The pilot studies showed that several assays could be performed in samples maintained at 
4°C for up to 36 hours prior to processing and storage. The only processing that was done 
immediately involved inverting the tubes, followed by a 30-minute rest to allow the serum 
tube to clot at room temp. Tubes were refrigerated until the end of the day when they were 
packed (with temperature logging devices) and transported to UK Biobank’s central 
processing and archiving facility in Stockport. At the central laboratory, automated systems 
were used to generate 1.4mL aliquots (up to four aliquots from a participant sample). There 
was an average time of 24 ± 2.5 hours between venepuncture and sample storage. 
Half of sample aliquots were stored in a fully automated -80°C working archive and half in a 
manual, nitrogen-vapour back-up archive located at separate sites in order to protect them. 
In order to ensure that samples from the same geography and same dates and times were 
not picked up and analysed in clusters, a sample selection algorithm was followed. This 
ensured a mixture of centres, dates, times etc. 
 
4.1.2.3.1.2 Problems identified during the quality control procedures 
Each assay was registered with an external quality assurance (EQA) scheme, and assay 
performance was externally verified. UK Biobank used different concentrations of Quality 
Control (QC) samples to estimate the within-laboratory precision. 
One of the issues identified during the checks was the so-called dilution issue. This 
happened during the initial processing of the samples when creating aliquots from the serum 
vacutainer. It was due to some mixing of the sample with system fluid (water); this occurred 
because of failed seals which could not hold a system vacuum in the handling systems.  
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An analysis was performed to determine the time points at which changes in mean assay 
levels occurred. The results over time were visually assessed and periods where “dips” in 
the results were observed, were excluded from the datasets (Figure 4-2).  
 
 
Figure 4-2: Results from calcium assays over time showing the dilution effect in aliquot 1 and 2.  
These results were excluded. Image used with permission by the UK Biobank 
 
4.1.2.4 Laboratory measurements relevant to this study 
Only the measurement methods relevant to this project will be further described (calcium, 
albumin, vitamin D, creatinine) (Table 4-2). 
 
4.1.2.4.1 Calcium and albumin 
The measurement for these two biomarkers was done using a colourimetric assay in a 
Beckman Coulter AU5800 analyser. The method follows the same principle as the one 
performed by the Sheffield Teaching Hospitals laboratory. The only difference is that the 
reagent used in the case of calcium was Arsenazo III (2,2’-[1,8-Dihydroxy-3,6-
disulphonaphthylene-2,7-bisazo]- bisbenzenear-sonic acid) (BeckmanCoulter, 2012; 2013) 
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4.1.2.4.2 Vitamin D 
The LIASION 25 OH Vitamin D assay is a direct competitive chemiluminescence 
immunoassay (CLIA). During the first incubation, 25(OH)D is dissociated from its binding 
protein and binds to the specific antibody on the solid phase. The tracer (vitamin D linked to 
an isoluminol derivative) is added after ten minutes. After a second ten-minute incubation, 
the unbound material is removed with a wash cycle. Subsequently, the starter reagents are 
added to initiate a flash chemiluminescent reaction. The light signal is measured by a 
photomultiplier as relative light units (RLU) and is inversely proportional to the concentration 
of 25(OH) vitamin D present in calibrators, controls, or samples (Diasorin, 2013). 
 
4.1.2.4.3 Creatinine 
The method followed to measure creatinine was an enzymatic one. This method utilizes a 
multi-step approach ending with a photometric end-point reaction. The enzyme creatinine 
amidohydrolase is used to convert creatinine to creatine. Creatine is in turn hydrolysed by 
creatinine amidohydrolase to sarcosine and urea. Sarcosine from this reaction is oxidized 
by sarcosine oxidase to glycine and formaldehyde. This reaction also produces hydrogen 
peroxide. The hydrogen peroxide reacts with 4-aminoantipyrine and N-ethyl-N-(3-
sulfopropyl)-3-methylaniline in the presence of peroxidase to yield a coloured chromogen 
read at 560 nm (quinoneimine dye). The resulting change in absorbance is proportional to 
the creatinine concentration in the sample (BeckmanCoulter, 2015). 
 
  ICQ level ICQ level Average 
within 
laboratory 
CV 
Average SD 
Low 1.44-1.66 1.61 0.03 
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Calcium 
(mmol/L) 
Medium 2.29-2.58 1.39 0.03 
High 2.96-3.30 1.29 0.04 
Albumin (g/L) Low 27.1-33.5  2.09 0.63 
Medium 41.8-49.7  2.20 1.00 
High 50-61.2  2.13 1.18 
Vitamin D 
(nmol/L) 
Low 26.0-49.9  6.14 2.21 
Medium 54.2-85.9  5.39 3.81 
High 78.1-116  5.04 4.73 
Creatinine 
(μmol/L) 
Low 55-68 2.75 1.71 
Medium 159-197 1.91 2.80 
High 470-529 1.39 6.92 
Table 4-2:  Internal Quality Control (ICQ) levels and within laboratory coefficient of variation (CV) given by the 
UK Biobank 
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4.1.3 Method development 
4.1.3.1 Application and databases 
In order for a researcher to apply for UK Biobank data, a registration has to be 
completed, followed by an application. This is necessary in order to assess whether 
the research meets legal and ethical standards, whether the study is scientifically 
justified and for determining the cost. If a study gets approved, the Material Transfer 
Agreement (MTA) gets executed and the cost is paid before the release of the data.  
The University of Liverpool (Dr Fadil Hannan) in collaboration with the University of 
Sheffield, applied for access to the data, to complete a research project called 
“Biochemical evaluation of secondary osteoporosis: A UK Biobank study” (application 
23448). This would compare subjects with osteoporosis, as diagnosed by the 
presence of low bone mineral density (BMD) values and/or fractures and identify 
whether they have more frequent blood test abnormalities compared to subjects 
without osteoporosis. These findings would establish which blood tests are of help for 
the clinical assessment of osteoporosis. The MTA for the study was executed on the 
20th March 2018 and access to a variety of data including laboratory measurements 
was achieved. It was decided to use part of this data to complement the studies of the 
current thesis and to plan future analyses from the origins of this collaboration.  
There were several datasets received after the MTA was executed and they all had to 
be assessed before use to identify their eligibility for use (Table 4-3). The initial 
databases received lacked information on all the patients and could not be used for 
the analysis. The ones used are shown in bold in the table (Table 4-3). 
Database Information  Date released Number of patients 
21553 General information 19/04/2018 2178 
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22444 General information 01/06/2018 54091 
27608 General information 10/04/2019 502536 
29169 
29859  
Biochemical 
measurements 
17/04/2019 
10/05/2019 
All patients 
37987 General information 27/09/2019 502524 
Table 4-3: Table of databases received from UK Biobank and were assessed for this study.  
Some databases were refreshed to include more updated data or data from a third instance (2018 
onwards). The ones in bold are the ones used for the final analysis 
 
4.1.3.2 Processing of the databases and statistical analysis 
The processing of the databases received by UK Biobank and the statistical analyses 
have been performed using the R studio statistical software (RStudio, Inc. Boston) and 
Microsoft Excel (Microsoft Office). 
In general, the independent student’s t test was used to compare numerical values 
between the two assessments after checking for normality of the data using 
histograms. The paired t test was used when comparing the results from the same 
individuals on two occasions. The chi square test was used to compare categorical 
data.  
 
4.1.3.2.1 Calculation of the within-subject standard deviation 
As described in Chapter 2, when having multiple measurements from an individual, 
these measurements are generally not equal to each other and tend to vary around a 
“true average”. Each individual then has a standard deviation of these measurements 
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which can easily be calculated. If there are only two measurements, the method 
described in Chapter 2 can be simplified. In this case, the variance is half the square 
of their differences (Di: difference for two observations for subject i) and the within-
subject standard deviation (Sw) equation is:  ]oF = TFp ∑ijF, k being the number of 
subjects. If two measurements are used, one first needs to check the assumption that 
the standard deviation is unrelated to the magnitude of the mean by plotting the 
absolute value of the difference for each subject (Di) against the mean (Bland & 
Altman, 1996a). 
In the case where there is a correlation, a way to overcome this issue is by log 
transforming the data and a plot of the log standard deviation against the log mean 
has to be performed. If there is no evidence of a relationship, the analysis of variance 
can be used to calculate the within-subject standard deviation (Sw) as described in 
Chapter 2. The only difference is that in this case, the calculated Sw is in a logarithmic 
scale, thus the antilog has to be calculated (asw). The value calculated, is not the 
standard deviation, but a quantity called geometric standard deviation. The coefficient 
of variation is the ratio of standard deviation to the mean in the original data. Thus, in 
logarithmic data, if we calculate the asw-1, this would be the within subject coefficient 
of variation (Bland & Altman, 1996b). In order to give a rough calculation of the 
variability of calcium, the within-standard deviation was still calculated even if this 
method would not overcome the evidence of a correlation. In these cases, the results 
have to be interpreted with caution. 
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4.1.3.3 Processes followed before the final analysis 
The initial step was to combine all the databases together (general information 
database and laboratory evaluations) and assign the different codes given by the UK 
Biobank to the data. The code used to do this is shown in the Supplementary material 
(code 5.1).  
 
4.1.3.3.1 Adjusted calcium equation 
As the UK Biobank did not give an adjusted calcium equation for use, a similar 
approach to the one described in Chapter 2 used by the Sheffield Teaching Hospitals 
laboratory, was followed to calculate the equation using data from the UK Biobank. 
The mean of the Pathology Harmony Range was used to normalise the data (2.40 
mmol/L). Unfortunately, potassium was not available at the time of the study so it was 
not used for the selection of patients. In terms of liver function tests, alanine 
transaminase (ALT) was the one available and the one used.  
Therefore, out of all the patients with biochemical data, only the ones with the following 
characteristics were selected.  
• Albumin ≤ 55 g/L and >20g\L 
• Urea ≤ 15 mmol/L 
• Creatinine ≤ 200 µmol/L 
• ALT ≤ 41 U/L, <33 U/L for females 
• Alkaline phosphatase ≤ 130 U/L 
In total, 374565 patients were selected and a plot was created of total calcium (y axis) 
against albumin (x axis) (Figure 4-3).  
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Figure 4-3: Graph of the 374565 patients selected for the calculation of the adjusted calcium equation. 
The y intercept was found to be 1.57822 while the slope of the graph was 0.01769   
 
The y intercept was found to be 1.57822 while the slope of the graph was 0.01769. 
Thus, the equation y=(slope)x + intercept, became y = 0.0177x + 1.58. This was further 
processed according to the method described in Chapter 2 and the following steps 
were followed: 
Total calcium (TCa) = 0.0177 [albumin] + 1.58 
Since Adjusted calcium = total calcium - (slope * albumin) + (mean normal total 
calcium - intercept calcium) 
Adjusted calcium (ACa) = TCa – 0.0177 [albumin] + (mean total calcium – 1.58) 
If the total calcium reference interval is 2.20 – 2.60 mmol/L the mean calcium of 
reference interval is 2.40, then 2.40 – 1.58 = 0.82 
ACa = TCa – 0.0177 [albumin] + 0.82 
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ACa = TCa – 0.0177 ([albumin] – 0.82/0.0177) 
ACa = TCa – 0.0177 ([albumin] – 46.3) 
Adjusted calcium = Total calcium + 0.0177 (46.3 – albumin) 
The codes used to perform the selection of patients and the analysis can be found in 
the  Supplementary material (code 5.2 & 5.3).  
 
4.1.3.3.2 Glomerular Filtration Rate 
As the UK Biobank did not give information on eGFR, the 2009 CKD-EPI creatinine 
equation was used for its calculation. The equation can then be broken down into 
different categories to allow a more automated calculation of eGFR (Table 4-4) 
(KDIGO, 2012).  
Race Gender Creatinine (μmol/L) Equation 
Black Female ≤62 eGFR = 166 × (Scr/62) -0.329 × (0.993) age 
Black Female >62 eGFR = 166 × (Scr/62) -1.209 × (0.993) age 
Black Male ≤80 eGFR = 163 × (Scr/80) -0.411 × (0.993) age 
Black  Male >80 eGFR = 163 × (Scr/80) -1.209 × (0.993) age 
White or other Female ≤62 eGFR = 144 × (Scr/62) -0.329 × (0.993) age 
White or other Female >62 eGFR = 144 × (Scr/62) -1.209 × (0.993) age 
White or other Male ≤80 eGFR = 141 × (Scr/80) -0.411 × (0.993) age 
White or other Male >80 eGFR = 141 × (Scr/80) -1.209 × (0.993) age 
Table 4-4: Different formats of the 2009 CKD-EPI equation according to race, gender and creatinine 
level (adapted from original (KDIGO, 2012)) 
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These different formats were used to estimate the GFR levels to the included subjects 
from the UK Biobank. UK Biobank uses different codings for ethnic backgrounds and 
defines as “black” the following categories: 
• 4: Black or Black British 
• 4001: Caribbean 
• 4002: African 
• 4003: Any other black background 
The code to complete this process can be found in the Supplementary material (code 
5.3). 
 
4.1.3.4 Definitions used 
In the second part of the analysis, and in order to compare our results with the studies 
using data from the Metabolic Bone Centre population, I selected the participants who 
had normal values of eGFR (≥60 ml/min/1.73 m2) and were vitamin D replete (≥50 
nmol/L) according to the National Osteoporosis Society guidelines at baseline (Aspray 
et al, 2014). 
The participants were first divided to different categories based on their adjusted 
calcium results at baseline (hypocalcaemic: AdjCa<2.20 mmol/L, normocalcaemic: 
AdjCa: ≥2.20 and ≤2.60 mmol/L, hypercalcaemic: AdjCa >2.60 mmol/L).  
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4.1.4 Results 
The results are divided in two parts. First, the results of the analysis including all 
available participants are shown. In the second part, the results shown are from 
participants who had normal values of eGFR and were vitamin D replete at baseline. 
The code for the first part of this analysis (including all participants) can be found in 
the Supplementary material (code 5.4). The code with the logarithmic transformations 
can also be found in the Supplementary material (code 5.5). As the codes for 
participants who had normal values of vitamin D and eGFR at baseline followed the 
same process as in codes 5.4 and 5.5, they were not included in the Supplementary 
material. 
 
4.1.4.1 All participants 
The study included 502524 participants, with a mean age of 57 years (SD 8.10). Out 
of them, 54% were female. At baseline, 429762 (86%) had adjusted calcium available 
(mean 2.40 mmol/L). Out of them, 1632 (0.4%) were hypocalcaemic, 6212 (1.4%) 
were hypercalcaemic and 421918 (98.2%) were normocalcaemic. Out of the 448368 
having vitamin D values, 44.6% were vitamin D replete. Out of the 469375 with eGFR 
values, 97.9% had a normal level. The information on both baseline and first follow up 
values can be found in Table 4-5.  
Groups Baseline First follow 
up 
p value   
Participants with adjusted calcium measurements, number  429762  15683  
Hypocalcaemic participants, number (%) 1632  
(0.4) 
38  
(0.2) 
0.007 
Hypercalcaemic participants, number (%) 6212  
(1.4) 
358  
(2.3) 
<0.001 
Normocalcaemic participants, number (%) 421918  
(98.2) 
15287  
(97.5) 
0.540 
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Participants with vitamin D measurements, number  448368 17039  
Participants with low vitamin D, number (%) 248235  
(55.4) 
9855 
(57.8) 
<0.001 
Table 4-5: Information on the UK Biobank participants at baseline and first follow up. The p values show 
the statistical differences between the numbers of participants at baseline and follow up 
The mean adjusted calcium at assessment 1 was 2.41 mmol/L versus 2.40mmol/L at 
baseline (p<0.001). The results were more marked when comparing only the 
measurements of individuals attending both assessments (adjusted calcium at 
baseline 2.39 vs 2.41mmol/L at the first follow up, p<0.001). There were similar 
percentages of people in the normocalcaemic category (p>0.05). However, when 
comparing the numbers in the hypercalcaemic category, a greater number was found 
at the first follow up (p<0.001).  A smaller number of hypocalcaemic patients was found 
in the follow up (p 0.007). 
Comparison of the means of other variables between the two assessments also 
showed statistically significant differences [total calcium (2.38 vs 2.40 mmol/L, 
p<0.001), eGFR (91.2 vs 86.0 ml/min/1.73m2), 25(OH)D (49 vs 48 nmol/L, p<0.001)]. 
The different categories of chronic kidney disease (CKD) can be found in Table 4-6. 
Chronic kidney disease stages Baseline 
Number (%) 
First follow up 
Number (%) 
p value 
G1 289988 (61.78) 8114 (45.47) <0.001 
G2 169713 (36.16) 9137 (51.20) <0.001 
G3a 7902 (1.68) 510 (2.86) <0.001 
G3b 1317 (0.28) 65 (0.36) 0.047 
G4 318 (0.07) 14 (0.08) 0.695 
G5 137 (0.03) 4 (0.02) 0.760 
Table 4-6: Categories of chronic kidney disease in the UK Biobank population at baseline and first follow 
up.  
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G1: ≥90, G2: 60-89, G3a: eGFR 45-59, G3b: 30-44, G4: 15-29, G5: <15 ml/min/1.73 m2 (KDIGO, 2012). 
In total, 469375 participants had eGFR values at baseline and 17844 at the first follow up. The p values 
show the statistical differences between the numbers of participants at baseline and follow up 
Out of the 1632 hypocalcaemic participants at baseline, 52 had two measurements 
available. Only one of them remained hypocalcaemic on the second occasion (0.007% 
of the population with two calcium measurements, n=13419). Out of the 159 
hypercalcaemic subjects with two measurements, 74 (47%) remained hypercalcaemic 
on the second occasion (0.55% of the population with two calcium measurements). 
Finally, 97% (n=12973) of the normocalcaemic participants had a persistently normal 
measurement of adjusted calcium.  
Values Hypocalcaemic 
(n=1632) 
Hypercalcaemic 
(n=6212) 
Normocalcaemic 
(n=421918) 
Number of participants with two 
measurements 
52 159 13208 
Mean adjusted calcium at 
baseline (mmol/L) 
2.15 2.68 2.40 
Mean adjusted calcium at first 
follow up (mmol/L) 
2.37 2.60 2.41 
P value <0.001 <0.001 <0.001 
Table 4-7: Mean values of adjusted calcium in the three different groups studied (hypocalcaemic, 
hypercalcaemic and normocalcaemic).  
The p values show the statistical differences between the biochemical measurements at baseline and 
follow up 
In order to calculate the within-subject SD for each group, the absolute value of the 
difference for each subject against the mean was plotted. On all occasions, there was 
a correlation (p<0.001). A log transformation of the data was attempted as described 
in the methods. This did not change the existing correlations for the hypocalcaemic 
and hypocalcaemic groups (p<0.001), but it changed the correlation for the 
normocalcaemic group (p>0.05). The calculated coefficient of variation for the 
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normocalcaemic group was 3.3%. Although the assumptions were not met, the 
coefficient of variation for the hypocalcaemic and hypercalcaemic groups were 
calculated, in order to get an estimate of their magnitudes. The values were 7.3% and 
4.7% respectively (Table 4-10). 
A further calculation was performed for the persistent hypercalcaemic (n=74) and the 
persistent normocalcaemic (n=12973). The coefficients of variation were 3.4% and 
3.1% respectively. 
 
4.1.4.2 Vitamin D replete participants with normal eGFR  
The next step was to select participants with normal eGFR who were also vitamin D 
replete at baseline. This included 178377 participants (35% of the total population), 
with a mean age of 57 years (SD 8.01). Out of them, 54% were female. Table 4-8 
shows the information on both baseline and first follow up values. 
Groups with normal vitamin D and eGFR at their 
baseline evaluation 
Baseline First follow 
up 
p value 
Participants with adjusted calcium measurements, number  178377 6406  
Hypocalcaemic participants, number (%) 512  
(0.3) 
12  
(0.2) 
0.249  
 
Hypercalcaemic participants, number (%) 2358  
(1.3)  
125  
(2.1) 
<0.001  
Normocalcaemic participants, number (%) 175507  
(98.4) 
6744  
(97.7) 
0.704  
Table 4-8: Information on the UK Biobank participants who had normal vitamin D and eGFR at their 
baseline evaluation.  
The p values show the statistical differences between the numbers of participants at baseline and follow 
up 
Out of the 512 hypocalcaemic participants at baseline, 18 had two measurements 
available. None of one of them remained hypocalcaemic on the second occasion. Out 
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of the 2358 hypercalcaemic patients at baseline, 61 had two measurements and 24 
(39%) remained hypercalcaemic on the second occasion. Finally, 98% of the 
normocalcaemic participants had a persistently normal measurement of adjusted 
calcium (Table 4-9). 
The mean adjusted calcium at assessment 1 was 2.42 mmol/L versus 2.40 mmol/L at 
baseline (p<0.001). There were similar percentages of people in the hypocalcaemic 
and normocalcaemic category (p>0.05). However, when comparing the numbers in 
the hypercalcaemic category, a greater number was found at the first follow up 
(p<0.001).  
 
Values Hypocalcaemic 
(n=512) 
Hypercalcaemic 
(n=2358) 
Normocalcaemic 
(n=175507) 
Number of participants with two 
measurements 
18 61 5802 
Mean adjusted calcium at 
baseline (mmol/L) 
2.15 2.67 2.39 
Mean adjusted calcium at first 
follow up (mmol/L) 
2.37 2.59 2.42 
P value <0.001 <0.001 <0.001 
Table 4-9: Mean values of adjusted calcium in the three different groups studied (hypocalcaemic, 
hypercalcaemic and normocalcaemic).  
This table only contains information on participants who had normal vitamin D and eGFR at their 
baseline evaluation. The p values show the statistical differences between the biochemical 
measurements at baseline and follow up 
In order to calculate the within-subject SD for each group, the absolute value of the 
difference for each subject against the mean was plotted. On all occasions, there was 
a correlation (p<0.001). A log transformation of the data was attempted as described 
in the methods. This did not change the existing correlations for the hypocalcaemic 
and hypocalcaemic groups (p<0.001), but it changed the correlation for the 
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normocalcaemic group (p>0.05). The calculated coefficient of variation for the 
normocalcaemic group was 3.2%. Although the assumptions were not met, the 
coefficient of variation for the hypocalcaemic and hypercalcaemic groups were 
calculated, in order to get an estimate of their magnitudes. The values were 6.1% and 
4.2% respectively, these slightly lower from the population with all values of vitamin D 
and eGFR included (Table 4-10). 
CV, % Hypocalcaemic Hypercalcaemic Normocalcaemic 
All 7.3 (N) 4.7 (N) 3.3 (Y) 
VitD and eGFR normal 6.1 (N) 4.2 (N) 3.2 (Y) 
Table 4-10: Table of the coefficients of variation (CV) calculated for the different groups.  
The groups were defined according to the adjusted calcium measurements at baseline. Y (yes) or N 
(no) indicates whether assumptions for the tests were met. All the calculations were performed after log 
transforming the data 
 
 
4.1.5 Discussion 
I have provided some information on the variability of adjusted calcium in the general 
population, using data from the UK Biobank. Regardless of vitamin D and CKD status, 
hypocalcaemic patients seem to have the greatest variability, followed by the 
hypercalcaemic ones. The majority of normocalcaemic subjects kept a persistent 
normal value of adjusted calcium, although their mean measurement increased over 
time.  
The mean adjusted calcium at baseline was 2.39 mmol/L versus 2.41 mmol/L at the 
first follow up (p<0.001) for the participants that attended both assessments. This 
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increase could be due to biological or methodological reasons. Some of the 
characteristics of the participants were different at the first follow up (eg they were 
older), and that could have had an effect on the results, as primary 
hyperparathyroidism is more frequent in older individuals. Moreover, participants 
taking part on a study might be more self-motivated and might had started taking 
calcium or vitamin D supplements after their recruitment. Surprisingly, in analyses 
performed for this study, adjusted calcium was positively correlated with age. 
Moreover, the percentage of patients with CKD G2 and G3a increased at the first 
follow up, while the percentage of G1 decreased. A negative correlation was found 
with adjusted calcium and eGFR, thus the decrease in the mean eGFR at the first 
follow up could theoretically be part of the explanation for the increase in adjusted 
calcium. However, this is not what would be expected, as 1,25 dihydroxyvitamin D 
decreases as CKD progresses, therefore one would expect lower calcium levels. 
According to the UK Biobank, there was no change in the assay used over this period 
of time and the repeat samples were performed at the same time as the baseline ones, 
so any changes in the levels could not be due to a drift in the assay. The fact that the 
participants were not fasting could have had an impact in the results. Overall, the 
change in calcium is probably due to biological reasons, with PHPT being the most 
likely reason. 
There were similar percentages of people in the hypocalcaemic and normocalcaemic 
category. However, when comparing the numbers in the hypercalcaemic category, a 
greater number was found at the first follow up (p<0.001). This is consistent with the 
increase in the level of calcium described above and probably due to an increased 
prevalence of PHTP. 
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Most of the patients originally identified as hypocalcaemic or hypercalcaemic at 
baseline had a normal calcium at the first follow up, with patients with low calcium 
having the greatest variability. There are two reasons why subjects may go from high 
or low to normal calcium. The first is regression to the mean which is a consequence 
of simple variability over time, and the second is treatment of patients found to have 
abnormalities at baseline (eg treatment of low calcium with supplements).  
The persistence of abnormal values was higher in the hypercalcaemic group, due to 
the fact that causes of hypercalcaemia like cancer and primary hyperparathyroidism, 
can be found in older subjects. The prevalence of persistent hypocalcaemia was really 
low (0.006%), while the respective one for hypercalcaemia was 0.47%. This 
percentage is lower to previous reports but most studies only assess one 
measurement (Dent et al, 1987). 
This study identified 0.4% hypocalcaemic patients at baseline and 1.4% 
hypercalcaemic (total of 1.8%). This percentage is unexpectedly low, as we would 
expect approximately 5% of the general population to be outside this interval. This 
could be due to the selection of the Pathology Harmony Range as the reference 
interval to use, which might be too wide. I used the data from the UK Biobank 
measurement at baseline to establish a reference interval for adjusted calcium. This 
was 2.26 to 2.56 mmol/L. The percentages of hypocalcaemia and hypercalcaemia in 
this case would be 1.8% and 2.9% respectively, thus the total percentage of outliers 
would be closer to the expected. 
The strengths of this study include the fact that a large number of participants from 
throughout the UK was studied. Some of the limitations of this study include the fact 
that the subjects’ ages were limited between 40 to 69 years and probably the majority 
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of them were in relatively good health and not confined to home or in care homes. 
Parathyroid hormone was not available to enable full assessment of the calcium 
metabolism. Only a maximum of two measurements were available, so the 
calculations are not so robust. On top of that, not all participants had two laboratory 
assessments available and there were differences in the characteristics of the 
participants as mentioned above which could have affected the results. Some of the 
samples were affected by dilution and although this was assessed in most cases, it 
might have had a small impact on the overall results. Figure 4-3 shows that there were 
some extreme values of calcium that would be incompatible with life and thus probably 
there were issues with the methods not completely resolved.  As UK Biobank did not 
give an adjusted calcium equation, one had to be calculated from the given data as 
mentioned in a previous study (Barth et al, 1996). Potassium measurements were not 
available by the UK Biobank, therefore patients with low potassium could not be 
excluded to precisely mirror the protocol.  
The implications of this analysis may become more relevant when the results of a 
related study have been released. The calculations and results of this project will be 
used in an analysis trying to identify genetic loci that regulate circulating mineral 
parameters such as calcium, phosphate and alkaline phosphatase. Persistent 
abnormalities might be more closely linked to gene polymorphisms.   
Overall, this study provides a further understanding of the variability of calcium in the 
general population. When laboratory measurements are repeated, people with 
abnormal values of adjusted calcium are likely to have normal values, with the 
hypocalcaemic having the greatest variability.  
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Section 2: Comparing the UK Biobank population to the Metabolic Bone 
centre population 
4.2.1 Introduction 
Up to now, the results of the above studies at the Metabolic Bone Centre (MBC) 
population, have shown that persistent normocalcaemia in normocalcaemic 
hyperparathyroidism and hypoparathyroidism is rare and these patients often 
experience intermittent hypercalcaemia (NPHPT) and hypocalcaemia (NHYPO). I 
calculated the within-subject CV for adjusted calcium and this variability likely explains 
the changing of category from normal to abnormal adjusted calcium.  
I wanted to find out whether the changing of category was the same in the general 
population as it was in the Metabolic Bone Centre and so I studied the UK Biobank. 
In the UK Biobank study, it was observed that when laboratory measurements were 
repeated, people with abnormal values of adjusted calcium were likely to have normal 
values, with the hypocalcaemic having the greatest variability. However, the 
comparison between the MBC and the UK Biobank could not be done directly, as 
participants in the UK Biobank only had two measurements.   
In order to check whether the same findings would be found in the MBC population, 
and be able to compare the two populations, extra data was requested on these 
patients. 
 
4.2.2 Methods 
In order to do this analysis, data of calcium and albumin after the baseline assessment 
were requested for all the MBC participants included in the study (n=6280). The timing 
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had to be after the index date and there had to be a gap of at least two years, to 
resemble the UK biobank gap between the two measurements. The adjusted calcium 
equation was calculated using the formula given in the methods section in Chapter 2.  
 
4.2.3 Results 
4.2.3.1 All participants 
The MBC population had a mean age of 66 years, while the UKBB population had a 
mean age of 57 years (p<0.001). In the MBC population, 72% were female compared 
to 54% in the UKBB (p<0.001).  
The percentages of hypocalcaemia, hypercalcaemia and normocalcaemia in the two 
populations are seen in Table 4-11. In both groups, the percentage of hypercalcaemic 
patients at follow up, was statistically higher than baseline. The mean adjusted calcium 
at baseline was 2.40 mmol/L, versus 2.41mmol/L at the first follow up (p<0.001) for 
the UK Biobank. The respective values for the MBC population were 2.37 and 2.42 
mmol/L (p<0.001). 
Groups (MBC population) Baseline First follow up p value   
Participants with adjusted calcium measurements, 
number  
6280 2765 NA 
Hypocalcaemic participants, number (%) 179 
(2.9) 
73 
(2.6) 
0.634 
Hypercalcaemic participants, number (%) 245 
(3.9) 
227 
(8.2) 
<0.001 
Normocalcaemic participants, number (%) 5856 
(93.2) 
2465 
(89.2) 
0.180 
  
Groups (UKBB) Baseline First follow up p 
value   
Participants with adjusted calcium measurements, number  429762  15683 NA 
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Hypocalcaemic participants, number (%) 1632  
(0.4) 
38  
(0.2) 
0.007 
Hypercalcaemic participants, number (%) 6212  
(1.4) 
358  
(2.3) 
<0.001 
Normocalcaemic participants, number (%) 421918  
(98.2) 
15287  
(97.5) 
0.540 
Table 4-11: Information at baseline and first follow up for the MBC population (top) and the UK Biobank 
population (below).  
The p values show the statistical differences between the numbers of participants at baseline and follow 
up. In both groups, The percentage of hypercalcaemic patients at follow up, is statistically higher than 
baseline. That is probably due to the fact that subjects with high calcium are more likely to have their 
calcium repeated and the mean calcium at follow up is larger than at baseline 
The persistence of the laboratory investigations throughout the follow up was checked. 
Using the UK Biobank data, 2% of the hypocalcaemic patients remained in the same 
category, 47% of the hypercalcaemic and 98% of the normocalcaemic. The respective 
percentages for the MBC population were 15%, 58% and 92% (Table 4-13). The 
consistency of hypocalcaemia was statistically greater in the MBC population (p 
0.042), while the other categories did not have significant differences.  
 
Values (referral) Hypocalcaemic at 
baseline (n=179) 
Hypercalcaemic at 
baseline (n=245) 
Normocalcaemic at 
baseline (n=5856) 
Number of participants 
with two measurements 
91 154 2520 
Mean adjusted calcium at 
baseline (mmol/L) 
2.14 2.74 2.37 
Mean adjusted calcium at 
first follow up (mmol/L) 
2.30 2.63 2.41 
P value <0.001 <0.001 <0.001 
 
Values (UKBB) Hypocalcaemic at 
baseline (n=1632) 
Hypercalcaemic at 
baseline (n=6212) 
Normocalcaemic at 
baseline (n=421918) 
Number of participants 
with two measurements 
52 159 13208 
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Mean adjusted calcium at 
baseline (mmol/L) 
2.15 2.68 2.40 
Mean adjusted calcium at 
first follow up (mmol/L) 
2.37 2.60 2.41 
P value <0.001 <0.001 <0.001 
Table 4-12: Mean values of adjusted calcium in the three different groups studied (hypocalcaemic, 
hypercalcaemic and normocalcaemic).  
The numbers included are for subjects that had two measurements available. The top table shows data 
from the MBC population, while the bottom one shows data from the UK Biobank. The p values show 
the statistical differences between the biochemical measurements at baseline and follow up 
 
Values (MBC population) Hypocalcaemic 
at baseline 
(n=179) 
Hypercalcaemic 
at baseline 
(n=245) 
Normocalcaemic 
at baseline 
(n=5856) 
Number of participants having two 
measurements 
91  154  2520  
Number of subjects that remained 
in the same category at follow up 
(%) 
14 (15) 89 (58) 2328 (92) 
Values (UKBB) Hypocalcaemic 
at baseline 
(n=1632) 
Hypercalcaemic 
at baseline 
(n=6212) 
Normocalcaemic 
at baseline 
(n=421918) 
Number of participants having two 
measurements 
52 159 13208 
Number of subjects that remained 
in the same category at follow up 
(%) 
1 (2) 74 (47) 12942 (98) 
P value 0.042 0.307 0.062 
Table 4-13: Table showing the number of subjects in each category (hypocalcaemic, hypercalcaemic 
and normocalcaemic) at baseline and follow up.  
The number of subjects remaining on the same category at follow up are then compared.  
In order to calculate the within-subject SD for each group, the absolute value of the 
difference for each subject against the mean was plotted. On all occasions, there was 
a correlation (p<0.001). A log transformation of the data was attempted as described 
in the methods. This did not change the existing correlations for the hypocalcaemic 
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and hypocalcaemic groups (p<0.001), but it changed the correlation for the 
normocalcaemic group (p>0.05). The calculated coefficient of variation for the 
normocalcaemic group was 3.5% (UKBB 3.2%). Although the assumptions were not 
met, I also calculated the coefficient of variation for the hypocalcaemic and 
hypercalcaemic groups to get an estimate of their magnitudes. The values were 7.5% 
and 6.7% respectively, The values from the UK Biobank analysis were 7.3 and 4.7% 
respectively (Table 4-17). 
 
4.2.3.2 Vitamin D replete participants with normal eGFR  
To start with, the percentages of hypocalcaemia, hypercalcaemia and 
normocalcaemia in the two populations are seen in Table 4-11. In both groups, the 
percentage of hypercalcaemic patients at follow up, was statistically higher than 
baseline.  
Groups (MBC population) Baseline First follow 
up 
p value   
Participants with adjusted calcium measurements, number  2451 1045 NA 
Hypocalcaemic participants, number (%) 55 
(2.24) 
31 
(2.97) 
0.219 
Hypercalcaemic participants, number (%) 57 
(2.33) 
63 
(6.03) 
<0.001 
Normocalcaemic participants, number (%) 2339 
(95.43) 
951 
(91.00) 
0.373 
 
Groups (UKBB) Baseline First follow 
up 
p value 
Participants with adjusted calcium measurements, 
number  
178377 6406  
Hypocalcaemic participants, number (%) 512  
(0.3) 
12  
(0.2) 
0.249  
 
Hypercalcaemic participants, number (%) 2358  
(1.3)  
125  
(2.1) 
<0.001  
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Normocalcaemic participants, number (%) 175507  
(98.4) 
6744  
(97.7) 
0.704  
  
Table 4-14: Information at baseline and first follow up for the MBC population (top) and the UK Biobank 
population (below).  
The p values show the statistical differences between the numbers of participants at baseline and follow 
up. In both groups, The percentage of hypercalcaemic patients at follow up, is statistically higher than 
baseline. That is probably due to the fact that subjects with high calcium are more likely to have their 
calcium repeated and the mean calcium at follow up is larger than at baseline 
The persistence of the laboratory investigations throughout the follow up was checked. 
Using the UK Biobank data,  0% of the hypocalcaemic remained in the same category, 
39% of the hypercalcaemic and 99% of the normocalcaemic. The respective 
percentages for the MBC population were 18%, 57% and 93% (Table 4-16).  
 
Values (referral) Hypocalcaemic at 
baseline (n=55) 
Hypercalcaemic at 
baseline (n=57) 
Normocalcaemic at 
baseline (n=2339) 
Number of participants with 
two measurements 
27 35 983 
Mean adjusted calcium at 
baseline (mmol/L) 
2.13 2.74 2.38 
Mean adjusted calcium at 
first follow up (mmol/L) 
2.17 2.66 2.40 
P value 0.006 0.009 <0.001 
 
Values (UKBB) Hypocalcaemic 
(n=512) 
Hypercalcaemic 
(n=2358) 
Normocalcaemic 
(n=175507) 
Number of participants with two 
measurements 
18 61 5802 
Mean adjusted calcium at 
baseline (mmol/L) 
2.15 2.67 2.39 
Mean adjusted calcium at first 
follow up (mmol/L) 
2.37 2.59 2.42 
P value <0.001 <0.001 <0.001 
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Table 4-15: Mean values of adjusted calcium in the three different groups studied (hypocalcaemic, 
hypercalcaemic and normocalcaemic).  
The numbers included are for subjects that had two measurements available. The top table shows data 
from the MBC population, while the bottom one shows data from the UK Biobank. The p values show 
the statistical differences between the biochemical measurements at baseline and follow up 
 
Values (MBC population) Hypocalcaemic 
at baseline 
(n=55) 
Hypercalcaemic 
at baseline 
(n=57) 
Normocalcaemic 
at baseline 
(n=2339) 
Number of participants having two 
measurements 
27  35  983  
Number of subjects that remained 
in the same category at follow up 
(%) 
5 (18.5) 20 (57.1) 914 (93.0) 
Values (UKBB) Hypocalcaemic 
at baseline 
(n=512) 
Hypercalcaemic 
at baseline 
(n=2358) 
Normocalcaemic 
at baseline 
(n=175507) 
Number of participants having two 
measurements 
18 61 5802 
Number of subjects that remained 
in the same category at follow up 
(%) 
0 (0.0) 24 (39.3) 5744 (99.0) 
P value 0.202 0.312 0.206 
Table 4-16: Table showing the number of subjects in each category (hypocalcaemic, hypercalcaemic 
and normocalcaemic) at baseline and follow up.  
The number of subjects remaining on the same category at follow up are then compared.  
In order to calculate the within-subject SD for each group for the MBC population, the 
absolute value of the difference for each subject against the mean was plotted. In all 
the occasions, there was a correlation (p<0.001). I then tried doing the same by log 
transforming the data as described in the methods. This changed the existing 
correlations for all the groups (p>0.05). The calculated coefficient of variation for the 
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hypocalcaemic group was 5.5% (6.1% for UKBB), for the hypercalcaemic 5.5% (4.2% 
for UKBB) and 3.3% for the normocalcaemic (UKBB 3.2%) (Table 4-17).  
 
CV, % Hypocalcaemic Hypercalcaemic Normocalcaemic 
UKBB: All 
VitD and eGFR normal 
7.3 (N) 
6.1 (N) 
4.7 (N) 
4.2 (N)  
3.3 (Y) 
3.2 (Y) 
Referral: All 
VitD and eGFR normal 
7.5 (N) 
5.5 (Y) 
6.7 (N) 
5.5 (Y) 
3.5 (Y) 
3.3 (Y) 
Table 4-17: Table of the coefficients of variation (CV) calculated for the different groups.  
The groups were defined according to the adjusted calcium measurements at baseline. Y (yes) or N 
(no) indicates whether assumptions for the tests were met. All the calculations were performed after log 
transforming the data 
 
4.2.4 Discussion 
Overall, I observed similar patterns in the two populations (the hypocalcaemic patients 
were more variable followed by the hypercalcaemic ones), although the characteristics 
of the two groups were significantly different (older and more likely to be female in the 
MBC population). 
In both groups, the percentage of hypercalcaemic patients at follow up was statistically 
higher at follow-up than baseline. For the MBC population, this is probably due to the 
fact that subjects with high calcium are more likely to have their calcium repeated. 
Moreover, in both populations, the mean calcium at follow up was greater than at 
baseline, with MBC having the greatest increase which could explain the greater 
percentage of hypercalcaemia at the first follow up. 
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The consistency of hypocalcaemia was statistically greater in the MBC population (p 
0.042) when analysing the whole cohort, while the other categories did not have 
significant differences. That is probably due to the fact that truly diseased patients are 
more likely to be found in a MBC population. On the contrary, the general population 
can have incidental extreme values which then return to normal. This could be due to 
simple variability over time, or even treatment of patients found to have abnormalities 
at the first visit.  
Although not all the assumptions were met and the results have to be taken with 
caution, the variability of calcium in the in both populations was greater in the 
hypocalcaemic participants, followed by the hypercalcaemic. These percentages 
followed the same pattern when only vitamin D replete participants with normal eGFR 
were included, although the results were decreased, which means that part of the 
variability could be due to vitamin D and eGFR variations as expected. Not 
surprisingly, the coefficient of variation that was not similar between the two groups, 
was the one of the hypercalcaemic participants; the MBC hypercalcaemic participants 
had a higher CV (6.7% vs 4.7%). This result probably shows that there is an increased 
likelihood of extreme values in a MBC population. These differences cannot be 
explained by different preparation of the patients, as in both occasions the individuals 
were not fasting and the samples were taken at any point of the day.    
The clinical implications of this study will be discussed further in the final chapter. 
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Section 3: Reference range for adjusted calcium 
4.3.1 Introduction 
As seen above, the UK Biobank study identified 0.4% hypocalcaemic patients at 
baseline and 1.4% hypercalcaemic (total of 1.8%). This percentage is unexpectedly 
low, as we would expect approximately 5% of the general population to be outside this 
interval. This could be due to the selection of the Pathology Harmony Range as the 
reference interval to use, which might be too wide. 
In order to check how the results would differ by using a different reference interval, 
the data from the UK Biobank were used to establish a population reference range for 
adjusted calcium.  
 
 
4.3.2 Methods 
In order to establish the UK Biobank reference range, all participants with a 
measurement of adjusted calcium at baseline were included. Exclusion criteria were 
low eGFR (<60 ml/min/m2) and/or low vitamin D (<50 nmol/L) (Group 1). 
The analysis was done using the results from the adjusted calcium calculated with the 
equation derived from the UK Biobank: Adjusted calcium = Total calcium + 0.0177 
(46.3 – albumin). A second analysis was done using the standard equation for 
adjusted calcium: Adjusted calcium =Total calcium + 0.02 (40-albumin) (Crowley & 
Gittoes, 2016). 
The analysis was performed using the reference range function of MedCalc Software 
(Belgium). The data were normally distributed, so the normal approach was used for 
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the calculation of the intervals. Reed’s criterion was used to define outliers. This 
evaluates the difference between the extreme value and the next highest (or lowest). 
The extreme value is then rejected if this difference is more than one-third of the 
absolute range of values (highest minus lowest) (Fraser, 2013). Any further 
calculations were performed using the R studio statistical software (RStudio, Inc. 
Boston). 
 
4.3.2.1 Validation analysis  
According to literature, data mining is an indirect method for establishing reference 
intervals. This is done by using large databases obtained from the laboratory. The 
caveat of doing so, is that no clinical information is usually available on these patients 
and so, especially when dealing with hospital data, the population would include two 
subpopulations: the “healthy” and the “non-healthy”. Each subpopulation would then 
have its own distribution of data and the distribution of the “non-healthy” can be 
excluded before calculating the reference intervals.  There are several mathematical 
approaches to calculate these intervals (Ferré-Masferrer et al, 1999; Labrtorian, 
2017).  
Although the UK Biobank population is part of the general population and not part of 
the hospital population, so presumably they are healthier, I decided to use one of these 
analyses in order to check the reference interval obtained in analysis 1.  
In this analysis, I included all the participants with a measurement of adjusted calcium 
at baseline without any exclusions (Group 2). I only calculated the reference interval 
for the adjusted calcium calculated with the equation derived from the UK Biobank: 
Adjusted calcium = Total calcium + 0.0177 (46.3 – albumin). 
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The analysis was performed using the R studio statistical software (RStudio, Inc. 
Boston) according to a previously used code (Labrtorian, 2017). 
 
4.3.3 Results 
In total, 178377 participants with available calcium measurements, normal eGFR and 
who were also vitamin D replete at baseline were included [mean age of 57 years (SD 
8.01)]. Out of them, 54% were female. 
The calculated reference interval was 2.25 to 2.56 mmol/L (Table 4-18).  The 
percentage of subjects with hypocalcaemia and hypercalcaemia in this case would be 
1.4% and 2.8% respectively, thus the total percentage of outliers would be closer to 
the expected. Using the standard equation for adjusted calcium, the respective 
percentages would be 0.05% and 26.75%.  
 
 Adjusted calcium using 
calculated equation (mmol/L) 
Adjusted calcium using 
standard equation (mmol/L) 
Total calcium 
(mmol/L) 
Lower limit 2.247 2.123 2.205 
90% confidence 
intervals 
2.246 to 2.247 2.122 to 2.123 2.205 to 2.206 
Higher limit 2.558 2.435 2.564 
90% confidence 
intervals 
2.558 to 2.559 2.435 to 2.436 2.563 to 2.564 
Mean (SD) 2.40 (0.079) 2.27 (0.079) 2.38 (0.094) 
Table 4-18: Table with calculated reference intervals for adjusted calcium and total calcium.  
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The second column shows the results of the adjusted calcium calculated with the equation derived from 
the UK Biobank, while the third column provides  data from the adjusted calcium calculated with the 
standard equation: Adjusted calcium =Total calcium + 0.02 (40-albumin) (Crowley & Gittoes, 2016)  
 
4.3.3.1 Validation analysis 
At baseline, 429762 participants had adjusted calcium available (mean 2.40 mmol/L). 
The results of the different analyses are shown below (Table 4-19). As the results of 
this analysis are based on visual assumptions to which population is the healthy and 
the unhealthy, the results were only used for validation purposes (Figure 4-4). 
Adjusted calcium (mmol/L) Healthy Non-healthy 
 Lower limit Upper limit Lower limit Upper limit 
Gaussian Mixture Model, n=429762 2.25 2.53 2.19 2.75 
Analysis 1, n=178377 2.25 2.56 NA NA 
Table 4-19: Results from the reference interval analysis using one of the data mining mathematical 
approaches for defining the healthy population.  
This is compared with the results from analysis 1. NA: not available 
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Figure 4-4: Results from the histogram showing the “healthy” (red) and “non-healthy” (green) subgroup 
distributions 
 
4.3.4 Discussion 
After studying the large dataset of the UK Biobank, my conclusion is that probably the 
Pathology Harmony Range for adjusted calcium is not the ideal to use, although it has 
the benefit of being comparable between laboratories. The calculated reference 
interval for this population was 2.25 to 2.56 mmol/L. Interestingly, the confidence 
intervals of the lower and upper limit did not include the current limits of 2.20 and 2.60 
mmol/L. This interval would give a percentage of outliers that is closer to the expected 
one. Interestingly, the results from the mathematical approach that divides participants 
into “healthy” and “non-healthy” subgroups, were similar (reference interval 2.25-2.53 
mmol/L).  
This observation has clinical consequences. Moving the reference range to either 
direction would affect the number of individuals that are labelled as having a disorder 
of calcium metabolism. In the case of normocalcaemic hyperparathyroidism studied in 
Chapter 3, it was interesting to see that after carefully evaluating these patients at 
baseline, their adjusted calcium levels were between 2.49 to 2.60 mmol/L, thus in the 
upper normal range for calcium. A change of the upper limit of the reference range 
would include at least some of these patients in the primary hyperparathyroidism 
group. In more detail, out of the 11 NPHPT patients identified, six (55%) would had 
been classified as PHPT, as they had a calcium higher than 2.56 mmol/L. Out of these, 
only one would be persistently normocalcaemic throughout the follow up (S0911). This 
patient did not have persistently high PTH as seen in Chapter 3.  
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A topic of debate in the latest literature, has been whether clinicians should use the 
albumin-adjusted calcium or not. This was addressed by a recent study performed in 
Norway where the researchers evaluated the laboratory tests of 6549 patients (two 
years or older, both inpatient and outpatient) from 2006 to 2015. These patients had 
free (ionised) calcium measured with an ion-selective electrode in a blood analyser 
and standardised at a pH of 7.40. They then divided their population into two 
subgroups: patients with eGFR<60 ml/min/1.73m2 and patients with eGFR≥60 
ml/min/1.73m2. They divided the second subgroup further to the ones having albumin 
below or above 30g/L, as their local scatterplots of total calcium against showed 
linearity above and below this level. They then created different equations for the three 
subgroups based on the following equation: Adjusted calcium = calcium + coefficient 
× (40−albumin). The relevant coefficients were estimated using multiple linear 
regression; total calcium was the dependent variable, while free calcium, albumin, 
phosphate, eGFR, gender, age and hospitalisation (or not) as the explanatory 
variables. In order to resemble the approach used in other labs and this study, they 
also performed a simple linear regression analysis with total calcium (dependent 
variable) and albumin (explanatory variable). The results of the coefficients were 
different than the ones with simple linear regression. This provided the unadjusted 
albumin coefficients. Then, they assessed the diagnostic accuracy of the equations 
using ROC curves and ionised calcium as their gold standard. They also assessed 
previously published equations. Overall, they found that the unadjusted calcium was 
not inferior to any of the adjusted formulas. In more detail, it performed better in 
patients with decreased eGFR, but when diagnosing hypercalcaemia some of the 
adjusted calcium equations performed better. In their limitations they mentioned that 
they could only use the pH-adjusted free calcium and not the actual one. They also 
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did not have any clinical information on these patients. Their recommendation is to 
measure ionised calcium (Lian & Åsberg, 2018). However, as pointed out in the 
introduction of the thesis, ionised calcium is not reliable and its measurement has 
several problems. Measuring the total calcium and albumin and then adjusting is the 
recommended approach in the UK and I followed this recommendation (NICE, 2019).  
This chapter raises another issue. A lot of the studies use previously published 
equations for adjusted calcium as the one mentioned above, in order to establish their 
prevalence of NPHPT. I have shown, that when evaluating patients for disorders of 
calcium metabolism calcium, a derived regression equation based on the local 
population should be used as the published one might not perform as well. This was 
suggested previously (Crowley & Gittoes, 2016).  
Overall, probably the Pathology Harmony Range for adjusted calcium is not the ideal 
to use, although it has the benefit of being comparable between laboratories. The 
calculated reference interval for the UK Biobank population was 2.25 to 2.56 mmol/L. 
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Section 4:  Further analyses 
After  the completion of the previous analyses, I realised that using  the  mean of the 
Pathology Harmony range when calculating the adjusted calcium equation was 
probably wrong. The mean of the  total calcium of the population would had been a 
better  option.  
Therefore, using the mean  of total calcium of the population described in  Table 4-18 
(2.38 mmol/L), I followed the  steps described below to get the updated adjusted 
calcium equation: 
Total calcium (TCa) = 0.0177 [albumin] + 1.58 
Since Adjusted calcium = total calcium - (slope * albumin) + (mean normal total 
calcium - intercept calcium) 
Adjusted calcium (ACa) = TCa – 0.0177 [albumin] + (mean total calcium – 1.58) 
If the total calcium reference interval is 2.21 – 2.56 mmol/L (Table 4-18), the mean 
calcium of reference interval is 2.38, then 2.38 – 1.58 = 0.80 
ACa = TCa – 0.0177 [albumin] + 0.82 
ACa = TCa – 0.0177 ([albumin] – 0.80/0.0177) 
ACa = TCa – 0.0177 ([albumin] – 45.2) 
Adjusted calcium = Total calcium + 0.0177 (45.2 – albumin) 
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Using this equation,  the  results of the above mentioned table are to be adjusted to 
the following. 
 
 Adjusted calcium using updated 
calculated equation (mmol/L) 
Adjusted calcium using 
standard equation 
(mmol/L) 
Total calcium 
(mmol/L) 
Lower limit 2.227 2.123 2.205 
90% confidence 
intervals 
2.227 to 2.228 2.122 to 2.123 2.205 to 2.206 
Higher limit 2.539 2.435 2.564 
90% confidence 
intervals 
2.538 to 2.540 2.435 to 2.436 2.563 to 2.564 
Mean (SD) 2.38 (0.079) 2.27 (0.079) 2.38 (0.094) 
Table 4-20b: Table with calculated reference intervals for adjusted calcium and total calcium.  
The second column shows the results of the adjusted calcium calculated with the equation derived from 
the UK Biobank, while the third column provides  data from the adjusted calcium calculated with the 
standard equation: Adjusted calcium =Total calcium + 0.02 (40-albumin) (Crowley & Gittoes, 2016)  
Using this updated reference interval of adjusted calcium (2.23 to 2.54 mmol/L), 0.96% 
would be classified as hypocalcaemic and 4.15 as hypercalcaemic. The results of the 
Gaussian mixture model analysis in this case would be 2.24 to 2.51 mmol/L.  
For total calcium (calculated reference range 2.21 to 2.56 mmol/L), the results of the 
Gaussian mixture model analysis would be 2.21 to 2.56 mmol/L 
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This study has focused on studying two newly described disorders of calcium 
metabolism, normocalcaemic hyperparathyroidism (NPHPT) and normocalcaemic 
hypoparathyroidism (NHYPO). Using data from a tertiary metabolic bone centre, it 
addressed the issues of the prevalence, natural history and variability of adjusted 
calcium.  
A summary of the findings from each chapter is provided below along with a short 
discussion around the main challenges, strengths and limitations of the study and its 
clinical implications. 
 
Section 1: Metabolic Bone Centre studies 
5.1.1 Normocalcaemic hyperparathyroidism 
5.1.1.1 Summary of findings  
According to the proceedings of the Fourth International Workshop on Asymptomatic 
Primary Hyperparathyroidism, NPHPT remains incompletely described, especially 
regarding its epidemiology, natural history and management (Silverberg et al, 2014). 
The prevalence of NPHPT described in the literature varies significantly and as 
described in Chapter 3, it is reported to be between 0.1 to 8.9% (Pawlowska & Cusano, 
2015). This is due to the different definitions and methodologies used in the described 
studies. Causes of secondary hyperparathyroidism were not always excluded and 
some studies did not address the issue of persistence of laboratory investigations as 
defined by the international guidelines on asymptomatic primary hyperparathyroidism 
(PHPT) (Eastell et al, 2014). Instead, they used data from baseline visits and thus 
might have overestimated the prevalence. 
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Trying to address the issues from the previous studies, I have studied the prevalence 
in a referral population having access to follow-up measurements for these patients 
over a period of up to five years. I used data from 6280 patients attending the Metabolic 
Bone Centre in Sheffield Teaching Hospitals National Health Service Foundation Trust 
(STH NHS FT) in the United Kingdom. Based on the baseline characteristics, I have 
excluded causes of secondary hyperparathyroidism. These were medications known 
to affect parathyroid hormone (PTH) levels (diuretics, lithium, denosumab, 
bisphosphonates, anticonvulsants, phosphorus), low vitamin D (<50nmol/L), chronic 
kidney disease (eGFR <60 ml/min/1.73m2), renal calcium loss (hypercalciuria) and 
diseases of the gastrointestinal tract known to affect calcium absorption (coeliac 
disease, inflammatory bowel disease, bariatric surgery)  (Eastell et al, 2009; Eastell et 
al, 2014; Yacobi-Bach et al, 2015). I then checked for persistence of adjusted calcium 
on at least two occasions and any patients not fulfilling this criterion were excluded. In 
total, thirteen patients were identified as having NPHPT. The prevalence was 0.18%. 
The mean age of these patients was 69 years, and 91% were female.    
The results for the natural history remain controversial with some studies reporting no 
conversion to hypercalcemia  (Ayturk et al, 2006; Garcia-Martin et al, 2012; Tordjman 
et al, 2004), while others report a small percentage of patients becoming 
hypercalcemic (Cusano et al, 2013a; Diri et al, 2014; Silverberg & Bilezikian, 2003; 
Siprova et al, 2016). The problem with the studies on natural history is that, although 
they might check persistence at baseline on two to three occasions, they then check 
the laboratory measurements on only one occasion after a certain period; if at that 
point the patient has high calcium, they conclude that the patient has progressed to 
hypercalcemia. I believe that this approach is not the correct one, as the 
hypercalcaemia may be intermittent.  
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Therefore, I studied the NPHPT patients further by looking at their follow up 
measurements and I identified two patterns, persistent normocalcaemia and 
intermittent hypercalcaemia. Intermittent hypercalcaemia was the common pattern, 
occurring in 7 out of 11 patients. Persistent normocalcemia was uncommon and only 
occurred in four patients (0.06% of the whole population).  However, only two of these 
patients had consistently high PTH, but they were not consistently vitamin D replete 
or did not have consistently normal eGFR.  If the international guidelines were strictly 
applied, the prevalence of NPHPT in this population would be zero.  
At the time of this study, this finding of intermittent hypercalcaemia in these patients, 
had only been reported in one previous study from the Czech Republic, who followed 
up 187 patients with NPHPT for one to seven years. Out of them, 36% had intermittent 
hypercalcemia (Siprova et al, 2016). After the completion of our study, a further study 
evaluating NPHPT patients going through parathyroidectomy, reported that 40.8% of 
these patients had episodes of hypercalcaemia >1 year prior to surgery (Sho et al, 
2019). 
My study suggests that NPHPT is probably a variant of PHPT, as several PHPT 
patients in this study also had intermittent hypercalcaemia and the variability of 
adjusted calcium found, was similar in these two groups and slightly higher than the 
control group. This theory contradicts the one described before, that NPHPT is the first 
phase of a biphasic disease course, which can be followed by hypercalcemic 
hyperparathyroidism (Silverberg & Bilezikian, 2003). 
In conclusion, this study describes the largest population ever studied to identify 
NPHPT and provides data during a long follow up period (five years). The prevalence 
reported is small and persistent normocalcemia in patients with NPHPT is rare. This 
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study is the first that evaluates the natural history of patients with NPHPT in so much 
detail and provides data from a long follow up period. Subsequent hypercalcemia in 
these patients should be treated with caution, and not be automatically addressed as 
progression to hypercalcaemia. I suggest that the definition should be revisited and 
normocalcemic hyperparathyroidism should be defined as having the average calcium 
within normal limits and not persistently normal.  
 
5.1.1.2 Clinical relevance  
Patients with elevated PTH and normal calcium are frequently assessed in referral 
centres and the question remains to whether they should be followed up or treated 
with surgery according to the PHPT guidelines. From my clinical experience, these 
patients are discussed in meetings, labelled as normocalcaemic hyperparathyroidism 
at first and then maybe discharged to their general practitioners for follow up with the 
instruction to be referred back in case of elevated calcium. However, elevated calcium 
at least on some occasions, could be part of their natural history. This variability 
complicates their monitoring. I have provided estimates of variability for these groups 
which can be used in everyday practice for monitoring. I have provided standard 
estimates of the within-subject SD but also more conservative ones using the 90th 
centile of the variance. The least significant change given, could be used in two ways 
in these patients. First, it gives a range to which values are expected. For example, 
for a patient with NPHPT having an adjusted Ca of 2.55 mmol/L, the LSC is 0.25, so 
the next measurement would lie between 2.30 and 2.80 mmol/L, hence could be high. 
This can provide some reassurance for the patient and the physician. Moreover, it can 
be a marker of whether an individual has an actual significant change of their calcium. 
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Some patients with NPHPT are being operated and using the given LSC estimates, 
the physician can make sure that there was a statistically significant drop in calcium 
as a result of the parathyroidectomy.  
Identifying patients with NPHPT and excluding causes of secondary 
hyperparathyroidism based on the international criteria was sometimes challenging for 
this research project and I anticipate similar challenges in the everyday clinical 
practice. Patients who had vitamin D deficiency at some point during these five years, 
were difficult to assess, as the subsequent finding of high PTH after correcting the 
deficiency could had been a true finding of NPHPT or a consequence of chronic 
vitamin D deficiency. It has been reported in literature, that even several months after 
vitamin D replacement, PTH remains elevated in a percentage of people. Shibli-
Rahhal et al performed a retrospective analysis and reported that after an average of 
ten months of treatment with different protocols, only 44% of the patients achieving 
25(OH)D≥ 30ng/ml had normalised their PTH. They conclude their study by saying 
that the use of PTH to monitor the response to therapy is limited (Shibli-Rahhal & 
Paturi, 2014). Another group randomised 64 postmenopausal women to either 300000 
IU colecalciferol at baseline and at three months or 1000 IU per day and had 
measurements at three and at six months. Some of the subjects that achieved a 
25(OH)D ≥30 ng/ml, still had a PTH above the reference interval (13.3% in the 1000 
IU and 17% in the 300000 IU group) (Giusti et al, 2010). Presumably these patients 
have autonomous parathyroid function as a result of parathyroid hyperplasia from 
longstanding vitamin D deficiency. This could had been an issue in studies for NPHPT 
in which patients with vitamin D deficiency have been treated first and then re-
assessed after a few months (Siprova et al, 2016). In these studies, the prevalence 
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might had been an overestimation. The same challenges could be faced in the clinical 
setting.  
A further challenge which is often an issue of debating is the correct level of vitamin D 
deficiency. I have used a cut-off of 50 nmol/L as advised by the Royal Osteoporosis 
Society guidelines and the Fourth International Workshop on Asymptomatic Primary 
Hyperparathyroidism (Aspray et al, 2014; Eastell et al, 2014). Many researchers 
recommend using a higher cut-off of 75 nmol/L. I found no patients with NPHPT using 
this cut-off. If I had used a higher one, it would not had made any difference in the 
results.  
Furthermore, when estimating the persistence of a disease using databases, certain 
filters need to be applied in the software used. Therefore, these cut-offs in the data 
like vitamin D <50 nmol/L are strict and do not allow any flexibility. Therefore, patients 
with levels really close to these cut-offs (eg vitamin D 49 nmol/L) would still be 
excluded even though their PTH might not be elevated due to the vitamin D deficiency. 
As the study of the prevalence of NPHPT has many challenges, that is probably one 
of the reasons that the reported studies vary significantly. I used a statistical approach 
to identify these patients and graphed the results of adjusted calcium against PTH. I 
observed that a lot of patients with high PTH values according to the reference 
intervals, were found to be “normal” by using a method for defining outliers. The 
subjects that were normal but had higher PTH than the reference interval, were found 
to be significantly older than the ones that were normal and also had normal PTH 
according to the current reference interval. These results align well with the fact that 
PTH is known to increase with age. It has been previously suggested that age-related 
PTH reference intervals should be established (Eastell et al, 2014). My study supports 
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this statement.  This adjustment for the range becomes more relevant now that 
NPHPT is further described in literature. By using the current reference interval in 
everyday practice we are probably overdiagnosing NPHPT and maybe subjecting 
older individuals to unnecessary testing.  A change of the upper limit of the reference 
interval in PTH could alter the number of patients diagnosed with this disorder.  
A further observation after studying the large dataset of the UK Biobank, is that 
probably the Pathology Harmony Range is also not the ideal one to use, although it 
has the benefit of being widely used. It was interesting to see that after carefully 
evaluating the NPHPT patients at baseline, their adjusted calcium levels were 
between 2.49 to 2.60 mmol/L, thus in the upper normal range for calcium. A change 
of the upper limit of the reference range would include at least some of these patients 
in the PHPT group. 
The question resulting from this study is whether NPHPT exists and, if it does, whether 
the current definition used is the most appropriate. This, obviously, is not only an issue 
in research studies such as the current one. This mainly affects decisions in everyday 
clinical practice when patients are assessed, and a diagnosis and a management plan 
have to be decided. Some patients might be subjected to unnecessary testing for an 
abnormality that is part of normal ageing. Moreover, in younger patients, the 
complexity of making the diagnosis might result in delayed surgery and further 
complications. As mentioned above, the variability described in calcium in these 
patients complicates their monitoring. According to the international guidelines, 
calcium and PTH should be tested every year, while a BMD check should be 
performed every one to two years.  If there is a progression to hypercalcaemia, 
patients should be treated according to the guidelines on asymptomatic primary 
hyperparathyroidism (Bilezikian et al, 2014). However, a majority of these patients 
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have intermittent hypercalcaemia; the subsequent results might be confusing for both 
the care provider and the patient on whether surgery would be recommended.  
I believe that there are three ways forward to the issue of diagnosing NPHPT. If we 
adjust the reference interval for PTH for age, and use the current definition, NPHPT 
may not exist, as shown in this study, at least in older individuals. Another approach 
would be to revisit the current definition and normocalcemic hyperparathyroidism 
should be defined as having the average calcium within normal limits (and not 
requiring it to be persistently normal). Using this approach, PHPT should be 
considered as having a high average calcium.  In this case, 10 out of our 11 included 
patients would be classified as NPHPT. This could be challenging as we cannot be 
sure how many measurements of calcium would be enough for this. Hypothetically, 
and using the results from this study, if a person was in the upper normal of the range, 
they would need more measurements than a person with a baseline calcium that is in 
the mid of the interval. This approach could be further evaluated in a research setting.  
Another way forward would be to consider NPHPT as a variant of PHPT and follow up 
and treat according to the current guidelines. This issue has been recently addressed 
by the first European Society of Endocrinology Workshop (PARAT). In their consensus 
statement, they mentioned that the individual variation in total calcium is four times 
narrower than the population reference interval and the inter individual variability. I 
have found similar results in my study. In order to make sure that a person has normal 
calcium or not, one needs to know their individual range of variability. There is a 
chance that an individual might have an elevated calcium in comparison with their 
individual range, but still within the normal population reference interval for calcium. 
They conclude that these patients should probably be characterised as having primary 
hyperparathyroidism and not normocalcaemic hyperparathyroidism and be followed 
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up and treated accordingly. This is of course after excluding causes of secondary 
hyperparathyroidism (Bollerslev et al, 2019). This is supported by many studies in the 
literature showing similar characteristics from these two groups of patients. It is also 
supported by the fact that the underlying pathology of NPHPT seems to be similar to 
PHPT.  I believe, based on the results from this study, that this might be the best 
approach to follow in clinical practice. 
This study did not find any NPHPT patients according to the international criteria. 
However, I do understand that in everyday practice, physicians might evaluate 
patients with different characteristics than this cohort and some patients with classic 
NPHPT might be identified. This analysis was based on a large group and provided 
some lessons that can be applied to individuals in everyday practice even if the 
population is different. I have shown that probably the PTH reference range for older 
people is wrong and needs to be re-evaluated. I have also shown, using the large 
dataset of the UK Biobank, that probably the Pathology Harmony Range is also not 
the ideal to use. Patients with NPHPT can often have high values of calcium and that 
is normal for them and I have provided estimates of variability that can be used in 
everyday practice. It is crucial that all causes of secondary hyperparathyroidism have 
to be excluded before labelling a patient with a disorder and this can be challenging 
as mentioned above. Overall, I believe that NPHPT patients should be followed up 
and managed according to the PHPT guidelines. 
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5.1.2 Normocalcaemic hypoparathyroidism 
5.1.1.3 Summary of findings 
A pathophysiological counterpart to NPHPT is normocalcaemic hypoparathyroidism 
(NHYPO), which is characterised by normal levels of calcium with persistent low levels 
of parathyroid hormone (PTH). There is little in the current literature about this disease, 
with only two studies (reporting three different populations) published on its 
prevalence, whilst its natural history remains relatively unknown (Cusano et al, 2013a; 
Palermo et al, 2015). Two of these populations were then checked six and eight years 
later and only 0.6% and 0.09% respectively were still characterised as having NHYPO. 
None developed hypoparathyroidism. Serum calcium and PTH was only checked on 
two occasions in these studies, so the natural history of serum calcium is unclear. To 
my knowledge, this is the first study of the prevalence in a referral centre and the also 
the first study of the natural history of this disease.   
I retrospectively evaluated 6280 patients attending a referral centre and identified 
eighteen patients (mean age 45 years, 61% female) with NHYPO on the index date 
(prevalence 0.29%).  Out of them, approximately a third of them had intermittent 
hypocalcaemia. None developed hypoparathyroidism as evidenced by persistent 
hypocalcaemia.  There was a limited number of PTH measurements throughout the 
patients’ follow up in this study; eight patients out of the eighteen identified as having 
NHYPO had only one measurement available. This indicates, that probably physicians 
are not so concerned about finding a low level of PTH and they do not tend to follow 
up this further. However, this disorder could be the subclinical form of 
hypoparathyroidism.  
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5.1.1.4 Clinical relevance and challenges 
Normocalcemic hypoparathyroidism is a disorder poorly characterised, with unknown 
consequences. When physicians are faced with the biochemical findings of low PTH 
and normal calcium, they usually ignore the finding and try to re-assure the patient. 
However, these patients might be prone to hypocalcaemic after receiving certain 
medication. Moreover, simple symptoms like vomiting could precipitate low calcium 
levels. Hypocalcaemia could be related to clinical implications like cardiac arrhythmias 
and epileptic seizures (Cooper & Gittoes, 2008). I believe that these patients should 
be monitored. Further information on this disorder is needed before any official 
recommendations are made but I think that NHYPO should be mentioned in any future 
guidelines on hypoparathyroidism. 
Addressing the prevalence of NHYPO also had its challenges. As several patients 
have episodes of hypocalcaemia, a different number could be found according to the 
date of the study. I have shown, in the UK Biobank study, that patients with 
hypocalcaemia have the greatest variability. This could complicate the monitoring of 
these patients.  
I have also provided estimates of the least significant change. The least significant 
change given, could be used in two ways in these patients. First, it gives a range to 
which values are expected as mentioned above for NPHPT. This can provide some 
reassurance for the patient and the physician. Moreover, it can be a marker of whether 
an individual has an actual significant change of their calcium in case of observed 
hypocalcaemia after an intercurrent illness or drug therapy that can cause low calcium. 
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5.1.3 Strengths, limitations and challenges of the metabolic bone centre studies 
5.1.1.5 Using a referral centre  
The main part of this study has been completed using data from a tertiary metabolic 
bone referral centre. This has some strengths and limitations.  The subjects in this 
study had been evaluated for causes of secondary osteoporosis and so they might be 
different from the general population. On the other hand, disorders of calcium 
metabolism are often usually diagnosed during the evaluation of secondary 
osteoporosis and thus, mainly found in referral centres. In the case of NPHPT, 
studying a referral population has the advantage of evaluating how common NPHPT 
is in a referral population with osteoporosis and whether screening for NPHPT is 
useful.  
I compared the MBC population with the UK Biobank population, which is believed to 
represent the wider UK general population. The UK Biobank population was younger 
and had a similar number of female and male participants, but these characteristics 
were the inclusion criteria for the study. The distribution of hypocalcaemia and 
hypercalcaemia was somewhat similar, with hypercalcaemia being more common in 
the MBC. The variability of calcium was also similar; hypocalcaemic patients were the 
most variable.  
This was a retrospective observational study and the number of measurements varied 
from patient to patient. The interval between the measurements was not the same, nor 
was the number of measurements, as expected in a real-life setting. Obtaining data 
retrospectively also had challenges, like different coding used from the laboratory at 
different time points, making the acquisition of data not as straightforward.  
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Studies using real-life data have further limitations like not ideal blood sampling 
techniques. The patients were not fasting and a tourniquet was usually used. The 
methods for vitamin D and eGFR changed during the follow up period and that might 
have affected some results. The impact of implementing the CKD-EPI equation is that 
it may have improved the accuracy in patients with an eGFR of 50-60 ml/min/1.73 m2 
and might have resulted in fewer people being clustered as CKD. However, it might 
have increased the number of older people having CKD.   
 
5.1.1.6 Statistical approaches 
5.1.1.6.1 Mahalanobis distance for identifying outliers 
Most studies on calcium disorders use the laboratory reference intervals of calcium 
and PTH to define NHYPO and NPHPT. I decided to use a statistical approach called 
Mahalanobis distance which is a robust way of identifying outliers when there is 
correlation between the values. As calcium and PTH are not independent, I thought 
this would be the best approach as it takes this correlation into account. As mentioned 
above, this approach also took into account the fact that PTH reference intervals are 
probably not ideal, as they do not take into account the fact that PTH could increase 
in older individuals. It has been suggested that age-related PTH reference intervals 
should be established (Eastell et al, 2014) and, using this approach in this study, I 
support this statement. 
Mahalanobis distance on the other hand is specific for the population as it takes into 
account the available data given and establishes the centre of the cluster; it then 
measures how far each observation is from this centre, taking into account the shape 
of the cluster. Therefore, if one patient from this centre was then studied in another 
Chapter 5: Discussion and future plans 
Section 1:Metabolic Bone Centre studies 
 
 336 
centre using the same approach, they might have been identified differently (normal 
or abnormal respectively). 
Mahalanobis distance only defines the outliers in a multi-dimensional space (in this 
case, two-dimensional). The next step in this study was to define the different 
disorders of calcium metabolism. There was a previous study in which Mahalanobis 
distance was used to describe the same disorders, using data from the general 
population. My study is the first to use Mahalanobis distance in a referral population. 
In order to get the different categories described above, Palermo et al used the 
reference interval for adjusted calcium, but for PTH, they used the geometric mean of 
the healthy women reference interval (Palermo et al, 2015). Using this approach, the 
authors probably assumed that the reference intervals for adjusted calcium were the 
correct ones and that the ones for PTH were not. Using the geometric mean in this 
population, they also avoided having “unclassified” subjects as seen in our study. 
However, this was a hybrid approach, as a range of values was used for one 
measurement, while a line was used for the other measurement. The geometric mean 
was also based on the measurements of young individuals.  
As seen in both our ellipse and the ellipse by Palermo et al, there are patients that are 
“normal” as defined the ellipse but are above or below the reference interval for 
adjusted calcium respectively. A different approach would be to ignore reference 
intervals. This would mean that there would be five categories: normal, 
hypoparathyroidism, non-PTH induced hypercalcaemia, hyperparathyroid 
hypercalcaemia and secondary hyperparathyroidism as shown in Figure 5-1. Based 
on my findings that both NPHPT and NHYPO often have intermittent hypercalcaemia 
and hypocalcaemia respectively, this approach could be used if NPHPT would be 
considered as a variant of PHPT and NHYPO as a variant of hypoparathyroidism.  
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Figure 5-1: A graphical representation of the ellipse in case the geometric mean of calcium and PTH 
(shown in dashed lines) was used instead of the reference intervals to identify categories 
I decided to use reference intervals for both calcium and PTH, to take into account not 
only the results of a statistical approach on outliers, but also what would be used in 
everyday clinical practice. If I had used Palermo’s et al approach, the prevalence of 
both NPHPT and NHYPO would probably be higher.  
By using the clinical reference intervals and the results from Mahalanobis distance, I 
believe that the people would be better characterised. Taking only the reference 
intervals has limitations. Following only the statistical approach has limitations. Taking 
both I removed any uncertainty and I believe that if a person is defined to be in a group, 
then they truly belong to that group. 
 
5.1.1.6.2 Within subject standard deviation approach 
To calculate the within-standard deviation for adjusted calcium, I used an approach 
described by Bland & Altman. They describe that when having multiple measurements 
from an individual, these measurements are generally not equal to each other and 
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tend to vary around a “true average”. Each individual then has a standard deviation of 
these measurements which can easily be calculated. Since the number of 
measurements for each subject was different, I used the analysis of variance method 
to calculate the within-subject standard deviation (Sw). To follow this method, one first 
needs to check the assumption that the standard deviation is unrelated to the 
magnitude of the measurement (Bland & Altman, 1996a).  
In order to perform this analysis, the assumption that standard deviations across the 
subjects are similar should be made. However, this is not true in all clinical situations. 
Using a single “mean” within-standard deviation might underestimate the variability for 
some patients. A suggested approach to overcome this problem is to use the 90th 
centile of the within subject variance (Masse, 1997). I have provided these estimates 
in Chapter 3 and I believe that they can be used for the monitoring of patients as 
mentioned above.  
The approach described above is usually used to calculate the so-called measurement 
error. In the example given by Bland & Altman, data from repeated peak expiratory 
flow measurements were given. These measurements were performed close to each 
other and the authors were trying to calculate the variability of the assay (Bland & 
Altman, 1996a). I used this approach to calculate the long-term variability of calcium. 
I therefore assumed that when taking measurements close to each other, then the 
pooled SD estimates the method variation and the variability of the assay. As the 
measurements in this population were further away, I believe that the variability is due 
to the within subject variability. 
Another limitation of using this approach is that I am making the assumption that all 
patients remain stable and there is not disease progression, therefore that variations 
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are due to natural variation. To check this assumption, I used the history graphs of 
adjusted calcium over time for every subject. I have excluded any patients with 
progression and the estimates were similar. 
This was a retrospective observational study and the number of measurements varied 
from patient to patient. The interval between the measurements was not the same, as 
expected in a real-life setting. This limited the possibility of further analyses. The 
analysis for the within-subject SD did not take into account the effect of time. Ideally, 
to give a more accurate estimate of the variance, a prospective observational study 
should be designed, having the same number of measurements for each patient at 
regular intervals. The analysis should be preferably done using a model that takes 
time into account. Despite the limitations, this study provided a guide to how adjusted 
calcium varies between the different groups described.  
 
5.1.1.6.3 Regression to the mean  
This is a statistical phenomenon where a variable is extreme when measured for the 
first time but then is closer to the mean when it is measured a second time. Some 
examples given in literature are blood pressure measurements; if an individual’s blood 
pressure is measured and found to be high, and then measured again on a second 
occasion, then it’s likely that it is going to be closer to normal. Moreover, patients with 
higher blood pressure measurements starting antihypertensive drugs will have greater 
reductions in blood pressure due to this phenomenon (Bland & Altman, 1994). 
I understand that this could be a limitation in the studies where the variability was 
evaluated using only two measurements. 
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Section 2: UK Biobank studies 
5.2.1 Summary of findings and clinical relevance 
The UK Biobank study has provided some further understanding on the variability of 
adjusted calcium in different populations (hypocalcaemic, hypercalcaemic and 
normocalcaemic). I have observed that hypocalcaemic patients, regardless of their 
vitamin D and CKD status, are the most variable and this, as mentioned above, can 
complicate their monitoring. These were followed by the hypercalcaemic ones. The 
majority of normocalcaemic subjects kept a persistent normal value of adjusted 
calcium, although their mean measurement increased over time.  
When performing a similar analysis in the MBC population, using just two 
measurements,  I observed similar patterns in the two populations (hypocalcaemic 
patients being the most variable followed by the hypercalcaemic ones), although the 
characteristics of the two groups were significantly different (older and more likely to 
be female in the MBC population).  
In both groups, the percentage of hypercalcaemic patients at follow-up was statistically 
higher at follow-up than baseline. For the MBC population, this is probably due to the 
fact that subjects with high calcium are more likely to have their calcium repeated. 
Moreover, in both populations, the mean calcium at follow up was greater than at 
baseline, with MBC having the greatest increase which could explain the greater 
percentage of hypercalcaemia at the first follow up. 
The consistency of hypocalcaemia was statistically greater in the MBC population 
when analysing the whole cohort, while the other categories did not have significant 
differences. That is probably due to the fact that truly diseased patients are more likely 
to be found in the MBC population. On the contrary, the general population can have 
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incidental extreme values which then return to normal. This could be due to simple 
variability over time, or even treatment of patients found to have abnormalities at the 
first visit.  
After studying the large dataset of the UK Biobank, the result suggests that the 
Pathology Harmony Range (2.20 to 2.60 mmol/L) is not the ideal one to use, although 
it has the benefit of being comparable between laboratories. The calculated reference 
range for this population was 2.25 to 2.56 mmol/L. Interestingly, the confidence 
intervals of the lower and upper limit did not include the current limits of 2.20 and 2.60 
mmol/L.  
This observation has clinical consequences. Moving the reference range to either 
direction, would affect the number of individuals that are labelled as having a disorder 
of calcium metabolism as described above.  
The implications of this analysis may become more relevant when the results of a 
related study have been released. The calculations and results of this project will be 
used in an analysis trying to identify genetic loci that regulate circulating mineral 
parameters such as calcium, phosphate and alkaline phosphatase. Persistent 
abnormalities might be more closely linked to gene polymorphisms. Moreover, since 
UK Biobank did not provide an equation for adjusted calcium and a reference interval, 
the results of this analysis can be used to determine the different populations, not only 
in this study, but in other future UK Biobank studies. 
 
5.2.2 Strengths and limitations 
The strengths of this study include the fact that a large number of participants from 
throughout the UK was studied. Some of the limitations of this study include the fact 
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that the subjects’ ages were limited between 40 to 69 years and probably the majority 
of them were in relatively good health and not confined to home or in care homes. 
Parathyroid hormone was not available to enable full assessment of the calcium 
metabolism. Only a maximum of two measurements were available, so the 
calculations are not so robust. On top of that, not all participants had two laboratory 
assessments available and there were differences in the characteristics of the 
participants as mentioned above which could have affected the results. Some of the 
samples were affected by dilution and although this was identified and excluded in 
most cases, it might have had a small impact on the overall results.  Moreover, patients 
were not fasting, and a tourniquet was used. As UK Biobank did not give an adjusted 
calcium equation, one had to be calculated from the given data as mentioned in a 
previous study (Barth et al, 1996). Potassium measurements were not available by 
the UK Biobank, therefore patients with low potassium could not be excluded to 
precisely mirror the protocol.  
Another limitation of this study was the fact that the assumptions for calculating the 
within-subject SD were not always met and the estimates should be treated with 
caution.  
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Section 3: Future plans 
The study of normocalcaemic hyperparathyroidism and hypoparathyroidism provided 
some further understanding on these disorders. As mentioned above, my opinion 
agrees with the approach suggested by other researchers, which is to consider 
NPHPT as a variant of PHPT. If this approach is adopted, I do not think that a lot of 
research in this field is required.  
I think a priority in the field of calcium metabolism is to establish the age-adjusted 
reference intervals for PTH and to evaluate whether the Pathology Harmony range 
should be used for calcium or not. When this is decided and agreed, then a further 
prospective study of the natural history of NPHPT could be performed, using 
measurements in a fasting state and at regular intervals. This would allow a better 
estimate of the within-subject SD and thus the least significant change. One of the 
limitations of my study is that the follow up was up to five years, and thus long-term 
changes of calcium could not be assessed.  Therefore, in a future study, the patients 
could be followed for years and identify if they maintain the same levels of calcium, or 
if they at some point get persistent high levels. A similar study should be performed 
for NHYPO. The challenge with planning these studies would be to find patients that 
are suitable. Some of the issues would be the definition used, which reference range 
is the appropriate one to define these patients and the fact that is difficult to maintain 
similar conditions throughout the follow up, for example initiation of medications known 
to affect the calcium levels.  
Furthermore, as mentioned above, we do not know much about NHYPO. Its clinical 
consequences, if any are unknown. Moreover, we are still unsure how often 
hypocalcaemia occurs. A prospective study should be designed to evaluate these 
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patients, with regular follow up and compare this group with patients with 
hypoparathyroidism and a control population.  
The UK Biobank studies can continue when further data are available. Hopefully, 
measurements of PTH will be available at some point, to allow an assessment of the 
prevalence of NPHPT and NHYPO in the general population in UK.  Moreover, data 
will be released on BMD evaluation and fracture numbers on these patients. This 
would allow a further estimate of the skeletal implications of NPHPT and NHYPO. 
As mentioned above, the calculations and results of this project will be used in an 
analysis trying to identify genetic loci that regulate circulating mineral parameters such 
as calcium, phosphate and alkaline phosphatase. Persistent abnormalities might be 
more closely linked to gene polymorphisms. 
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Section 1: Tables 
Table 6-1: Studies on the skeletal and renal effects of normocalcaemic hyperparathyroidism - data on imaging 
 
Publications Recruitment Study 
population 
(n), age 
(years), 
gender 
Criteria Baseline  
laboratory 
differences 
in study 
group  
Tc99m-
sestamibi  
Kidney 
presentati
on at 
baseline 
Skeletal 
presentation 
at baseline 
Other 
(Alyne layane pe
reira et al, 2019) 
 
Pernambuco, 
Brazil 
 
Prospectively 
recruited 
patients from an 
Endocrinology 
department in 
Brazil 
NPHPT 25 
age 63.2 
±10.7 years, 
96% female 
 
Normal calcium 
and high PTH, 
25(OH)D >30 
ng/ml, 
eGFR>60 
ml/min/1.73m2. 
Exclusions: 
medication 
(thiazides, 
lithium, 
antiresorptive 
agents), history 
of urolithiasis 
 NA 20% 
nephrolithia
sis on 
ultrasound,  
 
NS 
difference 
in age, 
weight, 
PTH, 
25(OH)D, 
calcium, 
phosphate, 
creatinine, 
urinary pH 
and 
24hurinary 
calcium 
between 
the ones 
having 
kidney 
stones and 
NA NA 
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the ones 
not  
(Amaral et al, 
2012) 
 
Pernambuco, 
Brazil 
Retrospectively 
evaluated 70 
patients with 
PHPT from an 
endocrine centre 
NPHPT 33, 
age 
63.67±13.83 
years, 78.8% 
female 
 
PHPT 37  
 
NS difference 
in age, BMI 
and gender 
Normal total 
calcium and 
high PTH, 
25(OH)D >30 
ng/ml, GFR>60 
ml/min 
 
Excluded: use 
of drugs 
(bisphosphonat
es, thiazides, 
anticonvulsants, 
lithium), 
gastrointestinal 
diseases with 
malabsorption, 
liver disease, 
hypercalciuria 
(urinary 
Ca/Cr>240mg/g 
Cr) 
Higher 
25(OH)D in 
NPHPT 
 
Similar levels 
of PTH, CTX, 
creatinine 
 NA Nephrolithi
asis 18.2%  
(NS 
difference 
with PHPT) 
Previous 
history of 
fractures 
15.2%  
(NS difference 
with PHPT) 
Higher BMD 
in distal 
radius in 
NPHPT 
(0.54±0.15g/
m2 vs 
0.45±0.18, 
p=0.046) 
 
No statistical 
difference in 
spine and hip 
BMD 
(Cakir et al, 
2012) 
 
Kayseri, Turkey 
 
 
Recruited 
patients from an 
endocrinology 
centre 
NPHPT 18, 
age 49.9±2.4 
years, 89% 
female 
 
Controls 18 
(matched for 
age, gender 
and BMI) 
Normal total 
calcium and 
high PTH, 
25(OH)D >20 
ng/ml, repeated 
Ca and PTH 
measurements 
3 times with 2-
week intervals, 
no history of 
Higher 
calcium, ALP 
and PTH in 
NPHPT 
No difference 
in phosphate 
Performed in 
17 
 
17.6% positive 
23.5% 
suspicious 
58.5% 
negative 
Nephrolithi
asis 11.1% 
in NPHPT 
 
No 
comparison
s available 
Osteoporosis 
47% in 
NPHPT 
 
No 
comparisons 
available 
 NA 
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  renal or liver 
diseases, no 
prescriptions 
known to affect 
calcium level 
(Castrillon et al, 
2015) 
 
Valladolid, Spain 
Prospective  
study of PHPT 
and NPHPT 
patients 
NPHPT 26, 
age 65 (11) 
 
PHPT 16 
 
NS difference 
in age, sex, 
BMD 
Persistently 
normal total, 
adjusted and 
ionised calcium 
and high PTH 
on at least two 
occasions. 
Exclusion 
criteria: 
secondary 
elevations of 
PTH (unclear) 
 
Lower levels 
of PTH, 
osteocalcin, 
PINP in 
NPHPT. 
Higher levels 
of phosphate 
 
No 
differences in 
CTX, 
25(OH)D, 
1,25 
dihydroxyvita
min D 
NA NA Osteoporosis 
29%, NS 
difference 
from PHPT 
No difference 
in hip and 
spine BMD. 
Radius not 
available 
(Cusano et al, 
2013a) 
 
New York, USA 
Osteoporotic 
Fractures in Men 
(MrOS) study 
NPHPT 9, 
age 70.0±6 
years, 0% 
female 
 
Controls 
2224  
 
NS 
differences in 
age, BMI 
Normal total 
calcium and 
high PTH 
Excluded renal 
insufficiency, 
25(OH)D≤20 
ng/ml, thiazide 
use 
NS 
differences in 
phosphate, 
CTX, PINP, 
TRAP 5b, 
testosterone, 
oestradiol, 
SHBG 
 NA NA NA NS difference 
in lumbar 
spine or 
femoral BMD 
or cQCT 
(Diaz-Soto et al, 
2015) 
Prospectively 
enrolled 61 
NPHPT, 
n=41, 83% 
Normal total, 
adjusted and 
Lower levels 
of PTH,  
NA NA NA NS 
differences in 
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Valladolid, Spain 
NPHPT and 
asymptomatic 
PHPT patients 
from their 
Endocrinology 
Service  
female, mean 
age 63 years 
 
PHPT, n=20, 
80% female, 
mean age 66 
years 
 
(no 
differences in 
age, sex) 
ionised calcium 
on two 
occasions within 
one year 
 
Exclusion 
criteria: 
eGFR<60 
ml/min, 
25(OH)D<30 
ng/ml, FHH, 
hypercalciuria 
(>250mg/24h in 
females and 
>300mg/24h in 
men), other 
metabolic 
diseases and 
medications 
(thiazides, 
bisphosphonate
s, lithium) 
bone 
turnover 
markers 
(ALP, PINP, 
osteocalcin) 
in NPHPT 
Higher levels 
of 25(OH)D, 
serum 
phosphate,  
magnesium 
and 
phosphate 
tubular 
reabsorption 
BMD (spine 
and hip) 
(Gómez-Ramírez 
et al, 2019) 
 
Madrid, Spain 
Prospectively 
104 enrolled all 
patients (77.0% 
female, mean 
age 60.5) 
referred for 
parathyroidecto
my between 
2015-2017 in an 
Endocrine 
Surgery 
NPHPT: 45 
had normal 
adjusted 
calcium, only 
16 also had 
normal 
ionised 
calcium 
(15.4% of the 
original) 
NPHPT: Normal 
adjusted and 
ionised calcium 
with high PTH in 
on at least 3 
occasions 
separated by 
at least 3 
months). 
Normal 
creatinine and 
Similar levels 
of PTH, 
urinary 
calcium, ALP 
 
NPHPT had 
higher levels 
of 25(OH)D. 
Lower levels 
of PINP, 
Tc-sestamibi: 
sensitivity in 
PHPT 81% vs 
56.2% in 
NPHPT 
 
Ultrasound 
sensitivity in 
PHPT 50.6% 
vs 31.2% in 
NPHPT 
History of 
nephrolithia
sis 25%, 
NS 
difference 
NA Similar results 
of BMD (hip, 
radius and 
spine) in the 
two groups 
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department in 
Madrid. 
Excluded those 
who had 
treatment, family 
history of PHPT 
Age 60.6±11, 
68% female 
 
PHPT:88 
NS difference 
in age, 
gender 
 
GFR, vitamin 
D> 30 ng/ml;. 
Excluded: 
malabsorption, 
history of gastric 
bypass, 
medications 
(thiazides, 
lithium, 
bisphosphonate
s)  
osteocalcin, 
CTX 
 
NS difference 
(Koumakis et al, 
2013) 
 
Paris, France 
Prospectively 
screened 413 
consecutive 
patients referred 
to their centre. 
193 fulfilled the 
criteria for 
PHPT. 
Evaluated the 
data of 60 
patients who 
were operated 
and had 
longitudinal 
BMD follow up 
NPHPT 39, 
age 66.1±9.1, 
92.3% female 
41% had 
normal iCa 
 
PHPT 21 (no 
difference in 
age and 
gender) 
Normal adjusted 
calcium and 
high PTH 
Excluded 
causes of 
25(OH)D<20 
ng/ml, renal 
impairment 
(GFR<40 
ml/min/1.73m2), 
bisphosphonate
, thiazides, 
anticonvulsants, 
lithium, 
gastrointestinal 
diseases related 
to 
malabsorption, 
liver disease. A 
thiazide diuretic 
test in those 
with 
Higher 
phosphate 
and eGFR in 
NPHPT  
Lower CTX 
 
Similar levels 
of PTH, 24h 
urine 
calcium, 
ALP, 
osteocalcin, 
25(OH)D 
 NA History of 
nephrolithia
sis 17.9%  
(NS 
difference 
with PHPT) 
T score ≤-2.5 
in at least one 
site 89.7%  
(vs 61.9% in 
PHPT, 
P=0.02) 
 
History of 
fracture 39.5% 
(NS difference 
from PHPT) 
Similar results 
in BMD 
(spine, distal 
radius) 
between the 
two groups 
apart from 
femoral neck 
T score being 
significantly 
lower in 
NPHPT 
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hypercalciuria 
Oral ± iv 
calcium load 
test (NPHPT: 
tCa and/or iCa 
increasing to 
supranormal 
values with only 
a minimal 
reduction in 
PTH) 
41% had both 
iCa and tCa 
normal 
(Lowe et al, 
2007) 
 
New York, USA 
Longitudinal 
study 
 
Referral to 
Metabolic Bone 
Disease Unit  
NPHPT 37, 
age 58±2 
years, 95% 
female (29 
postmenopau
sal, 6 
premenopaus
al) 
Elevated PTH 
with normal 
adjusted 
calcium 
 
Excluded cases 
with 
25(OH)D<20 
ng/ml, GFR<40 
ml/min/1.73m2, 
liver disease, 
hypercalciuria 
>350mg/24h, 
thiazide or 
lithium use, 
metabolic bone 
diseases 
 NA 
comparisons 
 
Phosphate, 
ALP, urinary 
calcium were 
normal.  
 
In 24% of 
patients 
elevated 1,25 
dihydroxyvita
min D 
16 tested 
8 adenoma 
History of 
nephrolithia
sis 14% 
Recent 
fragility 
fracture 11% 
   
History of 
fracture in 
adulthood 
46% 
 
Osteoporosis 
57% (19% 
osteoporosis 
at 2/3 sites, 
8% 
osteoporosis 
at all three 
sites) 
Osteoporosis 
more 
frequent in 
spine (34%) 
and hip 
(38%) than 
distal radius 
(28%) 
(Marques et al, 
2011) 
Analysed 
records of 156 
NPHPT 14, 
age 
At least two 
samples of total 
Higher PTH 
in NPHPT 
 NA Kidney 
stones 
Fractures 
21.4% vs 
Osteoporosis 
more frequent 
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Pernambuco, 
Brazil 
postmenopausal 
women who 
came to hospital 
to be screened 
for osteoporosis 
(referral) 
60.6±14.8 
years, 100% 
female  
 
Controls 142 
(no difference 
in age, BMI, 
time since 
menopause) 
calcium and 
PTH 
Excluded: 
25(OH)D<30 
ng/ml, GFR<40 
ml/min, taking 
bisphosphonate
s, thiazides, 
lithium, 
metabolic bone 
diseases, 
gastrointestinal 
diseases with 
malabsorption, 
liver disease, 
incomplete 
records 
group, similar 
levels of 
calcium, 
CTX. 
Lower levels 
of 25(OH)D 
in controls 
28.6%  
(vs 0.7% in 
controls, 
P<0.001) 
16.2% (NS 
difference 
from controls) 
 
Osteoporosis 
35.7%  
Similar levels 
of BMD at hip 
and spine 
in spine 
(28.5%) and 
distal radius 
(28.5%)  than 
hip (21.4%) in 
NPHPT 
patients 
(Maruani et al, 
2003) 
 
Paris, France 
178 patients 
referred for 
PHPT 
NPHPT 34  
Age 53±14 
years, 68% 
female 
 
PHPT 144 
(34 matched 
for age, 
gender, PTH) 
Normal total 
calcium and 
high PTH, 
iCa≤1.35 
mmol/L, (5 had 
PTH in the 
upper normal 
range), oral 
calcium test 
 
Excluded cases 
with: 
25(OH)D<15 
nmol/L,  Mg 
deficiency <0.71 
mmol/L, 
Significantly 
lower PTH, 
urine calcium 
excretion, 
1,25(OH)D 
than PHPT 
patients  
  Nephrolithi
asis 35% 
Hypercalciu
ria 18% 
Chondrocalcin
osis 6% 
Radiographic 
bone 
demineralizati
on 18% 
27 out of 144 
hypercalcaem
ic patients 
had normal 
tCa but 
elevated iCa 
Appendix  
Table 1: The skeletal and renal effects of NPHPT 
 
 358 
creatinine 
>110μmol/L or 
GFR<50 
ml/min/1.73m2, 
medications 
(bisphosphonat
es, Li, loop 
diuretics, 
thiazides, 
corticosteroids), 
associated 
diseases 
(progressive 
endocrine 
disorder, 
granulomatosis, 
neoplasia) 
(Pierreux et al, 
2018) 
 
Brussels, 
Belgium 
Retrospectively 
reviewed the 
medical records 
of 659 patients 
with PHPT and 
‘hyperparathyroi
dism of 
undefined origin’ 
Excluded 
subjects 
because of 
active malignity, 
insufficient data, 
post-renal 
transplant 
patients, 
NPHPT 25, 
age 62±12, 
76% female 
 
PHPT 106 
 
NS difference 
in age, sex, 
BMI, 
25(OH)D 
Normal adjusted 
calcium and 
elevated or 
inappropriately 
high PTH. 
Exclusions: 
25(OH) < 20 
ng/ml, eGFR < 
60 ml/min, 
medications 
(loop and 
thiazide 
diuretics, 
bisphosphonate
s, denosumab, 
lithium), gastro-
NPHPT: 
Higher 
phosphate, 
eGFR, lower 
urinary 
calcium 
NA NPHPT: 
nephrolithia
sis 36% 
 
Similar 
rates in 
PHPT 
NPHPT: 
vertebral 
fractures 12%, 
osteopenia 
56%, 
osteoporosis 
25% 
 
Similar rates 
in PHPT 
Similar BMD 
results at 
spine and hip 
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secondary 
hyperparathyroid
ism, PHPT in the 
context of a 
MEN-1 or 2. 
Final number, 
131 
intestinal 
malabsorption 
disorders 
(coeliac, 
pancreatic, and 
biliary 
insufficiency) 
and 
hypercalciuria 
(urinary Ca/Cr 
ratio more than 
240 mg/g Cr) 
(Silverberg & 
Bilezikian, 2003) 
 
New York, USA 
Recruited 
eligible patients 
from referral 
centre 
NPHPT 22; 
age 57±10 
Normal adjusted 
calcium and 
high PTH 
Confirmed on 
at least two 
occasions, 
eight patients 
also had 
normal iCa, 
25(OH)D>20 
ng/ml. 
Excluded FHH, 
liver disease, 
renal disease, 
urinary 
calcium>87.5 
mmol/24h, 
gastrointestinal 
disease with 
malabsorption, 
metabolic bone 
No 
comparisons 
 
Four patients 
had mild 
hypercalciuri
a, seven had 
elevated 
levels of 1,25 
dihydroxyvita
min D and 
phosphate 
was low in 
one patient 
NA 14% had 
kidney 
stone 
The 
biochemical 
testing did 
not differ 
between 
the ones 
with and 
without 
kidney 
stones 
(calcium, 
PTH, 
urinary 
calcium) 
45% had 
osteoporosis 
and 5% had 
vertebral 
fracture 
More patients 
had 
osteoporosis 
at the spine 
(23%) and hip 
(27%) than 
the distal 
radius (14%)  
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disease, 
medications 
(lithium, 
thiazide, 
oestrogens, 
loop diuretics, 
bisphosphonate
s, 
anticonvulsants) 
(Siprova et al, 
2016) 
 
Czech Republic 
1180 referrals to 
Endocrine 
Centre 
NPHPT 187 
PHPT 31 
Normal total 
calcium and 
high PTH 
25(OH)D≥20 
ng/ml (patients 
with low vit D 
were treated 
and PTH had to 
be elevated 
after retested at 
3 months).  
Excluded cases 
with: renal 
insufficiency, 
calcium 
malabsorption, 
hypercalciuria, 
medications 
(PPI, thiazides, 
lithium) 
Lower PTH 
values 
NPHPT 
patients: 
118/187 (63%) 
tested 
 
Patients with 
permanent 
normocalcae
mia: 6% 
adenoma  
 
Patients 
evolved to 
hypercalcae
mia: 14% 
adenoma in 
normocalcaem
ic state,  
73% 
adenoma in 
hypercalcae
mic state,  
(P=0.001) 
 
Nephrolithi
asis 4% (vs 
22% in 
PHPT) 
Reduced BMD 
42% (vs 22% 
in PHPT) 
Less 
frequent 
symptoms 
(fatigue, 
indigestion, 
mood 
disorders, 
musculoskel
etal pain) in 
NPHPT 
(23.5% vs 
71% in PHPT, 
P=<0.001) 
 
76% another 
endocrine 
disease, 
mainly thyroid 
diseases 
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PHPT 
patients: 
31/31 tested. 
68% adenoma 
(Tordjman et al, 
2004) 
 
Tel Aviv, Israel 
Retrospectively 
evaluated 
records of 
patients with 
PHPT 
NPHPT 32, 
age 
60.5±10.5, 
84% female 
Normal total 
calcium and 
high PTH 
Secondary 
hyperparathyroi
dism excluded 
(impaired renal 
function). Three 
patients had low 
vitamin D levels, 
however 
correction did 
not alter PTH 
levels and did 
not unmask 
hypercalcaemia. 
Six patients with 
urine calcium 
>300mg/24h, 
were given 
thiazides 
without affecting 
PTH levels 
  22 tested, 
73% adenoma 
 
48% enlarged 
gland in 
ultrasound 
Nephrolithi
asis in 
9.4% 
Spine:  
77% 
osteopenia, 
46% 
osteoporosis 
 
Hip:  
64% 
osteopenia, 
36% 
osteoporosis 
 NA 
(Traini et al, 
2018) 
 
Rome, Italy 
Retrospectively 
evaluated 
records from 
731 patients 
who had 
parathyroidecto
NPHPT 154 
(21%), age 
59 ± 12.1, 
88% female 
 
PHPT 577 
Normal adjusted 
calcium and 
high PTH, 
25OHD ≥ 20 
ng/ml, exclusion 
of impaired 
NPHPT: 
Higher 
phosphate, 
lower PTH 
The sensitivity 
and positive 
predictive 
value of 
imaging 
studies was 
NPHPT: 
urinary 
symptoms 
and/or 
kidney 
stones: 
BMD 
decrease: 
25.3%, NS 
difference 
from PHPT 
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my between 
1998 and 2016 
 
NS 
differences in 
age and 
gender 
renal function, 
medications,  
malabsorption 
similar. 
Sestamibi and 
ultrasound 
together failed 
in detecting all 
the diseased 
glands in 
85.0% NPHPT 
patients and in 
79.5% PHPT 
16.2%, NS 
difference 
from PHPT 
 
 
(Tuna et al, 2015) 
 
Ankara, Turkey 
Retrospectively 
evaluated 307 
records of PHPT 
patients  
NPHPT 23, 
age 
54.1±11.4, 
87% female 
 
PHPT 284 
(no difference 
in age and 
gender) 
Normal adjusted 
calcium and 
high PTH, 
investigated on 
three 
consecutive 
occasions within 
1-3 months. 
Excluded cases 
with impaired 
renal function, 
25(OH)D≤20 
ng/ml, liver 
failure, 
metabolic bone 
disease, 
medications 
(lithium, 
phenytoin, 
thiazide, loop 
diuretic), FHH 
(family history of 
hypercalcaemia, 
Higher 
25(OH)D, 
lower ALP, 
24h urine 
calcium 
 
Similar levels 
of 
phosphate, 
PTH, 
creatinine 
NA Nephrolithi
asis 15.4% 
(vs 19.4% 
in PTHP, 
NS 
difference) 
Osteopenia 
23.3%(vs 
36.7% in 
PHPT) 
Osteoporosis 
53.3% (vs 
43.8% in 
PHPT) 
NS differences 
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urinary calcium 
<100mg/day) 
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Table 6-2: Studies on the metabolic abnormalities and cardiovascular risks of normocalcaemic hyperparathyroidism 
 
 
Publications Recruitment Study 
population 
(n), age, 
gender 
Criteria Glucose 
metabolism 
Lipid profile Other 
cardiovascular 
abnormalities 
Limitations 
(Beysel et 
al, 2019) 
 
Ankara, 
Turkey 
Recruited PHPT 
patients from an 
Endocrinology 
Centre and 
controls from 
population-
based screening 
programs 
NPHPT: 35 
 
PHPT: 60 
 
Controls: 60 
 
Matched for 
age and 
gender 
Similar rates 
of obesity, 
smoking 
Normal adjusted calcium, 
high PTH on two 
separate occasions. 
25(OH)D ≥30 ng/ml. 
Excluded renal 
insufficiency (creatinine 
clearance < 90 mL/ min), 
liver disease, significant 
hypercalciuria (urinary 
calcium > 350 mg per 24 
h), thiazide, lithium, 
bisphosphonate use and 
other metabolic bone 
diseases 
Glucose 
metabolism 
(glucose, 
insulin, 
HOMA-IR) 
were similar 
between the 
NPHPT and 
PHPT groups 
(p > 0.05) 
and 
statistically 
greater than 
controls 
 
Prevalence of 
diabetes was 
similar 
between the 
PHPT and 
NPHPT. No 
comparison 
with controls 
Similar prevalence of 
dyslipidaemia in PHPT 
and NPHPT, higher 
than in controls.  
 
Elevated cholesterol, 
LDL and triglycerides 
at similar levels in 
PHPT and NPHPT, 
higher than in 
controls. 
BMI was higher 
in the PHPT 
group 
 
Cardiovascular 
risk score was 
lower in controls, 
but similar 
between the 
NPHPT and 
PHPT groups 
 
Higher levels of 
both systolic and 
diastolic blood 
pressure at 
similar levels in 
PHPT and 
NPHPT, higher 
than in controls 
 
(Cakir et al, 
2012) 
 
Recruited 
patients from an 
endocrinology 
centre 
NPHPT 18, 
age 49.9±2.4, 
89% female 
 
Normal total calcium and 
high PTH, 25(OH)D >20 
ng/ml, repeated Ca and 
PTH measurements 3 
NS difference 
on insulin 
responses to 
OGTT and 
NS difference in lipid 
profile (total 
cholesterol, HDL, LDL, 
triglycerides) 
 NA   
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Istanbul, 
Turkey 
Controls 18 
(matched for 
age, gender 
and BMI) 
times with 2-week 
intervals, no history of 
renal or liver diseases, no 
prescriptions known to 
affect calcium level 
 
No history of 
hypertension, diabetes 
mellitus, family history of 
diabetes, any 
medications affecting 
glucose or lipid 
metabolism 
HOMA-IR 
[fasting 
insulin  (μu/ml
) x fasting 
glucose ( 
mmol/L)/22.5] 
(Chen et al, 
2015) 
 
Fuzhou, 
China 
Retrospectively 
enrolled 940 
Chinese 
subjects who 
visited the 
hospital for 
examination or 
treatment and 
had calcium and 
PTH 
measurements 
NPHPT 11, 
age 
60.3±18.5 
years, 45.5% 
female 
 
Controls 296 
[NS 
differences in 
age, sex, 
BMI, Ca, 
glucose, 
lipids, 
25(OH)D, 
creatinine] 
Normal adjusted calcium 
and high PTH 
Excluded vitamin D 
deficiency (≤20 ng/ml), 
renal insufficiency 
(GFR<60 ml/min), 
thiazide use, 
hypercalciuria, 
malabsorption 
NS difference 
in fasting 
glucose 
NS difference in lipid 
profile (total 
cholesterol, HDL, LDL, 
triglycerides) 
Higher levels of 
SBP (140±20.2 
vs 131.2±16.5, 
p=0.041) and 
DBP (85.2±12.4 
vs 76.8±10.3, 
p=0.026) in 
NPHPT group vs 
controls 
 
After adjusting 
for all the 
potential 
confounders, 
odds ratio of 
SBP and DBP in 
NPHPT were 
1.035 (1.000 to 
1.071) and 
Not surveyed 
smoking, 
alcohol 
consumption, 
physical 
activity, diets  
Appendix  
Table 2: The metabolic abnormalities and cardiovascular risks of NPHPT 
 
 366 
1.063 (1.004 to 
1.125) 
(Diri et al, 
2014) 
 
Istanbul, 
Turkey 
NPHPT patients 
from Cakir et al 
2012 study, 
follow up for 4 
years 
NPHPT 15, 
88% female 
Definition by Cakir et al 
2012  
Did not include the 
patient progressing to 
hypercalcaemia 
3/5 patients 
with IGT 
developed 
DM (overall 
18.75% of 
patients with 
NHPER had 
DM). none of 
the patients 
with normal 
glucose 
tolerance 
developed 
glucose 
intolerance 
Lipid levels remained 
at similar levels during 
the 4 years 
 NA   
(Hagstrom 
et al, 2006) 
 
Uppsala, 
Sweden 
Population-
based screening 
of 5202 
postmenopaus
al women 
NPHPT 30, 
mean age 
66.4, 100% 
female 
 
Controls 30, 
normal 
calcium and 
PTH 
(matched for 
age and 
gender, 
similar levels 
of exercise 
and smoking) 
Serum Ca 2.50-2.60 
(normal <2.6 mmol/L) 
and PTH≥35 (normal 12-
55 ng/L) or  
▪Ca <2.5 mmol/L and 
PTH>55 ng/L 
Investigated 4 
consecutive occasions, 
Normal iCa, normal 
creatinine values<98 
μmol/L (except one 
subject 122 μmol/L), no 
family history of 
hypercalcaemia, normal 
or high urinary excretion 
(excluding FHH)  
Higher 
levels of 
glucose vs 
controls 
(5.29±2.1 
mmol/L vs 
4.75±1.2, 
P=0.007) 
NS difference 
in HbA1c 
Lower levels of HDL 
(1.31±0.31 mmol/L vs 
1.40±0.36, P=0.013) 
Higher levels of 
VLDL and 
triglycerides 
(0.62±0.63 mmol/L vs 
0.528±0.46, P=0.032) 
and (1.93±1.1 mmol/L 
vs 1.72±0.88, 
P=0.007) 
Higher LDL/HDL 
ratio (3.92±1.3 vs 
3.64±1.2, P=0.035) 
Higher levels of 
urate (338±90 
mmol/L vs 
251±60, 
P=0.004) 
 
Higher BMI  
(28.5±4.8 kg/m2 
vs 26.1±4.3, 
P=0.009) 
Absence of 
vitamin D 
measuremen
t 
Some cases 
treated with 
lipid lowering 
therapy 
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(Mesquita et 
al, 2017) 
 
Pernambuc
o, Brazil 
Recruited 
patients with 
NPHPT from an 
endocrinology 
centre 
 
NPHPT 13 
66.15±7.71 
 
Control 16 
 
All female, 
matched for 
age 
Normal adjusted calcium, 
high PTH.  
Exclusions: GFR <60 
mL/min, 25(OH)D< 20 
ng/ml, use of thiazide 
diuretic or lithium, and 
presence of 
gastrointestinal disorders 
associated with 
malabsorption 
Lower fasting 
glucose and 
HbA1C in 
NPHPT 
 
Same rates 
of diabetes 
mellitus 
Similar lipid profile 
(cholesterol, LDL, 
HDL, triglycerides) 
Similar rates of statin 
use 
Lower BMI in 
NPHPT but 
similar waist 
circumference 
 
Similar 
hypertension 
rates 
Similar 
smoking 
rates, family 
history of 
early heart 
disease 
(Tassone et 
al, 2013) 
 
Turin, Italy 
Recruited 
patients with 
NPHPT out of 
357 consecutive 
patients with 
PHPT from an 
endocrinology 
centre.  
 
Recruited 
normocalcaemic 
controls from 
outpatients 
clinics; these 
were followed up 
for diseases not 
affecting insulin 
sensitivity (eg 
goitre) 
NPHPT 23, 
age 
58.7±11.5 
 
Controls 23 
(matched for 
age, gender 
and BMI) 
High PTH and normal 
total and ionised 
calcium in more than 
two separate 
occasions, 25(OH)D>20 
ng/ml, GFR>40 
ml/min/1.73m2. Excluded 
liver disease, significant 
hypercalciuria (urinary 
calcium>350mg/24h), 
medications (thiazides, 
lithium), metabolic bone 
diseases 
NS difference 
in insulin 
sensitivity 
and glucose 
tolerance. 
 
NS difference 
in frequency 
of DM and 
IGT 
 NA NA  Absence of 
PTH, 
25(OH)D, 
ionised 
calcium in the 
control group 
(Temizkan 
et al, 2015) 
 
Recruited 
patients referred 
to an 
endocrinology 
NPHPT 25, 
age 48.1 
(8.4). 100% 
female 
Serum and iCa normal, 
persistently high PTH 
on two occasions, 
25(OH)D≥20 ng/dl, 
NS difference 
in OGTT 
responses 
NS differences in lipid 
profile (cholesterol, 
LDL, HDL, 
triglycerides) 
NS difference in 
blood pressure, 
uric acid, CRP, 
TSH 
All patients 
female 
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Istanbul, 
Turkey 
centre for high 
PTH, normal Ca 
 
Controls 
recruited from 
research centre, 
having normal 
PTH and 
25(OH)D≥20 
ng/dl 
 
Controls 25 
(matched for 
age, gender, 
vitamin D, 
BMI) 
GFR≥60 ml/min. 
Excluded : 
hypercalciuria>400mg/d, 
medications (lithium, 
phenytoin, thiazides, loop 
diuretics, malabsorption 
(gluten enteropathy, 
bariatric surgery, urine 
calcium <50mg/d) 
 
Did not include 
participants with 
conditions that might 
affect glucose 
metabolism 
and HOMA-
IR 
 
No 
correlation 
between PTH 
and glucose 
metabolism 
markers 
(Tordjman 
et al, 2010) 
 
Tel Aviv, 
Israel 
Retrospective 
study 
consecutive 
PHPT patients 
seen in a referral 
centre 
(Endocrinology 
centre in Tel 
Aviv) 
NPHPT 32, 
age 
60.5±10.5, 
84% female 
 
PHPT 81 (no 
difference in 
age, gender) 
 
Controls 25- 
to study 
arterial 
stiffness 
(matched to 
13 NPHPT 
and 12 PHPT 
patients 
based on 
Normal total calcium and 
high PTH 
Secondary 
hyperparathyroidism 
excluded (impaired renal 
function). Three patients 
had low vitamin D levels, 
however correction did 
not alter PTH levels and 
did not unmask 
hypercalcaemia. Six 
patients with urine 
calcium >300mg/24h, 
were given thiazides 
without affecting PTH 
levels 
Diabetes or 
IFG 6% (NS 
difference 
from PHPT) 
Hyperlipidaemia 10%  
(NS difference from 
PHPT) 
Hypertension 
20%  
(NS difference 
from PHPT) 
 
Less frequent 
ischaemic 
heart disease 
(IHD) and/or 
cerebrovascula
r accident 
(CVA) in the 
NPHPT vs 
PHPT (3.1% vs 
24.7%, P=0.007) 
 
NS differences 
in non-invasive 
IMT not 
evaluated 
Retrospective 
study 
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age, gender, 
cardiovascula
r risk factors) 
arterial 
stiffness 
parameters in 
the 3 groups  
(Tuna et al, 
2015) 
 
Ankara, 
Turkey 
Retrospectively 
evaluated 307 
records of PHPT 
patients 
NPHPT 23, 
age 
54.1±11.4, 
87% female 
 
PHPT 284 
(no difference 
in age and 
gender) 
Normal adjusted calcium 
and high PTH, 
investigated on three 
consecutive occasions 
within 1-3 months. 
Excluded cases with 
impaired renal function, 
25(OH)D≤20 ng/ml, liver 
failure, metabolic bone 
disease, medications 
(lithium, phenytoin, 
thiazide, loop diuretic), 
FHH (family history of 
hypercalcaemia, urinary 
calcium <100mg/day) 
Diabetes or 
IFG 21.7%  
(NS 
difference 
from PHPT) 
Higher LDL levels in 
NPHPT vs 
PHPT(145.2±27.6mg'/
dl vs 125.7±33.2, 
P=0.022), but with 
higher TSH levels 
(2.40±1.38μIU/ml vs 
1.79±1.14 , P=0.011) 
Similar levels of 
triglycerides, HCL and 
uric acid 
Hypertension 
53.8% (NS 
difference from 
PHPT) 
 
(Yener 
Ozturk et al, 
2015) 
 
Istanbul, 
Turkey 
Patients referred 
for osteoporosis 
screening  
Cross-sectional 
NPHPT 25, 
age 
52.88±11.71, 
92% female 
 
PHPT 24 
 
Healthy 
controls 30  
 
(age, gender 
and BMI 
matched) 
Concomitantly elevated 
PTH, repeatedly normal 
iCa and  adjusted Ca, 
25(OH)D ≥30 ng/dl (when 
low levels where 
corrected with 50.000IU 
for 8 weeks, PTH still 
remained elevated, with 
normal Ca) 
Excluded cases with: 
hypercalciuria>400mg/24
h, GFR<60 ml/min,, 
medications (lithium, 
phenytoin, thiazide, loop 
Higher 
levels of 
fasting 
glucose and 
higher pre-
existing 
glucose 
intolerance 
(IGT/DM) in 
NPHPT vs 
controls.  
Similar 
levels in 
NPHPT and 
NS difference in lipid 
profile (except higher 
cholesterol level in 
control group); higher 
usage of 
antihyperlipidemic 
therapy in NPHPT and 
PHPT groups 
 
PTH positively 
correlated with 
triglyceride levels 
NS difference for 
blood pressure, 
but higher 
prevalence of 
pre-existing 
hypertension 
or 
antihypertensiv
e medications 
in the NPHPT 
and PHPT 
groups 
compared to 
controls 
Small 
sample, cross 
sectional 
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diuretics), GI disorders, 
low urinary calcium 
(<50mg/day), FHH 
PHPT 
 
PTH 
concentration 
was 
significantly 
higher in the 
IGT/DM 
group  
 
Positive 
correlation 
of both 
calcium and 
PTH to 
fasting 
insulin and 
HOMA-IR 
 
Similar 
prevalence of 
metabolic 
syndrome in 
NHPER and 
PHPT patients 
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Table 6-3: Studies on the surgical management of normocalcaemic hyperparathyroidism 
Publications Recruitment NPHPT population 
(n) 
Criteria Changes in 
subjects 
undergone 
surgery 
Histology Adenoma weight 
(Gómez-
Ramírez et 
al, 2019) 
 
Madrid, 
Spain 
Prospectively 104 
enrolled all patients 
(77.0% female, mean 
age 60.5) referred for 
parathyroidectomy 
between 2015-2017 in 
an Endocrine Surgery 
department in Madrid. 
Excluded those who 
had treatment, family 
history of PHPT 
NPHPT: 45 had 
normal adjusted 
calcium, only 16 
also had normal 
ionised calcium 
(15.4% of the 
original) 
Age 60.6±11, 68% 
female 
 
PHPT:88 
NS difference in 
age, gender 
 
NPHPT: Normal 
adjusted and ionised 
calcium with high PTH 
in on at least 3 
occasions separated 
by at least 3 months). 
Normal creatinine and 
GFR, vitamin D> 30 
ng/ml;. Excluded: 
malabsorption, history 
of gastric bypass, 
medications (thiazides, 
lithium, 
bisphosphonates)  
Follow up 1 year 
later. There was a 
reduction in bone 
markers and 
improvement in 
BMD (no p values). 
Any statistical 
differences prior to 
surgery between 
the two groups were 
diminished 
Incidence in 
multiglandular 
disease higher in 
NPHPT (7.1% vs 
4.1%) but no 
statistical 
difference (p=0.84) 
Weight of 
adenoma lower 
(497 ± 268 mg vs 
1153 ± 1065 mg, 
p= 0.058) 
(Koumakis 
et al, 2013) 
 
Paris, 
France 
Prospectively screened 
413 consecutive 
patients referred to their 
centre. 193 fulfilled the 
criteria for PHPT. 
Evaluated the data of 
60 patients who were 
operated and had 
longitudinal BMD follow 
up (1 year) 
NPHPT 39 
41% had normal 
iCa 
 
Surgery to all 
patients recruited 
(n=39 NPHPT, 
n=21 PHPT) 
Normal adjusted 
calcium and high PTH 
Excluded causes of 
25(OH)D<20 ng/ml, 
renal impairment 
(GFR<40 
ml/min/1.73m2), 
bisphosphonate, 
thiazides, 
anticonvulsants, lithium, 
gastrointestinal 
diseases related to 
malabsorption, liver 
disease. A thiazide 
Significant 
increase of BMD in 
NPHPT.  
Spine +2.3±5.0% 
(P=0.016) 
Hip +1.9±5.7% 
(P=0.048) 
 
Significant increase 
in BMD in PHPT 
patients.  
 
NS difference 
between groups 
Parathyroid 
hyperplasia or 
multiple 
adenomas more 
frequent in 
NPHPT (28.2% vs 
4.8% in PHPT, 
P=0.04) 
Lower adenoma 
weight in NPHPT 
(189±181.5mg vs 
354.4±296.8 in 
PHPT, P=0.03) 
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diuretic test in those 
with hypercalciuria 
Oral ± iv calcium load 
test (NPHPT: tCa 
and/or iCa increasing to 
supranormal values with 
only a minimal reduction 
in PTH) 
41% had both iCa and 
tCa normal 
 
Significant 
decrease in distal 
1/3 of radius BMD 
in NPHPT (-
1.5±3.5%, P=0.02).  
BMD remained 
stable in the radius 
in the PHPT group 
(Koumakis 
et al, 2014) 
 
Paris, 
France 
Further analysis of 
above mentioned 
patients by Koumakis et 
al 2013 
 
Excluded 5 lacking 
BMD for one of the 
three investigated sites 
NPHPT 36  
 
Only 15 (42%) had 
normal iCa 
See Koumakis et al 
2013 
Considered BMD gain 
significant for an 
individual patient if it 
was ≥0.030g/cm2 at any 
site, without any loss of 
BMD of ≥0.030g/cm2 at 
another site during the 
same period of time 
 
Individual BMD 
gain in the 
normocalcaemic 
group in 44.4% vs 
73.7% of the 
hypercalcaemic 
patients, P=0.049) 
 
NS difference when 
comparing the gain 
to patients with 
normal or elevated 
iCa 
 
Pre-surgery ALP 
value above 
median: predictive 
factor for BMD 
gain in NPHPT 
 NA  NA 
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(Lim et al, 
2017) 
 
New York, 
USA 
Retrospective cohort 
review of all patients 
who underwent para- 
thyroidectomy from 
2006–2012 (New York), 
n=675. Excluded if they 
underwent operation for 
secondary or tertiary 
hyperparathyroidism, 
had prior 
parathyroidectomy, or 
incomplete data, final 
number n=573 
NPHPT 96 
 
Normoparathyroid 
hypercalcaemia  
(NH) 72 
 
PHPT 405 
 
NS difference 
differences in age, 
race, history of 
neck irradiation, 
lithium usage, 
family history of 
parathyroid 
disease, or 
presence of 
osteoporosis and 
kidney stones 
 
 
Not clear but included 
patients with eGFR<60 
ml/min/1.73m2, lithium 
use, 25(OH)D<30 ng/ml 
NA Multigland 
disease: 
NPHPT (43, 45%) 
NH (7, 10%) 
PHPT (36, 9%)  
 
Significant 
predictors for 
multigland disease 
were the NPHPT 
and positive family 
history 
 
Patients with 
NPHPT were over 
eight times as 
likely to have 
multiglandular 
disease (odds 
ratio 8.17, 95% 
confidence interval 
4.49 to 14.83) 
NA 
(Lowe et al, 
2007) 
 
New York, 
USA 
Referral to Metabolic 
Bone Disease Unit  
NPHPT 37 
 
Surgery to three 
NPHPT patients 
who progressed to 
hypercalcaemia 
and to four 
normocalcaemic 
ones 
Elevated PTH with 
normal adjusted calcium 
 
Excluded cases with 
25(OH)D<20 ng/ml, 
GFR<40 ml/min/1.73m2, 
liver disease, 
hypercalciuria 
>350mg/24h, thiazide or 
lithium use, metabolic 
bone diseases 
Normalisation of 
calcium in the 
hypercalcaemic, no 
change in the 
normocalcaemic 
despite significant 
fall in PTH (returned 
to normal) 
Hypercalcaemic 
patients:  
single adenoma 
(n=2),  
two hyperplasic, 
glands (n=1) 
 
Normocalcaemic:  
single adenoma  
(n=1),  
Hypercalcaemic 
patients: single 
adenoma 500 mg 
two hyperplasic, 
glands weighted 
100mg each 
 
Normocalcaemic: 
single adenoma 
200mg, 
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one hyperplastic 
gland (n=2),  
two hyperplastic 
glands (n=1) 
hyperplastic 
glands (140-
700mg)  
(Maruani et 
al, 2003) 
 
 
 
 
178 patients referred for 
PHPT 
NPHPT 34  
 
Surgery:  
21 
normocalcaemic,  
73 hypercalcaemic 
Normal total calcium 
and high PTH, iCa≤1.35 
mmol/L, (5 had PTH in 
the upper normal 
range), oral calcium 
test 
 
Excluded cases with: 
25(OH)D<15 nmol/L, 
Mg deficiency <0.71 
mmol/L, creatinine 
>110μmol/L or GFR<50 
ml/min/1.73m2,taking 
drugs 
(bisphosphonates, Li, 
loop diuretics, thiazides, 
corticosteroids), 
associated diseases 
(progressive endocrine 
disorder, 
granulomatosis, 
neoplasia) 
 NA Normocalcaemic: 
adenoma to all 
 
Hypercalcaemic:  
65 single 
adenomas, 2 
double adenomas, 
6 hyperplasia 
 Parathyroid gland 
mass (mg), 
expressed in 
geometric mean, 
95% confidence 
intervals  
 
Lower in NPHPT  
[229 (36-1464) vs 
500(70-3575), 
p<0.05)] 
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Persistence not 
checked at baseline 
(Pandian et 
al, 2019) 
 
Boston, 
USA 
Evaluated data from 
7569 patients who 
underwent 
parathyroidectomy from 
the Collaborative 
Endocrine Surgery 
Quality Improvement 
Program database.  
Excluded patients with 
familial, secondary or 
tertiary 
hyperparathyroidism. 
 
733 (9.7% NPHPT) 
NPHPT 733 (9.7%) Normal calcium and 
elevated PTH 
preoperatively 
 
Note: 25.6% of patients 
had low vitamin D and 
15.7% not recorded  
 
Kidney function not 
available on this 
database 
NA NPHPT: lower 
rates of single 
parathyroid 
removed (47.5%,  
vs 73.3%, p 
<0.05).  
 
Higher frequency 
of multigland 
hyperplasia in 
NPHPT (43.1% vs 
21.9%, p < 0.05). 
NA 
(Sho et al, 
2019) 
 
Los 
Angeles, 
USA 
Evaluated all the 
patients that had 
parathyroidectomy 
between 2006-2016 
NPHPT 90 (18%), 
71 had a 
biochemical follow 
up>6months after 
surgery 
 
Median age 67 
years, 89% female 
Normal calcium and 
high PTH. Only patients 
with peak calcium within 
the reference range 
within 1 year prior to 
surgery. Excluded 
patients with 
25(OH)D<20 nmol/L 
Significant 
reductions on 
calcium and PTH in 
all 
 
Normal PTH after > 
6 months: 53.5%, 
detected after a 
Multigland 
disease: 38 of 71 
patients (53.5%) 
 
Out of them, 23 
(60.5%) had 
hyperplasia and 
NA 
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and eGFR<60 
ml/min/1.73m2 
 
10 patients had 
normal adjusted 
calcium but high 
ionised calcium 
median of 7.7 
months 
 
BMD improvement 
of 5.6% after >2  
years in patients 
normalising their 
PTH after surgery. 
NS change in the 
ones that had 
elevated PTH 
 
15 (39.5%) had 
double adenomas 
(Silverberg 
& Bilezikian, 
2003) 
 
New York, 
USA 
Recruited eligible 
patients from referral 
centre, n=2055 
NPHPT 22 (18%) Normal adjusted 
calcium and high PTH 
Confirmed on at least 
two occasions, eight 
patients also had 
normal iCa, 
25(OH)D>20 ng/ml. 
Excluded FHH, liver 
disease, renal disease, 
urinary calcium>87.5 
mmol/24h, 
gastrointestinal disease 
with malabsorption, 
metabolic bone disease, 
medications (lithium, 
thiazide, oestrogens, 
loop diuretics, 
bisphosphonates, 
anticonvulsants) 
 NA One patient that 
progressed to 
hypercalcaemia 
operated: two 
adenomas 
 NA 
(Tordjman 
et al, 2004) 
Retrospectively 
evaluated records of 
NPHPT 32 Normal total calcium 
and high PTH 
 NA Surgery to 12/32 
  
688±541mg 
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Tel Aviv, 
Israel 
 
patients with PHPT in a 
referral centre 
 
follow up 20 
 
surgery 12 
Secondary 
hyperparathyroidism 
excluded (impaired 
renal function). Three 
patients had low vitamin 
D levels, however 
correction did not alter 
PTH levels and did not 
unmask 
hypercalcaemia. Six 
patients with urine 
calcium >300mg/24h, 
were given thiazides 
without affecting PTH 
levels 
Pathology report in 
11 
 
9 single adenoma,  
2 hyperplasia 
(Traini et al, 
2018) 
 
Rome, Italy 
Retrospectively 
evaluated records from 
731 patients who had 
parathyroidectomy 
between 1998 and 2016 
NPHPT 154 (21%), 
age 59 ± 12.1, 88% 
female 
 
PHPT 577 
 
NS differences in 
age and gender 
Normal adjusted 
calcium and high PTH, 
25OHD ≥ 20 ng/ml, 
exclusion of impaired 
renal function, 
medications,  
malabsorption 
BMD results in 12 
patients, 6 (50%) 
had stability, 5 
(41.7) had an 
improvement after 
72.9 ± 46.8 months 
 
Ten patients with 
prior kidney stones 
before surgery had 
a follow up: No 
evidence of kidney 
stones in 4 (40%). 
One patient had 
persistence of 
microlithiasis. The 
rest had stable 
results 
Multigland disease 
higher in NPHPT 
(13% vs 6.8%, 
p<0.05) 
NA 
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(Wade et al, 
2012) 
 
Wisconsin, 
USA 
Retrospectively 
evaluated records from 
771 patients who had 
parathyroidectomy 
between 1999 and 2008 
58; out of them 50 
had ionised 
calcium elevated 
and 8 had normal 
 
All had surgery 
 
Normal total calcium 
three months prior to 
surgery. Patients with 
recurrent, familial, 
secondary or tertiary 
hyperparathyroidism 
were excluded 
The results of the 
surgery did not 
differ between the 
groups (similar 
number of single 
gland and multiple 
gland disease) and 
the intraoperative 
PTH measurement 
was successful in 
the same number of 
patients 
Sestamibi and 
ultrasound were 
performed in 98%. 
NS difference 
regarding the 
sensitivity of 
positive predictive 
value in regards to 
detecting single 
gland disease. 
In patients with 
multigland 
disease, no 
method identified 
all abnormal 
glands 
Similar gland 
weight: median of 
360mg in the 
elevated iCa 
group vs 285 mg 
in the normal iCa 
(p 0.27) 
(Yu et al, 
2019) 
 
Harbin, 
China 
Retrospectively 
evaluated 197 patients 
that had 
parathyroidectomy 
between 2008-2017 
NPHPT 35 (18%), 
age 48.39±12.04, 
75% female 
 
PHPT 162 
 
NS difference in 
gender and age 
Normal adjusted 
calcium and high PTH, 
histologically proven, 
25(OH)D>30 ng/ml, 
GFR> 60 ml/min. 
Exclusions: 
bisphosphonates, 
thiazides, 
anticonvulsants, lithium; 
metabolic bone 
diseases or 
gastrointestinal 
diseases associated 
with malabsorption, liver 
disease 
NA NPHPT vs PHPT 
 
Adenoma: 77% vs 
83% 
Hyperplasia: 23% 
vs 14% 
Carcinoma: 0% vs 
2% 
 
p=0.108 
Similar lesion 
diameter in cm 
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Section 2: Intermediate analyses on NPHPT 
6.2.1 Analysis 1 
6.2.1.1 Problems identified in Analysis 1  
6.2.1.1.1 Assay change 
As mentioned in the Methods section, a new method for measuring total calcium was 
introduced in January 2013. Moreover, there were four changes in the adjusted 
calcium equation during the period of this study. According to the laboratory, these 
changes affected the adjusted calcium results and therefore, affected patient care. 
To test the effect of these changes in the population studied, a parametric test 
(independent Student’s t-test) was performed to check whether there was any 
statistical difference between the means of the patients with calcium with index day 
before January 2013 and the patients with index day after. The mean calcium of the 
first group was 2.40 mmol/L (n=2390) and the mean of the second group was 2.35 
mmol/L (n=4676). There was a statistically significant difference between the two 
groups (p value <0.001).  
Since adjusted calcium is a crucial result for this study, the changes of the methods 
might have had an effect on the number of NPHPT patients found.  
 
6.2.1.1.2 Mahalanobis distance calculation  
Up to this point, the Mahalanobis distance analysis was not performed by myself; it 
was considered a complicated analysis performed in R software which I did not have 
the knowledge to use.  By the end of the study on NPHPT, there was an attempt to 
reproduce the results of the Mahalanobis analysis. The results of the outlier number 
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were slightly different each time the analysis was attempted. The differences were due 
to random sampling using the estimation of the covariance matrix. The “cov.mve” 
function used in the R statistical software was searching the bivariate space for the 
minimum ellipsoid and was finding different solutions based on a random staring point. 
In order to be able to reproduce the same results each time the code is run, a random 
sampling seed has to be set in the beginning of the analysis. The problem was that 
the initial seed was not known and that is why the results would not be able to be 
reproduced again. 
 
6.2.1.1.3  Problems with database 
There was a column with the age on the day of the scan, but it only included the ages 
of subjects still alive on the day of the database acquisition, so there were data 
missing. The database only included results for adjusted calcium as given by the 
laboratory and did not have any measurements of total calcium and albumin to allow 
manual calculations of adjusted calcium.  
 
6.2.1.2 The decision to address the problems 
Since the previous analysis was not reproducible and the results were probably 
affected by the change in the calcium measurement and the adjusted calcium 
equation, a new approach was attempted using updated patient data. 
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6.2.1.3 Databases received before analysis 2 and their problems 
In order to run the updated analysis, a new database containing patients referred for 
a BMD until 2017 was requested and retrieved. All of them had laboratory work-up 
performed within 28 days from their scan. In the previous analysis, several of the 
subjects did not have results on both calcium and PTH and that is why there were not 
included. To address that issue, the subjects in the updated database had to have 
both calcium and PTH available. Moreover, in the original database, only adjusted 
calcium was included; total calcium and albumin were also requested in the 
subsequent databases, to allow the calculation of adjusted calcium.  
There were several different databases received and checked before the analysis. The 
issues with each one are described below. A summary of all the received databases 
can be also be seen in Table 6-7. For each database received, there was an initial 
check to make sure that there not any issues.  
• Database “SearchServiceResultsSTH15691_AllUpdated 
It contained data for 12623 patients attending the Metabolic Bone Centre for a BMD 
from 01/12/2011 to 10/1/2017.  
Problems: Out of the 12623 patients, 6062 had both adjusted calcium and PTH 
compared to 5977 in the old one, therefore, it only contained 85 new patients 
compared to the previous one 
Reason: The code for PTH had changed, so the patients with updated PTH codes 
could not be identified 
• Database “SearchServiceResultsSTH15691_WithPTHCorrected 
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It contained data for 7885 patients attending the MBC for a BMD from 01/12/2011 to 
31/1/2017. The patients had to have both adjusted calcium and PTH available to be 
included.  
Problems: The referring clinician was not included 
• Database “SearchServiceResultsSTH15691_WithLabsRequestingClinician” 
Same database as before but with name of the consultant who requested the test 
available. 
Problems: The dates for adjusted calcium, calcium and albumin should be the same, 
since the laboratory used the calcium and albumin values to calculate the adjusted 
calcium. There were differences in these dates, e.g. a patient had adjusted calcium in 
2012 and calcium in 2014. Moreover, date of birth (DOB) was not available and some 
patients did not have their age recorded 
Reason: The extractor was looking for the first available value for the DXA scan 
columns, so in some instances when there was no Z-score available on their first scan, 
it looked for the next result which would be from a later scan. Thus, when the date for 
the Z-score was different to the T-score, some laboratory columns were referencing 
one or the other.  
To get the next database, all the laboratory columns referenced the first T-score 
column (lumbar spine). As a result, some patients did not have Z-scores at the same 
day. 
• Database “SearchServiceResultsSTH15691_WithDOB” 
Contained data form 7792 patients. Some patients were not included because of the 
change in the extractor script code. 
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Problems: The calculated age on the day of the scan (= day of scan – date of birth) 
and the given age on the database were not always the same. 
Moreover, there were a lot of eGFR measurements missing (72.9%), although 
creatinine measurements were available. Since the eGFR value is included in the 
definition on NPHPT, the missing data would affect the results.  
Reason: The age column given was calculated when the data were loaded into the 
system and was not accurate, so I was advised to stop using it. The reason there were 
so many eGFR values missing was because the laboratory changed the code used in 
the system and both the old and new code had to be included in the extractor code.  
• Database “SearchServiceResultsSTH15691_WithAllEGFRCodes” 
Contained 7809 patients attending the MBC between 01/12/2011 and 31/1/2017 for a 
DXA scan. Only the ones having adjusted calcium and PTH available were included. 
This database was used for the analysis 2 described below. 
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6.2.2 Analysis 2 (completed in 2017) 
6.2.2.1 Preparation of database 
The steps described below were followed for this analysis. The software used in 
general was Microsoft Excel, while R studio was used for the Mahalanobis distance 
analysis. As mentioned above, this database contained 7809 patients attending the 
MBC between 01/12/2011 and 31/1/2017.  
• Add study numbers A1 to A7809 
• Calculate age on day of scan 
(Date when they had lumbar T score- date birth)/365 
• Calculate (recorded in one decimal place) and check BMI as mentioned above  
• PTH columns. In May 2015 there was a change in the PTH units and so the 
updated databases included subjects with PTH in ng/L and others with PTH in 
pmol/L. Two extra columns were added containing PTH in ng/L and pmol/L for 
all the patients. The results in pmol/L had to be multiplied by 9.43 to be 
transformed into ng/L and were recorded with zero decimal places. The results 
in ng/L were multiplied by 0.106 to be transformed to pmol/L and were rounded 
to one decimal place. There were fourteen patients with no PTH available, 
because instead of a value they had the clinician’s name recorded. There also 
two patients with no calcium available. All these patients were excluded from 
the analysis. The number of patients described from this point forward was 
7793. The ng/L values were used and extra columns defining high, normal and 
low PTH were added  
o Low PTH (<15 ng/L), n=39  
o Normal PTH [15-65 ng/L], n=5981 
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o High PTH (>65 ng/L), n= 1773  
• Calcium, adjusted calcium and albumin. The new method for measuring 
calcium was introduced on the 14th January 2013. 
o Calcium measurement before the change, n=2080 
o Calcium measurement after the change, n=5713 
Only the 5713 patients with the new method calcium were used for the next 
steps. Moreover, from September 2013 onwards, there was a change in the 
adjusted calcium equation. Out of the 5713 patients included, 3064 had their 
equation calculated with the previous method. The new equation was used 
to calculate adjusted calcium for all the patients 
!"#$%&'"	)* = ,-&*.	)* + [0.0172(43 − !.:$;<=)] 
As a result, 172 patients had low levels of adjusted calcium (<2.20 mmol/L) 
and 233 had high levels (>2.60 mmol/L). 
• 25(OH)D levels. Out of the 5713 patients, 2325 (41%) had low levels (<50 
nmol/L) and 2784 had normal (≥50 nmol/L). The rest (n=604) did not have any 
result available. 
• eGFR levels. Out of the 5713 patients, 1045 (18%) had low levels (<60 
mol/min/1.73 m2) and 4565 had normal (≥60 mol/min/1.73 m2). The rest (n=103) 
did not have any result available. 
• Save file with only new method calcium patients and with both PTH and 
adjusted calcium available. Number of patients to analyse: 5713. Patient 
characteristics: Mean age 66 years, 72% female. 
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6.2.2.1.1 Normocalcaemic hyperparathyroidism patients 
Based on the laboratory results on the index day, 226 patients being outside the ellipse 
and having normal adjusted calcium and high PTH, were identified. Using the 
international criteria on NPHPT, 129 patients were excluded because of either low 
eGFR or no eGFR measurement. Moreover, 76 patients with normal eGFR, were 
excluded because of 25(OH)D<50nmol/L (n=67) or no vitamin D measurement (n=9) 
(Table 6-4). This resulted in identifying 21 patients, with likely NPHPT (Table 6-5). 
  25(OH)D (nmol/L) 
≥50 <50 NA 
eGFR 
(ml/min/1.73m2) 
≥60 21  67 9 
<60 39 76  9  
NA 0 0 5 
Table 6-4: Data for the 226 patients having normal adjusted calcium and high PTH, but being outside 
the ellipse (analysis 2).  
After applying the cut-off for 25(OH)D<50nmol/L and/or eGFR<60ml/min/1.73m2. 265 patients were 
excluded from having NPHPT. Only 21 of the 226 were left for further evaluation (seen in bold). NA: not 
available 
 
 Frequency Percentage 
Normal 5080 88.9 
Hyperparathyroid hypercalcaemia (HH) 160 2.8 
Hypoparathyroidism 1 0.0 
Secondary hyperparathyroidism 254 4.4 
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Non-PTH hypercalcaemia 6 0.1 
Normocalcaemic hyperparathyroidism (NPHPT) 21 0.4 
Normocalcaemic hypoparathyroidism (NHYPO) 22 0.4 
Normoparathyroid hypercalcaemia 67 1.2 
Normoparathyroid hypocalcaemia 43 0.8 
Unclassified abnormal 59 1.0 
Total 5713 100.0 
Table 6-5: The different patient categories based on their calcium metabolism disorders, after applying 
the criteria for 25(OH)D<50nmol/L and/or eGFR<60 ml/min/1.73m2 
 
A further evaluation of their medical notes, excluded fifteen patients due to other 
exclusion criteria (Table 6-6). The number of NPHPT patients identified after applying 
the exclusion criteria in our referral population was six. 
  Study 
number  
Analysis 2 
Include/ Exclude 
Analysis 1 results Comments 
1 A303 Exclude 
Sodium valproate 
Only one PTH available 
    
2 A664 Exclude  
Treated 
pseudohypoparathyroidism 
6177: Excluded – treated 
pseudohypoparathyroidism 
  
3 A843 Exclude 
Tertiary hyperparathyroidism 
Renal transplant 
    
4 A1023 Include 3831: Excluded – just one 
measurement of PTH 
Although excluded 
in previous 
analysis, more 
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available, on 
bisphosphonates 
abnormal results of 
PTH were available 
during the second 
analysis. The 
patient had stopped 
risedronate after 
first analysis 
5 A1114 Exclude 
Secondary 
hyperparathyroidism (low 
GFR) 
    
6 A1287 Exclude 
Only one PTH 
On bisphosphonates 
    
7 A1349 Exclude 
Inconsistency of PTH 
6181: Excluded – just one 
measurement of PTH 
  
8 A1742 Exclude 
On bisphosphonates 
Borderline eGFR 
    
9 A2308 Include     
10 A2487 Include     
11 A3329 Exclude 
No persistence of high PTH 
(only one high result) 
1977: Excluded – no 
persistence of high PTH 
(only one high result) 
  
12 A3656 Exclude 
Crohn's 
Bisphosphonates- 
furosemide 
    
13 A3732 Exclude 
Just one measurement of 
PTH 
3584: Excluded – just one 
measurement of PTH and 
calcium available 
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14 A4137 Exclude 
Inconsistency of PTH 
    
15 A5113 Exclude 
Only one abnormal result of 
PTH with normal VitD 
(chronic vitamin D 
deficiency) 
    
16 A5137 Exclude 
Bisphosphonates 
8483: Excluded – 
bisphosphonates  
  
17 A5179 Include     
18 A5754 Include 1849: Included   
19 A6009 Exclude 
Only one abnormal result of 
PTH with normal VitD 
(chronic vitamin D 
deficiency) 
6715: Excluded – just one 
measurement of PTH and 
calcium available 
  
20 A6344 Exclude 
Renal transplant 
    
21 A6855 Include   Although this 
patient had coeliac 
disease, she had 
normal vitamin D 
levels and urine 
calcium without 
taking 
supplements, which 
means calcium 
absorption was not 
affected 
Table 6-6: Exclusion criteria for patients identified as likely NPHPT. Fifteen patients out of 21 were 
excluded. The table also summarises whether these patients were identified in the previous analysis 
(analysis 1) 
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6.2.2.1.2 Conclusions 
The prevalence of NPHPT in the Metabolic Bone Centre referral population using 
analysis 2, was 0.10% (six patients out of 5713). Their mean age was 72 years. Out 
of them, 83% were female.  
 
6.2.2.2 Problems identified in Analysis 2  
The patients identified up to this point, were found because they had an available T-
score at the spine. However, some of the patients attending the Metabolic Bone Centre 
for a BMD did not have available spine measurements, due to degenerative changes 
at the spine, multiple vertebral fractures etc. In this case a hip BMD measurement 
would be the only available. Moreover, patients with bilateral hip replacements would 
not have BMD measurements at the hip and the only available BMD measurement 
could be the one at the forearm. By including patients based on the spine BMD, some 
of the patients attending the department would be excluded and that could lead to 
underestimation of the prevalence. 
For that reason, another database was requested, including all the patients with results 
on spine, hip or forearm BMD measurement and the analysis was repeated as 
described below. 
 
6.2.2.3 Databases received before analysis 3 and their problems 
In order to run the updated analysis, a new database containing patients referred for 
a BMD until 2017 was requested and retrieved. Once again, there were several 
different databases received and checked before the analysis. The issues with each 
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one are described below. A summary of all the received databases can be also be 
seen in Table 6-7. For each database received, there was an initial check to make 
sure that there not any issues.  
• Database “SearchServiceResultsSTH15691_NonSpineDXAPatients” 
This contained data on 111 patients who had a scan between December 2011 and 
June 2017 and their results did not include a spine DXA.  
Problems: Urine results did not correspond to the BMD results and not all 24-hour 
urine collections for calcium also had creatinine available. The reason was that the 
extractor was giving the first available urine calcium 
• Database “SearchServiceResultsSTH15691_NonSpineDXAPatientsCorrected” 
and Database “SearchServiceResultsSTH15691_SpineDXAPatients” 
These included data on 113 and 8244 patients respectively that had scans 
between December 2011 and July 2017. It was difficult to work on two separate 
databases, so a new one was received. 
• Database “SearchServiceResultsSTH15691_AllDXAPatients” 
Contained information on 8411 patients attending the MBC between 
01/12/2011 and 27/7/2017 for a DXA scan at either the spine, hip (neck T-
score) or forearm and a laboratory. Only the ones having adjusted calcium and 
PTH available were included. This is the database used for the following 
analyses 
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Name of database Date run 
Number of 
patients 
First date 
Last date 
Patients 
included 
Problems Reasons/Requested changes Notes 
0a. Original 
Used in Analysis 1 
(5 NPHPT patients) 
01/09/2015 
 
9224 
01/12/2011 
 
29/05/2015 
All patients 
attending 
MBC 
 
  Study numbers: 1 
to 9224 
0b. FromAugust2015 21/03/2016 
 
2167 
03/08/2015 
 
22/02/2016 
All patients 
attending 
MBC after 
August 
2015 
    Did not use this one 
1. AllUpdated 31/01/2017 
 
12623 
01/12/2011 
 
10/01/2017 
All patients 
attending 
MBC 
Only 85 new 
patients to analyse 
compared to 
previous one 
Reason: Laboratory changed the code for 
PTH after changing units, so patients with 
new codes could not be identified 
Did not use this one 
2. WithPTHCorrected 22/01/2017 
 
7885 
01/12/2011 
 
31/01/2017 
Only 
patients 
with both 
adjusted 
calcium 
AND PTH 
  Consultant who requested labs would be 
useful to have 
Study numbers: 1 
to 7885 
3. WithLabsRequestingClinician 16/03/2017 
 
7885 
01/12/2011 
 
31/01/2017 
Same as 
above 
Dates for adjusted 
calcium and 
calcium not the 
same. PTH 
referring clinician 
missing. DOB was 
Reason: The extractor was looking for the 
first available value for the DXA scan 
columns, so in some instances when there 
was no Z-score available on their first scan, 
it looked for the next result which would be 
from a later scan. Thus, when the date for 
Study numbers: 1 
to 7885 
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missing and some 
patients did not 
have age recorded 
the Z-score was different to the T-score, 
some laboratory columns were referencing 
one or the other. Date of birth requested 
4. WithDOB 24/03/2017 
 
7792 
01/12/2011 
 
31/01/2017 
Same as 
above 
Calculated age and 
provided age are 
not the same. 
A lot of eGFR 
values are missing 
although creatinine 
values are 
available 
Reason: The age column given was 
calculated when the data were loaded into 
the system and is not accurate, so I was 
advised to stop using it.  
 
The laboratory changed the code for eGFR, 
so patients with new codes were not 
identified 
Study numbers: 1 
to 7792 
5. WithAllEGFRCodes 
Used in Analysis 2 
(6 NPHPT patients) 
30/03/2017 
 
7809 
01/12/2011 
 
31/01/2017 
Same as 
above 
  The databases contained spine DXA. 
Patients not having a spine result were 
missed 
Study numbers: A1 
to A7809. Excluded 
patients with old 
measurement of 
calcium 
6. NonSpineDXAPatients 21/07/2017 
 
111 
01/12/2011 
 
09/06/2017 
Same as 
above 
Patients 
with no 
spine result 
available 
Urine calcium and 
BMD values are on 
different dates 
Many have urine 
calcium but not 
urine creatinine 
Reason: It was giving the first available urine 
calcium 
Did not use this one 
7. 
NonSpineDXAPatientsCorrected 
03/08/2017 
 
113 
01/12/2011 
 
09/06/2017 
Same as 
above  
  A single database would be more useful Did not use this one 
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8. SpineDXAPatients 08/08/2017 
 
8244 
01/12/2011 
 
29/06/2017 
Patients 
with spine 
result 
available  
  Did not use this one 
9. AllDXAPatients 
Used in Analysis 3 
(8 NPHPT patients) 
16/08/2017 
 
8411 
01/12/2011 
 
27/07/2017 
Contains 
spine, hip, 
forearm 
results 
    Study numbers: C1 
to C8411. Changed 
to S1- S6280 after 
excluding patients 
with old calcium 
measurement 
Table 6-7: Information on the databases received and used throughout the study of prevalence of Normocalcaemic hyperparathyroidism (NPHPT)
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6.2.3 Analysis 3 (completed in 2017) 
6.2.3.1 Preparation of database 
The steps described below were followed for this analysis. 
• Add study numbers C1 to C8411 
• Calculate age on day of scan 
o For patients with BMD at the lumbar spine (n=8284) 
(Date of lumbar T score - date of birth)/365 
o For other patients (n=127) 
(Date of T score neck hip - date of birth)/365, (n=118) 
(Date of T score forearm – date of birth)/365, (n=9) 
• Problems with filters and decimal places 
To define whether the measurements of PTH, calculated adjusted calcium, 
25(OH)D and eGFR were high, normal or low, the filter function was used in 
Microsoft Excel.  
When calculations for adjusted calcium and PTH (conversion of units) had to 
be performed, the numbers had to be shown in certain decimal places. For 
example, adjusted calcium had to be rounded to two decimal places; a value of 
2.598 mmol/L (value A) would be shown as 2.60 mmol/L and so would a value 
of 2.604 mmol/L (value B). Since the upper normal level of calcium is 2.60 
mmol/L, some values shown as 2.60 were considered as normal (value A), and 
some were considered high (value B). That is because Excel showed only two 
decimal places, but kept the whole number in the system. That caused 
misclassification of patients and confusion.  
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For that reason, another column was formed with the calculated values copied 
and rounded using the ROUND (name of column, number of decimal places) 
function. This column was then used to define the level of measurement (low, 
normal, high) using the filter function in Excel. 
• Calcium, adjusted calcium and albumin. The new method for measuring calcium 
was introduced in January 2013 
o Calcium measurement before the change, n= 2118 
o Calcium measurement after the change, n=6293 
Only the 6293 patients with the new method calcium were used for the next 
steps. Moreover, from 2013 onward, there was a change in the adjusted 
calcium equation. Out of the 6293 patients included, 3101 had their equation 
calculated with the previous method. The new equation was used to 
calculate adjusted calcium for all the patients 
!"#$%&'"	)* = ,-&*.	)* + [0.0172(43 − !.:$;<=)] 
As a result, 203 patients had low levels of adjusted calcium (<2.20 mmol/L) 
and 260 had high levels (>2.60 mmol/L). 
The mean given adjusted calcium for the patients with the previous equation 
was 2.35 mmol/L, while their mean calculated adjusted calcium was 2.38 
mmol/L. The calculated adjusted calcium was higher from their given 
adjusted calcium, by a mean of 0.03 mmol/L, as described by the laboratory. 
For patients with the new equation, both the mean of the given and 
calculated adjusted calcium were 2.37 mmol/L. 
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• PTH columns. Two extra columns were added containing PTH in ng/L and pmol/L 
for all the patients. The results in pmol/L had to be multiplied by 9.43 to be 
transformed into ng/L and were recorded with zero decimal places with the 
ROUND function. The results in ng/L were multiplied by 0.106 to be transformed 
to pmol/L and were rounded to one decimal place. There were 13 patients with 
no PTH available because instead of a value they had the clinician’s name 
recorded. Twenty-nine patients had a low PTH (<15 ng/L), 4850 had a normal 
one and 1401 had a high level (>65 ng/L). 
• Calculate (recorded in one decimal place) and check BMI as mentioned above. 
There were some patients with extreme BMIs (>100kg/m2, n=33). For some of 
them, it was obvious that the height and weight had been reversely recorded in 
the database, and so they were corrected automatically. There were two patients 
with BMI>100kg/m2. The next step was to check the form completed by the 
technician on the day of the BMD measurement; subject C2128 had a BMI of 
142.7 kg/m2 (height was 70.1cm, weight 70.1kg). Correct height was 151.7cm. 
Subject C4365 had a BMI of 1800.0 kg/m2 (height 15 cm, weight 40.5 kg). Correct 
height was 151 cm. There were also patients with BMI<5 kg/m2 (n=10). This was 
because weight was not available 
• Save file with only new method calcium patients and with both PTH and adjusted 
calcium available. The thirteen patients without a PTH available were excluded. 
Total number of patients, n=6280 
o 25(OH)D levels. Out of the 6280 patients, 2531 (40%) had low levels 
(<50 nmol/L) and 3038 had normal (≥50 nmol/L). The rest (n=711) did 
not have any result available. Therefore, from the subjects that had a 
measurement available, 45% had low vitamin D 
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o eGFR levels. Out of the 6280 patients, 1137 (18%) had low levels (<60 
mol/min/1.73 m2) and 5035 had normal (≥60 mol/min/1.73 m2). The rest 
(n=108) did not have any result available. The numbers according to 
different CKD stages can be seen in Table 6-8. 
o Number of patients to analyse: 6280. Mean age 66 years (range 16-100 
years), 72% female (n=4527), 40% vitamin D deficient 
• Add new study numbers: S1 to S6280 
Category GFR 
ml/min/1.73 m2 
Number of patients 
G1  ≥90 2232 
G2 60-89 2803 
G3a 45-59 733 
G3b 30-44 311 
G4 15-29 72 
G5 <15 21 
Not available  108 
Table 6-8: Distribution of the 6280 patients that were included in the analysis into chronic kidney disease 
stages 
6.2.3.1.1 Mahalanobis distance, the different ellipses 
The Mahalanobis distance analysis was performed to define the outliers and divide 
the patients into different categories. The ellipse in Figure 6-1 is also included in 
the final manuscript in Chapter 3.  
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Figure 6-1: Data results from adjusted calcium and PTH.  
The ellipse was formed using a statistical method (Mahalanobis distance) to identify “normal” subjects 
(black dots) and “abnormal” ones (red dots). The reference range of both adjusted calcium and PTH 
(horizontal and vertical dashed lines respectively), were used to identify patient categories as seen 
above. The white area includes patients with normal adjusted calcium and high PTH (n=265); these 
were either potentially NPHPT patients [given that 25(OH)D≥50nmol/L and eGFR≥60 ml/min/1.73m2] 
or secondary hyperparathyroidism patients [given that 25(OH)D<50nmol/L and/or eGFR<60 
ml/min/1.73m2]. The Pearson correlation coefficient was 0.034 (95% CI: 0.009 to 0.058, p value 0.007). 
The regression line is indicated in blue.  
 
6.2.3.1.2 Normocalcaemic hyperparathyroidism patients 
Based on laboratory results on the index day, 265 patients being outside the ellipse 
and having normal adjusted calcium and high PTH, were identified. Using the 
international criteria on NPHPT, 145 patients were excluded because of either low 
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eGFR (<60 ml/min/1.73m2) or no eGFR measurement. Moreover, 82 patients with 
normal eGFR, were excluded because of 25(OH)D<50 nmol/L (n=78) or no vitamin D 
measurement (n=14) (Table 6-9). This resulted in identifying 28 patients, with likely 
NPHPT.  The rest of the patient categories can be seen in Table 6-10. 
  25(OH)D (nmol/L) 
≥50 <50 NA 
eGFR 
(ml/min/1.73m2) 
≥60 28 78 14 
<60 46 83 11 
NA 0 0 5 
Table 6-9: Data for the 265 patients having normal adjusted calcium and high PTH (analysis 3).  
After applying the cut-off for 25(OH)D<50nmol/L and/or eGFR<60ml/min/1.73m2, 237 patients were 
excluded from having NPHPT. Only 28 of the 265 were left for further evaluation (seen in bold). NA: not 
available 
Categories Number (%) 
Normal 5574 (88.76) 
Hyperparathyroid hypercalcemia (HH) 172 (2.74) 
Hypoparathyroidism 1 (0.02) 
Secondary hyperparathyroidism 291 (4.63) 
Non-PTH hypercalcemia 6 (0.10) 
Normocalcemic hyperparathyroidism (NPHPT) 28 (0.45) 
Normocalcemic hypoparathyroidism (NHYPO) 22 (0.35) 
Normoparathyroid hypercalcemia  67 (1.07) 
Normoparathyroid hypocalcemia 43 (0.68) 
Unclassified abnormal  76 (1.21) 
Table 6-10: The different patient categories based on their calcium metabolism disorders  
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Note: The results of analysis 3 up to this point, are the ones that are also 
included in the final analysis (Chapter 3) and were not further altered. The final 
code used to calculate Mahalanobis distance is included in the Supplementary 
material (code 1.1).  
The process of selecting the final NPHPT patients was challenging and was 
updated. The thought process and intermediate results are described below.  
 
6.2.3.1.2.1 Selecting the final normocalcaemic hyperparathyroidism patients 
A further evaluation of the likely NPHPT patients’ medical notes and their follow up 
laboratory investigations from 2011 to the end of 2017, excluded twenty patients 
(Table 6-11). Once again, it was obvious that there were two patterns of calcium 
variations in these patients; some patients had persistent normocalcaemia throughout 
their follow up and some had intermittent hypercalcaemia (Table 6-12).  
 
6.2.3.1.3 Conclusions  
In total, eight patients out of a population of 6280, were identified as having NPHPT 
based on the index day, without checking the persistence of their laboratory 
evaluations (adjusted calcium and PTH). Their mean age was 70 years and seven 
were female. The prevalence of NPHPT using data from the index date was 0.13%. 
Once again, two patterns of adjusted calcium variations were identified. The majority 
of patients had intermittent hypercalcaemia (six out of eight). Only two patients (0.03% 
of the whole population) had persistent normocalcaemia throughout the follow up 
period (2011 to 2017).  
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Study 
number  
Index date Age Gender Result in analysis 3 Result in analysis 2 Result in analysis 1 Comments 
S189 28/08/2014 65 F Excluded - sodium 
valproate - only one PTH 
available 
A303: Excluded - sodium 
valproate -only one PTH 
available 
Not identified 
 
S227 01/03/2017 
 
59 F Excluded - probably 
chronic vitamin D 
deficiency 
Not identified Not identified 17/6/11: high PTH, low 
vitD, 29/11/11: normal 
PTH, normal vitD, 
26/1/12: normal PTH, 
?vitD, 16/2/12: high 
PTH, ?vitD, 5/12/16:? 
PTH, low vitD, 1/3/17: 
high PTH, normal vitD, 
probably high PTH 
from recent vitamin D 
deficiency (4m before) 
S449 02/09/2014 65 F Excluded - treated 
pseudohypoparathyroidism 
A664: Excluded - treated 
pseudohypoparathyroidism 
6177: Excluded – treated 
pseudohypoparathyroidism 
  
S567 04/09/2015 72 F Excluded - tertiary 
hyperparathyroidism-renal 
transplant 
A843: Excluded - tertiary 
hyperparathyroidism-renal 
transplant 
Not identified   
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S696  
09/01/2015 
75 F Included A1023: Included 3831: Excluded – just one 
measurement of PTH 
available, on 
bisphosphonates 
Laboratory 
investigations because 
of accelerated bone loss 
9/1/15: high PTH, 
normal vitD, on 
risedronate since 
2003. Stopped on 
index day 
17/1/17: high PTH, 
normal vitD 
S757 04/09/2013 68 F Excluded - secondary 
hyperparathyroidism (low 
eGFR) 
A1114: Excluded - 
secondary 
hyperparathyroidism (low 
GFR) 
Not identified eGFR always< 60 apart 
from index day (62) 
S871 21/07/2015 83 M Excluded - only one PTH 
(deceased)-on 
bisphosphonates 
A1287: Excluded - only 
one PTH (deceased)-on 
bisphosphonates 
Not identified 21/7/15: high PTH, 
normal vitD, on 
alendronate since 
2011 
S911 04/09/2014 70 F Excluded - inconsistency 
of PTH 
A1349: Excluded - 
inconsistency of PTH 
6181: Excluded – just one 
measurement of PTH 
4/9/14: high PTH, 
normal vitD, 16/10/14: 
high PTH, ? vitD (not 
enough time between 
this and previous 
measurement) 
29/5/15: normal PTH, 
started zol 2014, 
5/11/15: high PTH, 
normal vitD, on zol, 
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22/9/17: normal PTH, 
normal vitD, ? zol 
S1194 08/01/2016 74 F Excluded - on 
bisphosphonates- 
borderline GFR 
A1742: Excluded - on 
bisphosphonates- 
borderline GFR 
Not identified Borderline eGFR (29-
67), on risedronate from 
2011-2016 
S1620 02/12/2015 75 F Included A2308: Included Not identified Laboratory investigation: 
low BMD for age 
S1692 10/03/2013 79 F Excluded - 
bisphosphonates 
(zoledronic acid) on index 
day 
A2409: Identified as HH 1236: Excluded – 
bisphosphonates 
(zoledronic acid) on index 
day 
Oral bisphosphonates 
2004-2008, Zoledronic 
acid 2009-2013. 
Measurements of PTH:  
4/11/08, 7/1/09, 12/8/09, 
11/3/13 - all high, 
7/4/16: high PTH, 
normal vitD,? zol, 
18/7/17: high PTH, 
?vitD, ?zol 
S1753 21/07/2016 86 M Included A2487: Included Not identified Laboratory investigation: 
PHPT workup 
S2406 28/10/2014 67 F Excluded - no persistence 
of high PTH (only one high 
result) 
A3329: Excluded - no 
persistence of high PTH 
(only one high result) 
1977: Excluded – no 
persistence of high PTH 
(only one high result) 
16/1/14:  normal PTH, 
?vitD, 28/10/14: high 
PTH, normal vitD, 
4/11/16: normal PTH, 
normal vitD, 19/12/16: 
normal PTH, normal vitD 
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S2453 11/03/2014 57 F Included A3400: Identified as HH 4777: Included Laboratory investigation 
because of low BMD for 
age 
S2654 17/07/2015 88 F Excluded - Crohn's- 
bisphosphonates- 
furosemide 
A3656: Excluded - 
Crohn's- bisphosphonates- 
furosemide 
Not identified 17/5/15: received 5 
zoledronate infusions 
S2720 12/12/2013 83 F Excluded - just one 
measurement of PTH 
A3732: Excluded - just one 
measurement of PTH 
3584: Excluded – just one 
measurement of PTH and 
calcium available 
Only one measurement 
on index day 
S3021 07/08/2015 64 F Excluded - inconsistency 
of PTH 
A4137: Excluded - 
inconsistency of PTH 
Not identified 7/8/15: high PTH, 
normal vitD, 10/11/15: 
normal PTH, ?vitD, 
20/5/16: normal PTH, 
?vitD, 27/4/17: high 
PTH, normal vitD 
S3703 11/05/2017 72 F Excluded- on 
carbamazepine 
Not identified Not identified 2 measurements 
available 3/17, 5/17, 
both on carbamazepine 
for trigeminal neuralgia 
S3812 11/04/2014 70 F Included A5105: Identified as HH 5489: Included Laboratory investigation 
as a follow up to 
endocrine clinic 
S3820 14/07/2015 49 F Excluded - Inconsistency 
of PTH 
A5113: Excluded - 
Inconsistency of PTH 
Not identified 14/7/15: high PTH, 
normal vitD, 6/10/16: 
normal PTH, ? vitD, 
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1/3/17: high PTH, low vit 
D 
S3841 11/09/2014 84 F Excluded - 
bisphosphonates 
(aledronic acid) on index 
day - PTH high after 
A5137: Excluded - 
bisphosphonates 
(aledronic acid) on index 
day 
8483. Excluded – 
bisphosphonates 
(aledronic acid) on index 
day 
14/9/09: normal PTH, 
11/9/14: high PTH, 
normal vitD, on 
alendronate since 
2009, 5/10/15: high 
PTH, ? alendronate 
S3882 30/11/2015 69 F Included A5179: Included Not identified Laboratory investigation 
because of vertebral 
fractures 
S4392 28/01/2014 66 F Included A5754: Included 1849: Included Laboratory investigation 
as follow up to clinic 
appointment 
S4618 07/07/2014 59 F Excluded - only one 
abnormal result of PTH 
with normal VitD (chronic 
vitamin D deficiency) 
A6009: Excluded - only 
one abnormal result of 
PTH with normal VitD 
(chronic vitamin D 
deficiency) 
6715: Excluded – just one 
measurement of PTH and 
calcium available 
16/6/14: ? PTH, low 
vitD, 7/7/14: high PTH, 
borderline normal vitD 
(probably due to 
recent vitD deficiency), 
29/3/17: high PTH, low 
vitD, 19/7/17: high PTH, 
normal vitD (only 4 
months after previous, 
probably PTH high due 
to recent vitD deficiency) 
S4903 02/11/2015 59 M Excluded - renal transplant A6344: Excluded - renal 
transplant 
Not identified Renal transplant 
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S5321 07/07/2014 78 F Excluded – 
bisphosphonates 
(aledronic acid) on index 
day 
Not identified 4403: Excluded – 
bisphosphonates 
(aledronic acid) on index 
day 
4/7/14: normal PTH, 
normal vitD, alendronate 
recently started, 
21/7/14: high PTH, 
normal vitD, 
alendronate recently 
started, 10/1/15: normal 
PTH, ? alendronate, 
30/11/16: high PTH 
normal vitD, zol, 
10/5/17: high PTH, ? 
vitD, zol 
S5369 10/10/2013 64 F Included A6855: Included 5208: Identified as 
normocalcaemic 
Although patient has 
coeliac disease, she has 
normal vitD and high 
urine calcium without 
supplements - well 
controlled- no problem 
in calcium absorption 
S5408 19/05/2017 82 F Excluded - on furosemide Not identified Not identified Identified from hip BMD, 
10/2/16: not furosemide, 
high PTH but low vitD 
(secondary 
hyperparathyroidism), 
19/5/17: furosemide, 
high PTH, normal vitD. 
14/6/17: furosemide, 
high PTH, ?vitD 
Table 6-11: Exclusion criteria for patients identified as likely NPHPT.  
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Thirteen patients out of 28 were excluded. The table also summarises whether these patients were identified in the previous analysis. The bold letters in the 
comments column, indicate information for the index date. Zol: zoledronic acid
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Study  
number 
Persistent  Age Gender BMD result Mean 
PTH 
(ng/L) 
Mean 
calcium 
(mmol/L) 
Follow 
up 
(years) 
Phosphate 
on index 
day 
ALP 
on 
index 
day 
Previous 
Fractures 
Parathyroid Laboratory 
investigation 
S696 Y 75 F Osteoporosis, 
within 
expected 
range 
74 2.53 6 Normal Normal Y   Accelerated 
bone loss 
S1620 Y 75 F Osteoporosis, 
below the 
average 
121 2.44 5 Normal Normal Y   Low BMD for 
age 
S1753 N 86 M Osteopenia, 
within 
expected 
range 
151 2.58 6 Normal Normal N   Workup due 
to PHPT 
S2453 N 57 F Osteoporosis, 
below the 
average 
124 2.55 4 Normal Normal Y Patient’s wish: surgery Low BMD for 
age 
S3812 N 70 F Osteopenia, 
within 
expected 
range 
106 2.62 3 Borderline  
low 
(0.8mmol/L) 
Normal N   Follow up 
S3882 N 69 F Osteoporosis, 
within 
expected 
118 2.51 7 Normal Normal N Surgery: adenoma?  
hyperplasia? 
Vertebral 
fracture 
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S4392 N 66 F Osteoporosis, 
within 
expected 
185 2.52 6 Normal High 
(148 
IU/L) 
N FNA:  
Parathyroid 
adenoma? 
Follow up 
S5369 N 64 F Osteoporosis, 
below the 
average 
81 2.58 3 Normal Normal Y US: Adenoma?  
MIBI: Negative 
Low BMD for 
age 
Table 6-12: Characteristics of the eight NPHPT patients selected from analysis 3. Y: yes, N: no, F: female; M: male
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6.2.3.1.4 Problems identified from Analysis 3 
In Analysis 3, patients with likely NPHPT were excluded based on the repeated vitamin 
D and eGFR measurements. Some were also excluded because they had inconsistent 
measurements of PTH throughout their follow up. After reviewing this approach, it was 
decided that a different approach should be followed. According to the definition of 
NPHPT, PTH should be persistent on several occasions, but not necessarily 
throughout the follow up. The same is true for vitamin D and eGFR. Checking for follow 
up results in order to decide about whether a patient should be included in the NPHPT 
group had been proven troublesome and would not always result in the same 
decisions. It was also based on speculations like in the case of patient S227, to whom 
likely chronic vitamin D deficiency was defined as the cause of high PTH. Patients on 
bisphosphonates on index date and who then stopped, were included if they had only 
one measurement available consistent with NPHPT after the index date (S696). 
Therefore, it was decided to follow a different approach to improve consistency. 
Inclusion and exclusion criteria on NPHPT would only be based on laboratory results 
of the index date, information from the medical records (medical problems) and not on 
follow up results. Once these patients were identified, a further review of them would 
be possible.  
At this point, it should be mentioned that defining NPHPT patients was difficult in this 
thesis and as will also be mentioned later, I believe that the definition of NPHPT should 
be updated. 
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6.2.4 Analysis 4 (completed in 2018) 
6.2.4.1 Checking results on index date 
Using the data Analysis 3, twenty-eight patients were identified as having likely 
NPHPT. Going back through their records and only considering the laboratory 
measurements at the index date, thirteen patients were excluded (Table 6-13).  
Study 
number 
Age Gender Analysis 4: Result of index 
NPHPT (just from the information 
from the measurements on index 
day and the notes) 
Result in analysis 3 
S189 65 F Excluded - sodium valproate Excluded - sodium valproate - 
only one PTH available 
S227 59 F Included Excluded - probably chronic 
vitamin D deficiency 
S449 65 F  Excluded - treated 
pseudohypoparathyroidism 
Excluded - treated 
pseudohypoparathyroidism 
S567 72 F Excluded - tertiary 
hyperparathyroidism-renal transplant 
Excluded - tertiary 
hyperparathyroidism-renal 
transplant 
S696 75 F Excluded - on bisphosphonates Included because one result 
available after stopping 
bisphosphonates 
S757 68 F Included Excluded - secondary 
hyperparathyroidism (low 
eGFR) 
S871 83 M Excluded -on bisphosphonates Excluded - only one PTH-on 
bisphosphonates 
S911 70 F Included Excluded - inconsistency of 
PTH 
S1194 74 F Excluded - on bisphosphonates Excluded - on 
bisphosphonates- borderline 
GFR 
S1620 75 F Included Included 
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S1692 79 F Excluded - on bisphosphonates Excluded - bisphosphonates  
S1753 86 M Included Included 
S2406 67 F Included Excluded - no persistence of 
high PTH  
S2453 57 F Included Included 
S2654 88 F Excluded - Crohn's- 
bisphosphonates- furosemide 
Excluded - Crohn's- 
bisphosphonates- furosemide 
S2720 83 F Included Excluded - just one 
measurement of PTH 
S3021 64 F Included Excluded - inconsistency of 
PTH 
S3703 72 F Excluded- on carbamazepine Excluded- on carbamazepine 
S3812 70 F Included Included 
S3820 49 F Included Excluded - Inconsistency of 
PTH 
S3841 84 F Excluded - on bisphosphonates Excluded - bisphosphonates  
S3882 69 F Included Included 
S4392 66 F Included Included 
S4618 59 F Included Excluded - chronic vitamin D 
deficiency 
S4903 59 M Excluded - renal transplant Excluded - renal transplant 
S5321 78 F Excluded - on bisphosphonates Excluded – bisphosphonates  
S5369 64 F Included Included 
S5408 82 F Excluded - on furosemide Excluded - on furosemide 
Table 6-13: Checking the 28 likely NPHPT patients for inclusion and exclusion criteria based on the 
index date.  
Thirteen patients were excluded. The inclusions are shown in green 
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6.2.4.2 Further steps decided after Analysis 4 
The next step was to study the natural history of the disease in more detail. Having 
seen two patterns of variations of calcium (persistent normocalcaemia and intermittent 
hypercalcaemia), it was decided to also check a group of patients identified with 
hyperparathyroid hypercalcaemia (HH). By definition, this group mainly consists of 
PHPT patients, but a small number of FHH patients might be included. As NPHPT 
patients had normal 25(OH)D and eGFR on their index date, I decided to compare this 
group with a sample of HH patients having the same characteristics (normal eGFR 
and vitamin D) on the index date. That could ensure, to some extent, that any 
variations in calcium were because of the disease and not because of other factors.  
The question was whether the patients with primary hyperparathyroidism would have 
a similar pattern of intermittent hypercalcaemia as the NPHPT patients, and if yes, 
whether the variation of adjusted calcium was similar between this group and the 
NPHPT group.  
It was also decided that it would be useful to compare these findings with a group of 
subjects with no problems in calcium metabolism. Based on the analysis with the 
Mahalanobis distance, 5574 subjects were identified as “normal”. A sample of patients 
from this population was decided to be used as the control group. I understand that 
this is a referral centre and all these patients were investigated for secondary 
osteoporosis, but comparing their results to the groups mentioned above would still 
give useful information on the variation of adjusted calcium. Once again, the control 
group should have normal 25(OH)D and eGFR on the index date.  
Moreover, as the analysis would involve patients with primary hyperparathyroidism, 
information on whether these patients had parathyroid surgery would be useful. That 
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would ensure that all the measurements included in the study of natural history were 
due to the disease, as all measurements after surgery should be excluded. Having a 
list of all the parathyroid surgeries performed at Sheffield Teaching Hospitals would 
help with identifying these patients and supplement the manual check performed 
through the NHS computers.  
 
6.2.4.3 Problems identified from Analysis 4 
Up to this point, all the laboratory measurements (between 2011 and 2017) were 
extracted manually from ICE by checking each patient’s results. ICE contained all the 
laboratory information performed from 2009 at Sheffield Teaching Hospitals. Once a 
laboratory evaluation had been reviewed and acted on upon a health care provider, 
this was then filed. The results that had been filed, were then archived and access to 
this data was not always possible at the first instance when the patient information 
was accessed. The way to overcome this was by asking the system to show the 
archived results and then refresh the page. Once again, this approach had limitations. 
The page had to be refreshed several times, especially for patients having a lot of 
information archived. There was no way to know when all the information were seen. 
There were occasions when going back on ICE on a further occasion, more results 
not seen on the first time were available. When dealing with a small number of patients, 
this process could be repeated to ensure that all results were shown. However, as the 
approach from this point forward was decided to change, it was considered better to 
ask the IT Department to extract all the information on the patients of interest. This 
would also extend the follow up period to the time point where the extraction took place 
and could alter the previous results. 
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Finally, although the laboratory’s manufacturer changed to Roche in 2011, there was 
also a change in the method used for the measurement of calcium in January 2013 
(as described in the Methods in Chapter 2). Although having a long follow up period 
available (2011-2018) has its advantages, it was considered best to only include 
measurements after 2013 to ensure that the change in method would not affect the 
results of the natural history. 
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6.2.5 Preparation for the analysis 5 
As mentioned before, in order to study the natural history of NPHPT in more detail, 
new databases on the follow up measurements of these patients had to be retrieved. 
Moreover, the PHPT patients and the control group had to be characterised and 
databases on available follow up laboratory measurements for these groups also had 
to be requested. 
As the analysis from this point onward would become more challenging and involve a 
variety of databases and more complex approaches, it was decided to start using R 
studio for the manipulation of the databases. There were many R codes used 
throughout these analyses; the  ones are included in the Supplementary material. 
 
6.2.5.1 Getting the repeated measurements 
Using the final database described above to calculate persistence (Database 
“SearchServiceResultsSTH15691_AllDXAPatients” (Table 6-7), the study IDs for 
patients fulfilling the following criteria were retrieved and sent to the IT department.  
• For the NPHPT group: patients who on the index date had 
o Normal adjusted calcium 
o High PTH 
o Normal eGFR 
Total number, n=120 
The database “SearchServiceResults_sheet3NPHPT” was received in 
August 2018. It contained information on repeated measurements adjusted 
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calcium, 25(OH)D, eGFR, PTH, 24h-urine calcium, fractionated urine 
calcium, calcium and albumin from January 2009 to the end July 2018.  
• For the HH group: patients who on the index date had 
o High adjusted calcium 
o High PTH 
o Normal eGFR 
Total number, n=111 
The database “SearchServiceResults_sheet2HH” was received in August 
2018. It contained information on repeated measurements of adjusted 
calcium, 25(OH)D, eGFR, PTH, 24h urine calcium, fractionated urine 
calcium, total calcium and albumin from January 2009 to the end July 2018.  
• For the normal population sample: patients who on the index date had 
o Normal eGFR 
o Normal vitamin D 
Total number, n=2292. The first 300 were chosen 
The database “SearchServiceResults_sheet1Normal” was received in 
August 2018. It contained information on repeated measurements of 
adjusted calcium, 25(OH)D, eGFR, PTH, total calcium and albumin from 
January 2009 to the end of July 2018.  
The codes built would have to look through the files received, confirm the study IDs of 
the likely NPHPT patients identified before (Table 6-13) and apply the relevant 
exclusion criteria. After doing so, and in order to be in line with the international 
guidelines on persistence, only patients with persistently normal adjusted calcium and 
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elevated PTH on two consecutive occasions would be included in the analysis. The 
aim was to make graphs of the means and range of values of different analytes in the 
final NPHPT patients. The same process would be followed for PHPT and the control 
group. 
The codes are included in the Supplementary material. A summary of the process can 
be seen below. 
 
6.2.5.2 Process of analysing the data and descriptions of R codes used 
• Code 2.1. Hospital to Study ID. Once the repeated measurements databases 
were received, the first thing was to match the Hospital IDs from the new 
databases to the study IDs used for this project. Code 2.1 went through this 
process for the NPHPT and HH group. As mentioned above, the NPHPT group 
consisted of patients who on the index date had normal adjusted calcium, high 
PTH, normal eGFR (n=120) and the HH group consisted of patients who on the 
index date had high adjusted calcium, high PTH, normal eGFR (n=111) 
• Code 2.2 followed a similar approach for the control group. For the control group, 
a random sample of 300 subjects was chosen from all the participants being in 
the ellipse and who on the index date had normal eGFR and normal vitamin D 
• Code 2.3. Surgery information. The received database for parathyroidectomies 
had to be corresponded to the study IDs included in the project. All the patients 
with NPHPT and HH found and included in the study also had to be looked up 
on ICE, in case surgery was missed from this list. An updated file containing the 
subject IDs of the participants of this project was made, and the extra surgery 
dates found were added manually 
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• Code 2.4. Confirm the NPHPT patients according to index date. Code 2.4 took 
the comma-separated values (CSV) files with the repeated biochemical 
measurements for all the patients described above patients, calculated the 
adjusted calcium using the equation given in the Methods and formatted the files 
for further analysis. It kept only the measurements after January 2013 as 
described above and excluded any measurements after parathyroid surgery. 
The different statistical values of these measurements were calculated for each 
patient (maximum, minimum, mean, SD, variance, degrees of freedom).  
The code then selected the patients that fulfilled the biochemical criteria for 
NPHPT. After doing so, the same 28 likely NPHPT patients were found and the 
exclusion criteria were applied (Table 6-13). Thirteen patients were excluded. 
At this point, and in order to be in line with the international guidelines on 
persistence, only patients with persistently normal adjusted calcium and 
elevated PTH on two consecutive occasions were included. Therefore, two 
further patients were excluded because of PTH inconsistency (S2406 and 
S3820).  
The graphs of the means of the measurements (adjusted calcium, PTH, vitamin 
D and eGFR) and their ranges in each patient were formed. Finally, the within-
subject standard deviation of adjusted calcium was calculated using the 
approach described in the Methods. 
• Code 2.5. A similar process was followed for the HH group in code 2.5. Once 
again, only patients with consistently high calcium and PTH on at least two 
consecutive occasions were included. Moreover, in order to only include 
patients with PHPT in this group, one or more of the following criteria were used:  
o 24-hour urine calcium> 2.5 mmol/24h  
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o fractional calcium excretion >0.02 
o surgically proven PHPT (correction of high calcium after parathyroid 
surgery).  
This was done to exclude patients with FHH 
In more detail, one patient was excluded because of renal transplant done 
previously (S2706), eight patients due to only one PTH result available 
(S0444, S5484, S0262, S2842, S6275, S6123, S2187, S4366), one patient 
due to the fact that they did not fulfil the criterion on persistence of calcium 
(S0441) and one patient due to the fact that no 24h urine calcium was 
available to allow the exclusion of FHH (S2031). At this point, all remaining 
patients in this group were defined as primary hyperparathyroidism (PHPT).  
The graphs of the means of the measurements and their ranges in each 
patient were formed. Finally, the within-subject standard deviation of 
adjusted calcium was calculated using the approach described in the 
Methods.  
• Code 2.6. The sixth code took the CSV files with the repeated measurements 
for all the NPHPT and PHPT patients and created their graphs over time 
• Code 2.7. This code followed a similar approach with codes 2.4 and 2.5 for the 
control group 
• Code 2.8. This code took the CSV files with information on the selected NPHPT 
and PHPT patients and the control group and binded the necessary information 
together to allow further analyses. The graphs of the means of the 
measurements (PTH and adjusted calcium) and their ranges in each patient 
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were formed, this time combining information from all groups. Box plots of the 
information on age, adjusted calcium and PTH of the three groups were formed. 
• Code 2.9. This code took the baseline measurements for the three groups 
(NPHPT and control) and formatted the files for further analysis. The 
comparisons for baseline characteristics were made (gender distribution, age, 
different measurements) after checking for the necessary assumptions eg 
normal distribution of samples. The results were extracted in a table to be used 
for Chapter 2 
• Code 2.10. This code took the files with the repeated measurements for the 
control group, the NPHPT and PHPT patients and used a mixed linear model as 
described in the Methods, to compare the overall measurements of PTH and 
adjusted calcium resulting from follow up. 
Appendix: Intermediate analyses on NPHPT 
Final analysis 
 
 426 
6.2.6 Final analysis 
After the completion of this analysis, a further consideration was given to the definition 
of hypercalciuria used up to this point (>10 mmol/24h). It was considered best to adapt 
this to the international definition of 24-hour urine calcium ≥6.25 mmol/24h for women 
or 7.5 mmol/24h for men and/or ≥ 0.1 mmol/kg/24h (Worcester & Coe, 2008). The 
results presented in Chapter 3 have implemented this change and two further patients 
from Analysis 5 have been excluded. 
 
6.2.7 Normocalcaemic hypoparathyroidism study (NHYPO) 
There were twenty-two likely NHYPO patients identified in analysis 3. The patients’ 
medical notes were reviewed to look for other causes of the abnormalities (non-PTH 
induced hypocalcaemia due to cancer) and some patients were excluded. Any 
unconfirmed data were also excluded. The remaining patients were used for the 
analysis described in chapter 3  (final one). Their repeated calcium, albumin and PTH 
measurements were retrieved manually for the hospital laboratory software (ICE). The 
analysis was done in R studio and final codes used can be found in the Supplementary 
material. The process followed in the different R codes is summarised below.  
• Code 3.1. The first code took the comma-separated values (CSV) files with the 
repeated calcium, albumin and PTH measurements for all the NHYPO patients, 
calculated the adjusted calcium using the equation given in the Methods and 
formatted the files for further analysis. It kept only the measurements after 
January 2013 as described above. The different statistical values of these 
measurements were calculated for each patient (maximum, minimum, mean, 
SD, variance, degrees of freedom). The graphs of the means of the 
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measurements (PTH and adjusted calcium) and their ranges in each patient 
were formed. Finally, the within-subject standard deviation was calculated 
using the approach described in the Methods 
• Code 3.2. The second code took the CSV files with the repeated adjusted 
calcium and PTH measurements for all the NHYPO patients and created their 
graphs over time 
• Code 3.3. The third code took the CSV files with information on the selected 
NHYPO patients and the control group and binded the necessary information 
together to allow further analyses. For the control group, a random sample of 
300 subjects was chosen from all the participants being in the ellipse and who 
on the index date had normal eGFR and normal vitamin D. The graphs of the 
means of the measurements (PTH and adjusted calcium) and their ranges in 
each patient were formed, this time combining information from both groups. 
Box plots of the information on age, adjusted calcium and PTH of the two 
groups were formed and basic statistical comparisons were made 
• Code 3.4. The fourth code used the baseline measurements for the two groups 
(NHYPO and control) and formatted the files for further analysis. The 
comparisons for baseline characteristics were made (gender distribution, age, 
different measurements) after checking for the necessary assumptions eg 
normal distribution of samples. The results were extracted in a table to be used 
for Chapter 3 
• Code 3.5. The fifth code used the files with the repeated measurements for the 
control group and the NHYPO group and used a mixed linear model as 
described in the Methods, to compare the overall measurements of PTH and 
adjusted calcium resulting from follow up 
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• Code 3.6. Finally, the sixth code compared the persistent versus non-persistent 
NHYPO patients and looked for any statistical differences in age, gender and 
biochemical measurements 
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Section 4: Supplementary material 
The R codes used for the analyses can be found in Supplementary material (included 
in the attached CD). 
 
